Compounds and compositions as modulators of gpr119 activity

ABSTRACT

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority to U.S. ProvisionalPatent Application No. 60/974,064, filed 20 Sep. 2007 and U.S.Provisional Patent Application No. 61/045,263, filed 15 Apr. 2008. Thefull disclosures of these applications are incorporated herein byreference in their entirety and for all purposes.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention provides compounds, pharmaceutical compositions comprisingsuch compounds and methods of using such compounds to treat or preventdiseases or disorders associated with the activity of GPR119.

2. Background

GPR119 is a G-protein coupled receptor (GPCR) that is mainly expressedin the pancreas, small intestine, colon and adipose tissue. Theexpression profile of the human GPR119 receptor indicates its potentialutility as a target for the treatment of obesity and diabetes. The novelcompounds of this invention modulate the activity of GPR119 and are,therefore, expected to be useful in the treatment of GPR119-associateddiseases or disorders such as, but not limited to, diabetes, obesity andassociated metabolic disorders.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides a compound of Formula I:

in which:

Q is a divalent or trivalent radical selected from C₆₋₁₀aryl,C₁₋₁₀heteroaryl, C₃₋₈cycloalkyl and C₃₋₈heterocycloalkyl; wherein saidaryl, heteroaryl, cycloalkyl or heterocycloalkyl of Q is optionallysubstituted with up to 3 radicals independently selected from halo,C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl, C₁₋₆alkoxy,halo-substituted-C₁₋₆alkoxy, —C(O)R₂₀ and —C(O)OR₂₀; wherein R₂₀ isselected from hydrogen and C₁₋₆alkyl; and optionally connecting a carbonadjacent to W₂ through a CR₃₁, O, S or NR₃₁ with a carbon of Q(indicated by the dotted line) to form a 5-membered ring fused to ringsA and Q (such as the fused rings in examples V1-V5, infra); wherein R₃₁is selected from hydrogen and C₁₋₆ alkyl;

W₁ and W₂ are independently selected from CR₂₁ and N; wherein R₂₁ isselected from hydrogen, cyano, C₁₋₆alkyl and —C(O)OR₂₅; wherein R₂₅ isselected from hydrogen and C₁₋₆alkyl; ring A can have up to 2 ringcarbons substituted with a group selected from —C(O)—, —C(S)— and—C(═NOR₃₀)— and can be partially unsaturated with up to 2 double bonds;wherein R₃₀ is selected from hydrogen and C₁₋₆alkyl;

L is selected from C₁₋₆alkylene, C₂₋₆alkenylene, —(CH₂)_(n)O—,—OC(O)(CH₂)_(n)—, —C(O)O(CH₂)_(n)—, —NR₂₆(CH₂)_(n)— and —O(CH₂)_(n)—;wherein R₂₆ is selected from hydrogen and C₁₋₆alkyl; and n is selectedfrom 0, 1, 2, 3, 4 and 5; wherein any alkyl of L can be optionallysubstituted with 1 to 3 radicals independently selected from halo, C₁₋₆alkyl, halo-substituted-C₁₋₆ alkyl, C₁₋₆ alkoxy,halo-substituted-C₁₋₆alkoxy, —C(O)R₂₂ and —C(O)OR₂₂; wherein R₂₂ isselected from hydrogen and C₁₋₆alkyl;

m is selected from 0, 1, 2, 3 and 4;

q is selected from 0, 1, 2, 3 and 4;

t₁, t₂, t₃ and t₄ are each independently selected from 0, 1 and 2;

R₁ is selected from —X₁S(O)₀₋₂X₂R_(6a), —X₁S(O)₀₋₂X₂OR_(6a),—X₁S(O)₀₋₂X₂C(O)R_(6a), —X₁S(O)₀₋₂X₂C(O)OR_(6a), —X₁S(O)₀₋₂X₂OC(O)R_(6a)and —X₁S(O)₀₋₂NR_(6a)R_(6b); wherein X₁ is selected from a bond, O,NR_(7a)R_(7b) and C₁₋₄alkylene; X₂ is selected from a bond andC₁₋₄alkylene; R_(6a) is selected from hydrogen, halo, C₁₋₆alkyl,C₂₋₆alkenyl, C₆₋₁₀aryl, C₁₋₁₀heteroaryl, C₃₋₈heterocycloalkyl andC₃₋₈cycloalkyl; wherein said aryl, heteroaryl, cycloalkyl andheterocycloalkyl of R_(6a) is optionally substituted with 1 to 3radicals independently selected from hydroxy, halo, C₁₋₆alkyl,halo-substituted-C₁₋₆alkyl, hydroxy-substituted-C₁₋₆alkyl,cyano-substituted-C₁₋₆alkyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆alkoxy andC₆₋₁₀aryl-C₁₋₄alkoxy; R_(6b) is selected from hydrogen and C₁₋₆alkyl;and R_(7a) and R_(7b) are independently selected from hydrogen andC₁₋₆alkyl;

R₂ and R₃ are independently selected from hydrogen, halo, hydroxy,C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl, hydroxy-substituted-C₁₋₆alkyl,C₁₋₆alkoxy, halo-substituted-C₁₋₆alkoxy, —C(O)R₂₃, and —C(O)OR₂₃;wherein R₂₃ is selected from hydrogen and C₁₋₆alkyl;

R₄ is selected from R₈ and —C(O)OR₈; wherein R₈ is selected fromC₁₋₆alkyl, C₆₋₁₀aryl, C₁₋₁₀heteroaryl, C₃₋₈cycloalkyl andC₃₋₈heterocycloalkyl; wherein said aryl, heteroaryl, cycloalkyl orheterocycloalkyl of R₈ is optionally substituted with 1 to 3 radicalsindependently selected from halo, C₁₋₆alkyl, C₃₋₁₂cycloalkyl,C₃₋₈heterocycloalkyl, halo-substituted-C₁₋₆alkyl,hydroxy-substituted-C₁₋₆alkyl, C₁₋₆alkoxy andhalo-substituted-C₁₋₆alkoxy;

R₅ is selected from hydrogen, C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl,hydroxy-substituted-C₁₋₆alkyl, C₁₋₆alkoxy andhalo-substituted-C₁₋₆alkoxy.

In a second aspect, the present invention provides a pharmaceuticalcomposition which contains a compound of Formula I or a N-oxidederivative, individual isomers and mixture of isomers thereof; or apharmaceutically acceptable salt thereof, in admixture with one or moresuitable excipients.

In a third aspect, the present invention provides a method of treating adisease in an animal in which modulation of GPR119 activity can prevent,inhibit or ameliorate the pathology and/or symptomology of the diseases,which method comprises administering to the animal a therapeuticallyeffective amount of a compound of Formula I or a N-oxide derivative,individual isomers and mixture of isomers thereof, or a pharmaceuticallyacceptable salt thereof.

In a fourth aspect, the present invention provides the use of a compoundof Formula I in the manufacture of a medicament for treating a diseasein an animal in which GPR119 activity contributes to the pathologyand/or symptomology of the disease.

In a fifth aspect, the present invention provides a process forpreparing compounds of Formula I and the N-oxide derivatives, prodrugderivatives, protected derivatives, individual isomers and mixture ofisomers thereof, and the pharmaceutically acceptable salts thereof.

DETAILED DESCRIPTION OF THE INVENTION Definitions

“Alkyl” as a group and as a structural element of other groups, forexample halo-substituted-alkyl and alkoxy, can be straight-chained,branched, cyclic or spiro. C₁₋₆alkoxy includes methoxy, ethoxy, and thelike. Halo-substituted alkyl includes trifluoromethyl, pentafluoroethyl,and the like.

“Aryl” means a monocyclic or fused bicyclic aromatic ring assemblycontaining six to ten ring carbon atoms. For example, aryl can be phenylor naphthyl, preferably phenyl. “Arylene” means a divalent radicalderived from an aryl group. “Heteroaryl” is as defined for aryl whereone or more of the ring members are a heteroatom. For example,C₁₋₁₀heteroaryl includes pyridyl, indolyl, indazolyl, quinoxalinyl,quinolinyl, benzofuranyl, benzopyranyl, benzothiopyranyl,benzo[1,3]dioxole, imidazolyl, benzo-imidazolyl, pyrimidinyl, furanyl,oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, thienyl,1H-pyridin-2-onyl, 6-oxo-1,6-dihydro-pyridin-3-yl, etc.“C₆₋₁₀arylC₀₋₄alkyl” means an aryl as described above connected via aalkylene grouping. For example, C₆₋₁₀arylC₀₋₄alkyl includes phenethyl,benzyl, etc. Heteroaryl also includes the N-oxide derivatives, forexample, pyridine N-oxide derivatives with the following structure:

“Cycloalkyl” means a saturated or partially unsaturated, monocyclic,fused bicyclic or bridged polycyclic ring assembly containing the numberof ring atoms indicated. For example, C₃₋₁₀cycloalkyl includescyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.“Heterocycloalkyl” means cycloalkyl, as defined in this application,provided that one or more of the ring carbons indicated, are replaced bya moiety selected from —O—, —N═, —NR—, —C(O)—, —S—, —S(O)— or —S(O)₂—,wherein R is hydrogen, C₁₋₄alkyl or a nitrogen protecting group. Forexample, C₃₋₈heterocycloalkyl as used in this application to describecompounds of the invention includes morpholino, pyrrolidinyl,piperazinyl, piperidinyl, piperidinylone,1,4-dioxa-8-aza-spiro[4.5]dec-8-yl, 2-oxo-pyrrolidin-1-yl,2-oxo-piperidin-1-yl, etc.

GPR119 means G protein-coupled receptor 119 (GenBank® Accession No.AAP72125) is also referred to in the literature as RUP3 and GPR116. Theterm GPR119 as used herein includes the human sequences found inGeneBank accession number AY288416, naturally-occurring allelicvariants, mammalian orthologs, and recombinant mutants thereof.

“Halogen” (or halo) preferably represents chloro or fluoro, but can alsobe bromo or iodo.

“Treat”, “treating” and “treatment” refer to a method of alleviating orabating a disease and/or its attendant symptoms.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention provides compounds, compositions and methods forthe treatment of diseases in which modulation of GPR119 activity canprevent, inhibit or ameliorate the pathology and/or symptomology of thediseases, which method comprises administering to the animal atherapeutically effective amount of a compound of Formula I.

In one embodiment, with reference to compounds of Formula I, arecompounds of Formula Ia:

in which:

Q is a divalent or trivalent radical selected from C₆₋₁₀aryl,C₁₋₁₀heteroaryl, C₃₋₈cycloalkyl and C₃₋₈heterocycloalkyl; wherein saidaryl, heteroaryl, cycloalkyl or heterocycloalkyl of Q is optionallysubstituted with up to 3 radicals independently selected from halo,C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl, C₁₋₆alkoxy,halo-substituted-C₁₋₆alkoxy, —C(O)R₂₀ and —C(O)OR₂₀; wherein R₂₀ isselected from hydrogen and C₁₋₆alkyl; and optionally connecting a carbonadjacent to W₂ through a CR₃₁ or O with a carbon of Q (indicated by thedotted line in Formula Ia) to form a 5-membered ring fused to rings Aand Q (such as the fused rings in examples V1-V5, infra); wherein R₃₁ isselected from hydrogen and C₁₋₆alkyl;

W₁ and W₂ are independently selected from CR₂₁ and N; wherein R₂₁ isselected from hydrogen, cyano, C₁₋₆alkyl and —C(O)OR₂₅; wherein R₂₅ isselected from hydrogen and C₁₋₆alkyl; ring A can have up to 2 ringcarbons substituted with a group selected from —C(O)—, —C(S)— and—C(═NOR₃₀)— and can be partially unsaturated with up to 2 double bonds;wherein R₃₀ is selected from hydrogen and C₁₋₆alkyl;

L is selected from C₁₋₆alkylene, C₂₋₆alkenylene, —(CH₂)_(n)O—,—NR₂₆CH₂)_(n)—, —OC(O)(CH₂)_(n)—, —C(O)O(CH₂)_(n)— and —O(CH₂)_(n)—;wherein R₂₆ is selected from hydrogen and C₁₋₆alkyl; wherein n isselected from 0, 1, 2, 3, 4 and 5; wherein any alkyl of L can beoptionally substituted with 1 to 3 radicals independently selected fromhalo, C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl, C₁₋₆alkoxy,halo-substituted-C₁₋₆alkoxy, —C(O)R₂₂ and —C(O)OR₂₂; wherein R₂₂ isselected from hydrogen and C₁₋₆alkyl;

t₁ and t₂ are each independently selected from 0, 1 and 2;

q is selected from 0, 1, 2, 3 and 4;

R₁ is selected from —X₁S(O)₀₋₂X₂R_(6a), —X₁S(O)₀₋₂X₂OR_(6a),—X₁S(O)₀₋₂X₂C(O)R_(6a), —X₁S(O)₀₋₂X₂C(O)OR_(6a), —X₁S(O)₀₋₂X₂OC(O)R_(6a)and —X₁S(O)₀₋₂NR_(6a)R_(6b); wherein X₁ is selected from a bond, O,NR_(7a)R_(7b) and C₁₋₄alkylene; X₂ is selected from a bond andC₁₋₄alkylene; R_(6a) is selected from hydrogen, halo, C₁₋₆alkyl,C₂₋₆alkenyl, C₆₋₁₀aryl, C₁₋₁₀heteroaryl, C₃₋₈heterocycloalkyl andC₃₋₈cycloalkyl; wherein said aryl, heteroaryl, cycloalkyl andheterocycloalkyl of R_(6a) is optionally substituted with 1 to 3radicals independently selected from hydroxy, halo, C₁₋₆alkyl,halo-substituted-C₁₋₆alkyl, hydroxy-substituted-C₁₋₆alkyl,cyano-substituted-C₁₋₆alkyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆alkoxy andC₆₋₁₀aryl-C₁₋₄alkoxy; R_(6b) is selected from hydrogen and C₁₋₆alkyl;and R_(7a) and R_(7b) are independently selected from hydrogen andC₁₋₆alkyl;

R₃ is selected from hydrogen, halo, hydroxy, C₁₋₆alkyl,halo-substituted-C₁₋₆alkyl, hydroxy-substituted-C₁₋₆alkyl, C₁₋₆alkoxy,halo-substituted-C₁₋₆alkoxy, —C(O)R₂₃, and —C(O)OR₂₃; wherein R₂₃ isselected from hydrogen and C₁₋₆alkyl;

R₄ is selected from R₈ and —C(O)OR₈; wherein R₈ is selected fromC₁₋₆alkyl, C₆₋₁₀aryl, C₁₋₁₀heteroaryl, C₃₋₈cycloalkyl andC₃₋₈heterocycloalkyl; wherein said aryl, heteroaryl, cycloalkyl orheterocycloalkyl of R₈ is optionally substituted with 1 to 3 radicalsindependently selected from halo, C₁₋₆alkyl, C₃₋₁₂cycloalkyl,C₃₋₈heterocycloalkyl, halo-substituted-C₁₋₆alkyl,hydroxy-substituted-C₁₋₆alkyl, C₁₋₆alkoxy andhalo-substituted-C₁₋₆alkoxy;

R₅ is selected from hydrogen, C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl,hydroxy-substituted-C₁₋₆alkyl, C₁₋₆alkoxy andhalo-substituted-C₁₋₆alkoxy.

In a further embodiment, Q is a divalent or trivalent radical selectedfrom phenyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl,1,2,4-oxadiazolyl, and thiazolyl; wherein said phenyl, pyridinyl,pyrazinyl, pyridazinyl, pyrimidinyl and thiazolyl of Q is optionallysubstituted with up to 3 radicals independently selected from halo,C₁₋₆alkyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆alkyl, —C(O)OR₂₀ and—C(O)R₂₀; wherein R₂₀ is selected from hydrogen and C₁₋₆alkyl; andoptionally connecting a carbon adjacent to W₂ through a CR₃₁ or O with acarbon of Q to form a 5-membered ring fused to rings A and Q; whereinR₃₁ is selected from hydrogen and C₁₋₆alkyl.

In a further embodiment, W₁ and W₂ are independently selected from CR₂₁and N; wherein R₂₁ is selected from hydrogen, cyano, C₁₋₆alkyl and—C(O)OR₂₅; wherein R₂₅ is selected from hydrogen and C₁₋₆alkyl; ring Acan have a ring carbon substituted with a group selected from —C(O)—,—C(S)— and —C(═NOR₃₀)— and can be partially unsaturated with a doublebond; wherein R₃₀ is selected from hydrogen and C₁₋₆alkyl; and L isselected from —O(CH₂)₀₋₄—, —(CH═CH)—, —OC(O)—, —NH(CH₂)₀₋₄—,—NCH₃(CH₂)₀₋₄— and —(CH₂)₁₋₄—.

In another embodiment, R₁ is selected from —X₁S(O)₀₋₂X₂R_(6a),—X₁S(O)₀₋₂X₂OR_(6a), —X₁S(O)₀₋₂X₂C(O)OR_(6a), —X₁S(O)₀₋₂X₂OC(O)R_(6a)and —X₁S(O)₀₋₂NR_(6a)R_(6b); wherein X₁ is selected from a bond and O;X₂ is selected from a bond and C₁₋₄alkylene; R_(6a) is selected fromhydrogen, halo, cyano, methyl, ethyl, propyl, isopropyl, ethenyl,pyridinyl, pyrrolidinyl, piperidinyl, morpholino, isoxazolyl,tetrazolyl, phenyl and imidazolyl; wherein said piperidinyl, pyridinyl,pyrrolidinyl, morpholino, isoxazolyl, tetrazolyl, phenyl or imidazolylof R_(6a) is optionally substituted with 1 to 3 radicals independentlyselected from hydroxy, halo, C₁₋₆alkyl and benzoxy; and R_(6b) isselected from hydrogen, methyl and ethyl.

In another embodiment, R₄ is selected from R₈ and —C(O)OR₈; wherein R₈is selected from isopropyl, cyclopropyl, t-butyl, 1,2,4-oxadiazolyl,pyrimidinyl, pyridinyl, pyridazinyl, tetrahydro-2H-pyranyl,tetrahydrofuranyl, oxetanyl, 2H-tetrazolyl and thiazolyl; wherein saidcyclopropyl, 1,2,4-oxadiazolyl, pyrimidinyl, pyridinyl, pyridazinyl,tetrahydro-2H-pyranyl, tetrahydrofuranyl, oxetanyl, 2H-tetrazolyl orthiazolyl of R₈ is optionally substituted with 1 to 3 radicalsindependently selected from halo, trifluoromethyl, isopropyl, t-butyl,methyl, ethyl and cyclopropyl optionally substituted with methyl; and R₅is selected from hydrogen and methoxy.

In another embodiment are compounds selected from: isopropyl4-((4-((4-methanesulfonylpiperazin)-1-yl)phenoxy)methyl)piperidine-1-carboxylate,isopropyl4-(2-(4-(4-(methylsulfonyl)piperazin-1-yl)phenoxy)ethyl)piperidine-1-carboxylate,isopropyl4-(3-(4-(4-(methylsulfonyl)piperazin-1-yl)phenoxy)propyl)piperidine-1-carboxylate,isopropyl4-(4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenoxy)butyl)piperidine-1-carboxylate,Isopropyl4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate,tert-Butyl4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate,Isopropyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,tert-Butyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,3-Cyclopropyl-5-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole,5-Cyclopropyl-3-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole,2-(4-(Methylsulfonyl)piperazin-1-yl)-5-((1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)methoxy)pyrazine,5-Isopropyl-3-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole,Tetrahydro-2H-pyran-4-yl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,(S)-Tetrahydrofuran-3-yl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,(R)-Tetrahydrofuran-3-yl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,2-Isopropyl-5-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)thiazole,2-((1-(2-methyl-2H-tetrazol-5-yl)piperidin-4-yl)methoxy)-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazine,Oxetan-3-yl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,Isopropyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidine-1-carboxylate,Isopropyl4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridazin-3-yloxy)methyl)piperidine-1-carboxylate,Isopropyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrimidin-2-yloxy)methyl)piperidine-1-carboxylate,(E)-isopropyl4-(2-(6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)vinyl)piperidine-1-carboxylate,Isopropyl4-(2-(6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)ethyl)piperidine-1-carboxylate,(E)-Isopropyl4-(2-(2-(4-(methylsulfonyl)piperazin-1-yl)pyrimidin-5-yl)vinyl)piperidine-1-carboxylate,5-Ethyl-2-(4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)pyrimidine,1-(Methylsulfonyl)-4-(5-((1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)methoxy)pyridin-2-yl)piperazine,1-Methylcyclopropyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,5-Ethyl-2-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)pyrimidine,2-((1-(5-Methylpyridin-2-yl)piperidin-4-yl)methoxy)-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazine,1-Methylcyclopropyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidine-1-carboxylate,5-Ethyl-2-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidin-1-yl)pyrimidine,3-Isopropyl-5-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole,3-Isopropyl-5-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole,1-Methylcyclopropyl4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate,5-Isopropyl-3-(4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole,2-((1-(5-Fluoropyridin-2-yl)piperidin-4-yl)methoxy)-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazine,3-Isopropyl-5-(4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole,tert-Butyl4-((5-(4-(methylsulfonyl)-1,4-diazepan-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,tert-Butyl4-((5-(4-(methylsulfonyl)-1,4-diazepan-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,tert-butyl4-((5-(4-(methylsulfonyl)piperidin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,1-Methylcyclopropyl4-((5-(4-(methylsulfonyl)piperidin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,tert-Butyl4-(2-(3-(4-(methylsulfonyl)piperazin-1-yl)-1,2,4-oxadiazol-5-yl)ethyl)piperidine-1-carboxylate,tert-Butyl4-(3-(3-(4-(methylsulfonyl)piperazin-1-yl)-1,2,4-oxadiazol-5-yl)propyl)piperidine-1-carboxylate,5-(3-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)propyl)-3-(4-(methylsulfonyl)piperazin-1-yl)-1,2,4-oxadiazole,Isopropyl4-(3-(3-(4-(methylsulfonyl)piperazin-1-yl)-1,2,4-oxadiazol-5-yl)propyl)piperidine-1-carboxylate,3-Isopropyl-5-(4-(2-(5-(4-(methylsulfonyl)piperazin-1-yl)thiazol-2-yl)ethyl)piperidin-1-yl)-1,2,4-oxadiazole,Isopropyl4-((4-(1-methanesulfonyl-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)methyl)piperidine-1-carboxylate,isopropyl4-(4-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)piperidine-1-carboxylate,isopropyl4-(2-(4-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)ethyl)piperidine-1-carboxylate,isopropyl4-(3-(4-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)propyl)piperidine-1-carboxylate,isopropyl4-(4-(4-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)butyl)piperidine-1-carboxylate,1-methylcyclopropyl4-((4-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)methyl)piperidine-1-carboxylate,5-isopropyl-3-(4-((4-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole,Isopropyl4-((4-(1-methanesulfonylpiperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate,isopropyl4-(4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)piperidine-1-carboxylate,isopropyl4-(2-(4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)ethyl)piperidine-1-carboxylate,isopropyl4-(3-(4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)propyl)piperidine-1-carboxylate,isopropyl4-(4-(4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)butyl)piperidine-1-carboxylate,1-Methylcyclopropyl4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate,2-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)-5-(trifluoromethyl)pyridine,5-isopropyl-3-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole,3-chloro-2-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)-5-(trifluoromethyl)pyridine,5-chloro-2-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)pyridine,3-chloro-6-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)pyridazine,5-bromo-2-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)pyrimidine,5-ethyl-2-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)pyrimidine,5-fluoro-2-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)pyridine,3-isopropyl-5-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole,3-tert-butyl-6-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)pyridazine,5-fluoro-2-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)pyrimidine,Isopropyl4-(2-(3-(1-methanesulfonyl-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)ethyl)piperidine-1-carboxylate,1-Methylcyclopropyl4-methoxy-4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,1-methylcyclopropyl4-((6-formyl-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,1-Methylcyclopropyl4-((6-chloro-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,1-Methylcyclopropyl4-((5-(4-(3-methoxy-3-oxopropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate,3-(4-(5-((1-((1-methylcyclopropoxy)carbonyl)-piperidin-4-yl)methoxy)pyrazin-2-yl)piperazin-1-ylsulfonyl)propanoicacid,3-(4-(5-((1-((1-methylcyclopropoxy)carbonyl)piperidin-4-yl)methoxy)pyrazin-2-yl)piperazin-1-ylsulfonyl)propanoicacid,3-(4-(5-((1-((1-methylcyclopropoxy)carbonyl)piperidin-4-yl)methoxy)pyrazin-2-yl)piperazin-1-ylsulfonyl)propanoicacid,3-(4-(5-((1-((1-methylcyclopropoxy)carbonyl)piperidin-4-yl)methoxy)pyrazin-2-yl)piperazin-1-ylsulfonyl)propanoicacid,3-(4-(5-((1-((1-methylcyclopropoxy)carbonyl)piperidin-4-yl)methoxy)pyrazin-2-yl)piperazin-1-ylsulfonyl)propanoicacid,3-(4-(5-((1-((1-methylcyclopropoxy)carbonyl)piperidin-4-yl)methoxy)pyrazin-2-yl)piperazin-1-ylsulfonyl)propanoicacid; 1-methylcyclopropyl4-((5-(4-(3-cyanopropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(3-(1H-tetrazol-5-yl)propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(vinylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(2-(piperidin-1-yl)ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(2-morpholinoethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(2-(dimethylamino)ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;tert-butyl4-((5-(4-(3-chloropropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;tert-butyl4-((5-(4-(3-acetoxypropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(3-aminopropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(2-ethoxyethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(3-(pyrrolidin-1-yl)propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(3-(2-methyl-1H-imidazol-1-yl)propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(3-(dimethylamino)propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(isopropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(isobutylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(sec-butylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(3-acetoxy-2,2-dimethylpropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((5-(4-(3-hydroxy-2,2-dimethylpropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-Methylcyclopropyl4-((5-(4-(2-(pyridin-3-yl)ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-Methylcyclopropyl4-((5-(4-(2-(pyridin-4-yl)ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-Methylcyclopropyl4-((5-(4-sulfamoylpiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;tert-Butyl4-((5-(4-(morpholinosulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((6-(4-(ethylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((6-(4-(ethylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((6-(4-(ethylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((6-(4-(ethylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((6-(4-(ethylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((6-(4-(ethylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate;1-Methylcyclopropyl4-((5-fluoro-6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate;tert-Butyl4-((5-(4-(methylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-Methylcyclopropyl4-((5-(4-(methylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-Methylcyclopropyl4-((5-(2-oxo-4-(propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-Methylcyclopropyl4-((5-(4-(isopropylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-Methylcyclopropyl4-((5-(4-(isopropylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((6-(2-oxo-4-(propylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-((6-(4-(isopropylsulfonyl)-2-oxopiperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate;1-(5-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)pyrazin-2-yl)-4-(methylsulfonyl)piperazin-2-one;1-(5-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)pyridin-2-yl)-4-(methylsulfonyl)piperazin-2-one;tert-Butyl4-((2,6-difluoro-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate;tert-butyl4-((2-methyl-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate;tert-butyl4-((3-methoxy-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate;tert-butyl4-((2,6-dimethyl-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate;tert-butyl4-((2,5-dimethyl-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate;tert-butyl4-((2-(methoxycarbonyl)-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate;tert-butyl4-((2-chloro-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate;tert-butyl4-((3-methyl-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate;tert-butyl4-((2,3-dimethyl-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate;tert-butyl4-((2-fluoro-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate;tert-butyl4-((4-(1-(methylsulfonyl)piperidin-4-yl)-2-(trifluoromethyl)phenoxy)methyl)piperidine-1-carboxylate;2-(4-((2,6-Difluoro-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)-5-ethylpyrimidine;1-Methylcyclopropyl4-((2,6-difluoro-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate;3-(4-(4-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)-3,5-difluorophenyl)piperidin-1-ylsulfonyl)propylacetate; 1-Methylcyclopropyl4-((4-(1-(3-acetoxypropylsulfonyl)piperidin-4-yl)-2,6-difluorophenoxy)methyl)piperidine-1-carboxylate;3-(4-(4-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)-3,5-difluorophenyl)piperidin-1-ylsulfonyl)propan-1-ol;1-Methylcyclopropyl4-((2,6-difluoro-4-(1-(3-hydroxypropylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate;Isopropyl4-((5-(1,2,3,6-tetrahydro-1-methanesulfonylpyridin-4-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate;1-Methylcyclopropyl4-((6-(1,2,3,6-tetrahydro-1-methanesulfonylpyridin-4-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate;Isopropyl4-(2-(6-(1,2,3,6-tetrahydro-1-methanesulfonylpyridin-4-yl)pyridin-3-yloxy)ethyl)piperidine-1-carboxylate;2-(4-((5-(1,2,3,6-Tetrahydro-1-methanesulfonylpyridin-4-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-5-ethylpyrimidine;2-(4-((6-(1,2,3,6-Tetrahydro-1-methanesulfonylpyridin-4-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)-5-ethylpyrimidine;2-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)-5-(1-methanesulfonylpiperidin-4-yl)pyrazine;2-(4-((6-(1-Methanesulfonylpiperidin-4-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)-5-ethylpyrimidine;3-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)-6-(1-methanesulfonylpiperidin-4-yl)pyridazine;2-(4-((5-(1-Methanesulfonylpiperidin-4-yl)pyridin-2-yloxy)methyl)piperidin-1-yl)-5-ethylpyrimidine;1-tert-Butyl4-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)piperazine-1,4-dicarboxylate;N-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methyl)-4-(1-(methylsulfonyl)piperidin-4-yl)aniline;N-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methyl)-N-methyl-4-(1-(methylsulfonyl)piperidin-4-yl)aniline;4-(4-((1-(5-fluoropyrimidin-2-yl)piperidin-4-yl)methoxy)phenyl)-1-(methylsulfonyl)piperidine-4-carboxylicacid;2-[(2-{4-[5-({1-[(1-methylcyclopropoxy)carbonyl]piperidin-4-yl}methoxy)pyrazin-2-yl]-3-oxopiperazine-1-sulfonyl}ethyl)amino]aceticacid; 1-methylcyclopropyl4-{[5-{4-[(2-carbamimidamidoethane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[5-{4-[(3-methyl-3-nitrobutane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-(1-benzylpyrrolidine-3-sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(carbamoylmethane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(1-carbamoyl-1-methylethane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(2-oxo-4-{[2-(pyrrolidin-1-yl)ethane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[2-(morpholin-4-yl)ethane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[3-(dimethylamino)propane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)ethane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[(dimethylcarbamoyl)methane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[1-(2-methylpropyl)pyrrolidine-3-sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(2-oxo-4-{[3-(1H-pyrazol-1-yl)propane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[2-oxo-4-(pyrrolidine-3-sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(2-amino-2-methylpropane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[(1-methylpyrrolidin-3-yl)methane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[2-(azetidin-1-yl)ethane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(2-oxo-4-{[2-(1H-pyrazol-1-yl)ethane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-(1-methylpyrrolidine-3-sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[1-(dimethylcarbamoyl)-1-methylethane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[2-(3,3-difluoroazetidin-1-yl)ethane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[3-(dimethylamino)-3-methylbutane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(2-{[2-(tert-butoxy)-2-oxoethyl]amino}ethane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-(azetidine-3-sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[3-(3,3-difluoroazetidin-1-yl)propane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[3-(azetidin-1-yl)propane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{2-oxo-4-[(3S)-pyrrolidine-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(3S)-1-methylpyrrolidine-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(3R)-1-methylpyrrolidine-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(3S)-pyrrolidine-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(3R)-pyrrolidine-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-(azetidine-3-sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{2-oxo-4-[(pyrrolidin-3-ylmethane)sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-(1-hydroxy-2-methylpropane-2-sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(2-hydroxyethane)sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(azetidin-3-ylmethane)sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[(1-methylpyrrolidin-2-yl)methane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{2-oxo-4-[(3R)-pyrrolidine-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-(1-methylazetidine-3-sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-(1-methylazetidine-3-sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[(1-methylazetidin-3-yl)methane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[(1-methylazetidin-3-yl)methane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-({3-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]propane}sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-({2-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]ethane}sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(azetidin-3-ylmethane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{2-oxo-4-[(pyrrolidin-2-ylmethane)sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(3-aminopropane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(2-aminoethane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(3-methanesulfonamidoazetidin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[2-(dimethylamino)ethane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(2-oxo-4-{[3-(pyrrolidin-1-yl)propane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[3-(morpholin-4-yl)propane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[(3-methyloxetan-3-yl)methane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[3-(acetyloxy)propane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(3,3,3-trifluoropropane)sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[(2E)-2-(hydroxyimino)-4-methanesulfonylpiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(3-chloropropane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(3-hydroxypropane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-({[1-(dimethylamino)cyclopropyl]methane}sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-({[1-(dimethylamino)cyclopropyl]methane}sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4-[(3-hydroxy-3-methylbutane)sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{2-oxo-4-[(3R)-oxolane-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{2-oxo-4-[(3S)-oxolane-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[3-(acetyloxy)-3-methylbutane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-[({6-[4-({[1-(azetidin-1-yl)cyclopropyl]methane}sulfonyl)piperazin-1-yl]pyridin-3-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-({[1-(benzylamino)cyclopropyl]methane}sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-({[1-(azetidin-1-yl)cyclopropyl]methane}sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[(1-hydroxycyclopropyl)methane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[2-(1-hydroxycyclopropyl)ethane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-({2-[1-(acetyloxy)cyclopropyl]ethane}sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-({[1-(benzyloxy)cyclopropyl]methane}sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[(1-aminocyclopropyl)methane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[2-(1-hydroxycyclopropyl)ethane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-{2,6-difluoro-4-[3-(N-methylmethanesulfonamido)azetidin-1-yl]phenoxymethyl}piperidine-1-carboxylate;1-methylcyclopropyl4-[2,6-difluoro-4-(3-methanesulfonamidoazetidin-1-yl)phenoxymethyl]piperidine-1-carboxylate;1-methylcyclopropyl4-{2,6-difluoro-4-[3-(2-methylpropane-1-sulfonamido)azetidin-1-yl]phenoxymethyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{4-[3-(N,2-dimethylpropane-1-sulfonamido)azetidin-1-yl]-2,6-difluorophenoxymethyl}piperidine-1-carboxylate;5-ethyl-2-{4-[({2-methanesulfonyl-1H,2H,3H,4H-pyrazino[1,2-a]indol-8-yl}oxy)methyl]piperidin-1-yl}pyrimidine;11-{[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]oxy}-5-methanesulfonyl-8-oxa-5-azatricyclo[17.4.0.0{2,7}]-trideca-1(13),2(7),9,11-tetraene;11-{[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]methoxy}-5-methanesulfonyl-8-oxa-5-azatricyclo[7.4.0.0{2,7}]trideca-1(13),2(7),9,11-tetraene;tert-butyl4-[({2-methanesulfonyl-1H,2H,3H,4H-pyrazino[1,2-a]indol-8-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-[({2-methanesulfonyl-1H,2H,3H,4H-pyrazino[1,2-a]indol-8-yl}oxy)methyl]piperidine-1-carboxylate;propan-2-yl4-{3-[3-(1-methanesulfonylpiperidin-4-yl)phenoxy]propyl}piperidine-1-carboxylate;propan-2-yl4-{2-[3-(1-methanesulfonylpiperidin-4-yl)phenoxy]ethyl}piperidine-1-carboxylate;propan-2-yl4-[3-(1-methanesulfonylpiperidin-4-yl)phenoxymethyl]piperidine-1-carboxylate;propan-2-yl4-{3-[3-(1-methanesulfonyl-1,2,3,6-tetrahydropyridin-4-yl)phenoxy]propyl}piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-methanesulfonyl-2-sulfanylidenepiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl(3S,4S)-3-hydroxy-4-{[(6-{4-[(2-methylpropane)sulfonyl]piperazin-1-yl}pyridin-3-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl(3R,4S)-3-hydroxy-4-{[(6-{4-[(2-methylpropane)sulfonyl]piperazin-1-yl}pyridin-3-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-hydroxy-4-{[(6-{4-[(2-methylpropane)sulfonyl]piperazin-1-yl}pyridin-3-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[(6-{4-[(2-hydroxy-2-methylpropane)sulfonyl]piperazin-1-yl}pyridin-3-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl(3S,4R)-3-methoxy-4-{[(6-{4-[(2-methylpropane)sulfonyl]piperazin-1-yl}pyridin-3-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[3-(3,3-difluoroazetidin-1-yl)propane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[3-(azetidin-1-yl)propane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-{[(5-{4[(3-methoxypropane)sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-{[(6-{4-[3-chloropropane)sulfonyl]-2-oxopiperazin-1-yl}pyridin-3-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[2-(azetidin-1-yl)ethane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-({[6-(4-{[3-(azetidin-1-yl)propane]sulfonyl}piperazin-1-yl)pyridin-3-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-[({5-[4-(pyrrolidine-3-sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate;1-methylcyclopropyl4-({[5-(4-{[2-(3,3-difluoroazetidin-1-yl)ethane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-{[(6-{4-[(3-hydroxypropane)sulfonyl]-2-oxopiperazin-1-yl}pyridin-3-yl)oxy]methyl}piperidine-1-carboxylate;1-methylcyclopropyl4-({[6-(4-{[3-(azetidin-1-yl)propane]sulfonyl}-2-oxopiperazin-1-yl)pyridin-3-yl]oxy}methyl)piperidine-1-carboxylate;1-methylcyclopropyl4-[2,6-difluoro-4-(4-methanesulfonyl-2-oxopiperazin-1-yl)phenoxymethyl]piperidine-1-carboxylate;and 1-methylcyclopropyl4-[({5-[4-(oxetane-3-sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate.

Further compounds of the invention are detailed in the Examples andTables, infra.

The present invention includes all pharmaceutically acceptableisotopically-labeled compounds of the invention, i.e. compounds offormula (I), wherein one or more atoms are replaced by atoms having thesame atomic number, but an atomic mass or mass number different from theatomic mass or mass number usually found in nature. Examples of isotopessuitable for inclusion in the compounds of the invention comprisesisotopes of hydrogen, such as ²H and ³H, carbon, such as ¹¹C, ¹³C and¹⁴C, chlorine, such as ³⁶Cl, fluorine, such as ¹⁸F, iodine, such as ¹²³Iand ¹²⁵I, nitrogen, such as ¹³N and ¹⁵N, oxygen, such as ¹⁵O, ¹⁷O and¹⁸O, phosphorus, such as ³²P, and sulphur, such as ³⁵S.

Certain isotopically-labelled compounds of formula (I), for example,those incorporating a radioactive isotope, are useful in drug and/orsubstrate tissue distribution studies. The radioactive isotopes tritium,i.e. ³H, and carbon-14, i.e. ¹⁴C, are particularly useful for thispurpose in view of their ease of incorporation and ready means ofdetection. Substitution with heavier isotopes such as deuterium, i.e.²H, may afford certain therapeutic advantages resulting from greatermetabolic stability, for example, increased in vivo half-life or reduceddosage requirements, and hence may be preferred in some circumstances.

Substitution with positron emitting isotopes, such as ¹¹C, ¹⁸F, ¹⁵O and¹³N, can be useful in Positron Emission Topography (PET) studies forexamining substrate receptor occupancy.

Isotopically-labeled compounds of formula (I) can generally be preparedby conventional techniques known to those skilled in the art or byprocesses analogous to those described in the accompanying Examples andPreparations using an appropriate isotopically-labeled reagents in placeof the non-labeled reagent previously employed.

Pharmacology and Utility

Compounds of the invention modulate the activity of GPR119 and, as such,are useful for treating diseases or disorders in which the activity ofGPR119 contributes to the pathology and/or symptomology of the disease.This invention further provides compounds of this invention for use inthe preparation of medicaments for the treatment of diseases ordisorders in which GPR119 activity contributes to the pathology and/orsymptomology of the disease.

The resultant pathologies of Type II diabetes are impaired insulinsignaling at its target tissues and failure of the insulin-producingcells of the pancreas to secrete an appropriate degree of insulin inresponse to a hyperglycemic signal. Current therapies to treat thelatter include inhibitors of the β-cell ATP-sensitive potassium channelto trigger the release of endogenous insulin stores, or administrationof exogenous insulin. Neither of these achieves accurate normalizationof blood glucose levels and both carry the risk of inducinghypoglycemia. For these reasons, there has been intense interest in thedevelopment of pharmaceuticals that function in a glucose-dependentaction, i.e. potentiators of glucose signaling. Physiological signalingsystems which function in this manner are well-characterized and includethe gut peptides GLP-1, GIP and PACAP. These hormones act via theircognate G-protein coupled receptor to stimulate the production of cAMPin pancreatic β-cells. The increased cAMP does not appear to result instimulation of insulin release during the fasting or pre-prandial state.However, a series of biochemical targets of cAMP signaling, includingthe ATP-sensitive potassium channel, voltage-sensitive potassiumchannels and the exocytotic machinery, are modified in such a way thatthe insulin secretory response to a postprandial glucose stimulus ismarkedly enhanced. Accordingly, agonists of novel, similarlyfunctioning, β-cell GPCRs, including GPR119, would also stimulate therelease of endogenous insulin and consequently promote normoglycemia inType II diabetes. It is also established that increased cAMP, forexample as a result of GLP-1 stimulation, promotes β-cell proliferation,inhibits β-cell death and thus improves islet mass. This positive effecton β-cell mass is expected to be beneficial in both Type II diabetes,where insufficient insulin is produced, and Type I diabetes, whereβ-cells are destroyed by an inappropriate autoimmune response.

Some β-cell GPCRs, including GPR119, are also present in thehypothalamus where they modulate hunger, satiety, decrease food intake,controlling or decreasing weight and energy expenditure. Hence, giventheir function within the hypothalamic circuitry, agonists or inverseagonists of these receptors mitigate hunger, promote satiety andtherefore modulate weight.

It is also well-established that metabolic diseases exert a negativeinfluence on other physiological systems. Thus, there is often thecodevelopment of multiple disease states (e.g. type I diabetes, type IIdiabetes, inadequate glucose tolerance, insulin resistance,hyperglycemia, hyperlipidemia, hypertriglyceridemia,hypercholesterolemia, dyslipidemia, obesity or cardiovascular disease in“Syndrome X”) or secondary diseases which clearly occur secondary todiabetes (e.g. kidney disease, peripheral neuropathy). Thus, it isexpected that effective treatment of the diabetic condition will in turnbe of benefit to such interconnected disease states.

In an embodiment of the invention is a method for treatment of ametabolic disease and/or a metabolic-related disorder in an individualcomprising administering to the individual in need of such treatment atherapeutically effective amount of a compound of the invention or apharmaceutical composition thereof. The metabolic diseases andmetabolic-related disorders are selected from, but not limited to,hyperlipidemia, type 1 diabetes, type 2 diabetes mellitus, idiopathictype 1 diabetes (Type Ib), latent autoimmune diabetes in adults (LADA),early-onset type 2 diabetes (EOD), youth-onset atypical diabetes (YOAD),maturity onset diabetes of the young (MODY), malnutrition-relateddiabetes, gestational diabetes, coronary heart disease, ischemic stroke,restenosis after angioplasty, peripheral vascular disease, intermittentclaudication, myocardial infarction (e.g. necrosis and apoptosis),dyslipidemia, post-prandial lipemia, conditions of impaired glucosetolerance (IGT), conditions of impaired fasting plasma glucose,metabolic acidosis, ketosis, arthritis, obesity, osteoporosis,hypertension, congestive heart failure, left ventricular hypertrophy,peripheral arterial disease, diabetic retinopathy, macular degeneration,cataract, diabetic nephropathy, glomerulosclerosis, chronic renalfailure, diabetic neuropathy, metabolic syndrome, syndrome X,premenstrual syndrome, coronary heart disease, angina pectoris,thrombosis, atherosclerosis, myocardial infarction, transient ischemicattacks, stroke, vascular restenosis, hyperglycemia, hyperinsulinemia,hyperlipidemia, hypertrygliceridemia, insulin resistance, impairedglucose metabolism, conditions of impaired glucose tolerance, conditionsof impaired fasting plasma glucose, obesity, erectile dysfunction, skinand connective tissue disorders, foot ulcerations and ulcerativecolitis, endothelial dysfunction and impaired vascular compliance.

In an embodiment of the invention are therapeutic benefits of GPR119activity modulators derived from increasing levels of GIP and PPY. Forexample, neuroprotection, learning and memory, seizures and peripheralneuropathy.

GLP-1 and GLP-1 receptor agonists have been shown to be effective fortreatment of neurodegenerative diseases and other neurologicaldisorders. GLP-1 and exendin-4 have been shown to stimulate neuriteoutgrowth and enhance cell survival after growth factor withdrawal inPC12 cells. In a rodent model of neurodegeneration, GLP-1 and exendin-4restore cholinergic marker activity in the basal forebrain. Centralinfusion of GLP-1 and exendin-4 also reduce the levels of amyloid-βpeptide in mice and decrease amyloid precursor protein amount incultured PC12 cells. GLP-1 receptor agonists have been shown to enhancelearning in rats and the GLP-1 receptor knockout mice show deficienciesin learning behavior. The knockout mice also exhibit increasedsusceptibility to kainate-induced seizures which can be prevented byadministration of GLP-1 receptor agonists. GLP-1 and exendin-4 has alsobeen shown to be effective in treating pyridoxine-induced peripheralnerve degeneration, an experimental model of peripheral sensoryneuropathy.

Glucose-dependent insulinotropic polypeptide (GIP) has also been shownto have effects on proliferation of hippocampal progenitor cells and inenhancing sensorimotor coordination and memory recognition.

In an embodiment of the invention are therapeutic benefits of GPR119activity modulators. For example, GLP-2 and short bowel syndrome (SBS).Several studies in animals and from clinical trials have shown thatGLP-2 is a trophic hormone that plays an important role in intestinaladaptation. Its role in regulation of cell proliferation, apoptosis, andnutrient absorption has been well documented. Short bowel syndrome ischaracterized by malabsorption of nutrients, water and vitamins as aresult of disease or surgical removal of parts of the small intestine(e.g. Crohn's disease). Therapies that improve intestinal adaptation arethought to be beneficial in treatment of this disease. In fact, phase IIstudies in SBS patients have shown that teduglutide, a GLP-2 analog,modestly increased fluid and nutrient absorption.

In an embodiment of the invention are therapeutic benefits of GPR119activity modulators derived from increasing levels of GIP and PPY. Forexample, GLP-1, GIP and osteoporosis. GLP-1 has been shown to increasecalcitonin and calcitonin related gene peptide (CGRP) secretion andexpression in a murine C-cell line (CA-77). Calcitonin inhibits boneresorption by osteoclasts and promotes mineralization of skeletal bone.Osteoporosis is a disease that is characterized by reduced bone mineraldensity and thus GLP-1 induced increase in calcitonin might betherapeutically beneficial.

GIP has been reported to be involved in upregulation of markers of newbone formation in osteoblasts including collagen type I mRNA and inincreasing bone mineral density. Like GLP-1, GIP has also been shown toinhibit bone resorption.

In an embodiment of the invention are therapeutic benefits of GPR119activity modulators derived from increasing levels of GIP and PPY. Forexample, PPY and gastric emptying. GPR119 located on the pancreaticpolypeptide (PP) cells of the islets has been implicated in thesecretion of PPY. PPY has been reported to have profound effects onvarious physiological processes including modulation of gastric emptyingand gastrointestinal motility. These effects slow down the digestiveprocess and nutrient uptake and thereby prevent the postprandialelevation of blood glucose. PPY can suppress food intake by changing theexpression of hypothalamic feeding-regulatory peptides.PP-overexpressing mice exhibited the thin phenotype with decreased foodintake and gastric emptying rate.

In accordance with the foregoing, the present invention further providesa method for preventing or ameliorating the symptamology of any of thediseases or disorders described above in a subject in need thereof,which method comprises administering to said subject a therapeuticallyeffective amount (See, “Administration and Pharmaceutical Compositions”,infra) of a compound of Formula I or a pharmaceutically acceptable saltthereof. For any of the above uses, the required dosage will varydepending on the mode of administration, the particular condition to betreated and the effect desired.

Administration and Pharmaceutical Compositions

In general, compounds of the invention will be administered intherapeutically effective amounts via any of the usual and acceptablemodes known in the art, either singly or in combination with one or moretherapeutic agents. A therapeutically effective amount can vary widelydepending on the severity of the disease, the age and relative health ofthe subject, the potency of the compound used and other factors. Ingeneral, satisfactory results are indicated to be obtained systemicallyat daily dosages of from about 0.03 to 2.5 mg/kg per body weight. Anindicated daily dosage in the larger mammal, e.g. humans, is in therange from about 0.5 mg to about 100 mg, conveniently administered, e.g.in divided doses up to four times a day or in retard form. Suitable unitdosage forms for oral administration comprise from ca. 1 to 50 mg activeingredient.

Compounds of the invention can be administered as pharmaceuticalcompositions by any conventional route, in particular enterally, e.g.,orally, e.g., in the form of tablets or capsules, or parenterally, e.g.,in the form of injectable solutions or suspensions, topically, e.g., inthe form of lotions, gels, ointments or creams, or in a nasal orsuppository form. Pharmaceutical compositions comprising a compound ofthe present invention in free form or in a pharmaceutically acceptablesalt form in association with at least one pharmaceutically acceptablecarrier or diluent can be manufactured in a conventional manner bymixing, granulating or coating methods. For example, oral compositionscan be tablets or gelatin capsules comprising the active ingredienttogether with a) diluents, e.g., lactose, dextrose, sucrose, mannitol,sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum,stearic acid, its magnesium or calcium salt and/or polyethyleneglycol;for tablets also c) binders, e.g., magnesium aluminum silicate, starchpaste, gelatin, tragacanth, methylcellulose, sodiumcarboxymethylcellulose and or polyvinylpyrollidone; if desired d)disintegrants, e.g., starches, agar, alginic acid or its sodium salt, oreffervescent mixtures; and/or e) absorbents, colorants, flavors andsweeteners. Injectable compositions can be aqueous isotonic solutions orsuspensions, and suppositories can be prepared from fatty emulsions orsuspensions. The compositions can be sterilized and/or containadjuvants, such as preserving, stabilizing, wetting or emulsifyingagents, solution promoters, salts for regulating the osmotic pressureand/or buffers. In addition, they can also contain other therapeuticallyvaluable substances. Suitable formulations for transdermal applicationsinclude an effective amount of a compound of the present invention witha carrier. A carrier can include absorbable pharmacologically acceptablesolvents to assist passage through the skin of the host. For example,transdermal devices are in the form of a bandage comprising a backingmember, a reservoir containing the compound optionally with carriers,optionally a rate controlling barrier to deliver the compound to theskin of the host at a controlled and predetermined rate over a prolongedperiod of time, and means to secure the device to the skin. Matrixtransdermal formulations can also be used. Suitable formulations fortopical application, e.g., to the skin and eyes, are preferably aqueoussolutions, ointments, creams or gels well-known in the art. Such cancontain solubilizers, stabilizers, tonicity enhancing agents, buffersand preservatives.

Compounds of the invention can be administered in therapeuticallyeffective amounts in combination with one or more therapeutic agents(pharmaceutical combinations).

For example, synergistic effects can occur with other anti-obesityagents, anorectic agents, appetite suppressant and related agents. Dietand/or exercise can also have synergistic effects. Anti-obesity agentsinclude, but are not limited to, apolipoprotein-B secretion/microsomaltriglyceride transfer protein (apo-B/MTP) inhibitors, MCR-4 agonists,cholescystokinin-A (CCK-A) agonists, serotonin and norepinephrinereuptake inhibitors (for example, sibutramine), sympathomimetic agents,β3 adrenergic receptor agonists, dopamine agonists (for example,bromocriptine), melanocyte-stimulating hormone receptor analogs,cannabinoid 1 receptor antagonists [for example, compounds described inWO2006/047516), melanin concentrating hormone antagonists, leptons (theOB protein), leptin analogues, leptin receptor agonists, galaninantagonists, lipase inhibitors (such as tetrahydrolipstatin, i.e.,Orlistat), anorectic agents (such as a bombesin agonist), Neuropeptide-Yantagonists, thyromimetic agents, dehydroepiandrosterone or an analoguethereof, glucocorticoid receptor agonists or antagonists, orexinreceptor antagonists, urocortin binding protein antagonists,glucagon-like peptide-1 receptor agonists, ciliary neutrotrophic factors(such as Axokine™) human agouti-related proteins (AGRP), ghrelinreceptor antagonists, histamine 3 receptor antagonists or reverseagonists, neuromedin U receptor agonists, noradrenergic anorectic agents(for example, phentermine, mazindol and the like) and appetitesuppressants (for example, bupropion).

Where compounds of the invention are administered in conjunction withother therapies, dosages of the co-administered compounds will of coursevary depending on the type of co-drug employed, on the specific drugemployed, on the condition being treated and so forthours.

A combined preparation or pharmaceutical composition can comprise acompound of the invention as defined above or a pharmaceuticalacceptable salt thereof and at least one active ingredient selectedfrom:

a) anti-diabetic agents such as insulin, insulin derivatives andmimetics; insulin secretagogues such as the sulfonylureas, e.g.,Glipizide, glyburide and Amaryl; insulinotropic sulfonylurea receptorligands such as meglitinides, e.g., nateglinide and repaglinide; insulinsensitizer such as protein tyrosine phosphatase-1B (PTP-1B) inhibitorssuch as PTP-112; GSK3 (glycogen synthase kinase-3) inhibitors such asSB-517955, SB-4195052, SB-216763, N,N-57-05441 and N,N-57-05445; RXRligands such as GW-0791 and AGN-194204; sodium-dependent glucoseco-transporter inhibitors such as T-1095; glycogen phosphorylase Ainhibitors such as BAY R3401; biguanides such as metformin;alpha-glucosidase inhibitors such as acarbose; GLP-1 (glucagon likepeptide-1), GLP-1 analogs such as Exendin-4 and GLP-1 mimetics; DPPIV(dipeptidyl peptidase IV) inhibitors such as DPP728, LAF237(vildagliptin—Example 1 of WO 00/34241), MK-0431, saxagliptin, GSK23A;an AGE breaker; a thiazolidone derivative (glitazone) such aspioglitazone, rosiglitazone, or(R)-1-{4-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy]-benzenesulfonyl}-2,3-dihydro-1H-indole-2-carboxylicacid described in the patent application WO 03/043985, as compound 19 ofExample 4, a non-glitazone type PPAR gamma agonist e.g. GI-262570;Diacylglycerol acetyltransferase (DGAT) inhibitors such as thosedisclosed in WO 2005044250, WO 2005013907, WO 2004094618 and WO2004047755;

b) hypolipidemic agents such as 3-hydroxy-3-methyl-glutaryl coenzyme A(HMG-CoA) reductase inhibitors, e.g., lovastatin and related compoundssuch as those disclosed in U.S. Pat. No. 4,231,938, pitavastatin,simvastatin and related compounds such as those disclosed in U.S. Pat.Nos. 4,448,784 and 4,450,171, pravastatin and related compounds such asthose disclosed in U.S. Pat. No. 4,346,227, cerivastatin, mevastatin andrelated compounds such as those disclosed in U.S. Pat. No. 3,983,140,velostatin, fluvastatin, dalvastatin, atorvastatin, rosuvastatin andrelated statin compounds disclosed in U.S. Pat. No. 5,753,675,rivastatin, pyrazole analogs of mevalonolactone derivatives as disclosedin U.S. Pat. No. 4,613,610, indene analogs of mevalonolactonederivatives as disclosed in PCT application WO 86/03488,6-[2-(substituted-pyrrol-1-yl)-alkyl)pyran-2-ones and derivativesthereof as disclosed in U.S. Pat. No. 4,647,576, Searle's SC-45355 (a3-substituted pentanedioic acid derivative) dichloroacetate, imidazoleanalogs of mevalonolactone as disclosed in PCT application WO 86/07054,3-carboxy-2-hydroxy-propane-phosphonic acid derivatives as disclosed inFrench Patent No. 2,596,393, 2,3-disubstituted pyrrole, furan andthiophene derivatives as disclosed in European Patent Application No.0221025, naphthyl analogs of mevalonolactone as disclosed in U.S. Pat.No. 4,686,237, octahydronaphthalenes such as disclosed in U.S. Pat. No.4,499,289, keto analogs of mevinolin (lovastatin) as disclosed inEuropean Patent Application No. 0,142,146 A2, and quinoline and pyridinederivatives disclosed in U.S. Pat. Nos. 5,506,219 and 5,691,322. Inaddition, phosphinic acid compounds useful in inhibiting HMG CoAreductase suitable for use herein are disclosed in GB 2205837; squalenesynthase inhibitors; FXR (farnesoid X receptor) and LXR (liver Xreceptor) ligands; cholestyramine; fibrates; nicotinic acid and aspirin;

c) an anti-obesity agent or appetite regulating agent such as a CB1activity modulator, melanocortin receptor (MC4R) agonists,melanin-concentrating hormone receptor (MCHR) antagonists, growthhormone secretagogue receptor (GHSR) antagonists, galanin receptormodulators, orexin antagonists, CCK agonists, GLP-1 agonists, and otherPre-proglucagon-derived peptides; NPY1 or NPY5 antagonist, NPY2 and NPY4modulators, corticotropin releasing factor agonists, histaminereceptor-3 (H3) modulators, aP2 inhibitors, PPAR gamma modulators, PPARdelta modulators, acetyl-CoA carboxylase (ACC) inihibitors, II-β-HSD-1inhibitors, adinopectin receptor modulators; beta 3 adrenergic agonists,such as AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer)or other known beta 3 agonists as disclosed in U.S. Pat. Nos. 5,541,204,5,770,615, 5, 491,134, 5,776,983 and 5,488,064, a thyroid receptor betamodulator, such as a thyroid receptor ligand as disclosed in WO 97/21993(U. Cal SF), WO 99/00353 (KaroBio) and GB98/284425 (KaroBio), a SCD-1inhibitor as disclosed in WO2005011655, a lipase inhibitor, such asorlistat or ATL-962 (Alizyme), serotonin receptor agonists, (e.g.,BVT-933 (Biovitrum)), monoamine reuptake inhibitors or releasing agents,such as fenfluramine, dexfenfluramine, fluvoxamine, fluoxetine,paroxetine, sertraline, chlorphentermine, cloforex, clortermine,picilorex, sibutramine, dexamphetamine, phentermine, phenylpropanolamineor mazindol, anorectic agents such as topiramate (Johnson & Johnson),CNTF (ciliary neurotrophic factor)/Axokine® (Regeneron), BDNF(brain-derived neurotrophic factor), leptin and leptin receptormodulators, phentermine, leptin, bromocriptine, dexamphetamine,amphetamine, fenfluramine, dexfenfluramine, sibutramine, orlistat,dexfenfluramine, mazindol, phentermine, phendimetrazine, diethylpropion,fluoxetine, bupropion, topiramate, diethylpropion, benzphetamine,phenylpropanolamine or ecopipam, ephedrine, pseudoephedrine;

d) anti-hypertensive agents such as loop diuretics such as ethacrynicacid, furosemide and torsemide; diuretics such as thiazide derivatives,chlorithiazide, hydrochlorothiazide, amiloride; angiotensin convertingenzyme (ACE) inhibitors such as benazepril, captopril, enalapril,fosinopril, lisinopril, moexipril, perinodopril, quinapril, ramipril andtrandolapril; inhibitors of the Na-K-ATPase membrane pump such asdigoxin; neutralendopeptidase (NEP) inhibitors e.g. thiorphan,terteo-thiorphan, SQ29072; ECE inhibitors e.g. SLV306; ACE/NEPinhibitors such as omapatrilat, sampatrilat and fasidotril; angiotensinII antagonists such as candesartan, eprosartan, irbesartan, losartan,telmisartan and valsartan, in particular valsartan; renin inhibitorssuch as aliskiren, terlakiren, ditekiren, RO 66-1132, RO-66-1168;beta-adrenergic receptor blockers such as acebutolol, atenolol,betaxolol, bisoprolol, metoprolol, nadolol, propranolol, sotalol andtimolol; inotropic agents such as digoxin, dobutamine and milrinone;calcium channel blockers such as amlodipine, bepridil, diltiazem,felodipine, nicardipine, nimodipine, nifedipine, nisoldipine andverapamil; aldosterone receptor antagonists; aldosterone synthaseinhibitors; and dual ET/AII antagonist such as those disclosed in WO00/01389.

e) a HDL increasing compound;

f) Cholesterol absorption modulator such as Zetia® and KT6-971;

g) Apo-A1 analogues and mimetics;

h) thrombin inhibitors such as Ximelagatran;

i) aldosterone inhibitors such as anastrazole, fadrazole, eplerenone;

j) Inhibitors of platelet aggregation such as aspirin, clopidogrelbisulfate;

k) estrogen, testosterone, a selective estrogen receptor modulator, aselective androgen receptor modulator;

l) a chemotherapeutic agent such as aromatase inhibitors e.g. femara,anti-estrogens, topoisomerase I inhibitors, topoisomerase II inhibitors,microtubule active agents, alkylating agents, antineoplasticantimetabolites, platin compounds, compounds decreasing the proteinkinase activity such as a PDGF receptor tyrosine kinase inhibitorpreferably Imatinib({N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine})described in the European patent application EP-A-0 564 409 as example21 or4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamidedescribed in the patent application WO 04/005281 as example 92; and

m) an agent interacting with a 5-HT₃ receptor and/or an agentinteracting with 5-HT₄ receptor such as tegaserod described in the U.S.Pat. No. 5,510,353 as example 13, tegaserod hydrogen maleate, cisapride,cilansetron;

n) an agent for treating tobacco abuse, e.g., nicotine receptor partialagonists, bupropion hypochloride (also known under the tradename Zyban®)and nicotine replacement therapies;

o) an agent for treating erectile dysfunction, e.g., dopaminergicagents, such as apomorphine), ADD/ADHD agents (e.g., Ritalin®,Strattera®, Concerta® and Adderall®);

p) an agent for treating alcoholism, such as opioid antagonists (e.g.,naltrexone (also known under the tradename ReVia®) and nalmefene),disulfuram (also known under the tradename Antabuse®), and acamprosate(also known under the tradename Campral®)). In addition, agents forreducing alcohol withdrawal symptoms may also be co-administered, suchas benzodiazepines, beta-blockers, clonidine, carbamazepine, pregabalin,and gabapentin (Neurontin®);

q) other agents that are useful including anti-inflammatory agents(e.g., COX-2 inhibitors); antidepressants (e.g., fluoxetinehydrochloride (Prozac®)); cognitive improvement agents (e.g., donepezilhydrochloride (Aircept®) and other acetylcholinesterase inhibitors);neuroprotective agents (e.g., memantine); antipsychotic medications(e.g., ziprasidone (Geodon®), risperidone (Risperdal®), and olanzapine(Zyprexa®));

or, in each case a pharmaceutically acceptable salt thereof; andoptionally a pharmaceutically acceptable carrier.

The invention also provides for a pharmaceutical combinations, e.g. akit, comprising a) a first agent which is a compound of the invention asdisclosed herein, in free form or in pharmaceutically acceptable saltform, and b) at least one co-agent. The kit can comprise instructionsfor its administration.

The terms “co-administration” or “combined administration” or the likeas utilized herein are meant to encompass administration of the selectedtherapeutic agents to a single patient, and are intended to includetreatment regimens in which the agents are not necessarily administeredby the same route of administration or at the same time.

The term “pharmaceutical combination” as used herein means a productthat results from the mixing or combining of more than one activeingredient and includes both fixed and non-fixed combinations of theactive ingredients. The term “fixed combination” means that the activeingredients, e.g. a compound of Formula I and a co-agent, are bothadministered to a patient simultaneously in the form of a single entityor dosage. The term “non-fixed combination” means that the activeingredients, e.g. a compound of Formula I and a co-agent, are bothadministered to a patient as separate entities either simultaneously,concurrently or sequentially with no specific time limits, wherein suchadministration provides therapeutically effective levels of the 2compounds in the body of the patient. The latter also applies tococktail therapy, e.g. the administration of 3 or more activeingredients.

Processes for Making Compounds of the Invention

The present invention also includes processes for the preparation ofcompounds of the invention. In the reactions described, it can benecessary to protect reactive functional groups, for example hydroxy,amino, imino, thio or carboxy groups, where these are desired in thefinal product, to avoid their unwanted participation in the reactions.Conventional protecting groups can be used in accordance with standardpractice, for example, see T. W. Greene and P. G. M. Wuts in “ProtectiveGroups in Organic Chemistry”, John Wiley and Sons, 1991.

In the following schemes, several methods of preparing the compounds ofthe present invention are illustrative. One of skill in the art willappreciate that these methods are representative, and in no wayinclusive of all methods for preparing the compounds of the presentinvention. The radicals in the schemes are as described in Formula I.

A compound of Formula Ia, where W₂ is nitrogen, can be prepared as inreaction scheme I by reacting a compound of formula 3 (where X_(a)refers to a chloride, bromide, iodide, triflate, nonaflate, or the like)with a compound of the formula 2 (where X_(b) refers to a leaving groupsuch as an aryl- or alkylsulfonate ester, halide, epoxide where R₅ isthe oxygen of the epoxide, or other appropriate group familiar to oneskilled in the art) in a suitable solvent such as N,N-dimethylformamide,tetrahydrofuran and the like in the presence of a suitable base such asCs₂CO₃, NaH or the like at an elevated temperature of up to about 80° C.to generate an intermediate of the formula 4. A compound of the formula5 (where C═X can be a C═O or CH₂) can be coupled with a compound of theformula 4 using the Pd or Cu methodology known in the art (for example,Shafir, A, Buchwald, S. F.; J. Am. Chem. Soc. 2006, 128, 8742 andreferences cited therein and Hartwig, J. F. Handbook of OrganopalladiumChemistry for Organic Synthesis, Negishi, E., Ed., Wiley-Interscience:Weinheim, 2002). In this scheme, it is understood that the groups may beprotected versions of the radicals defined in the Summary of theInvention which may be deprotected and manipulated to a final compoundof the invention after completion of this scheme or in the middle of thescheme.

A compound of the Formula Ib, wherein W₂ is N and L can be —CH═CH— or—CH₂—CH₂—, can be prepared as in reaction scheme II. A compound of theformula 5 can be reacted with a compound of the formula 6 (where X_(c)and X_(d) both independently represent leaving groups such as F, Cl, Br,OTf, etc. with X_(c) being the more reactive group) using either thetransition metal catalysis mentioned in scheme 1 or using astoichiometric base such as K₂CO₃, triethylamine and the like in asuitable solvent such as N,N-dimethylformamide and the like at anelevated temperature to generate an intermediate of the formula 7.Intermediate 7 can then be reacted with an olefin of the formula 8 usingheck reaction conditions (for example, Littke, A. F.; Fu, G. C, J. Am.Chem. Soc. 2001, 123, 6989) to generate compounds where L is —(CH═CH)—which can subsequently be reduced using hydrogen and a catalytic amountof a transition metal such as Pd/C and the like to compounds where L is—(CH₂)₂—. In this scheme, it is understood that the groups can beprotected versions of the radicals defined in the Summary of theInvention which can be deprotected and manipulated to the final compoundafter completion of this scheme or in the middle of the scheme.

A compound of the Formula Ic, in which Q is a heteroaryl group such as1,2,4-oxadiazolyl (as shown) and W₂ is N, can be prepared as in reactionscheme III by reacting a compound of the formula 5 with cyanogen bromidein a suitable solvent system such as aqueous Na₂CO₃ and dichloromethaneand the to generate a compound of the formula 9. This intermediate canthen be reacted with hydroxylamine in an appropriate solvent such asethanol and the like at an elevated temperature such as 60° C. tofurnish a compound of the formula 10. Intermediate 10 can then bereacted with a compound of the formula 11 (where AE stands for an acidequivalent such as a carboxylic acid, alkyl ester or activated estersuch as an NHS ester and the like) using any of the protocols known inthe literature (such as Science of Synthesis 2004, 13, 127, TetrahedronLett. 2006, 47, 3629 and J. Med. Chem. 2004, 47, 5821) to afford thedesired compounds of the formula Ic. In this scheme, it is understoodthat the groups designated can be protected versions of the radicalsdefined in the Summary of the Invention which can be deprotected andmanipulated to the final compound after completion of this scheme or inthe middle of the scheme.

A compound of the Formula Id can be prepared as in reaction scheme IV byreacting a compound of the formula 9 with a compound of the formula 12in a solvent such as tetrahydrofuran or the like in the presence of aLewis acid such as ZnCl₂ and the like at an elevated temperature. Inthis scheme, it is understood that the groups designated can beprotected versions of the radicals defined in the Summary of theInvention which can be deprotected and manipulated to the final compoundafter completion of this scheme or in the middle of the scheme.

A compound of the Formula Ie, in which Q is thiazolyl (as shown above)and W₂ is N, can be prepared as in reaction scheme V by reacting acompound of the formula 5 with a protected glycine derivative of theformula 13 using appropriate coupling reagents followed by deprotectionand coupling with a carboxylate of the formula 14 to generate anintermediate of the formula 15. This intermediate can then be cyclizedusing Lawesson's reagent or other thiotransfer/dehydrating agent in anappropriate solvent such as xylene at an elevated temperature such as130° C. to generate the desired compound of the formula Ie. In thisscheme, it is understood that the groups designated can be protectedversions of the radicals defined in the Summary of the Invention whichcan be deprotected and manipulated to the final compound aftercompletion of this scheme or in the middle of the scheme.

A compound of the Formula If, can be prepared as in reaction scheme VI.A ketone derivative of formula 16 can be reacted with an organometalreagent of formula 17 such as a Grignard reagent or the like to furnishafter dehydration with an acid such as TFA and the like, an olefin ofthe formula 18. This material can be deprotected with the appropriatereagents followed by reaction with an electrophile of the formula 19where X₁ can be a leaving group such as mesylate, halide or the like inan appropriate solvent such as N,N-dimethylformamide or the like using abase such as Cs₂CO₃ or the like to afford 1f as the olefin. The olefincan then be reduced with a metal catalyst such as Pd/C or the like withhydrogen gas or the appropriate hydrogen transfer reagent to afford Ifas an alkane. In this scheme, it is understood that the groupsdesignated can be protected versions of the radicals defined in theSummary of the Invention which can be deprotected and manipulated to thefinal compound after completion of this scheme or in the middle of thescheme.

A compound of the Formula Ig, can be prepared as in reaction scheme VII.A vinyl metal derivative of formula 19 (where M is B, Sn, Si, Mg, Zn orother metals known to participate in metal catalyzed coupling reactions)can be reacted with a halide of formula 21 (where X_(f) refers to achloride, bromide, iodide, triflate, nonaflate, or the like) using anappropriate metal catalyst such as Pd with an appropriate hand systemsuch as familiar to those skilled in the art to generate an intermediateof formula 22. This intermediate can then be alkylated with anintermediate of formula 18 as outlined in scheme VI to afford Ig as anolefin. The olefin can then be reduced with a metal catalyst such asPd/C or the like with hydrogen gas or the appropriate hydrogen transferreagent to afford Ig as an alkane. Alternatively, Ig can be prepared bycarrying out a metal mediated coupling on a compound of formula 20 witha compound of formula 4 and manipulating as before to get to the alkane.In this scheme, it is understood that the groups designated can beprotected versions of the radicals defined in the Summary of theInvention which can be deprotected and manipulated to the final compoundafter completion of this scheme or in the middle of the scheme.

A compound of the Formula Ih, can be prepared as in reaction schemeVIII. A compound of formula 23 can be reductively aminated with acompound of formula 24 using the appropriate reductant such asNaHB(OAc)₃, NaCNBH₃ and the like in an appropriate solvent such asdichloromethane, methanol, ethanol and the like to afford I_(h). Theamine in I_(h) can then be further manipulated. In this scheme, it isunderstood that the groups designated can be protected versions of theradicals defined in the Summary of the Invention which can bedeprotected and manipulated to the final compound after completion ofthis scheme or in the middle of the scheme.

A compound of the Formula Ii, can be prepared as in reaction scheme IX.A compound of formula 25 (Where X_(g) and X_(h) can be chosen fromchloro, bromo, iodo, mesylate, tosylate and the like) can be reactedwith a compound of formula 26 using an appropriate base such as sodiumhydride, LDA and the like in an appropriate solvent such asN,N-dimethylformamide, N-methylpyrrolidinone, DMSO, tetrahydrofuran andthe like at an elevated temperature such as 75° C. or similar to affordan intermediate of formula 27. This material can then be manipulated ina similar fashion to intermediate 18 in scheme VI to arrive at I_(i). Inthis scheme, it is understood that the groups designated can beprotected versions of the radicals defined in the Summary of theInvention which can be deprotected and manipulated to the final compoundafter completion of this scheme or in the middle of the scheme.

A compound of the Formula Ij, can be prepared as in reaction scheme X. Acompound of formula 28 can be reacted with a compound of formula 29(where X_(g) can be chosen from chloro, bromo, iodo, mesylate, tosylateand the like) using an appropriate base such as cesium carbonate, sodiumhydride, LDA and the like in an appropriate solvent such asN,N-dimethylformamide, N-methylpyrrolidinone, DMSO, tetrahydrofuran andthe like to afford an intermediate of formula 30. This material can thenbe reduced using an appropriate metal hydride such as LAH or BH₃ andthen functionalized with the appropriate electrophile R₁X_(h) (whereX_(h) can be chosen from chloro, bromo, succinate, p-nitrophenyl and thelike) to afford an intermediate of the formula 31. This material canthen be manipulated in a similar fashion to intermediate 18 in scheme VIto arrive at I_(j). In this scheme, it is understood that the groupsdesignated can be protected versions of the radicals defined in theSummary of the Invention which can be deprotected and manipulated to thefinal compound after completion of this scheme or in the middle of thescheme.

A compound of the Formula Ik, can be prepared as in reaction scheme XI.A compound of formula 32 can be converted to an amide by reacting withan activating agent such as oxlyl chloride or the like in an appropriatesolvent such as dichloromethane or the like followed by reaction withammonia or an equivalent followed by reduction with an appropriatereagent such as LAH or BH₃ to afford an intermediate of the formula 33.This material can then be cyclized with formaldehyde and acid such asacetic acid or the like followed by functionalization with anappropriate R₁X_(h) (where X_(h) can be chosen from chloro, bromo,succinate, p-nitrophenyl and the like) to afford an intermediate of theformula 34. This material can then be manipulated in a similar fashionto intermediate 18 in scheme VI to arrive at I_(k). In this scheme, itis understood that the groups designated can be protected versions ofthe radicals defined in the Summary of the Invention which can bedeprotected and manipulated to the final compound after completion ofthis scheme or in the middle of the scheme.

Detailed descriptions of the synthesis of compounds of the Invention aregiven in the Examples, infra.

Additional Processes for Making Compounds of the Invention

A compound of the invention can be prepared as a pharmaceuticallyacceptable acid addition salt by reacting the free base form of thecompound with a pharmaceutically acceptable inorganic or organic acid.Alternatively, a pharmaceutically acceptable base addition salt of acompound of the invention can be prepared by reacting the free acid formof the compound with a pharmaceutically acceptable inorganic or organicbase. Alternatively, the salt forms of the compounds of the inventioncan be prepared using salts of the starting materials or intermediates.

The free acid or free base forms of the compounds of the invention canbe prepared from the corresponding base addition salt or acid additionsalt from, respectively. For example a compound of the invention in anacid addition salt form can be converted to the corresponding free baseby treating with a suitable base (e.g., ammonium hydroxide solution,sodium hydroxide, and the like). A compound of the invention in a baseaddition salt form can be converted to the corresponding free acid bytreating with a suitable acid (e.g., hydrochloric acid, etc.).

Compounds of the invention in unoxidized form can be prepared fromN-oxides of compounds of the invention by treating with a reducing agent(e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride,sodium borohydride, or the like) in a suitable inert organic solvent(e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80°C.

Prodrug derivatives of the compounds of the invention can be prepared bymethods known to those of ordinary skill in the art (e.g., for furtherdetails see Saulnier et al., (1994), Bioorganic and Medicinal ChemistryLetters, Vol. 4, p. 1985). For example, appropriate prodrugs can beprepared by reacting a non-derivatized compound of the invention with asuitable carbamylating agent (e.g., 1,1-acyloxyalkylcarbanochloridate,para-nitrophenyl carbonate, or the like).

Protected derivatives of the compounds of the invention can be made bymeans known to those of ordinary skill in the art. A detaileddescription of techniques applicable to the creation of protectinggroups and their removal can be found in T. W. Greene, “ProtectingGroups in Organic Chemistry”, 3^(rd) edition, John Wiley and Sons, Inc.,1999.

Compounds of the present invention can be conveniently prepared, orformed during the process of the invention, as solvates (e.g.,hydrates). Hydrates of compounds of the present invention can beconveniently prepared by recrystallization from an aqueous/organicsolvent mixture, using organic solvents such as dioxin, tetrahydrofuranor methanol.

Compounds of the invention can be prepared as their individualstereoisomers by reacting a racemic mixture of the compound with anoptically active resolving agent to form a pair of diastereoisomericcompounds, separating the diastereomers and recovering the opticallypure enantiomers. While resolution of enantiomers can be carried outusing covalent diastereomeric derivatives of the compounds of theinvention, dissociable complexes are preferred (e.g., crystallinediastereomeric salts). Diastereomers have distinct physical properties(e.g., melting points, boiling points, solubilities, reactivity, etc.)and can be readily separated by taking advantage of thesedissimilarities. The diastereomers can be separated by chromatography,or preferably, by separation/resolution techniques based upondifferences in solubility. The optically pure enantiomer is thenrecovered, along with the resolving agent, by any practical means thatwould not result in racemization. A more detailed description of thetechniques applicable to the resolution of stereoisomers of compoundsfrom their racemic mixture can be found in Jean Jacques, Andre Collet,Samuel H. Wilen, “Enantiomers, Racemates and Resolutions”, John WileyAnd Sons, Inc., 1981.

In summary, the compounds of Formula I can be made by a process, whichinvolves:

(a) that of reaction schemes Ito X₁; and

(b) optionally converting a compound of the invention into apharmaceutically acceptable salt;

(c) optionally converting a salt form of a compound of the invention toa non-salt form;

(d) optionally converting an unoxidized form of a compound of theinvention into a pharmaceutically acceptable N-oxide;

(e) optionally converting an N-oxide form of a compound of the inventionto its unoxidized form;

(f) optionally resolving an individual isomer of a compound of theinvention from a mixture of isomers;

(g) optionally converting a non-derivatized compound of the inventioninto a pharmaceutically acceptable prodrug derivative; and

(h) optionally converting a prodrug derivative of a compound of theinvention to its non-derivatized form.

Insofar as the production of the starting materials is not particularlydescribed, the compounds are known or can be prepared analogously tomethods known in the art or as disclosed in the Examples hereinafter.

One of skill in the art will appreciate that the above transformationsare only representative of methods for preparation of the compounds ofthe present invention, and that other well known methods can similarlybe used.

EXAMPLES

The present invention is further exemplified, but not limited, by thefollowing Examples that illustrate the preparation of compounds of theinvention.

Example A1 Isopropyl4-((4-((4-methanesulfonylpiperazin)-1-yl)phenoxy)methyl)piperidine-1-carboxylate

Step A: To a solution of A1a (5.26 g, 45.7 mmol) in dry dimethoxyethane(30 mL) is added triethylamine (8.0 g, 56.9 mmol). To the resultingmixture, a 1.0-M solution of isopropyl chloroformate in toluene (50 mL)is added dropwise, with vigorous stirring, over 10 min. A whiteprecipitate forms. The suspension is stirred at room temperature for 4hours; the white precipitate is filtered off, washed with moredimethoxyethane, and discarded. The resulting solution is concentratedto dryness to yield A1b; ¹H NMR (DMSO-d₆, 400.13 MHz): δ 4.75 (septet,J=6.2 Hz, 1H), 4.49 (t, J=5.3 Hz, 1H), 3.95 (dd, J=5.6, 5.6 Hz, 2H),3.24 (br, 2H), 1.63 (dd, J=2.0, 12.9 Hz, 2H), 1.51 (m, 1H), 1.17 (d,J=6.2 Hz, 6H), 0.98 (m, 2H); no mass spectrum could be obtained.

Step B: To a solution of A1b (4.25 g, 21.1 mmol) in dichloromethane (30mL) is added triethylamine (4.5 g, 32.0 mmol) in one portion. Theresulting mixture is cooled in an ice/water bath and methanesulfonylchloride (1.8 mL, 23.2 mmol) is added dropwise, with stiffing, over 5min. The bath is removed and the resulting solution is stirred at roomtemperature for 30 min. The reaction mixture is added to water (40 mL)and extracted with dichloromethane (2×40 mL). The combined organicextracts are washed with saturated ammonium chloride aqueous solution,dried over MgSO₄, and concentrated to yield A1c; ¹H NMR (CDCl₃, 400.13MHz): δ 4.74 (septet, J=6.2 Hz, 1H), 4.07 (d, J=6.4 Hz, 2H), 3.99 (d,J=11.0 Hz, 2H), 3.17 (s, 3H), 2.51 (br, 2H), 1.88 (dd, J=1.6, 14.6 Hz,2H), 1.68 (m, 1H), 1.18 (d, J=6.2 Hz, 6H), 1.17 (m, 2H); ESIMS calcd.for C₁₁H₂₂NO₅S (M+H⁺) 280.11, found 280.2.

Step C: A solution of A1c (0.42 g, 1.50 mmol) and 4-bromophenol (0.26 g,1.50 mmol) in acetonitrile (5.0 mL) is treated with powdered cesiumcarbonate (0.60 g, 1.84 mmol) and the mixture is stirred at 65° C. for16 hours. Cooling to room temperature, filtration and concentrationyields A1d; ¹H NMR (CDCl₃, 400.13 MHz): δ 7.36 (d, J=9.0 Hz, 2H), 6.76(d, J=9.0 Hz, 2H), 4.91 (septet, J=6.2 Hz, 1H), 4.19 (br, 2H), 3.76 (d,J=6.4 Hz, 2H), 3.26 (br, 2H), 2.78 (m, 2H), 1.96 (m, 1H), 1.82 (dd,J=1.6, 14.6 Hz, 2H), 1.30 (m, 2H), 1.28 (d, J=6.2 Hz, 6H); ESIMS calcd.for C₁₆H₂₃BrNO₃ (M+H⁺) 356.1, found 356.0.

Step D: A solution of A1d (0.55 g, 1.50 mmol),4-methanesulfonyl-piperazine (0.25 g, 1.52 mmol), andtri-t-butylphosphonium tetrafluoroborate (92.2 mg, 0.32 mmol) in drydioxane (6 mL) is treated with powdered cesium carbonate (1.03 g, 3.16mmol) and the mixture is degassed using argon. Tris(dibenzylideneacetone)dipalladium(0) (0.15 g, 0.16 mmol) is added and the mixture isdegassed again with argon. The suspension is stirred vigorously underargon at 110° C. for 18 hours. Cooling, filtration and purificationusing mass-triggered reverse phase HPLC yields A1; ¹H NMR (CDCl₃, 400.13MHz): δ 6.90 (d, J=8.9 Hz, 2H), 6.84 (d, J=8.9 Hz, 2H), 4.92 (septet,J=6.2 Hz, 1H), 4.19 (br, 2H), 3.76 (d, J=6.4 Hz, 2H), 3.39 (t, J=3.9 Hz,4H), 3.17 (t, J=3.9 Hz, 4H), 2.83 (s, 1H), 2.77 (t, J=11.2 Hz, 2H), 1.96(m, 1H), 1.83 (dd, J=1.4, 14.2 Hz, 2H), 1.27 (m, 2H), 1.24 (d, J=6.2 Hz,6H); ESIMS calcd. for C₂₁H₃₄N₃O₅S (M+H⁺) 440.2, found 440.2.

By following a similar procedure as the one used for preparing A1 fromA1a except substituting the appropriate alcohol for A1a, the followingexamples are obtained:

Example Structure Analytical data A2

ESIMS calcd. for C₂₂H₃₆N₃O₅S (M + H⁺) 454.2, found 454.2. A3

ESIMS calcd. for C₂₃H₃₈N₃O₅S (M + H⁺) 468.2, found 468.2. A4

ESIMS calcd. for C₂₄H₄₀N₃O₅S (M + H⁺) 482.2, found 482.2.

Example B1 Isopropyl4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing A1 fromA1a except substituting 2-chloro-5-hydroxypyridine for 4-bromophenol andperforming step D as follows, B1 is prepared;

A flask is charged with Pd₂ dba₃ (6 mg, 0.006 mmol), xantphos (11 mg,0.019 mmol), 1-(methylsulfonyl)piperazine (63 mg, 384 mmol), sodiumtert-butoxide (46 mg, 0.48 mmol), and a solution of isopropyl4-((6-chloropyridin-3-yloxy)methyl)piperidine-1-carboxylate (100 mg,0.32 mmol) in toluene (1 mL). The reaction is purged by bubblingnitrogen through the solution for 5 minutes and then sealed. Thereaction is then dipped into a pre-heated 100° C. bath and stirred atthis temperature for 3 hours. After cooling to room temperature, thereaction is treated with ethyl acetate and water and the aqueous phaseis isolated, washed with ethyl acetate once more and discarded. Thecombined organics are dried over MgSO₄ and the solvent is removed. Theresidue is purified on a silica gel column using a linear gradient of0-100% ethyl acetate in hexane as eluent to afford B1; ¹H NMR (CDCl₃,400 MHz): δ 7.92 (d, J=3.0, 1H), 7.18 (dd, J=3.0, 9.1, 1H), 6.67 (d,J=9.1, 1H), 4.91 (m, 1H), 4.20 (m, 2H), 3.78 (d, J=6.4, 2H), 3.56 (m,4H), 3.34 (m, 4H), 2.81 (s, 3H), 2.76 (m, 2H), 1.94 (m, 1H), 1.81 (m,2H), 1.29 (m, 2H), 1.24, d, J=6.2, 6H); ESIMS m/z for (M+H)⁺ C₂₀H₃₃N₄O₅Scalcd.: 441.2, found: 441.3.

Example B2 tert-Butyl4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of B2a (4.00 g, 23 mmol) and tert-butyl4-((methylsulfonyloxy)methyl)piperidine-1-carboxylate (7.08 g, 24 mmol)in N-methylpyrrolidinone (50 mL) is treated with Cs₂CO₃ (9.74 g, 30mmol) and heated to 100° C. overnight. The reaction is then diluted withethyl acetate, extracted with water 3 times, dried over MgSO₄, filtered,evaporated and crystallized from toluene/hexane to afford B2b; ESIMS m/zfor (M-tBu+H)⁺ C₁₂H₁₆BrN₂O₃ calcd.: 315.0, found: 315.0.

Step B: Following the procedure for the palladium coupling outlined forB1 above, substituting B2b for isopropyl4-((6-chloropyridin-3-yloxy)methyl)piperidine-1-carboxylate, B2 isprepared; ¹H NMR (CDCl₃, 400 MHz): δ 7.91 (d, J=2.9, 1H), 7.15 (dd,J=9.1, 3.1, 1H), 6.65 (d, J=9.0, 1H), 4.15 (m, 2H), 3.78 (d, J=6.4, 2H),3.54 (m, 4H), 3.33 (m, 4H), 2.81 (s, 3H), 2.72 (m, 2H), 1.93 (m, 1H),1.80 (m, 2H), 1.46 (s, 9H), 1.25 (m, 2H); ESIMS m/z for (M+H)⁺C₂₁H₃₅N₄O₅S calcd.: 455.2, found: 455.2.

Example B3 Isopropyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing B1 exceptusing 2-bromo-5-hydroxypyrazine as the heterocycle, B3 is prepared; ¹HNMR (CDCl₃, 400 MHz): δ 7.87 (d, J=1.4, 1H), 7.62 (d, J=1.5, 1H), 4.92(m, 1H), 4.18 (m, 2H), 4.08 (d, J=6.5, 2H), 3.52 (m, 4H), 3.37 (m, 4H),2.82 (s, 3H), 2.76 (m, 2H), 1.96 (m, 1H), 1.79 (m, 2H), 1.29 (m, 2H),1.24, (d, J=6.2, 6H); ESIMS m/z for (M+H)⁺ C₁₉H₃₂N₅O₅S calcd.: 442.2,found: 442.3.

Example B4 tert-Butyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: By following a similar procedure as the one used for preparingB2b from B2a except substituting B4a for B2a, B4b is prepared; ESIMS m/zfor (M-tBu+H⁺) C₁₁H₁₅BrN₃O₃ calcd.: 316.0, found: 316.0.

Step B: By following the procedure for the palladium coupling outlinedfor the preparation of B1 except substituting B4b for isopropyl4-((6-chloropyridin-3-yloxy)methyl)piperidine-1-carboxylate, B4 isprepared; ¹H NMR (CDCl₃, 400 MHz): δ 7.87 (d, J=1.2, 1H), 7.62 (d,J=1.2, 1H), 4.13 (m, 2H), 4.08 (d, J=6.8, 2H), 3.52 (m, 4H), 3.37 (m,4H), 2.82 (s, 3H), 2.72 (m, 2H), 1.93 (m, 1H), 1.46 (s, 9H), 1.26 (m,2H); ESIMS m/z for (M+H)⁺ C₂₀H₃₄N₅O₅S calcd.: 456.2, found: 456.2.

Example B53-Cyclopropyl-5-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole

By following a similar procedure as the one used for preparing B3 fromB2a except substituting B5c (see scheme below) for B2a, B5 is prepared;¹H NMR (CDCl₃, 400 MHz): δ 7.88 (d, J=1.3, 1H), 7.62 (d, J=1.4, 1H),4.16 (m, 2H), 4.10 (d, J=6.8, 2H), 3.53 (m, 4H), 3.37 (m, 4H), 3.05(ddd, J=12.9, 12.9, 2.8, 2H), 2.82 (s, 3H), 2.02 (m, 1H), 1.88 (m, 4H),1.41 (m, 2H), 0.94 (m, 4H); ESIMS m/z for (M+H)⁺ C₂₀H₃₀N₇O₄S calcd.:464.2, found: 464.3.

Step A: A sample of A1a (10.19 g, 84.9 mmol) is treated with a solutionof K₂CO₃ (24.5 g, 177 mmol) in water (100 mL). The reaction is cooled inan ice/water bath and treated with a solution of cyanogen bromide (10.31g, 97.3 mmol) in dichloromethane (100 mL) dropwise. After stirring foran hour, the organic layer is isolated and the aqueous layer isextracted once more with dichloromethane. The combined organic extractsare dried over MgSO₄, filtered and evaporated to afford B5a; ESIMS m/zfor (M+H)⁺ C₇H₁₃N₂O calcd.: 141.1, found: 141.1.

Step B: A solution of B5a (993 mg, 7.1 mmol), N′-hydroxycyclopropanecarboximidamide (1.064 g, 10.6 mmol) and ZnCl₂ (1.448 g, 10.6 mmol) indioxane (25 mL) is heated to 100° C. overnight. The reaction is thenevaporated to dryness and partitioned between ethyl acetate and 1 M HCl.The organics are isolated, extracted with 1 M HCl once more, dried overMgSO₄, filtered, evaporated and purified by silica gel to afford B5b;ESIMS m/z for (M+H)⁺ C₁₁H₁₈N₃O₂ calcd.: 224.1, found: 224.1.

Step C: A solution of B5b (278.4 mg, 1.25 mmol) and triethylamine (131mg, 130 mmol) in dichloromethane (1 mL) is cooled in an ice/water bath,treated with methanesulfonyl chloride (149 mg, 1.3 mmol) and stirredovernight. The reaction is diluted with water and extracted withdichloromethane. The organics are dried over MgSO₄, filtered, evaporatedand purified on silica gel using a linear gradient of 0 to 100% ethylacetate in hexane to afford E5c; ESIMS m/z for (M+H)⁺ C₁₂H₂₀N₃O₄Scalcd.: 302.1, found: 302.1.

Example B65-Cyclopropyl-3-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole

By following a similar procedure as the one used for B5 exceptsubstituting B6b (see scheme below) for B5b, B6 is obtained; ¹H NMR(CDCl₃, 400 MHz): δ 7.87 (d, J=1.5, 1H), 7.63 (d, J=1.5, 1H), 4.10 (d,J=6.8, 2H), 4.00 (m, 2H), 3.53 (m, 4H), 3.37 (m, 4H), 2.89 (ddd, J=12.7,12.7, 2.7, 2H), 2.82 (s, 3H), 2.00 (m, 1H), 1.86 (m, 4H), 1.40 (ddd,J=25.0, 12.4, 4.3, 2H), 1.14 (m, 4H); ESIMS m/z for (M+H)⁺ C₂₀H₂₉N₇O₄Scalcd.: 464.2, found: 464.3.

Step A: A solution of B5a (4.01 g, 28.6 mmol) and hydroxylamine (3.51 mLof a 50% by weight aqueous solution, 57.2 mmol) in ethanol (50 mL) issealed and heated to 60° C. overnight. The solvent is then removed toB6a; ESIMS m/z for (M+H)⁺ C₇H₁₆N₃O₂ calcd.: 174.1, found: 174.1.

Step B: A solution of B6a (905 mg, 5.2 mmol) and2,5-dioxopyrrolidin-1-yl cyclopropanecarboxylate (957 mg, 5.2 mmol) indioxane (50 mL) is heated to 80° C. for 3 hours and then 70° C.overnight. The reaction is then cooled to room temperature, concentratedand purified on silica gel using a linear gradient of 0-80% ethylacetate in hexane to afford B6b; ESIMS m/z for (M+H)⁺ C₁₁H₁₈N₃O₂ calcd.:224.1, found: 224.1.

Example B72-(4-(Methylsulfonyl)piperazin-1-yl)-5-((1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)methoxy)pyrazine

By following a similar procedure as the one used for preparing B3 fromB2a except substituting B7a (see scheme below) for A1b, B7 is prepared;¹H NMR (CDCl₃, 400 MHz): δ 8.37 (m, 1H), 7.88 (d, J=1.4, 1H), 7.63 (d,J=1.4, 1H), 7.60 (dd, J=9.1, 2.5, 1H), 6.65 (d, J=9.1, 1H), 4.45 (m,2H), 4.11 (d, J=6.5, 1H), 3.53 (m, 4H), 3.37 (m, 4H), 2.95 (m, 2H), 2.82(s, 3H), 2.11 (m, 1H), 1.93 (m, 2H), 1.37 (ddd, J=24.9, 12.5, 4.1, 2H);ESIMS m/z for (M+H)⁺ C₂₁H₂₈F₃N₆O₃S calcd.: 501.2, found: 501.3.

Step A: A mixture of A1a (522.5 mg, 4.5 mmol),2-chloro-5-trifluoromethylpyridine (1.19 g, 6.5 mmol) and K₂CO₃ (941 mg,6.8 mmol) in N,N-dimethylformamide (8 mL) is heated to 160° C. for 10minutes, cooled to room temperature and diluted with ethyl acetate andwater. The organics are extracted with water, dried over MgSO₄,filtered, evaporated and purified on silica gel using a linear gradientof 0 to 100% ethyl acetate in hexane to afford B1a; ESIMS m/z for (M+H)⁺C₁₂H₁₆F₃N₂O calcd.: 261.1, found: 261.1.

Example B85-Isopropyl-3-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole

By following a similar procedure as the one used for preparing B6 fromB6b except substituting B8a (see scheme below) for B6b, B8 is prepared;¹H NMR (CDCl₃, 400 MHz): δ 7.88 (d, J=1.5, 1H), 7.63 (d, J=1.5, 1H),7.60 (dd, J=9.1, 2.5, 1H), 4.11 (d, J=6.6, 1H), 3.53 (m, 4H), 3.37 (m,4H), 3.07 (m, 1H), 2.92 (ddd, J=12.7, 12.7, 2.7, 2H), 2.82 (s, 3H), 2.01(m, 1H), 1.88 (m, 2H), 1.42 (m, 2H), 1.35 (d, J=7.0, 6H); ESIMS m/z for(M+H)⁺ C₂₀H₃₂N₇O₄S calcd.: 466.2, found: 466.2.

Step A: A solution of B6a (460.3 mg, 2.7 mmol) and isobutyric anhydride(420 mg, 2.7 mmol) in dioxane (3 mL) is heated to 150° C. for 5 minutes.The reaction is cooled to room temperature and diluted with ethylacetate and water. The organics are isolated and washed once with water,dried over MgSO₄, filtered, evaporated and purified on silica using alinear gradient of ethyl acetate in hexane to afford B8a. A satisfactorymass spectal analysis could not be obtained.

Example B9 Tetrahydro-2H-pyran-4-yl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing B3 fromA1a except substituting 4-nitrophenyl tetrahydro-2H-pyran-4-yl carbonatefor isopropyl chloroformate in the first step, B9 is prepared; ¹H NMR(CDCl₃, 400 MHz): δ 7.87 (d, J=1.5, 1H), 7.62 (d, J=1.5, 1H), 4.87 (m,1H), 4.20 (m, 2H), 4.09 (d, J=6.5, 1H), 3.89 (m, 2H), 3.57 (m, 2H), 3.54(m, 4H), 3.46 (m, 4H), 2.82 (s, 3H), 2.80 (m, 2H), 1.95 (m, 3H), 1.82(m, 2H), 1.67 (m, 3H), 1.28 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₁H₃₄N₅O₆Scalcd.: 484.2, found: 484.2.

Example B10 (S)-Tetrahydrofuran-3-yl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing B3 fromA1a except substituting (S)-4-nitrophenyl tetrahydrofuran-3-yl carbonatefor isopropyl chloroformate in the first step, B10 is prepared; ¹H NMR(CDCl₃, 400 MHz): δ 7.87 (d, J=1.5, 1H), 7.62 (d, J=1.5, 1H), 5.26 (m,1H), 4.18 (m, 2H), 4.08 (d, J=6.5, 1H), 3.89 (m, 4H), 3.53 (m, 4H), 3.47(m, 4H), 2.82 (s, 3H), 2.80 (m, 2H), 2.17 (m, 1H), 2.00 (m, 2H), 1.82(m, 2H), 1.27 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₀H₃₁N₅O₆S calcd.: 470.2,found: 470.2.

Example B11 (R)-Tetrahydrofuran-3-yl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing B3 fromA1a except substituting (R)-4-nitrophenyl tetrahydrofuran-3-yl carbonatefor isopropyl chloroformate in the first step, B11 is prepared with dataidentical to B10.

Example B122-Isopropyl-5-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)thiazole

By following a similar procedure as the one used for preparing B3 fromA1d except substituting B12d (see scheme below) for A1d, B12 isprepared; ¹H NMR (CDCl₃, 400 MHz): δ 7.88 (d, J=1.5, 1H), 7.63 (d,J=1.5, 1H), 7.60 (dd, J=9.1, 2.5, 1H), 6.79 (s, 1H), 4.13 (d, J=6.2,1H), 3.53 (m, 4H), 3.46 (m, 2H), 3.37 (m, 4H), 3.14 (m, 1H), 2.82 (s,3H), 2.79 (m, 2H), 1.91 (m, 3H), 1.53 (m, 2H), 1.34 (d, J=6.9, 6H);ESIMS m/z for (M+H)⁺ C₂₁H₃₃N₆O₃S₂ calcd.: 481.2, found: 481.2.

Step A: A sample of B4b (5.55 g, 14.9 mmol) is treated with 4 M HCl indioxane (20 ml) and aged for 1 hour. The reaction is treated with waterand the solvent is removed in vacuo. The residue is partitioned betweenethyl acetate and 1 M NaOHOURS. The aqueous phase is isolated, extractedonce more with ethyl acetate and discarded. The combined organics aredried over MgSO₄, filtered and evaporated to afford B12a which is usedwithout further purification; ESIMS m/z for (M+H)⁺ C₁₀H₁₅BrN₃O calcd.:272.0, found: 272.0.

Step B: A solution of B12a (1 g, 3.7 mmol), Boc-gly (966 mg, 5.5 mmol)and HOBt (596 mg, 4.4 mmol) in N-methylpyrrolidinone (5 mL) is treatedwith EDC (845 mg, 845 mg, 4.4 mmol) and stirred for 1 hour. The reactionis then diluted with ethyl acetate and extracted with water andsaturated aqueous sodium hydrogencarbonate twice. The organics are driedover MgSO₄, filtered and evaporated. The residue is treated with excess4 M HCl in dioxane and aged for 1 hour. The mixture is slurried withether and the solid is collected to afford B12b; ESIMS m/z for (M+H)⁺C₁₂H₁₈BrN₄O₂ calcd.: 329.1, found: 329.1.

Step C: A suspension of B12b (400 mg, 1.1 mmol) in acetonitrile (8 mL)is treated with isobutyric anhydride (208 mg, 1.3 mmol) followed bytriethylamine (360 mg, 3.6 mmol) and stirred for 1 hour. The solvent isremoved and the residue is partitioned between ethyl acetate andsaturated aqueous sodium hydrogencarbonate. The aqueous phase isisolated, extracted once more with ethyl acetate and discarded. Thecombined organics are dried over MgSO₄, filtered and evaporated toafford B12c which is used without further purification; ESIMS m/z for(M+H)⁺ C₁₆H₂₄BrN₄O₃ calcd.: 399.1, found: 399.1.

Step D: A solution of B12c (440 mg, 1.1 mmol) in m-xylene (2 mL) istreated with Laewesson's reagent (446 mmol, 1.1 mmol) and heated to 140°C. for 5 minutes and then purified on silica gel using a linear gradientof 0-100% ethyl acetate in hexane. The resulting material is furtherpurified on preparative HPLC to afford B12d; ESIMS m/z for (M+H)⁺C₁₆H₂₂BrN₄OS calcd.: 397.1, found: 397.1.

Example B132-((1-(2-methyl-2H-tetrazol-5-yl)piperidin-4-yl)methoxy)-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazine

By following a similar procedure as the one used for preparing B3 fromA1d except substituting B13c (see scheme below) for A1d, B13 isprepared; ¹H NMR (400 MHz, CD₃CN) δ 7.84 (d, J=0.9 Hz, 1H), 7.72 (d,J=1.2 Hz, 1H), 4.10 (s, 3H), 4.10 (d, J=4.8 Hz, 2H), 4.02 (m, 2H), 3.51(t, J=3.9 Hz, 4H), 3.27 (t, J=3.9 Hz, 4H), 2.91 (dt, J=2.1, 9.6 Hz, 2H),2.79 (s, 3H), 1.39 (ddd, J=3.3, 9.3, 16.8 Hz, 4H), 2.20 (t, J=5.4 Hz,2H), 0.88 (m, 2H); ESIMS (M+H)⁺ C₁₇H₂₈N₉O₃S calcd.: 438.2, found 438.2(M+1).

Step A: To a stirred suspension of B12a (200 mg, 0.74 mmol) andsodiumhydrogencarbonate (0.15 g, 1.78 mmol) in a mixed solvent of water(0.1 mL) and dichloromethane (1 mL) at 0° C. is added cyanogen bromide(93 mg, 0.89 mmol) in one portion. The reaction is then stirred at roomtemperature for 4 h and additional cyanogen bromide (93 mg, 0.89 mmol)is added. After stirring overnight, the reaction is diluted withdichloromethane (30 mL), dried over MgSO₄, and evaporated to give B13a;ESIMS (M+H)⁺ C₁₁H₁₄BrN₄O calcd.: 297.0, found 297.0.

Step B: The above crude B13a is stirred with sodium azide (143 mg, 2.2mmol) and ammonium chloride (117 mg, 0.22 mmol) in anhydrousN,N-dimethylformamide (2 mL) at 110° C. for 2 hours. Additional sodiumazide (143 mg, 2.2 mmol) and ammonium chloride (117 mg, 0.22) are added.After stirring overnight, water is added slowly to precipitate theproduct. The off white solid is collected by filtration, washed withwater (10 mL) and dried in vacuo to afford B13b; ¹H NMR (400 MHz,DMSO-d₆) δ 8.41 (d, J=1.2 Hz, 1H), 8.20 (d, J=0.9 Hz, 1H), 4.18 (d,J=5.1 Hz, 2H), 3.86 (m, 2H), 3.02 (dt, J=2.1, 9.6 Hz, 2H), 2.03 (m, 1H),1.81 (m, 2H), 1.34 (ddd, J=3.3, 9.6, 18.9 Hz, 2H); ESIMS (M+H)⁺C₁₁H₁₅BrN₇O calcd.: 340.0, found: 340.0.

Step C: A mixture of B13b (50 mg, 0.15 mmol), iodomethane (14 uL, 0.22mmol) and K₂CO₃ (28 mg, 0.25 mmol) in anhydrous N,N-dimethylformamide (1mL) is stirred at room temperature for 3 hours. The solvent isevaporated in vacuo and the crude B13c is used without purification:ESIMS (M+H)⁺ C₁₂H₁₇BrN₇O calcd.: 354.1, found 354.0 (M+1).

Example B14 Oxetan-3-yl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing B3 fromA1a except substituting 4-nitrophenyl oxetan-3-yl carbonate forisopropyl chloroformate in the first step, B14 is prepared; ESIMS m/zfor (M+H)⁺ C₁₉H₃₀N₅O₆S calcd: 456.2, found: 456.0.

Example C1 Isopropyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of 2-chloro-5-bromopyridine (344 mg, 1.8 mmol) andA1b (300 mg, 1.5 mmol) in dimethylformamide (3 mL) is treated with NaH(43 mg, 1.8 mmol) and the reaction is allowed to stir overnight. Afterquenching by addition of water, the reaction is diluted with ethylacetate. The organics are isolated and extracted with water once more,dried over MgSO₄, filtered and evaporated. The residue is purified on asilica gel column using a linear gradient of 0-50% ethyl acetate inhexane to afford C1b; ESIMS m/z for (M+H)⁺ C₁₅H₂₂ClN₂O₃ calcd.: 313.1,found: 313.1.

Step B: By following a similar Pd coupling procedure described forpreparing B1 except substituting Cla as the bromide coupling partner,B14 is prepared; ¹H NMR (CDCl₃, 400 MHz): δ 7.78 (d, J=2.9, 1H), 7.18(dd, J=3.0, 8.9, 1H), 6.69 (d, J=8.9, 1H), 4.91 (m, 1H), 4.18 (m, 2H),4.09 (d, J=6.4, 2H), 3.38 (m, 4H), 3.17 (m, 4H), 2.84 (s, 3H), 2.77 (m,2H), 1.96 (m, 1H), 1.81 (m, 2H), 1.29 (m, 2H), 1.24, d, J=6.3, 6H);ESIMS m/z for (M+H)⁺ C₂₀H₃₃N₄O₅S calcd.: 441.2, found: 441.2.

Example C2 Isopropyl4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridazin-3-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing C1 fromA1b except substituting 2,5-dichloropyridazine for2-chloro-5-bromopyridine in the first step, C2 is prepared; ¹H NMR(CDCl₃, 400 MHz): δ 7.04 (d, J=9.6, 1H), 6.88 (d, J=9.6, 1H), 4.91 (m,1H), 4.29 (m, 2H), 4.18 (m, 2H), 3.64 (m, 4H), 3.35 (m, 4H), 2.81 (s,3H), 2.77 (m, 2H), 2.03 (m, 1H), 1.80 (m, 2H), 1.29 (m, 2H), 1.24, d,J=6.4, 6H); ESIMS m/z for (M+H)⁺ C₁₉H₃₂N₅O₅S calcd.: 442.2, found:442.3.

Example C3 Isopropyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrimidin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing C1 fromA1b except substituting 2-chloro-5-bromopyrimidine for2-chloro-5-bromopyridine in the first step, C3 is prepared; ¹H NMR(CDCl₃, 400 MHz): δ 8.38 (s, 2H), 4.91 (sept., J=6.3 Hz, 1H), 4.23 (m,5H), 3.50 (m, 4H), 3.29 (m, 4H), 2.87 (s, 3H), 2.76 (m, 2H), 2.04 (m,1H), 1.84 (m, 2H), 1.27 (m, 1H), 1.24 (d, J=6.3 Hz, 6H); ESIMS m/z for(M+H)⁺ C₁₉H₃₂N₅O₅S calcd.: 442.2, found: 442.3.

Example D1 (E)-isopropyl4-(2-(6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)vinyl)piperidine-1-carboxylate

Step A: A solution of D1a (10 g, 0.077 mol) in dichloromethane (100 mL)is treated with a solution of isopropyl chloroformate in toluene (93 mLof a 1M solution) dropwise. The reaction is then stirred at roomtemperature for 2.5 hours and quenched with saturated aqueous ammoniumchloride solution. The phases are separated and the aqueous phase isextracted once more with dichloromethane and discarded. The combinedorganics are extracted once with 1M HCl, once with saturated aqueoussodiumhydrogencarbonate, dried over MgSO₄, filtered and evaporated toafford D1b; ESIMS m/z for (M+H)⁺ C₇H₁₆NO calcd.: 130.1, found: 130.1.

Step B: A cold (ice/water bath) solution of D1b (9.9 g, 0.046 mol) andtriethylamine (6.7 mL, 0.048 mol) in dichloromethane is treated with thedropwise addition of methanesulfonyl chloride (3.7 mL, 0.048 mol) andstirred for 2 hours. The mixture is treated with water and extractedwith dichloromethane. The organics are pooled, dried over MgSO₄,filtered and concentrated. The crude material is diluted in acetone (10mL) and added dropwise to a slurry of lithium bromide (12 g, 0.138 mol)in acetone (50 mL). The reaction is heated to 35° C. and maintainedovernight. After cooling to room temperature, the reaction isconcentrated, diluted with ethyl acetate and washed with water. Theorganic phase is collected, dried over MgSO₄, and concentrated. Thisresidue is diluted in tetrahydrofuran (150 mL) and treated with theportionwise addition of potassium tert-butoxide (23.05 g, 0.2054 mol)every 30 min for 3 hours. Reaction is then heated to 40° C. andmaintained overnight. Once the reaction had cooled to room temperature,saturated aqueous ammonium chloride is introduced and the reactionextracted with Et₂O. Organics are collected, dried over MgSO₄,concentrated, and purified via distillation (68°-70° C., 180 mTorr) toafford D1c. ESIMS m/z for (M+H)⁺ C₁₁H₂₀NO₂ calcd.: 198.3 found: 198.1.

Step C: A solution of D1d (321 mg, 1.8 mmol) andmethanesulfonylpiperazine (300 mg, 1.8 mmol) in N-methylpyrrolidinone (2mL) is treated with K₂CO₃ (380 mg, 2.7 mmol) and heated to 160° C. for 5minutes. The reaction is then partitioned between ethyl acetate andwater and the organics are extracted with water again, dried over MgSO₄,filtered, evaporated and purified on silica gel using 0-100% ethylacetate in hexane to afford D1e; ESIMS m/z for (M+H)⁺ C₁₀H₁₅BrN₃O₂Scalcd.: 320.0, found: 320.1.

Step D: A solution of D1e (50 mg, 0.18 mmol), D1c (44 mg, 0.22 mmol)Pd₂dba₃ (5 mg, 0.006 mmol) and tri-tert-butylphosphoniumtetrafluoroborate (3.2 mg, 0.011 mmol) and dicyclohexylmethylamine (72mg, 0.37 mmol) in dioxane (1 mL) is heated to 120° C. for 1 hour. Thereaction is then partitioned between ethyl acetate and water and theorganics are extracted with water once more, dried over MgSO₄, filtered,evaporated and purified on silica gel using a gradient of 0-100% ethylacetate in hexane to afford D1; ¹H NMR (CDCl₃, 400 MHz): δ 8.11 (d,J=2.3, 1H), 7.57 (dd, J=8.8, 2.4, 1H), 6.63 (d, J=8.8, 1H), 6.27 (d,J=15.9, 1H), 5.99 (dd, J=16.0, 6.9, 1H), 4.91 (m, 1H), 4.17 (m, 2H),3.67 (m, 4H), 3.32 (m, 4H), 2.80 (m, 2H), 2.80 (s, 3H), 2.23 (m, 1H),1.77 (m, 2H), 1.38 (m, 2H), 1.24, d, J=6.2, 6H); ESIMS m/z for (M+H)⁺C₂₁H₃₃N₄O₄S calcd.: 437.2, found: 437.2.

Example D2 Isopropyl4-(2-(6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)ethyl)piperidine-1-carboxylate

A solution of D2 (25 mg, 0.057 mmol) in methanol (2 mL) is treated with10% Pd/C (5 mg) and hydrogenated for 1 hour. The atmosphere is exchangedback for nitrogen and the reaction is filtered though a plug of Celite®and the solvent is removed to afford D2; ¹H NMR (CDCl₃, 400 MHz): δ 8.02(d, J=2.2, 1H), 7.35 (dd, J=8.6, 2.4, 1H), 6.63 (d, J=8.6, 1H), 4.90 (m,1H), 4.12 (m, 2H), 3.62 (m, 4H), 3.32 (m, 4H), 2.80 (s, 3H), 2.68 (m,2H), 2.52 (m, 2H), 1.70 (m, 2H), 1.52 (m, 2H), 1.42 (m, 1H), 1.23 (d,J=6.2, 6H), 1.12 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₁H₃₅N₄O₄S calcd.:439.2, found: 439.3.

Example D3 (E)-Isopropyl4-(2-(2-(4-(methylsulfonyl)piperazin-1-yl)pyrimidin-5-yl)vinyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing D1 fromD1a except substituting 2-chloro-5-bromopyrimidine for D1d, D3 isprepared; ¹H NMR (CDCl₃, 400 MHz): δ 8.38 (s, 2H), 6.18 (d, J=16.2 Hz,1H), 6.05 (dd, J=16.1, 6.6 Hz, 1H), 4.92 (m, 1H), 4.18 (m, 2H), 3.98 (m,4H), 3.30 (m, 4H), 2.80 (s, 3H), 2.80 (m, 2H), 2.29 (m, 1H), 1.76 (m,2H), 1.38 (m, 2H), 1.24 (d, J=6.2 Hz, 6H); ESIMS m/z for (M+H)⁺C₂₀H₃₂N₅O₄S calcd.: 438.2, found: 438.3.

Example E15-Ethyl-2-(4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)pyrimidine

Step A: A sample of B2 (202 mg, 0.445 mmol) is treated with 4 M HCl indioxane (3 mL) and aged for 1 hour. The solvent is then removed and theresidue is partitioned between ethyl acetate and 1 M NaOH. The aqueousphase is isolated, extracted once more with ethyl acetate and discarded.The combined organics are dried over MgSO₄, filtered and evaporated toafford E1a; ESIMS m/z for (M+H)⁺ C₁₆H₂₇N₄O₃S calcd.: 355.2, found:355.2.

Step B: The resulting material is treated with2-chloro-5-ethylpyrimidine (121 mg, 0.85 mmol), CuI (12 mg, 0.063 mmol),diisopropylethylamine (176 mg, 1.4 mmol) and N-methylpyrrolidinone (2mL). The resulting solution is sealed in a reaction vial and heated to160° C. for 10 minutes using a microwave reactor. The reaction is thendiluted with ethyl acetate and extracted with water once, 1 M HCl onceand saturated aqueous sodiumhydrogencarbonate once, dried over MgSO₄,filtered, evaporated and purified on silica gel using a linear gradientof 0-100% ethyl acetate in hexane followed by lyophilization from 1 MHCl to afford E1 as the HCl salt; ¹H NMR (DMSO-d₆, 400 MHz): δ 8.27 (s,2H), 7.82 (d, J=2.9, 1H), 7.50 (m, 1H), 7.05 (m, 1H), 4.63 (m, 2H), 3.86(d, J=6.4, 2H), 3.57 (m, 4H), 3.22 (m, 4H), 2.91 (s, 3H), 2.91 (m, 2H),2.43 (dd, J=15.1, 7.6, 2H), 2.03 (s, 1H), 1.82 (m, 2H), 1.22 (m, 2H),1.13 (dd, J=7.6, 7.6, 36H); ESIMS m/z for (M+H)⁺ C₂₂H₃₃N₆O₃S calcd.:461.2, found: 461.2.

Example E21-(Methylsulfonyl)-4-(5-((1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)methoxy)pyridin-2-yl)piperazine

By following a similar procedure as the one used for preparing E1 fromB2 except substituting the following procedure for Step B, E2 isprepared;

A sample of E1a hydrochloride (900 mg, 2.3 mmol) is treated with2-chloro-3-trifluoromethylpyridine (501 mg, 2.76 mmol), K₂CO₃ (795 mg,5.8 mmol), N-methylpyrrolidinone (10 mL) and water (8 mL) and heated ina sealed vessel in a microwave reactor at 160° C. for 10 minutes. Theresulting suspension is treated with ethyl acetate and water andfiltered. The resulting solid is washed with water and ethyl acetate,dissolved in 1 M HCl and lyophilized to afford E2; ¹H NMR (CDCl₃, 400MHz): δ 8.22 (m, 1H), 8.10 (dd, J=9.8, 2.3, 1H), 7.86 (dd, J=9.9, 2.9,1H), 7.60 (d, J=2.9, 1H), 7.53 (d, J=9.8, 1H), 7.42 (d, J=9.1, 1H), 4.30(m, 2H), 3.94 (d, J=6.2, 1H), 3.71 (m, 4H), 3.37 (m, 4H), 2.86 (s, 3H),2.28 (m, 1H), 2.06 (m, 2H), 1.57 (m, 2H); ESIMS m/z for (M+H)⁺C₂₂H₂₉F₃N₅O₃S calcd.: 500.2, found: 500.2.

Example E3 1-Methylcyclopropyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A sample of B4 (745 mg, 0.16 mmol) is treated with 4 M HCl indioxane and stirred for 3 hours. The solvent is decanted and the residueis lyophilized from water to afford E3a; ESIMS m/z for (M+H)⁺C₁₅H₂₆N₅O₃S calcd.: 356.2, found: 356.2.

Step B: A sample of E3a (181.8 mg, 0.46 mmol) is treated withN,N-dimethylformamide (1.5 mL), E3b (110 mg, 0.46 mmol) anddiisopropylethylamine (242 μL, 1.4 mmol) and stirred overnight. Thereaction is then partitioned between ethyl acetate and water and theorganics are isolated, extracted with 1 M NaOH three times, dried overMgSO₄, filtered, evaporated and purified on silica gel using a lineargradient of 0-100% ethyl acetate in hexane to afford E3; ¹H NMR (CDCl₃,400 MHz): δ 7.87 (d, J=1.5, 1H), 7.62 (d, J=1.4, 1H), 4.18 (m, 2H), 4.08(d, J=6.5, 2H), 3.52 (m, 4H), 3.36 (m, 4H), 2.82 (s, 3H), 2.72 (m, 2H),1.93 (m, 1H), 1.80 (m, 2H), 1.56 (d, J=9.9, 3H), 1.23 (m, 2H), 0.87 (m,2H), 0.62 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₀H₃₂N₅O₅S calcd.: 454.2,found: 454.2.

Example E45-Ethyl-2-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)pyrimidine

By following a similar procedure as the one used for preparing E1 fromE1a except substituting E3a for E1a, E4 is prepared; ¹H NMR (CDCl₃, 400MHz): δ 8.17 (s, 2H), 7.88 (d, J=1.4, 1H), 7.63 (d, J=1.5, 1H), 4.76 (m,2H), 4.11 (d, J=6.6, 2H), 3.52 (m, 4H), 3.37 (m, 4H), 2.90 (m, 2H), 2.82(s, 3H), 2.45 (dd, J=15.2, 7.6, 2H), 2.08 (m, 2H), 1.90 (m, 2H), 1.33(ddd, J=24.9, 12.4, 4.2, 2H), 1.18 (dd, J=7.6, 7.6, 3H); ESIMS m/z for(M+H)⁺ C₂₁H₃₂N₇O₃S calcd.: 462.2, found: 462.3.

Example E52-((1-(5-Methylpyridin-2-yl)piperidin-4-yl)methoxy)-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazine

A mixture of E3a (103 mg, 0.26 mmol), 2-bromo-5-methylpyridine (45.3 mg,0.26 mmol), Pd₂dba₃ (4.8 mg, 0.005 mmol), xantphos (9.1 mg, 0.016 mmol),sodium tert-butoxide (78 mg, 0.815 mmol) and toluene (1.5 mL) is purgedwith nitrogen for 5 minutes and heated in an oil bath at 100° C.overnight. The reaction is cooled to room temperature and diluted withwater and ethyl acetate. The organics are dried over MgSO₄, filtered,evaporated and purified by silica gel column chromatography using alinear gradient of 0-100% ethyl acetate in hexane to afford E5; ¹H NMR(CDCl₃, 400 MHz): δ 8.01 (m, 1H), 7.88 (d, J=1.4, 1H), 7.30 (m, 1H),6.62 (d, J=8.6, 1H), 4.27 (m, 2H), 4.11 (d, J=6.6, 1H), 3.53 (m, 4H),3.37 (m, 4H), 2.82 (m, 2H), 2.82 (s, 3H), 2.19 (s, 3H), 2.02 (m, 1H),1.91 (m, 2H), 1.42 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₁H₃₁N₆O₃S calcd.:447.2, found: 447.3.

Example E6 1-Methylcyclopropyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing E3 fromB4 except substituting tert-butyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidine-1-carboxylatefor B4, E6 is prepared; tert-Butyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidine-1-carboxylateis prepared in an analogous fashion to B4 except using2-fluoro-5-bromopyridine instead of A1d; ¹H NMR (CDCl₃, 400 MHz): δ 7.78(d, J=2.9, 1H), 7.28 (dd, J=8.9, 3.0, 1H), 6.68 (d, J=8.9, 1H), 4.18 (m,2H), 4.08 (d, J=6.5, 2H), 3.38 (m, 4H), 3.14 (m, 4H), 2.83 (s, 3H), 2.73(m, 2H), 1.93 (m, 1H), 1.79 (m, 2H), 1.54 (s, 3H), 1.23 (m, 2H), 0.86(m, 2H), 0.61 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₁H₃₃N₄O₅S calcd: 453.2,found: 453.3.

Example E75-Ethyl-2-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidin-1-yl)pyrimidine

By following a similar procedure as the one used for preparing E1 fromE1a except substituting tert-butyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidine-1-carboxylatefor E1a, E7 is prepared; tert-Butyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidine-1-carboxylateis prepared in an analogous fashion to B4 except using2-fluoro-5-bromopyridine instead of A1d; ¹H NMR (CDCl₃, 400 MHz): δ 8.16(s, 2H), 7.78 (d, J=2.9, 1H), 7.28 (dd, J=8.9, 3.0, 1H), 6.69 (d, J=9.0,1H), 4.73 (m, 2H), 4.11 (d, J=6.6, 1H), 3.38 (m, 4H), 3.14 (m, 4H), 2.89(m, 2H), 2.83 (s, 3H), 2.44 (dd, J=15.2, 7.6, 2H), 2.08 (m, 1H), 1.90(m, 2H), 1.34 (ddd, J=24.8, 12.4, 4.1, 2H), 1.73 (dd, J=7.6, 7.6, 3H);ESIMS m/z for (M+H)⁺ C₂₂H₃₃N₆O₃S calcd.: 461.2, found: 461.3.

Example E83-Isopropyl-5-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole

Step A: A cold (ice/water bath) solution of E3a (256 mg, 0.65 mmol) indichloromethane (5 mL) is treated with a solution of K₂CO₃ (298 mg, 2.2mmol) in water (5 mL). The vigorously stirred solution is treated with asolution of cyanogen bromide (76.1 mg, 0.72 mmol) in dichloromethane (2mL) and the reaction is allowed to stir cold for 3 hours. The phases arethen separated and the organic phase is dried over MgSO₄, filtered andevaporated to afford E8a which is used without further purification;ESIMS m/z for (M+H)⁺ C₁₆H₂₅N₆O₃S calcd.: 381.2, found: 381.1.

Step B: A solution of E3a (215.5 mg, 0.57 mmol) in dioxane (2 mL) istreated with N′-hydroxyisobutyrimidamide (86.8 mg, 0.85 mmol) and ZnCl₂(115.8 mgL, 0.85 mmol) and stirred at 100° C. overnight. The reaction isthen partitioned between ethyl acetate and 1 M NaOH and the organics areisolated, dried over MgSO₄, filtered, evaporated and purified on silicagel using a linear gradient of 0-100% ethyl acetate in hexane to affordE8; ¹H NMR (CDCl₃, 400 MHz): δ 7.88 (d, J=1.4, 1H), 7.62 (d, J=1.4, 1H),4.19 (m, 2H), 4.11 (d, J=6.5, 2H), 3.53 (m, 4H), 3.37 (m, 4H), 3.08(ddd, J=12.9, 12.9, 2.8, 2H), 2.87 (m, 1H), 2.82 (s, 3H), 2.03 (m, 1H),1.91 (m, 2H), 1.43 (ddd, J=25.2, 12.5, 4.4, 2H), 1.28 (d, J=7.0, 3H);ESIMS m/z for (M+H)⁺ C₂₀H₃₂N₇O₄S calcd.: 466.2, found: 466.3.

Example E93-Isopropyl-5-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole

By following a similar procedure as the one used for preparing E8 fromB4 except substituting tert-butyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidine-1-carboxylatefor B4, E9 is prepared; tert-Butyl4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidine-1-carboxylateis prepared in an analogous fashion to B4 except using2-fluoro-5-bromopyridine instead of A1d; ¹H NMR (CDCl₃, 400 MHz): δ 7.78(d, J=2.9, 1H), 7.29 (dd, J=8.9, 3.0, 1H), 6.69 (d, J=8.9, 1H), 4.17 (m,2H), 4.13 (d, J=6.5, 1H), 3.40 (m, 4H), 3.17 (m, 4H), 3.08 (ddd, J=12.9,12.9, 2.8, 2H), 2.88 (m, 1H), 2.84 (s, 3H), 2.03 (m, 1H), 1.91 (m, 2H),1.34 (ddd, J=25.1, 12.5, 4.4, 2H), 1.28 (d, J=7.0, 3H); ESIMS m/z for(M+H)⁺ C₂₁H₃₃N₆O₄S calcd.: 465.2, found: 465.3.

Example E10 1-Methylcyclopropyl4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing E3 fromB4 except substituting B2 for B4, E10 is prepared; ¹H NMR (CDCl₃, 400MHz): δ 7.90 (d, J=2.9, 1H), 7.14 (dd, J=9.1, 3.0, 1H), 6.65 (d, J=9.0,1H), 4.12 (m, 2H), 3.77 (d, J=6.3, 1H), 3.54 (m, 4H), 3.33 (m, 4H), 2.80(s, 3H), 2.73 (m, 2H), 1.92 (m, 1H), 1.89 (m, 2H), 1.54 (s, 3H), 1.23(m, 2H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₁H₃₃N₄O₅Scalcd.: 453.2, found: 453.2.

Example E115-Isopropyl-3-(4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole

Step A: A mixture of E1a. HCl (202.3 mg, 0.52 mmol) and K₂CO₃ (143 mg,1.0 mmol) in water (3 mL) is cooled to ice/water bath temperature andtreated dropwise with a solution of cyanogen bromide (60.3 mg, 0.57mmol) in dichlormethane (3 mL) and stirred for 2 hours while cooled. Thereaction is then diluted with dichloromethane, extracted with water,dried over MgSO₄, filtered and evaporated to afford E11a which is usedwithout further purification; ESIMS m/z for (M+H)⁺ C₁₇H₂₆N₅O₃S calcd.:380.2, found: 380.2.

Step B: A solution of E11a (152.4 mg, 0.40 mmol) and hydroxylamine (492μL of a 50% aqueous solution, 0.80 mmol) in ethanol (2 mL) is heated to60° C. in a sealed vessel overnight. The reaction is cooled to roomtemperature and the resulting sample of E11b; ESIMS m/z for (M+H)⁺C₁₇H₂₉N₆O₄S calcd.: 413.2, found: 413.2.

Step C: A solution of E11b (134.2 mg, 0.32 mmol) and isobutyricanhydride (50 mg, 0.32 mmol) in dioxane is heated at 400 W in amicrowave reactor for 10 minutes (−120° C.). The reaction is cooled toroom temperature, evaporated and partitioned between ethyl acetate andsaturated aqueous sodium hydrogencarbonate. The organics are isolated,dried over MgSO₄, filtered, evaporated and purified on silica gel usinga linear gradient of 0-100% ethyl acetate in hexane and lyophilized from1 M HCl to afford E11 as an HCl salt; ¹H NMR (CDCl₃, 400 MHz): δ 7.92(d, J=3.0, 1H), 7.16 (dd, J=9.1, 3.0, 1H), 6.65 (d, J=9.1, 1H), 4.06 (m,2H), 3.80 (d, J=6.4, 1H), 3.54 (m, 4H), 3.33 (m, 4H), 3.07 (m, 1H), 2.92(ddd, J=12.7, 12.7, 2.7, 1H), 2.80 (s, 3H), 2.73 (m, 2H), 1.99 (m, 1H),1.88 (m, 2H), 1.42 (m, 2H), 1.34 (d, J=7.0, 6H); ESIMS m/z for (M+H)⁺C₂₁H₃₃N₆O₄S calcd.: 465.2, found: 453.3.

Example E122-((1-(5-Fluoropyridin-2-yl)piperidin-4-yl)methoxy)-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazine

By following a similar procedure as the one used for preparing E5 fromE3a except substituting 2-bromo-5-fluoropyridine for2-bromo-5-methylpyridine anddicyclohexyl(2′,6′-dimethoxybiphenyl-4-yl)phosphine for xantphos, E12 isprepared; ESIMS m/z for (M+H)⁺ C₂₀H₂₈FN₆O₃S calcd: 451.2, found: 451.2.

Example F13-Isopropyl-5-(4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole

Step A: By following a similar procedure as the one used for preparingB5c from B5b except substituting B8a for B5b, F1a is prepared; ESIMS m/zfor (M+H)⁺ C₁₂H₂₂N₃O₄S calcd: 304.1, found: 304.1.

Step B: A solution of F1b (3.00 g, 23.0 mmol) and benzyl chloride (2.93mL, 25.5 mmol) in acetonitrile (50 mL) is treated with Cs₂CO₃ (15.0 g,46.0 mmol) and the reaction mixture is heated at 90° C. for 2 hours,cooled and filtered. The solvents are evaporated and the crude compoundpurified on silica gel using a linear gradient of 0-100% ethyl acetatein hexane to afford F1c; ¹H-NMR (400 MHz, CDCl₃) δ 8.15 (dd, J=0.8, 2.8Hz, 1H), 7.42 (m, 4H), 7.39 (m, 1H), 7.25 (m, 2H), 5.12 (s, 2H); ESIMScalcd. for [M+H]⁺ C₁₂H₁₁ClNO: 220.1 found: 220.1.

Step C: F1c (2.67 g, 12.2 mmol), 1-methanesulfonyl piperazine (3 g, 18.3mmol), Pd(OAc)₂ (548 mg, 2.4 mmol), ((2-dicyclohexyl)phosphino)biphenyl(1.7 g, 4.8 mmol), NaOtBu (3.5 g, 36.6 mmol) and toluene (20 mL) arecharged to a sealed flask and degassed with bubbling Ar for 30 minutes.The mixture is heated at 120° C. for 18 h, then is hot filtered toremove particulates. The filter cake is washed with ethyl acetate (10mL) and water (20 mL) and the filtrates are combined and extracted withethyl acetate (20 mL). The organic layer is extracted with 1N HCl (3×20mL) and discarded. The acidic layer is then basified with NaOH andextracted with ethyl acetate (3×20 mL). The remaining organic layers arecombined, dried (MgSO₄), filtered and concentrated. The residue isrecrystallized from ethyl acetate/Hexane to provide F1d; ESIMS calcd.for [M+H]⁺ C₁₇H₂₂N₃O₃S: 348.1 found: 348.1.

Step D: A solution of F1d (1.3 g, 3.88 mmol) in EtOH is treated withPd/C (0.2 g of 10%, wet). The reaction is stirred under H₂ (1atmosphere) for 12 hours. The mixture is filtered and concentrated toprovide F1e which is used without further purification: ESIMS calcd. for[M+H]⁺ C₁₀H₁₆N₃O₃S: 258.1 found: 258.1.

Step E: A solution of F1e (97.7 mg, 0.38 mmol) and F1a (115.2 mg, 0.38mmol) in N,N-dimethylformamide (1.5 mL) is treated with Cs₂CO₃ (185.6mg, 0.57 mmol) and heated to 60° C. overnight. The reaction is cooled toroom temperature, diluted with ethyl acetate, extracted with water,dried over MgSO₄, filtered, evaporated and purified by silica gel columnchromatography using a linear gradient of 0 to 100% ethyl acetate inhexane and then lyophilized from HCl to afford F1 as an HCl salt; ¹H NMR(CDCl₃, 400 MHz): δ 8.01 (m, 0.5H), 7.92 (d, J=2.8, 1H), 7.16 (dd,J=9.1, 3.1, 1H), 6.66 (d, J=9.1, 1H), 4.20 (m, 2H), 3.81 (d, J=6.3, 1H),3.54 (m, 4H), 3.33 (m, 4H), 3.09 (m, 2H), 2.88 (m, 1H), 2.81 (s, 3H),2.00 (m, 1H), 1.92 (m, 2H), 1.44 (m, 2H), 1.28 (d, J=7.0, 3H); ESIMS m/zfor (M+H)⁺ C₂₁H₃₃N₆O₄S calcd.: 465.2, found: 465.3.

Example G1 tert-Butyl4-((5-(4-(methylsulfonyl)-1,4-diazepan-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A mixture of B4b (307.5 mg, 0.83 mmol), homopiperazine (248.2mg, 2.5 mmol), xantphos (28.7 mg, 0.050 mmol), sodium tert-butoxide 119mg, 1.2 mmol) and toluene (5 mL) is sparged with nitrogen for 5 minutesand treated with Pd₂dba₃ (15.1 mg, 0.017 mmol). The reaction is thensealed and dipped into a pre-heated oil bath at 100° C. The reaction isstirred at this temperature for 4 hours, cooled to room temperature,diluted with ethyl acetate and extracted with water twice. The organicsare dried over MgSO₄, filtered, evaporated and purified on a silica gelcolumn using 0-10% methanol in dichloromethane to afford G1a; ESIMS m/zfor (M+H)⁺ C₂₁H₃₅N₄O₃ calcd.: 391.3, found: 391.3.

Step B: A solution of G1a (139 mg, 3.6 mmol) in dichloromethane (0.25mL) is cooled to ice/water bath temperature and treated withtriethylamine (37.4 mg, 0.37 mmol) followed by methanesulfonyl chloride(42.3 mg, 0.37 mmol) and stirred overnight. The reaction is then pouredinto water and extracted with dichloromethane twice. The combinedorganics are dried over MgSO₄, filtered, evaporated and purified on asilica gel column using 0-100% ethyl acetate in hexane to afford G1; ¹HNMR (CDCl₃, 400 MHz): δ 7.79 (d, J=2.9, 1H), 7.49 (d, J=1.5, 1H), 4.13(m, 2H), 4.14 (d, J=6.5, 1H), 3.82 (m, 2H), 3.74 (dd, J=6.3, 6.3, 2H),3.49 (m, 2H), 3.26 (m, 2H), 2.78 (s, 3H), 2.73 (m, 2H), 2.07 (m, 2H),1.94 (m, 1H), 1.79 (m, 1H), 1.46 (s, 9H), 1.25 (m, 2H); ESIMS m/z for(M+H)⁺ C₂₁H₃₆N₅O₅S calcd.: 470.2, found: 370.2 (M-Boc+H⁺).

Example G2 tert-Butyl4-((5-(3-(methylsulfonyloxy)pyrrolidin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing G1 fromB4b except substituting pyrrolidin-3-ol for homopiperazine, G2 isprepared; ¹H NMR (CDCl₃, 400 MHz): δ 7.82 (d, J=1.5, 1H), 7.38 (d,J=1.5, 1H), 5.43 (m, 1H), 4.03 (m, 2H), 4.06 (d, J=6.6, 1H), 3.82 (m,21H), 3.74 (dd, J=12.4, 4.4, 1H), 3.58 (m, 2H), 3.05 (s, 3H), 2.72 (m,2H), 2.47 (m, 1H), 2.33 (m, 1H), 1.93 (m, 1H), 1.79 (m, 2H), 1.46 (s,9H), 1.26 (m, 2H); ESIMS m/z for (M-Boc+H)⁺ C₁₅H₂₅N₄O₄S calcd.: 357.2,found: 357.2.

Example G3 Tert-butyl4-((5-(4-(methylsulfonyl)piperidin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing G1a fromB4b except substituting 4-(methylsulfonyl)piperidine for homopiperazine,G3 is prepared; ESIMS m/z for (M-^(t)Bu+H)⁺ C₁₆H₂₇N₄O₃S calcd: 355.2,found: 355.2

Example G4 1-Methylcyclopropyl4-((5-(4-(methylsulfonyl)piperidin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing E3 fromB4 except substituting G3 for B4, G4 is prepared; ESIMS m/z for (M+H)⁺C₂₁H₃₄N₄O₅S calcd: 454.2, found: 454.2.

Example H1 tert-Butyl4-(2-(3-(4-(methylsulfonyl)piperazin-1-yl)-1,2,4-oxadiazol-5-yl)ethyl)piperidine-1-carboxylate

Step A: To a stirred a solution of potassium carbonate (2.78 g, 20.0mmol) in water (20 mL) is added H1a (3.0 g, 18.3 mmol). The solution iscooled to 10° C., then a solution of cyanogen bromide (2.12 g, 20.0mmol) in dichloromethane (20 mL) is added dropwise over 30 min. Thereaction is warmed to room temperature and stirred for 2 hours, thenextracted into dichloromethane. The organic layer is washed with 1N HCl(30 mL), dried over MgSO₄, filtered and concentrated. The product isused without further purification.

Step B: A solution of H1b (2.6 g, 13.7 mmol) and hydroxylamine (1 mL,15.1 mmol) in EtOH (10 mL) is heated in a sealed vial at 90° C. for 12hours. The mixture is concentrated in vacuo to provide H1c, which isused without further purification.

Step C: A solution of 1-Boc-piperidin-4-ylpropionic acid (112 mg, 0.44mmol) and N,N-carbonyl dimidazole (71 mg, 0.44 mmol) inN,N-dimethylformamide (0.5 mL) is stirred at room temperature for 30min. H1c (107 mg, 0.48 mmol) is added, the tube is sealed and heated at115° C. for 18 hours. The reaction mixture is cooled, extracted intoethyl acetate (10 mL), washed with water (2×10 mL), then brine (10 mL).The organic layer is dried over MgSO₄, filtered, concentrated, andpurified by mass triggered reverse phase HPLC to provide H1; ¹H NMR(CDCl₃, 400 MHz): δ 4.10 (br.s, 2H), 3.59 (m, 4H), 3.32 (m, 4H), 2.82(s, 3H), 2.79 (t, J=8.0 Hz, 2H), 2.68 (m, 2H), 1.71 (m, 4H), 1.46 (s,9H), 1.15 (m, 2H); ESIMS m/z for (M+H+Na)⁺ C₁₉H₃₃N₅O₅SNa calcd.: 466.2,found: 466.2.

Example H2 tert-Butyl4-(3-(3-(4-(methylsulfonyl)piperazin-1-yl)-1,2,4-oxadiazol-5-yl)propyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing H1 fromH1a except substituting 4-(1-Boc-piperidin-4-yl) butanoic acid for1-Boc-piperidin-4-yl propionic acid, H2 is prepared; ¹H NMR (CDCl₃, 400MHz): δ 4.08 (d, J=13.2 Hz, 2H), 3.59 (m, 4H), 3.32 (m, 4H), 2.82 (s,3H), 2.75 (t, J=7.6 Hz, 2H), 2.68 (dt, J=2.4, 13.2 Hz, 2H), 1.80 (m,2H), 1.68 (s, 1H), 1.65 (s, 1H), 1.46 (s, 9H), 1.42 (m, 1H), 1.34 (s,2H), 1.11 (m, 2H); ESIMS m/z for (M+H+Na)⁺ C₂₀H₃₅N₅O₅SNa calcd.: 480.2,found: 480.3.

Example H35-(3-(1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)propyl)-3-(4-(methylsulfonyl)piperazin-1-yl)-1,2,4-oxadiazole

Step A: A solution of H2 (261 mg, 0.57 mmol) in tetrahydrofuran (5 mL)is treated with HCl (5 mL of 4N in dioxane) and stirred at roomtemperature for 1 hour. The reaction is concentrated, dissolved indichloromethane (5 mL) and concentrated in vacuo to remove traces ofacid and provide H3a, which is used without further purification; ESIMSm/z for (M+H)⁺ C₁₅H₂₈N₅O₃S calcd.: 358.2, found: 358.2.

Step B: H3a (53 mg, 0.15 mmol) and 2-chloro-5-ethyl-pyrimidine (22 μL,0.18 mmol) are dissolved in 1,4-dioxane (1 mL). Cesium carbonate (120mg, 0.37 mmol) is added and the tube is sealed and heated at 150° C. for2 hours. The reaction mixture is cooled, filtered, and purified by masstriggered reverse phase HPLC to provide H3; ¹H NMR (CDCl₃, 400 MHz): δ8.27 (s, 2H), 4.70 (d, J=13.2 Hz, 2H), 3.60 (m, 4H), 3.33 (m, 4H), 2.93(dt, J=2.0, 13.2 Hz, 2H), 2.83 (s, 3H), 2.77 (t, J=7.6 Hz, 2H), 2.51 (q,J=7.6 Hz, 2H), 1.84 (m, 4H), 1.58 (m, 1H), 1.37 (m, 3H), 1.22 (t, J=7.6Hz, 3H; ESIMS m/z for (M+H)⁺ C₂₁H₃₄N₇O₃S calcd.: 464.2, found: 464.2.

Example H4 Isopropyl4-(3-(3-(4-(methylsulfonyl)piperazin-1-yl)-1,2,4-oxadiazol-5-yl)propyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing H1 fromH1a except substituting H4b (see scheme below) for1-Boc-piperidin-4-ylpropionic acid acid, H4 is prepared; ESIMS m/z for(M+H)⁺ C₁₉H₃₄N₅O₅S calcd.: 444.2, found: 480.3.

Commercially available H4a (20 g, 96 mmol) is suspended in drydimethylacetamide (100 mL). Triethylamine (34 mL, 240 mmol) is added andthe resulting mixture is cooled in an ice/water bath. A solution ofisopropyl chloroformate in toluene (1.0M, 150 mL) is added dropwise,forming a white precipitate. The suspension is stirred at roomtemperature for 18 hours, then the white precipitate is filtered, washedwith ethyl acetate, and discarded. The filtrate is concentrated in vacuoto yield H4b.

Example I13-Isopropyl-5-(4-(2-(5-(4-(methylsulfonyl)piperazin-1-yl)thiazol-2-yl)ethyl)piperidin-1-yl)-1,2,4-oxadiazole

Step A: To a stirred a suspension of sodiumhydrogencarbonate (2.80 g,33.3 mmol) in water (1.5 mL) is added I1a hydrochloride salt (2.00 g,11.1 mmol) and dichloromethane (2 mL). The mixture is cooled inice/water bath and stirred. A solution of cyanogen bromide (1.42 g, 13.4mmol) in dichloromethane (3 mL) is added over a period of 1 hour. Thecold bath is removed and the reaction is stirred overnight. 0.33 g ofNa₂CO₃ is added to ensure the reaction is basic. The reaction is dilutedwith dichloromethane (20 mL), dried with MgSO₄. The mixture is filtered,washed with dichloromethane, and evaporated to give I1b; ESIMS m/z for(M+H)⁺ C₉H₁₇N₂O calcd.: 169.1, found: 169.1.

Step B: A solution of I1b (1.87 g, 11.1 mmol) and N′-hydroxyisobutyrimidamide (1.70 g, 16.7 mmol) in ethyl acetate (40 mL) istreated with a solution of ZnCl₂ (16.7 mL, 1N in ether) dropwise. Awhite precipitate is formed. After stirring at room temperature for 15minutes, the precipitate stuck on the flask and made stirring difficult.The solid is triturated with ether (40 mL) and stirred for 4 hours untila yellow suspension is obtained. The solid is collected by filtration,washed with ether (30 mL) and dried to give a yellow solid which is usedwithout purification for the next step; ESIMS m/z for (M+H)⁺ C₁₃H₂₇N₄O₂calcd.: 271.2, found: 271.2. The intermediate material (422 mg) istreated with dioxane (10 mL) and 4M HCl in dioxane (0.5 mL) and heatedto 100° C. for 1 hour. The reaction is then cooled to room temperatureand the solvent is removed. The residue is diluted with ethyl acetateand extracted with 1 M HCl twice, dried over MgSO₄, filtered andevaporated to afford I1c; ESIMS m/z for (M+H)⁺ C₁₃H₂₄N₃O₂ calcd.: 254.2,found: 254.2.

Step C: A solution of I1c (368 mg, 1.45 mmol) in acetonitrile (8 mL) istreated with NaH₂PO₄ (218 mg, 1.8 mmol), Na₂HPO₄ (258 mg, 1.8 mmol),TEMPO free radical (16 mg, 0.1 mmol), NaClO₂ (328 mg of an 80% puresample, 2.91 mmol) and water (8 mL). After all the reagents went intosolution, 10% bleach (22 μL, 0.03 mmol) is added and the reaction isstirred overnight. The acetonitrile is removed in vacuo and theresulting solution is extracted with ethyl acetate once and the organicsare discarded. The aqueous phase is made acidic (pH<1) with concentratedHCl and extracted twice with ethyl acetate and discarded. The combinedorganics are dried over MgSO₄ and the solvent is removed to afford I1d;ESIMS m/z for (M+H)⁺ C₁₃H₂₂N₃O₃ calcd.: 268.2, found: 268.1.

Step D. A solution of I1e (250 mg, 1.4 mol) and methanesulfonylpiperazine (258 mg, 1.6 mmol) in dichloromethane (4 mL) is treated withHOBt hydrate (328 mg, 2.1 mmol) followed by EDC (356 mg, 1.9 mmol).After stirring for 3 hours, the reaction is diluted with ethyl acetateand extracted with water, 1M HCl and 1 M NaOH, dried over MgSO₄,filtered and evaporated to afford I2f; ESIMS m/z for (M+H)⁺ C₁₂H₂₄N₃O₅Scalcd.: 322.1, found: 322.2.

Step E. A sample of I1f (388 mg, 1.2 mmol) is treated with 4 M HCl indioxane (4 mL) and aged for 1 hour. The solvent is removed and theresidue is treated with I1d (298 mg, 1.1 mmol), HATU (502 mg, 1.3 mmol)and N-methylpyrrolidinone (4 mL). The solution is then treated withtriethylamine (0.39 mL, 2.8 mmol) and stirred for 2 hours. The reactionis then diluted with 1M NaOH and saturated with NaCl. The resultingsolution is extracted 4 times with ethyl acetate and discarded. Thecombined organics are dried over MgSO₄, filtered, evaporated and furtherpurified on a UV triggered HPLC to afford I1g; ESIMS m/z for (M+H)⁺C₂₀H₃₅N₆O₅S calcd.: 471.2, found: 471.1.

Step F. A suspension of I1g (354 mg, 0.75 mmol) and Lawesson's reagent(304 mg, 0.75 mmol) in m-xylene (3 mL) is dipped into an oil bath whichis preheated to 140° C. and stirred for 5 minutes. The reaction is thencooled to room temperature and loaded onto silica gel and purified usinga linear gradient of 0-100% ethyl acetate to afford F1; ¹H NMR (CDCl₃,400 MHz): δ 6.86 (s, 1H), 4.12, (2, 2H), 3.38 (m, 4H), 3.19 (m, 4H),3.02 (m, 2H), 2.99 (m, 3H), 2.83 (s, 3H), 1.80 (m, 2H), 1.73 (dd,J=15.3, 7.1, 21H), 1.40 (m, 1H), 1.24 (m, 2H), 1.28 (d, J=7.0, 6H);ESIMS m/z for (M+H)⁺ C₂₀H₃₃N₆O₃S₂ calcd.: 469.2, found: 469.1.

Example J1 Isopropyl4-((4-(1-methanesulfonyl-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)methyl)piperidine-1-carboxylate

Step A: 4-Bromoanisole (4.5 mL, 36.0 mmol) is dissolved in drytetrahydrofuran (50 mL) and cooled to −78° C. under nitrogen. A solutionof n-butyllithium (1.6 M in hexane (22.0 mL, 35.2 mmol) is slowly addedwith stirring. The mixture is stirred at −78° C. for 2 hours. A solutionof J1a (7.28 g, 36.5 mmol) in dry tetrahydrofuran (80 mL) under nitrogenis cooled to −78° C. The suspension of organolithium prepared above isslowly cannulated with stirring into the solution of J1a, using a 20-mLtetrahydrofuran rinse. The resulting mixture is stirred at −78° C. for30 minutes, then at 0° C. for 15 min. Addition of saturated ammoniumchloride solution (60 mL) and extraction with ethyl acetate, washingwith brine and concentration in vacuo yield an oil. The residue ispurified using a linear gradient of 10-80% ethyl acetate in hexane toafford J1b; ¹H NMR (CDCl₃, 400.13 MHz): δ 7.39 (d, J=8.9 Hz, 2H), 6.89(d, J=8.9 Hz, 2H), 3.99 (br., 2H), 3.81 (s, 3H), 1.96 (br, 2H), 1.71 (m,4H), 1.49 (s, 9H); no mass spectrum could be obtained.

Step B: To a solution of J1b (6.29 g, 20 mmol) in dichloromethane (120mL) is added trifluoroacetic acid (20 mL), slowly, with stirring. Theresulting solution is stirred at room temperature for 3 hours.Concentration, dilution with dichloromethane (50 mL), washing withsaturated aqueous sodiumhydrogencarbonate solution, drying over MgSO₄and concentration yields J1c; ¹H NMR (CDCl₃, 400.13 MHz): δ 7.30 (d,J=8.8 Hz, 2H), 6.88 (d, J=8.8 Hz, 2H), 5.93 (m, 1H), 3.82 (s, 5H), 3.40(t, J=6.0 Hz, 2H), 2.77 (m, 2H); ESIMS calcd. for C₁₂H₁₆NO (M+H⁺) 190.1,found 190.0.

Step C: To a solution of J1c (3.41 g, 18 mmol) in dichloromethane (80mL) is added triethylamine (4.5 mL, 32.0 mmol) in one portion. Theresulting mixture is cooled in an ice/water bath and methanesulfonylchloride (1.75 mL, 22.5 mmol) is added dropwise, with stirring, over 5minutes. The resulting solution is stirred at room temperature for 30min. The reaction mixture is added to water (40 mL) and extracted withdichloromethane (2×40 mL). The combined organic extracts are washed withsaturated ammonium chloride aqueous solution, dried over MgSO₄, andconcentrated to yield J1d; ¹H NMR (CDCl₃, 400.13 MHz): δ 7.31 (d, J=8.8Hz, 2H), 6.88 (d, J=8.8 Hz, 2H), 5.98 (m, 1H), 3.96 (q, J=3.2 Hz, 2H),3.82 (s, 3H), 3.52 (t, J=5.7 Hz, 2H), 2.86 (s, 3H), 2.64 (m, 2H); ESIMScalcd. for C₁₃H₁₈NO₃S (M+H⁺) 268.1, found 268.1.

Step D: A solution of J1d (3.71 g, 13.9 mmol) in dichloromethane (100mL) is treated with boron tribromide (5.0 mL, 51.9 mmol) slowly andstirred at room temperature for 3 hours. The mixture is poured overcrushed ice and, after the ice melts, it is extracted withdichloromethane. Washing with saturated aqueous sodiumhydrogencarbonatesolution, water, and saturated ammonium chloride, drying over MgSO₄ andconcentration yield J1e; ¹H NMR (CDCl₃, 400.13 MHz): δ 7.27 (d, J=8.7Hz, 2H), 6.81 (d, J=8.7 Hz, 2H), 5.97 (m, 1H), 4.85 (s, 1H), 3.95 (q,J=3.2 Hz, 2H), 3.52 (t, J=5.7 Hz, 2H), 2.86 (s, 3H), 2.63 (m, 2H); ESIMScalcd. for C₁₂H₁₆NO₃S (M+H⁺) 254.1, found 254.1.

Step E: A solution of J1e (0.12 g, 0.47 mmol) in acetonitrile (3 mL) istreated with A1c (0.16 g, 0.57 mmol) followed by powdered cesiumcarbonate (0.20 g, 0.6 mmol) and stirred at 60° C. for 5 hours. Cooling,filtration and purification using mass-triggered reverse phase HPLCaffords J1; ¹H NMR (CDCl₃, 400.13 MHz): δ 7.30 (d, J=8.7 Hz, 2H), 6.86(d, J=8.7 Hz, 2H), 5.97 (m, 1H), 4.92 (septet, J=6.2 Hz, 1H), 4.19 (br,2H), 3.95 (dd, J=2.6, 5.9 Hz, 2H), 3.81 (d, J=6.3 Hz, 2H), 3.52 (t,J=5.8 Hz, 2H), 2.85 (s, 3H), 2.78 (m, 2H), 2.63 (m, 2H), 1.97 (m, 1H),1.83 (dd, J=1.0, 13.4 Hz, 2H), 1.25 (m, 2H), 1.24 (d, J=6.2 Hz, 6H);ESIMS calcd. for C₂₂H₃₃N₂O₅S (M+H⁺) 437.2, found 437.1.

By following a similar procedure as the one used for preparing J1 fromHJ1a except substituting the appropriate methanesulfonate forintermediate A1c in Step E and/or 3-bromoanisole for 4-bromoanisole, thefollowing examples are prepared;

Example Structure Analytical data J2

ESIMS calcd. for C₂₁H₃₁N₂O₅S (M + H⁺) 423.2, found 423.1. J3

¹H NMR (CDCl₃, 400.13 MHz): δ 7.30 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7Hz, 2H), 5.97 (m, 1H), 4.92 (septet, J = 6.2 Hz, 1H), 4.12 (br, 2H),4.02 (t, J = 5.8, 2H), 3.95 (dd, J = 2.6, 5.9 Hz, 2H), 3.52 (t, J = 5.8Hz, 2H), 2.85 (s, 3H), 2.74 (m, 2H), 2.64 (m, 2H), 1.85 (m, 1H), 1.73(dd, J = 1.0, 13.4 Hz, 2H), 1.24 (d, J = 6.2 Hz, 6H), 1.18 (m, 2H);ESIMS calcd. for C₂₃H₃₅N₂O₅S (M + H⁺) 451.2, found 451.2. J4

¹H NMR (CDCl₃, 400.13 MHz): δ 7.29 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7Hz, 2H), 5.97 (m, 1H), 4.91 (septet, J = 6.2 Hz, 1H), 4.13 (br, 2H),3.52 (t, J = 5.8 Hz, 2H), 2.85 (s, 3H), 2.71 (m, 2H), 2.63 (m, 2H), 1.81(m, 2H), 1.70 (m, 5H), 1.42 (m, 4H), 1.24 (d, J = 6.2 Hz, 6H), 1.12 (m,2H); ESIMS calcd. for C₂₄H₃₉N₂O₅S (M + H⁺) 465.2, found 465.1. J5

ESIMS calcd. for C₂₅H₃₉N₂O₅S (M + H⁺) 479.3, found 479.1. J6

¹H-NMR (400 MHz, DMSO- d6) δ 7.37 (m, 2H), 6.90 (m, 2H), 6.08 (m, 1H),3.70-4.05 (m, 6H), 2.92 (s, 3H), 2.75 (m, 2H), 2.56 (m, 2H), 1.91 (m,1H), 1.73 (m, 2H), 1.46 (s, 3H), 1.13 (m, 2H), 0.76 (m, 2H), 0.59 (m,2H); ESIMS calcd. for C₂₃H₃₃N₂O₅S (M + H⁺) 449.2, found 448.8. J7

¹H-NMR (400 MHz, DMSO- d6) δ 7.38 (m, 2H), 6.92 (m, 2H), 6.08 (m, 1H),3.86 (m, 6H), 3.10 (h, 1H, J = 7.0 Hz), 2.92 (s, 3H), 2.91 (m, 2H), 2.56(m, 2H), 1.97 (m, 1H), 1.82 (m, 2H), 1.30 (m, 2H), 1.26 (d, 6H, J = 7.0Hz); ESIMS calcd. for C₂₃H₃₃N₄O₄S (M + H⁺) 461.2, found 460.8. J8

¹H NMR (CDCl₃, 400.13 MHz): δ 7.25 (dd, J = 7.8, 8.2 Hz, 1H), 6.95 (dd,J = 2.2, 7.8 Hz, 1H), 6.89 (dd, J = 1.9, 2.2 Hz, 1H), 6.81 (dd, J = 1.9,8.2 Hz, 1H), 6.07 (tt, J = 1.5, 3.5 Hz, 1H), 4.91 (septet, J = 6.2 Hz,1H), 4.13 (br. s, 2H), 3.96 (m, 4H), 3.52 (t, J = 5.7 Hz, 2H), 2.86 (s,3H), 2.73 (t, J = 12.4 Hz, 2H), 2.65 (m, 2H), 1.81 (m, 2H), 1.71 (d, J =12.7 Hz, 2H), 1.46 (m, 1H), 1.41 (m, 2H), 1.24 (d, J = 6.3 Hz, 6H), 1.12(ddd, J = 4.2, 12.7, 13.0 Hz, 2H); ESIMS calcd. for C₂₄H₃₇N₂O₅S (M + H⁺)465.2, found 465.2. J9

¹H NMR (CDCl₃, 400.13 MHz): δ 7.26 (dd, J = 7.9, 8.1 Hz, 1H), 6.96 (d, J= 7.8 Hz, 1H), 6.89 (dd, J = 1.8, 2.2 Hz, 1H), 6.82 (dd, J = 2.0, 7.8Hz, 1H), 6.07 (m, 1H), 4.91 (septet, J = 6.2 Hz, 1H), 4.13 (br, 2H),4.02 (t, J = 5.8 Hz, 2H), 3.97 (dd, J = 2.7, 6.0 Hz, 2H), 3.52 (t, J =5.7 Hz, 2H), 2.86 (s, 3H), 2.74 (t, J = 12.4 Hz, 2H), 2.66 (m, 2H), 1.80(m, 2H), 1.74 (m, 3H), 1.24 (d, J = 6.2 Hz, 6H), 1.20 (m, 2H); ESIMScalcd. for C₂₃H₃₅N₂O₅S (M + H⁺) 451.2, found 451.2.

Example J10 Isopropyl4-((4-(1-methanesulfonylpiperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate

A solution of J1 (0.18 g, 0.4 mmol) in ethanol (10 mL) and ethyl acetate(2 mL) is treated with palladium(0) on charcoal (5%, 0.12 g). Themixture is stirred under 1 atm hydrogen for 18 hours. Filtration,concentration, and purification using mass-triggered reverse phase HPLCyields J9; ¹H NMR (CD₃CN, 400.13 MHz): δ 7.19 (d, J=8.7 Hz, 2H), 6.88(d, J=8.7 Hz, 2H), 4.95 (septet, J=6.2 Hz, 1H), 4.16 (br, 2H), 3.83 (d,J=6.4 Hz, 2H), 3.78 (m, 2H), 2.81 (s, 3H), 2.78 (m, 4H), 2.61 (tt,J=3.6, 12.1 Hz, 1H), 2.01 (m, 1H), 1.90 (m, 2H), 1.81 (m, 2H), 1.71 (m,2H), 1.23 (d, J=6.2 Hz, 6H), 1.22 (m, 2H); ESIMS calcd. for C₂₂H₃₅N₂O₅S(M+H⁺) 439.2, found 439.2.

By following a similar procedure as the one used for preparing J10 fromJ1 except substituting the olefin for intermediate J1 or by following asimilar procedure as the one used for preparing J1 from J1a exceptsubstituting 4-(4-methoxyphenyl)piperidine or4-(3-methoxyphenyl)piperidine for J1c, the following examples areprepared;

Example Structure Analytical data J11

ESIMS calcd. for C₂₁H₃₃N₂O₅S (M + H⁺) 425.2, found 425.0. J12

ESIMS calcd. for C₂₃H₃₇N₂O₅S (M + H⁺) 453.2, found 453.2. J13

ESIMS calcd. for C₂₄H₃₉N₂O₅S (M + H⁺) 467.3, found 467.2. J14

ESIMS calcd. for C₂₅H₄₁N₂O₅S (M + H⁺) 481.3, found 481.1. J15

¹H-NMR (400 MHz, CDCl₃) δ 7.11 (m, 2H), 6.83 (m, 2H), 4.12 (m, 2H), 3.93(m, 2H), 3.77 (d, 2H, J = 6.3 Hz), 2.81 (s, 3H), 2.75 (m, 2H), 2.55 (tt,1H, J = 3.5, 12.1 Hz), 1.93 (m, 2H), 1.81 (m, 4H), 1.55 (s, 3H), 1.26(m, 2H), 0.86 (m, 2H), 0.62 (m, 2H). ESIMS calcd. for C₂₃H₃₅N₂O₅S (M +H⁺) 451.2, found 451.2. J16

ESIMS calcd. for C₂₂H₃₅N₂O₅S (M + H⁺) 439.2, found 439.1. J17

ESIMS calcd. for C₂₃H₃₇N₂O₅S (M + H⁺) 453.2, found 453.1. J18

ESIMS calcd. for C₂₄H₃₉N₂O₅S (M + H⁺) 467.3, found 467.1. J19

¹H-NMR (400 MHz, DMSO- d6) δ 8.38 (m, 1H), 7.75 (dd, 1H, J = 2.5, 9.2Hz), 7.16 (m, 2H), 6.96 (d, 1H, J = 9.2 Hz), 6.86 (m, 2H), 4.46 (m, 2H),3.82 (d, 2H, J = 6.4 Hz), 3.65 (m, 2H), 2.95 (m, 2H), 2.88 (s, 3H), 2.78(m, 2H), 2.56 (tt, 1H, J = 3.5, 12.3 Hz), 2.07 (m, 1H), 1.83 (m, 4H),1.62 (m, 2H), 1.24 (m, 2H). ESIMS calcd. for C₂₄H₃₁F₃N₃O₃S (M + H⁺)498.2, found 497.8. J20

¹H-NMR (400 MHz, DMSO- d6) δ 7.16 (m, 2H), 6.86 (m, 2H), 3.87 (m, 2H),3.82 (d, 2H, J = 6.5 Hz), 3.65 (m, 2H), 3.10 (h, 1H, J = 7.0 Hz), 2.90(m, 2H), 2.89 (s, 3H), 2.78 (m, 3H), 2.56 (tt, 1H, J = 3.4, 12.2 Hz),1.95 (m, 1H), 1.82 (m, 4H), 1.62 (m, 2H), 1.29 (m, 2H), 1.26 (d, 6H, J =7.0 Hz). ESIMS calcd. for C₂₃H₃₅N₄O₄S (M + H⁺) 463.2, found 463.2. J21

¹H-NMR (400 MHz, DMSO- d6) δ 8.54 (m, 1H), 8.16 (d, 1H, J = 2.0 Hz),7.17 (m, 2H), 6.88 (m, 2H), 4.04 (m, 2H), 3.86 (d, 2H, J = 6.4 Hz), 3.65(m, 2H), 2.93 (m, 2H), 2.89 (s, 3H), 2.78 (m, 2H), 2.56 (tt, 1H, J =3.5, 12.2 Hz), 2.01 (m, 1H), 1.86 (m, 4H), 1.62 (m, 2H), 1.43 (m, 2H).ESIMS calcd. for C₂₄H₃₀ClF₃N₃O₃S (M + H⁺) 532.2, found 531.9. J22

¹H-NMR (400 MHz, DMSO- d6) δ 8.08 (d, 1H, J = 2.5 Hz), 7.56 (dd, 1H, J =2.7, 9.1 Hz), 7.16 (m, 2H), 6.87 (m, 3H), 4.29 (m, 2H), 3.81 (d, 2H, J =6.4 Hz), 3.65 (m, 2H), 2.88 (s, 3H), 2.81 (m, 4H), 2.56 (tt, 1H, J =3.4, 11.9 Hz), 2.00 (m, 1H), 1.82 (m, 4H), 1.62 (m, 2H), 1.25 (m, 2H).ESIMS calcd. for C₂₃H₃₁ClN₃O₃S (M + H⁺) 464.2, found 464.2. J23

¹H-NMR (400 MHz, DMSO- d6) δ 7.50 (d, 1H, J = 9.6 Hz), 7.41 (d, 1H, J =9.7 Hz), 7.16 (m, 2H), 6.87 (m, 2H), 4.37 (m, 2H), 3.82 (d, 2H, J = 6.4Hz), 3.64 (m, 2H), 2.95 (m, 2H), 2.88 (s, 3H), 2.78 (m, 2H), 2.56 (tt,1H, J = 3.4, 11.9 Hz), 2.06 (m, 1H), 1.84 (m, 4H), 1.62 (m, 2H), 1.29(m, 2H). ESIMS calcd. for C₂₂H₃₀ClN₄O₃S (M + H⁺) 465.2, found 465.2. J24

¹H-NMR (400 MHz, DMSO- d6) δ 8.43 (s, 2H), 7.16 (m, 2H), 6.86 (m, 2H),4.61 (m, 2H), 3.81 (d, 2H, J = 6.6 Hz), 3.65 (m, 2H), 2.93 (m, 2H), 2.88(s, 3H), 2.78 (m, 2H), 2.55 (m, 1H), 2.05 (m, 1H), 1.82 (m, 4H), 1.62(m, 2H), 1.22 (m, 2H). ESIMS calcd. for C₂₂H₃₀BrN₄O₃S M + H⁺) 509.1,found 508.9. J25

¹H-NMR (400 MHz, DMSO- d6) δ 8.24 (s, 2H), 7.16 (m, 2H), 6.86 (m, 2H),4.65 (m, 2H), 3.81 (d, 2H, J = 6.4 Hz), 3.65 (m, 2H), 2.87 (m, 2H), 2.89(s, 3H), 2.78 (m, 2H), 2.56 (tt, 1H, J = 3.5, 11.9 Hz), 2.42 (q, 2H, J =7.6 Hz), 2.03 (m, 1H), 1.82 (m, 4H), 1.62 (m, 2H), 1.20 (m, 2H), 1.12(t, 3H, J = 7.6). ESIMS calcd. for C₂₄H₃₅N₄O₃S (M + H⁺) 459.2, found459.2. J26

¹H-NMR (400 MHz, DMSO- d6) δ 8.07 (d, 1H, J = 3.1 Hz), 7.49 (ddd, 1H, J= 3.1, 8.4, 9.2 Hz), 7.16 (m, 2H), 6.88 (m, 3H), 4.23 (m, 2H), 3.82 (d,2H, J = 6.4 Hz), 3.65 (m, 2H), 2.89 (s, 3H), 2.79 (m, 4H), 2.57 (tt, 1H,J = 3.5, 12.0 Hz), 1.98 (m, 1H), 1.82 (m, 4H), 1.62 (m, 2H), 1.27 (m,2H). ESIMS calcd. for C₂₃H₃₁FN₃O₃S (M + H⁺) 448.2, found 448.2 J27

¹H-NMR (400 MHz, DMSO- d6) δ 7.16 (m, 2H), 6.87 (m, 2H), 3.99 (m, 2H),3.83 (d, 2H, J = 6.4 Hz), 3.65 (m, 2H), 3.12 (m, 2H), 2.89 (s, 3H), 2.79(m, 3H), 2.56 (tt, 1H, J = 3.5, 11.9 Hz), 1.99 (m, 1H), 1.84 (m, 4H),1.62 (m, 2H), 1.31 (m, 2H), 1.18 (d, 6H, J = 6.9 Hz). ESIMS calcd. forC₂₃H₃₅N₄O₄S (M + H⁺) 463.2, found 463.2. J28

¹H-NMR (400 MHz, DMSO- d6) δ 8.10 (d, 1H, J = 10.0 Hz), 8.01 (d, 1H, J =10.0 Hz), 7.17 (m, 2H), 6.87 (m, 2H), 4.31 (m, 2H), 3.84 (d, 2H, J = 6.4Hz), 3.66 (m, 2H), 3.25 (m, 2H), 2.89 (s, 3H), 2.78 (m, 2H), 2.56 (tt,1H, J = 3.4, 12.3 Hz), 2.16 (m, 1H), 1.92 (m, 2H), 1.82 (m, 2H), 1.62(m, 2H), 1.41 (m, 2H), 1.32 (s, 9H). ESIMS calcd. for C₂₆H₃₉N₄O₃S (M +H⁺) 486.3, found 486.3. J29

¹H-NMR (400 MHz, DMSO- d6) δ 8.42 (d, 2H, J = 0.8 Hz), 7.16 (m, 2H),6.86 (m, 2H), 4.60 (m, 2H), 3.82 (d, 2H, J = 6.4 Hz), 3.65 (m, 2H), 2.91(m, 2H), 2.88 (s, 3H), 2.78 (m, 2H), 2.56 (tt, 1H, J = 3.5, 11.9 Hz),2.03 (m, 1H), 1.82 (m, 4H), 1.62 (m, 2H), 1.21 (m, 2H). ESIMS calcd. forC₂₂H₃₀FN₄O₃S (M + H⁺) 449.2, found 448.8.

Example J302-(4-((2-Bromo-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)-5-fluoropyrimidine

This material is prepared when a large scale preparation of J28 from4-(4-methoxyphenyl)piperidine in place of J1c following the schemeoutlined for J1 yielded a brominated byproduct in step D: ¹H-NMR (400MHz, DMSO-d6) δ 8.43 (d, 2H, J=0.8 Hz), 7.45 (d, 1H, J=2.1 Hz), 7.21(dd, 1H, J=2.1, 8.6 Hz), 7.04 (d, 1H, J=8.6 Hz), 4.61 (m, 2H), 3.91 (d,2H, J=6.3 Hz), 3.65 (m, 2H), 2.93 (m, 2H), 2.89 (s, 3H), 2.77 (m, 2H),2.59 (tt, 1H, J=3.5, 12.0 Hz), 2.07 (m, 1H), 1.84 (m, 4H), 1.62 (m, 2H),1.27 (m, 2H). ESIMS calcd. for C₂₂H₂₉BrFN₄O₃S (M+H⁺) 527.1, found 527.1.

Example K1 1-Methylcyclopropyl4-methoxy-4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of K1a (2.22 g, 10.4 mmol) and2-bromo-5-hydroxypyrazine (2 g, 11.4 mmol) in N-methylpyrrolidinone (10mL) is treated with K₂CO₃ (2.37 g, 17.1 mmol) and heated to 80° C.overnight. After cooling to room temperature, the reaction is dilutedwith ethyl acetate and extracted with water twice. The organics aredried over MgSO₄, filtered evaporated and purified by silica gel using alinear gradient of 0-100% ethyl acetate in hexane to afford K1b; ESIMSm/z for (M+H⁺) C₁₅H₂₃BrN₃O₄ calcd.: 388.1, found: 388.2.

Step B: By following a similar procedure as the one used for preparingB1 from isopropyl4-((6-chloropyridin-3-yloxy)methyl)piperidine-1-carboxylate exceptsubstituting K1b for isopropyl4-((6-chloropyridin-3-yloxy)methyl)piperidine-1-carboxylate, K1c isprepared; ESIMS m/z for (M+H⁺) C₂₀H₃₄N₅O₆S calcd.: 472.2, found: 472.2.

Step C: By following a similar procedure as the one used for preparingE3 from B4 except substituting K1c B4, K1d is prepared; ESIMS m/z for(M+H⁺) C₂₀H₃₂N₅O₆S calcd.: 470.2, found: 470.2.

Step D: A solution of K1d (75 mg, 0.16 mmol) in N,N-dimethylformamide istreated with dimethylsulfate (80 mg, 0.63 mmol) followed by NaH (30 mg,1.25 mmol). After stirring at room temperature for 1 hour, the reactionis treated with water and ethyl acetate. The organics are isolated,washed with water, dried over MgSO₄, filtered evaporated and purified bysilica gel using a linear gradient of 50-100% ethyl acetate in hexane toafford K1; ¹H NMR (CDCl₃, 400.13 MHz): δ 7.94 (d, J=1.5 Hz, 1H), 7.61(d, J=1.4 Hz, 1H), 4.20 (m, 2H), 3.91 (m, 2H), 3.54 (m, 4H), 3.37 (m,4H), 3.29 (s, 3H), 3.13 (m, 2H), 2.82 (s, 3H), 1.89 (m, 2H), 1.55 (m,2H), 1.55 s, 3H), 0.87 (m, 2H), 0.62 (m, 2H); ESIMS calcd. forC₂₁H₃₄N₅O₆S (M+H⁺) 484.2, found 484.1.

Example K2 1-methylcyclopropyl4-hydroxy-4-((6-(4-(isobutylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of K2a (2.0 g, 11.5 mmol) and benzyl bromide (2.36 g,13.8 mmol) in N-methylpyrrolidinone (15 mL) is treated with K₂CO₃ (2.38g, 17.2 mmol) and stirred at 60° C. overnight. The reaction is cooled toroom temperature, diluted with ethyl acetate and extracted with watertwice. The organics are then dried over MgSO₄, filtered evaporated andpurified on silica gel using a linear gradient of 0-100% ethyl acetatein hexane to afford K2b; ¹H NMR (CDCl₃, 400.13 MHz): δ 8.13 (d, J=3.1Hz, 1H), 7.38 (m, 6H), 7.15 (dd, J=3.2, 8.7 Hz, 1H), 5.09 (s, 2H); ESIMSm/z for (M+H)⁺ C₁₂H₁₁BrNO calcd: 264.0, found: 264.0.

Step B: A roundbottom flask is charged with K2b (2.55 g, 9.65 mmol),Pd₂dba₃ (177 mg, 0.19 mmol), xantphos (335 mg, 0.58 mmol) and tert-butylpiperazine-1-carboxylate (2.16 g, 11.6 mmol) followed by dry toluene (30mL). The flask is sparged with dry nitrogen, treated with NaOtBu (1.39g, 14.5 mmol), sealed, dipped into a pre heated 100° C. oil bath andstirred for 2 hours. The reaction is then cooled to room temperature,diluted with ethyl acetate and extracted with water twice. The organicsare then dried over MgSO₄, filtered evaporated and purified on silicagel using a linear gradient of 0-100% ethyl acetate in hexane to affordK2c; ESIMS m/z for (M+H)⁺ C₂₁H₂₈N₃O₃ calcd: 370.2, found: 370.1.

Step C: A solution of K2c (970 mg, 2.2 mmol) in 1:1 TFA/dichloromethane(10 mL) is aged for 1 hour and the solvent is removed. The resultingresidue is partitioned between ethyl acetate and 1 M HCl. The aqueousphase is collected and the organics are extracted once more with 1 M HCland discarded. The combined aqueous extracts are made basic with solidNa₂CO₃ and extracted three times with dichloromethane. The combinedorganics are dried over MgSO₄, filtered, evaporated, dissolved indichloromethane (10 mL) and treated with triethylamine (337 mg, 3.33mmol) followed by isobutanesulfonyl chloride (452 mg, 2.89 mmol). Afterstirring for 30 minutes, the reaction is diluted with ethyl acetate,extracted with saturated aqueous sodiumhydrogencarbonate twice, driedover MgSO₄, filtered and evaporated to afford K2d; ¹H NMR (CDCl₃, 400.13MHz): δ 7.99 (d, J=2.8 Hz, 1H), 7.38 (m, 5H), 7.22 (dd, J=3.2, 9.1 Hz,1H), 6.64 (d, J=9.0 Hz, 1H), 5.04 (s, 2H), 3.52 (m, 4H), 3.37 (m, 4H),2.76 (d, J=6.6 Hz, 2H), 1.12 (d, J=6.7 Hz, 6H); ESIMS m/z for (M+H)⁺C₂₀H₂₈N₃O₃S calcd: 390.2, found: 390.2.

Step D: A solution of K2d (0.80 g, 2.0 mmol) in ethanol (10 mL) istreated with Pd(OH)₂ (50 mg) and hydrogenated overnight. The catalyst isremoved by filtration through Celite® and resubjected to hydrogenationwith 100 mg of 10% Pd/C overnight. The catalyst is removed by filtrationthrough Celite® and the solvent is removed. The resulting material isslurried in hexane, collected and dried to afford K2e; ESIMS m/z for(M+H)⁺ C₁₃H₂₂N₃O₃S calcd: 300.1, found: 300.1.

Step E: A solution of K2e (75 mg, 0.25 mmol) and K1a (64 mg, 0.30 mmol)in N-methylpyrrolidinone (2 mL) is treated with K₂CO₃ (52 mg, 0.38 mmol)and stirred at 80° C. overnight. The reaction is then cooled to roomtemperature, partitioned between ethyl acetate and water and extractedwith water once more. The organics are dried over MgSO₄, filtered,evaporated, dissolved in dichloromethane (2 mL) and treated with TFA (2mL). After stirring for 1 hour, the solvent is removed and the residueis dissolved in dichloromethane, treated with E3b (59 mg, 0.25 mmol) andexcess triethylamine and stirred overnight. The reaction is thenpartitioned between ethyl acetate and water and extracted with wateronce more. The organics are dried over MgSO₄, filtered, evaporated andpurified on silica gel using a linear gradient of 0-100% ethyl acetatein hexane to afford K2; ¹H NMR (CDCl₃, 400.13 MHz): δ 7.93 (d, J=3.0 Hz,1H), 7.18 (dd, J=3.1, 9.1 Hz, 1H), 6.65 (d, J=9.2 Hz, 1H), 3.99 (m, 2H),3.77 (s, 2H), 3.52 (m, 4H), 3.37 (m, 4H), 3.20 (m, 2H), 2.77 (d, J=6.6Hz, 2H), 2.32 (m, 1H), 2.12 (s, 1H), 1.72 (m, 2H), 1.55 (m, 3H), 1.12(d, J=6.7 Hz, 6H), 0.87 (m, 2H), 0.63 (m, 2H); ESIMS m/z for (M+H)⁺C₂₄H₃₈N₄O₆S calcd: 510.3, found: 511.5.

Example K3 (+/−)-(cis)-1-methylcyclopropyl3-hydroxy-4-((6-(4-(isobutylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of K3a (420 mg, 1.4 mmol) (Helv. Chim. Acta 2004, 87,2629) in EtOH containing 1% by volume TFA (150 mL) is hydrogenated in anH-Cube apparatus at 50 atmospheres of H₂ and 70° C. The solvent is thenremoved and the residue is co-evaporated twice with toluene, dissolvedin dichloromethane (10 mL) and treated with E3b (342 mg, 1.4 mmol),excess triethylamine and a few crystals of DMAP. The reaction is stirredovernight, partitioned between ethyl acetate and saturated aqueoussodiumhydrogencarbonate and extracted with saturated aqueous sodiumcarbonate twice. The organics are then dried over MgSO₄, filteredevaporated and purified on silica gel using a linear gradient of 0-100%ethyl acetate in hexane to afford K3b; ESIMS m/z for (M+H)⁺ C₁₅H₂₄NO₆calcd: 314.2, found: 314.1.

Step B: A solution of K3b (333 mg, 1.1 mmol) in MeOH is treated with asolution of Mg(OMe)₂ (5.6 mL of a 0.57 M solution, 3.2 mmol) and stirredfor 1 hour. The reaction is then quenched with excess prewashedAmberlite IR-120 H⁺ resin and filtered. The solvent is removed to affordK3c; ESIMS m/z for (M+H)⁺ C₁₁H₂₀NO₄ calcd: 230.1, found: 230.1.

Step C: A solution of DIAD (88 mg, 0.22 mmol) in dichloromethane (0.5mL) is cooled in an ice bath and treated with a solution of PPh₃ (114mg, 0.44 mmol) in dichloromethane (1 mL). The solution is stirred for 15minutes and treated with a solution of K3c (50 mg, 0.22 mmol) and K2d(65 mg, 0.22 mmol) in dichloromethane (1.5 mL). The reaction is sealedand heated to 50° C. overnight. The reaction is cooled to roomtemperature and loaded onto a silica gel column and purified using alinear gradient of 0-100% ethyl acetate in hexane. The product fractionsare partitioned between ethyl acetate and 1 M HCl. The aqueous phase iscollected and the organics are extracted once more with 1 M HCl anddiscarded. The combined aqueous extracts are made basic with solidNa₂CO₃ and extracted three times with ethyl acetate. The combinedorganics are dried over MgSO₄, filtered and evaporated to afford K3; ¹HNMR (CDCl₃, 400.13 MHz): δ 7.93 (d, J=2.9 Hz, 1H), 7.17 (dd, J=3.1, 9.1Hz, 1H), 6.64 (d, J=9.1 Hz, 1H), 4.19 (m, 2H), 4.09 (m, 1H), 4.03 (dd,J=7.6, 9.1 Hz, 1H), 3.84 (dd, J=6.0, 9.1 Hz, 1H), 3.51 (m, 4H), 3.37 (m,4H), 2.91 (m, 1H), 2.78 (m, 1H), 2.76 (d, J=6.6 Hz, 2H), 2.32 (m, 1H),2.00 (m, 1H), 1.86 (m, 1H), 1.68 (m, 1H), 1.55 (s, 3H), 1.12 (d, J=6.7Hz, 6H), 0.88 (m, 2H), 0.62 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₄H₃₉N₄O₆Scalcd: 511.3, found: 511.4.

Example K4 (+/−)-(cis)-1-Methylcyclopropyl4-((6-(4-(isobutylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)-3-methoxypiperidine-1-carboxylate

A solution of K3 (25 mg, 0.22 mmol) in N,N-dimethylformamide (2 mL) istreated with excess (˜100 uL) dimethylsulfate and excess (˜40 mg) ofNaH. The reaction is stirred for 1 hour and then diluted with ethylacetate and water. The organics are isolated and washed once more withwater, dried over MgSO4, filtered, evaporated and purified on silica gelusing a linear gradient of 0-100% ethyl acetate in hexane to afford K4;¹H NMR (CDCl₃, 400.13 MHz): δ 7.93 (d, J=2.9 Hz, 1H), 7.16 (dd, J=3.0,9.1 Hz, 1H), 6.64 (d, J=9.1 Hz, 1H), 4.53 (m, 0.5H), 4.28 (m, 1H), 4.00(m, 1.5H), 3.78 (m, 1H), 3.52 (m, 4H), 3.75 (m, 7H), 2.76 (d, J=6.6 Hz,2H), 2.72 (m, 2H), 2.32 (m, 1H), 2.03 (m, 1H), 1.59 (m, 1H), 1.55 (s,3H), 1.48 (m, 1H), 1.12 (d, J=6.7 Hz, 6H), 0.87 (m, 2H), 0.61 (m, 2H);ESIMS m/z for (M+H)⁺ C₂₅H₄₁N₄O₆S calcd: 525.3, found: 525.2.

Example K5 (+/−)-(Trans)-1-methylcyclopropyl3-hydroxy-4-((6-(4-(isobutylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing K3 fromK3a except substituting the trans-isomer of K3a (Helv. Chim. Acta 2004,87, 2629) for K3a, K5 is prepared; ¹H NMR (CDCl₃, 400.13 MHz): δ 7.93(d, J=3.0 Hz, 1H), 7.24 (dd, J=3.0, 9.1 Hz, 1H), 6.69 (d, J=9.2 Hz, 1H),4.17 (m, 3H), 4.05 (m, 2H), 3.56 (m, 5 H), 3.37 (m, 4H), 2.77 (d, J=6.6Hz, 2H), 2.72 (m, 1H), 2.58 (m, 1H), 2.31 (m, 1H), 1.90 (m, 1H), 1.78(m, 1H), 1.55 (s, 3H), 1.40 (m, 1H), 1.12 (d, J=6.7 Hz, 6H), 0.87 (m,2H), 0.61 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₄H₃₉N₄O₆S calcd: 511.3, found:511.4.

Example L1 1-methylcyclopropyl4-((6-formyl-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of E3 (109 mg, 0.24 mmol) in N,N-dimethylformamide (2.2 mL)is treated with POCl₃ (165 mg, 1.1 mmol) and heated to 70° C. for 2hours. The reaction is then cooled to room temperature, quenched withwater and diluted with ethyl acetate. The organics are extracted withwater twice more, dried over MgSO₄, filtered evaporated and purified bysilica gel using a linear gradient of 50-100% ethyl acetate in hexane toafford L1; ¹H NMR (CDCl₃, 400.13 MHz): δ 9.93 (s, 1H), 8.04 (s, 1H),4.19 (d, J=6.4 Hz, 1H), 4.15 (m, 2H), 3.50 (m, 4H), 3.43 (m, 4H), 2.83(s, 3H), 2.74 (m, 2H), 1.97 (m, 1H), 1.81 (m, 2H), 1.55 (s, 3H), 1.27(m, 2H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS calcd. for C₂₁H₃₂N₅O₆S (M+H⁺)482.2, found 482.1.

Example L2 1-Methylcyclopropyl4-((6-chloro-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing L1 fromE3 except using NCS at 50° C. in dichloroethane overnight as thereaction conditions, K5 is prepared; ESIMS m/z for (M+H)⁺ C₂₀H₃₁ClN₅O₅Scalcd: 488.2, found: 487.7.

Example M1 1-Methylcyclopropyl4-((5-(4-(3-methoxy-3-oxopropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: By following a similar procedure as the one used for preparingE3 from E3a except substituting B12a for E3a, M1a is prepared; ESIMS m/zfor (M+H)⁺ C₁₅H₂₂BrN₃O₃ calcd: 371.2, found: 371.1.

Step B: By following a similar procedure as the one used for preparingB1 from isopropyl4-((6-chloropyridin-3-yloxy)methyl)piperidine-1-carboxylate exceptsubstituting M1a for isopropyl4-((6-chloropyridin-3-yloxy)methyl)piperidine-1-carboxylate and benzylpiperazine-1-carboxylate for 1-(methylsulfonyl)piperazine, M1b isprepared; ¹H NMR (400 MHz, CDCl₃) δ 7.85 (d, J=1.5 Hz, 1H), 7.59 (d,J=1.4 Hz, 1H), 7.35 (m, 5H), 5.16 (s, 2H), 4.18 (m, 2H), 4.06 (d, J=6.6Hz, 2H), 3.65 (m, 4H), 3.38 (m, 4H), 2.74 (m, 2H), 1.94 (m, 1H), 1.79(m, 2H), 1.54 (s, 3H), 1.24 (m, 2H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMSm/z for (M+H)⁺ C₂₇H₃₆N₅O₅ calcd: 510.3, found: 510.0.

Step C: A mixture of M1b (494 mg, 0.969 mmol) and 10% Pd/C (45 mg) inethanol (5 mL) is purged with H₂ (g) for 30 minutes and then left tostir at room temperature under an atmosphere of H₂ overnight. The crudereaction is then filtered through a pad of Celite® and M1c is obtainedwith 95%+ purity. ESIMS m/z for (M+H)⁺ C₁₉H₃₀N₅O₃ calcd: 376.2, found:376.0.

Step D: A solution of M1c (100 mg, 0.266 mmol) in dichloromethane (1 mL)is treated with triethylamine (74.2 mL, 0.533 mmol) followed by methyl3-(chlorosulfonyl)propanoate (50 mg, 0.27 mmol) and stirred at roomtemperature for 4 hours. The crude reaction is then concentrated andpurified directly via a mass-directed HPLC to afford M1; ¹H NMR (400MHz, CDCl₃) δ 7.86 (d, J=1.5 Hz, 1H), 7.61 (d, J=1.5 Hz, 1H), 4.18 (m,2H), 4.07 (d, J=6.5 Hz, 2H), 3.73 (s, 3H), 3.49 (m, 4H), 3.42 (m, 4H),3.28 (t, J=7.3H, 2H), 2.85 (t, J=7.7 Hz, 2H), 2.74 (m, 2H), 1.93 (m,1H), 1.81 (m, 2H), 1.54 (s, 3H), 1.24 (m, 2H), 0.86 (m, 2H), 0.62 (m,2H); ESIMS m/z for (M+H)⁺ C₂₃H₃₆N₅O₇S calcd: 526.2, found: 526.2.

By following a similar procedure as the one used for preparing M1 fromE12a except substituting commercially available sulfonyl chlorides formethyl 3-(chlorosulfonyl)propanoate (in the case of M5, alsosubstituting B4bB for M1a), the following examples are prepared;

Example Structure Analytical data M2

ESIMS m/z for (M + H)⁺ C₂₄H₃₅N₆O₆S calcd: 535.2, found: 535.2. M3

ESIMS m/z for (M)⁺ C₃₂H₃₉N₅O₆S calcd: 621.3, found: 621.7. M4

ESIMS m/z for (M + H)⁺ C₂₂H₃₂N₇O₅S calcd: 506.2, found: 506.2. M5

¹H NMR (400 MHz, CD₃CN) δ 7.87 (d, J = 1.4 hz, 1H), 7.62 (d, J - 1.5 Hz,1H), 4.15 (m, 2H), 4.08 (d, J = 6.6 Hz, 2H), 3.70 (t, J = 6.1 Hz, 2H),3.51 (m, 4H), 3.43 (m, 4H), 3.11 (t, J = 7.4 Hz, 2H), 2.73 (m, 2H), 2.32(m, 2H), 1.94 (m, 1H), 1.79 (m, 2H), 1.46 (s, 9H), 1.26 (m, 2H); ESIMSm/z for (M − Boc + H)⁺ C₁₇H₂₉ClN₅O₃S calcd: 481.2, found: 418.2. M6

¹H-NMR (400 MHz, CDCl₃) δ 7.87 (d, J = 1.4 Hz, 1H), 7.63 (d, J = 1.4 Hz,1H), 4.21 (m, 2H), 4.08 (d, J = 6.5 Hz, 2H), 3.70 (t, J = 6.1 Hz, 2H),3.51 (m, 4H), 3.44 (m, 4H), 3.12 (m, 2H), 2.74 (dd, J = 12.3, 12.2 Hz,2H), 2.32 (m, 2H), 1.95 (m, 1H), 1.79 (m, 2H), 1.55 (s, 3H), 1.25 (m,2H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS calcd. for C₂₂H₃₅ClN₅O₅S [M]⁺516.2, found 516.0. M7

¹H NMR (400 MHz, CD₃CN) δ 7.89 (d, J = 1.4 Hz, 1H), 7.82 (d, J = 1.2 Hz,1H), 4.19 (m, 2H), 4.10 (d, J = 6.5 Hz, 2H), 3.51 (m, 8H), 2.93 (m, 2H),2.74 (dd, J = 12.7, 12.0 Hz, 1H), 1.91 (m, 3H), 1.79 (m, 2H), 1.55 (s,3H), 1.25 (m, 2H), 1.07 (t, J = 7.4 Hz, 3H), 0.86 (m, 2H), 0.62 (m, 2H);ESIMS m/z for (M + H)⁺ C₂₂H₃₆N₅O₅S calcd: 482.3, found: 482.2. M8

¹H NMR (400 MHz, CD₃CN) δ 7.96 (s, 1H), 7.91 (d, J = 1.4 Hz, 1H), 4.17(m, 2H), 4.11 (d, J = 6.5 Hz, 2H), 3.58 (m, 4H), 3.54 (m, 4H), 3.01 (m,2H), 2.74 (dd, J = 12.2, 11.9 Hz, 2H), 1.95 (m, 1H), 1.79 (m, 2H), 1.55(s, 3H), 1.40 (t, J = 7.4 Hz, 3H), 1.25 (m, 2H), 0.86 (m, 2H), 0.62 (m,2H); ESIMS m/z for (M + H)⁺ C₂₁H₃₄N₅O₅S calcd: 468.2, found: 468.2. M9

¹H NMR (400 MHz, CD₃CN) δ 7.91 (m, 2H), 4.18 (m, 2H), 4.11 (d, J = 6.5Hz, 2H), 3.63 (m, 4H), 3.50 (m, 4H), 3.25 (sept., J = 6.8 Hz, 1H), 2.74(dd, J = 12.2, 12.1 Hz, 2H), 1.94 (m, 1H), 1.78 (m, 2H), 1.55 (s, 3H),1.37 (d, J = 6.9 Jz, 6H), 1.25 (m, 2H), 0.86 (m, 2H), 0.62 (m, 2H);ESIMS m/z for (M + H)⁺ C₂₂H₃₆N₅O₅S calcd: 482.2, found: 482.2. M10

¹H NMR (400 MHz, CD₃CN) δ 7.89 (d, J = 1.4 Hz, 1H), 7.81 (d, J = 1.1 Hz,1H), 4.18 (m, 2H), 4.10 (d, J = 6.5 Hz, 2H), 3.53 (m, 4H), 3.47 (m, 4H),2.79 (d, J = 6.6 Hz, 2H), 2.74 (m, 2H), 2.32 (m, 1H), 1.95 (m, 1H), 1.78(m, 2H), 1.55 (s, 3H), 1.24 (m, 2H), 1.12 (d, J = 6.7 Hz, 6H), 0.86 (m,2H), 0.62 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₃H₃₈N₅O₅S calcd: 496.3,found 496.3. M11

¹H NMR (400 MHz, CD₃CN) δ 7.87 (d, J = 1.5 Hz, 1H), 7.62 (d, J = 1.5 Hz,1H), 4.19 (m, 2H), 4.07 (d, J = 6.5 Hz, 2H), 3.50 (m, 4H), 3.46 (m, 4H),2.98 (m, 1H), 2.75 (dd, J = 12.2, 12.1 Hz, 2H), 2.03 (m, 1H), 1.80 (m,1H), 1.79 (m, 2H), 1.56 (m, 1H), 1.55 (s, 3H), 1.35 (d, J = 6.9 Hz, 3H),1.26 (m, 2H), 1.03 (t, J = 7.5 hz, 3H), 0.87 (m, 2H), 0.62 (m, 2H);ESIMS m/z for for (M + H)⁺ C₂₃H₃₈N₅O₅S calcd: 496.3, found: 496.2. M12

¹H-NMR (400 MHz, CDCl₃) δ 7.87 (d, J = 1.4 Hz, 1H), 7.62 (d, J = 1.4 Hz,1H), 4.20 (m, 2H), 4.08 (d, J = 6.5 Hz, 2H), 3.52 (m, 4H), 3.45 (m, 2H),3.52 (m, 4H), 2.74 (dd, J = 12.2, 12.2 Hz, 2H), 2.66 (m, 2H), 1.94 (m,1H), 1.79 (m, 2H), 1.56 (s, 3H), 1.25 (m, 2H), 0.86 (m, 2H), 0.62 (m,2H); ESIMS calcd. C₂₂H₃₃F₃N₅O₅S [M + H]⁺ 536.2, found 536.3.

Example M133-(4-(5-((1-((1-Methylcyclopropoxy)carbonyl)piperidin-4-yl)methoxy)pyrazin-2-yl)piperazin-1-ylsulfonyl)propanoicacid

A solution of M1 (18.8 mg, 0.035 mmol) in TETRAHYDROFURAN (1 mL) andwater (0.25 mL) is treated with LiOH (3 mg) and stirred overnight. Thecrude reaction is then concentrated and purified directly via amass-directed HPLC to afford M13. ESIMS m/z for (M+H)⁺ C₂₂H₃₄N₅O₇Scalcd: 512.2, found: 512.3.

Example M14 1-Methylcyclopropyl4-((5-(4-(3-hydroxypropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of M1 (18.8 mg, 0.035 mmol) in 2 M LiBH₄ in tetrahydrofuran(1 mL) is heated to 50° C. and stirred overnight. The crude reaction isthen concentrated and purified directly via a mass-directed HPLC toafford M14. ESIMS m/z for (M+H)⁺ C₂₂H₃₆N₅O₆S calcd: 498.2, found: 498.3.

Example M15 1-Methylcyclopropyl4-((5-(4-(4-hydroxyphenylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of M3 (44.5 mg, 0.071 mmol) in ethanol (2 mL) is treated with5% Pd/C (10 mg) and hydrogenated under atmospheric pressure overnight.The catalyst is removed by filtration through Celite® and the reactionis concentrated and purified directly via a mass-directed HPLC to affordM15. ESIMS m/z for (M+H)⁺ C₂₅H₃₃N₅O₆S calcd: 531.2, found: 531.7.

Example M16 1-Methylcyclopropyl4-((5-(4-(3-cyanopropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of M6 (19 mg, 0.037 mmol) in N,N-dimethylformamide (0.5 mL)is treated with KCN (3.6 mg, 0.055 mmol) and cesium carbonate (24 mg,0.077 mmol) and heated to 80° C. for 1.5 hours. The reaction is thendiluted with water and extracted with ethyl acetate three times anddiethyl ether twice. The combined organics are dried over MgSO₄,filtered evaporated and purified by silica gel using a linear gradientof 50-100% ethyl acetate in hexane to afford M16. ¹H NMR (400 MHz,CDCl₃) δ 7.87 (d, J=1.6 Hz, 1H), 7.62 (d, J=1.6 Hz, 1H), 4.28-3.95 (m,2H), 4.08 (d, J=6.4 Hz, 2H), 3.53-3.50 (m, 4H), 3.44-3.42 (m, 4H), 3.07(t, J=6.8 Hz, 2H), 2.74 (br t, J=12.0 Hz, 2H), 2.64 (t, J=7.2 Hz, 2H),2.24 (quintet, J=7.2 Hz, 2H), 2.01-1.89 (m, 1H), 1.81-1.77 (m, 2H), 1.54(s, 3H), 1.30-1.17 (m, 2H), 0.88-0.84 (m, 2H), 0.64-0.60 (m, 2H); ESIMSm/z for (M+H)⁺ C₂₃H₃₅N₆O₅S calcd: 507.2, found: 507.2.

Example M17 1-Methylcyclopropyl4-((5-(4-(3-(1H-tetrazol-5-yl)propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of M16 (12 mg, 0.024 mmol) in isopropanol (0.1 mL) and water(0.3 mL) is treated with ZnBr₂ (27 mg, 0.12 mmol) and NaN₃ (7.7 mg, 0.12mmol) and heated to 150° C. overnight. The reaction is filtered througha syringe filter and purified directly via a mass-directed HPLC toafford M17; ¹H NMR (400 MHz, CD₃CN) δ 7.83 (d, J=1.6 Hz, 1H), 7.71 (d,J=1.6 Hz, 1H), 4.16-3.89 (m, 2H), 4.06 (d, J=6.4 Hz, 2H), 3.49-3.46 (m,4H), 3.35-3.32 (m, 4H), 3.12-3.04 (m, 4H), 2.81-2.70 (m, 2H), 2.28-2.20(m, 2H), 1.78-1.71 (m, 3H), 1.48 (s, 3H), 1.22-1.12 (m, 2H), 0.81-0.78(m, 2H), 0.60-0.57 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₃H₃₆N₉O₅S calcd:550.3, found: 550.3.

Example M18 1-Methylcyclopropyl4-((5-(4-(3-aminopropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of M6 (113 mg, 0.22 mmol) in N,N-dimethylformamide (1 mL) istreated with NaN₃ (42.7 mg, 0.67 mmol) and heated to 90° C. overnight.The reaction is cooled to room temperature, partitioned between waterand ethyl acetate. The organics are extracted with water twice more,dried over MgSO₄, filtered evaporated and purified by silica gel using alinear gradient of 0-100% ethyl acetate in hexane to afford theintermediate azide which is dissolved in ethanol (1 mL) and treated with10% Pd/C (20 mg) and hydrogenated at room temperature overnight. Thecatalyst is removed by filtration through Celite® and the reaction isconcentrated and purified directly via a mass-directed HPLC to affordM18. ¹H NMR (400 MHz, CD₃CN) δ 7.86 (d, J=1.4 Hz, 1H), 7.61 (d, J=1.5Hz, 1H), 4.19 (m, 2H), 4.07 (d, J=6.5 Hz, 2H), 3.50 (m, 4H), 3.42 (m,4H), 3.05 (m, 2H), 2.88 (t, J=6.7 Hz, 2H), 2.74 (dd, J=13.0, 12.0 Hz,2H), 1.98 (m, 3H), 1.79 (m, 2H), 1.54 (s, 3H), 1.24 (m, 2H), 0.86 (m,2H), 0.62 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₂H₃₇N₆O₅S calcd: 497.3, found:497.6.

Example M19 Tert-butyl4-((5-(4-(3-acetoxypropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of M5 (154 mg, 0.30 mmol) in N,N-dimethylformamide (2 mL) istreated with sodium acetate (73 mg, 0.89 mmol) and sodium iodide (45 mg,0.30 mmol) and heated to 120° C. overnight. The reaction is cooled toroom temperature, partitioned between water and ethyl acetate. Theorganics are extracted with water twice more, dried over MgSO₄, filteredevaporated and purified by silica gel using a linear gradient of 0-100%ethyl acetate in dichloromethane to afford M19; ¹H NMR (400 MHz, CD₃CN)δ 7.87 (d, J=1.4 Hz, 1H), 7.83 (d, J=1.5 Hz, 1H), 4.20 (t, J=6.1 Hz,2H), 1.14 (m, 2H), 4.08 (d, J=6.6 Hz, 1H), 3.51 (m, 4H), 3.44 (m, 4H),3.02 (m, 2H), 2.74 (m, 2H), 2.19 (m, 2H), 2.07 (s, 3H), 1.95 (m, 1H),1.80 (m, 2H), 1.46 (s, 9H), 1.26 (m, 2H); ESIMS m/z for (M-Boc+H)⁺C₁₉H₃₂N₅O₅S calcd: 442.2, found: 442.3.

Example M20 1-Methylcyclopropyl4-((5-(4-(3-methoxypropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of M6 (26 mg, 0.049 mmol) in methanol (1 mL) is treated witha 0.5 M solution of sodium methoxide in methanol (0.2 mL, 0.1 mmol) andheated to 65° C. overnight and at 95° C. for 10 hours. The reaction iscooled to room temperature, the solvent is removed in vacuo and thecrude residue is purified by silica gel using a linear gradient of 0-80%ethyl acetate in hexane to afford M20. ¹H NMR (400 MHz, CDCl₃) δ 7.86(d, J=1.2 Hz, 1H), 7.61 (d, J=1.6 Hz, 1H), 4.15 (m, 2H), 4.07 (d, J=6.4Hz, 2H), 3.49 (m, 6H), 3.42 (m, 4H), 3.33 (s, 3H), 3.04 (m, 2H), 2.74(t, J=12.4 Hz, 2H), 2.09 (m, 2H), 1.94 (m, 1H), 1.79 (d, J=12.4 Hz, 2H),1.54 (s, 3H), 1.24 (m, 2H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS m/z for(M+H)⁺ C₂₃H₃₇N₅O₆S calcd: 511.3, found: 512.2.

Example M21 1-Methylcyclopropyl4-((5-(4-(3-(2-methyl-1H-imidazol-1-yl)propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of M6 (53 mg, 0.10 mmol) in tetrahydrofuran (1 mL) is treatedwith 2-methylimidazole (8.5 mg, 0.10 mmol) and heated to 65° C.overnight. The reaction is cooled to room temperature, the solvent isremoved in vacuo and the crude residue is purified directly via amass-directed HPLC to afford M21. ¹H NMR (400 MHz, CD₃CN) δ 7.86 (d,J=1.4 Hz, 1H), 7.62 (d, J=1.4 Hz, 1H), 7.29 (d, J=2.0 Hz, 1H), 7.18 (d,J=1.8 Hz, 1H), 4.34 (t, J=7.0 Hz, 2H), 4.18 (m, 2H), 4.07 (d, J=6.5 Hz,2H), 3.51 (m, 4H), 3.41 (m, 4H), 2.93 (m, 2H), 2.83 (s, 3H), 2.74 (m,2H), 2.42 (m, 2H), 1.94 (m, 1H), 1.79 (m, 2H), 1.54 (s, 3H), 1.25 (m,2H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₆H₄₀N₇O₅S calcd:562.3, found: 562.5.

By following the procedure for M21 using the appropriate aminenucleophiles, the following examples are obtained:

Example Structure Analytical data M22

¹H NMR (400 MHz, CD₃CN) δ 7.85 (d, J = 1.4 Hz, 1H), 7.61 (d, J = 1.5 Hz,1H), 4.18 (m, 2H), 4.07 (d, J = 6.5 Hz, 2H), 3.51 (m, 4H), 3.43 (m, 4H),3.19 (m, 6H), 2.74 (dd, J = 12.4, 12.3 Hz, 2H), 2.36 (m, 2H), 2.08 (m,5H), 1.94 (m, 2H), 1.79 (m, 2H), 1.54 (s, 3H), 1.25 (m, 2H), 0.86 (m,2H), 0.62 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₆H₄₃N₆O₆S calcd: 551.3,found 551.5. M23

¹H NMR (400 MHz, CD₃CN) δ 7.85 (d, J = 1.5 Hz, 1H), 7.61 (d, J = 1.5 Hz,1H), 4.18 (m, 2H), 4.07 (d, J = 6.6 Hz, 2H), 3.51 (m, 4H), 3.44 (m, 4H),3.18 (m, 2H), 2.98 (m, 2H), 2.74 (dd, J = 12.4, 12.3, Hz, 2H), 2.63 (s,6H), 2.30 (m, 2H), 1.94 (m, 1H), 1.79 (m, 2H), 1.54 (s, 3H), 1.25 (m,2H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₄H₄₁N₆O₅Scalcd: 525.3, found: 525.3. M-24

¹H NMR (400 MHz, CD₃CN) δ 7.86 (d, J = 1.2 Hz, 1H), 7.82 (d, J = 1.6 Hz,1H), 4.10 (d, J = 6.4 Hz, 2H), 4.07 (m, 2H), 3.55 (m, 2H), 3.41 (m, 2H),3.15 (t, J = 7.2 Hz, 4H), 3.01 (m, 2H), 2.83 (m, 2H), 2.74 (m, 2H), 1.95(m, 3H), 1.78 (m, 2H), 1.50 (s, 3H), 1.22 (m, 2H), 0.79 (m, 2H), 0.58(m, 2H); ESIMS m/z for (M + H)⁺ C₂₄H₃₈N₆O₅S calcd: 522.3, found: 523.2.M-25

¹H NMR (400 MHz, CD₃CN) δ 7.83 (d, J = 1.2 Hz, 1H), 7.71 (d, J = 1.6 Hz,1H), 4.06 (d, J = 6.8 Hz, 2H), 4.00 (m, 2H), 3.59 (t, J = 12.4 Hz, 4H),3.48 (m, 4H), 3.32 (m, 4H), 3.06 (m, 2H), 2.95 (m, 2H), 2.74 (m, 2H),2.10 (m, 1H), 1.76 (m, 2H), 1.49 (s, 3H), 1.17 (m, 2H), 0.79 (m, 2H),0.59 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₄H₃₆F₂N₆O₅S calcd: 558.2, found:559.2.

Example M26 1-Methylcyclopropyl4-((5-(4-(vinylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of M1c (308 mg, 0.82 mmol) in tetrahydrofuran (4 mL) iscooled in an ice/water bath and treated with triethylamine (299 mg, 3.0mmol) followed by 2-chloroethanesulfonyl chloride (401 mg, 2.5 mmol)added over 10 minutes. The reaction is stirred for an hour and thenevaporated and partitioned between water and ethyl acetate. The organicsare extracted with water twice more, dried over MgSO₄, filteredevaporated and purified by silica gel using a linear gradient of 0-100%ethyl acetate in hexane to afford M26; ¹H NMR (400 MHz, CD₃CN) δ 7.91(d, J=2.9 Hz, 1H), 7.15 (dd, J=9.1, 3.1 Hz, 1H), 6.65 (d, J=9.1 Hz, 1H),4.19 (m, 2H), 3.81 (d, J=6.3 Hz, 2H), 3.54 (m, 4H), 3.34 (m, 4H), 3.08(ddd, J=13.1, 2.8, 2.8 Hz, 2H), 2.80 (s, 3H), 2.04 (m, 1H), 1.92 (m,2H), 1.44 (m, 2H), 1.28 (m, 6H); ESIMS m/z for (M+H)⁺ C₂₁H₃₂N₅O₅S calcd:466.2, found: 466.2.

Example M27 1-Methylcyclopropyl4-((5-(4-(2-ethoxyethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing M20 fromM6 except substituting M26 for M6, M27 is prepared; ¹H NMR (400 MHz,CD₃CN) δ 7.86 (d, J=1.5 Hz, 1H), 7.61 (d, J=1.5 Hz, 1H), 4.18 (m, 2H),4.07 (d, J=6.6 Hz, 2H), 3.80 (t, J=6.0 Hz, 2H), 3.51 (m, 6H), 3.43 (m,4H), 3.24 (t, J=5.9 Hz, 2H), 2.74 (dd, J=12.3, 12.0 Hz, 2H), 1.94 (m,1H), 1.79 (m, 2H), 1.54 (s, 3H), 1.23 (m, 2H), 1.17 (t, J=7.0 Hz, 3H),0.86 (m, 2H), 0.62 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₃H₃₈N₅O₆S calcd:512.3, found: 512.6.

Example M28 1-Methylcyclopropyl4-((5-(4-(2-(piperidin-1-yl)ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of M26 (27 mg, 0.058 mmol) in ethanol (0.5 mL) is treatedwith piperidine (13.3 mg, 0.12 mmol) and stirred at room temperatureovernight. The reaction is diluted with N,N-dimethylformamide andpurified directly via a mass-directed HPLC to afford M27; ¹H NMR (400MHz, CD₃CN) δ 7.87 (d, J=1.4 Hz, 1H), 7.64 (d, J=1.4 Hz, 1H), 4.19 (m,2H), 4.07 (d, J=6.5 Hz, 2H), 3.70 (m, 2H), 3.49 (m, 8H), 3.42 (m, 4H),2.75 (m, 4H), 1.93 (m, 6H), 1.80 (m, 2H), 1.54 (s, 3H), 1.45 (m, 1H),1.24 (m, 2H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS m/z for (M+H)⁺C₂₆H₄₃N₆O₅S calcd: 551.3, found: 551.3.

By following a similar procedure as the one used for preparing M28 fromM26 except substituting a commercially available amine for piperidine,the following examples are prepared;

Example Structure Analytical data M29

¹H NMR (400 MHz, CD₃CN) δ 7.86 (s, 1H), 7.62 (s, 1H), 4.19 (m, 2H), 4.07(d, J = 6.5 Hz, 2H), 3.97 (m, 5H), 3.49 (m, 5H), 3.42 (m, 5H), 2.74 (m,2H), 1.94 (m, 1H), 1.79 (m, 2H), 1.54 (s, 3H), 1.24 (m, 2H), 0.86 (m,2H), 0.61 (m, 2); ESIMS m/z for (M + H)⁺ C₂₅H₄₁N₆O₆S calcd: 553.3,found: 553.2. M30

¹H NMR (400 MHz, CD₃CN) δ 7.88 (s, 1H), 7.64 (s, 1H), 4.18 (m, 2H), 4.07(d, J = 6.5 Hz, 2H), 3.51 (m, 8H), 3.44 (m, 4H), 2.94 (s, 6H), 2.76 (m,2H), 1.96 (m, 1H), 1.80 (m, 2H), 1.54 (s, 3H), 1.24 (m, 2H), 0.87 (m,2H), 0.62 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₃H₃₉N₆O₅S calcd: 511.3,found: 511.2. M31

¹H NMR (400 MHz, CD₃CN) δ 7.86 (d, J = 1.2 Hz, 1H), 7.82 (d, J = 1.6 Hz,1H), 4.10 (d, J = 6.4 Hz, 2H), 4.07 (m, 2H), 3.55 (m, 2H), 3.41 (m, 2H),3.15 (t, J = 7.2 Hz, 4H), 3.01 (m, 2H), 2.83 (m, 2H), 2.74 (m, 2H), 1.95(m, 3H), 1.78 (m, 2H), 1.50 (s, 3H), 1.22 (m, 2H), 0.79 (m, 2H), 0.58(m, 2H); ESIMS m/z for (M + H)⁺ C₂₄H₃₈N₆O₅S calcd: 522.3, found: 523.2.M32

¹H NMR (400 MHz, CD₃CN) δ 7.83 (d, J = 1.2 Hz, 1H), 7.71 (d, J = 1.6 Hz,1H), 4.06 (d, J = 6.8 Hz, 2H), 4.00 (m, 2H), 3.59 (t, J = 12.4 Hz, 4H),3.48 (m, 4H), 3.32 (m, 4H), 3.06 (m, 2H), 2.95 (m, 2H), 2.74 (m, 2H),2.10 (m, 1H), 1.76 (m, 2H), 1.49 (s, 3H), 1.17 (m, 2H), 0.79 (m, 2H),0.59 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₄H₃₆F₂N₆O₅S calcd: 558.2, found:559.2.

Example M33 1-Methylcyclopropyl4-((5-(4-((1-(dimethylamino)cyclopropyl)methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of M33a (5.0 g, 33 mmol) in acetic acid (50 mL) istreated with 30% aqueous hydrogen peroxide (7.92 g of solution, 70 mmol)and stirred at 100° C. for 1 hour. The solvent was then removed and thereaction was coevaporated with toluene 3 times.

A sample of M33a (4 g, 22 mmol) in tetrahydrofuran (40 mL) is cooled inan ice/water bath and treated with BuLi in hexane (13.2 mL of a 2 Msolution, 26 mmol) and stirred for 20 minutes. The resulting yellowsolution is treated with paraformaldehyde (1.65 g, 55 mmol) and allowedto stir for 1 hour. The reaction is then quenched with saturated aqueousammonium chloride and filtered through a pad of Celite® using ethylacetate. The organics are isolated, dried over MgSO₄, filtered,evaporated and purified on silica gel using a linear gradient of 0-100%ethyl acetate in hexane to afford M33b; ¹H NMR (400 MHz, CDCl₃) δ 7.91(m, 2H), 7.68 (m, 1H), 7.59 (m, 2H), 3.64 (d, J=6.4 Hz, 2H), 2.72 (dd,J=6.4, 6.4 Hz, 1H), 1.64 (m, 2H), 1.07 (m, 2H); ESIMS m/z for (M+H)⁺C₁₀H₁₃O₃S calcd: 213.1, found: 213.0.

Step B: A solution of M33b (4.2 g, 20 mmol) in dichloromethane (40 mL)is treated with triethylamine (3.0 g of solution, 30 mmol), cooled in anice/water bath and treated methanesulfonyl chloride (2.95 g, 26 mmol).The solution is stirred overnight an allowed to come to roomtemperature. The reaction is then quenched with aqueous 1 M HCl andextracted with dichloromethane twice. The organics are dried over MgSO₄,filtered, evaporated and triturated with diethyl ether to afford M33c;¹H NMR (400 MHz, CDCl₃) δ 7.92 (m, 2H), 7.68 (m, 1H), 7.59 (m, 2H), 4.41(s, 2H), 2.82 (s, 3H), 1.80 (m, 2H), 1.21 (m, 2H); ESIMS m/z for (M+H)⁺C₁₁H₁₅O₅S₂ calcd: 291.0, found: 291.0.

Step C: A solution of M33c (3 g, 10 mmol) in N,N-dimethylformide (30 mL)is treated with potassium thioacetate (1.3 g, 11 mmol) and water (20 mL)and stirred at 60° C. overnight. The reaction is diluted with ethylacetate and extracted with water twice. The organics are isolated, driedover MgSO₄, filtered, evaporated and purified on silica gel using alinear gradient of 0-100% ethyl acetate in hexane to afford M33d; ¹H NMR(400 MHz, CDCl₃) δ 7.88 (m, 2H), 7.69 (m, 1H), 7.59 (m, 2H), 3.26 (s,2H), 2.26 (m, 3H), 1.68 (m, 2H), 1.02 (m, 2H); ESIMS m/z for (M+H)⁺C₁₂H₁₅O₃S₂ calcd: 271.1, found: 271.0.

Step D: A cold (ice/water bath) solution of acetonitrile (2.1 mL) and 2M HCl (419 μL, 0.84 mmol) is treated with NCS (838 mg, 6.27 mmol),allowed to stir for 5 minutes and treated dropwise with a solution ofM33d (358 mg, 1.6 mmol) in acetonitrile (419 μL). After 30 minutes ofstirring, the reaction is diluted with diethyl ether and extracted withbrine, water and saturated sodium thiosulfate. The organics areisolated, dried over MgSO₄, filtered and to afford M33e; ESIMS m/z for(M+H)⁺ C₁₀H₁₂ClO₄S₂ calcd: 295.0, found: 294.9.

Step E: A cold (ice/water bath) solution of M1c (524 mg, 1.4 mmol) andtriethylamine (282 mg, 2.8 mmol) in dichloromethane (5 mL) is treatedwith a solution of M33e (solution of the crude from the last step) indichlormethane (3 mL). After 2 hours of stirring, the reaction isevaporated and purified silica gel using a linear gradient of 0-100%ethyl acetate in hexane to afford M33f; ESIMS m/z for (M+H)⁺C₂₉H₄₀N₅O₇S₂ calcd: 634.2, found: 634.2.

Step F: A solution of M33f (157 mg, 0.25 mmol) in 2 M dimethylamine intetrahydrofuran (2 mL, 4 mmol) is treated with potassium tert-butoxide(28 mg, 0.25 mmol) and stirred for 1 hour. The reaction is evaporated,diluted with methanol and purified directly via a mass-directed HPLC toafford M33; ¹H-NMR (400 MHz, CDCl₃) δ 7.86 (d, J=1.4 Hz, 1H), 7.61 (d,J=1.4 Hz, 1H), 4.20 (m, 2H), 4.07 (d, J=6.5 Hz, 2H), 3.50 (m, 4H), 3.39(m, 4H), 3.07 (s, 2H), 2.74 (dd, J=12.4, 12.3 Hz, 2H), 2.37 (s, 6H),1.94 (m, 1H), 1.79 (m, 2H), 1.55 (s, 3H), 1.25 (m, 2H), 0.93 (m, 2H),0.86 (m, 4H); ESIMS calcd. for C₂₅H₄₁N₆O₅S [M+H]⁺ 537.3, found 537.4.

By following the procedure for M33 using the appropriate aminenucleophiles in step F, the following examples are obtained:

Example Structure Analytical data M34

¹H-NMR (400 MHz, CDCl₃) δ 7.86 (d, J = 1.5 Hz, 1H), 7.61 (d, J = 1.5 Hz,1H), 7.31 (m, 5H), 4.14 (m, 2H), 4.09 (d, J = 6.5 Hz, 2H), 3.83 (s, 2H),3.49 (m, 4H), 3.38 (m, 4H), 3.06 (s, 2H), 2.75 (m, 2H), 1.94 (m, 1H),1.79 (m, 2H), 1.55 (s, 3H), 1.26 (m ,2H), 0.92 (m, 2H), 0.87 (m, 2H),0.71 (m, 2H), 0.62 (m, 2H); ESIMS calcd. for C₃₀H₄₃N₆O₅S [M + H]⁺ 599.3,found 599.5. M35

¹H-NMR (400 MHz, CDCl₃) δ 7.86 (d, J = 1.4 Hz, 1H), 7.61 (d, J = 1.4 Hz,1H), 3.82-4.21 (m, 6H), 4.07 (d, J = 6.5 Hz, 2H), 3.49 (m, 7H), 3.41 (m,5H), 2.74 (dd, J = 12.5, 12.3 Hz, 2H), 1.94 (m, 1H), 1.79 (m, 2H), 1.55(s, 3H), 1.24 (m, 6H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS calcd. forC₂₆H₄₁N₆O₅S [M + H]⁺ 549.3, found 549.4.

Example M36 1-Methylcyclopropyl4-((5-(4-((1-aminocyclopropyl)methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of M34 (29 mg, 0.048 mmol) in ethanol (1 mL) and acetic acid(0.1 mL) is treated with 10% Pd/C (Degussa type) and hydrogenated atroom pressure for 2 hours. The atmosphere is exchanged for nitrogen andthe catalyst is removed by filtration through Celite®. The crudematerial is diluted with methanol and purified directly via amass-directed HPLC to afford M36; ¹H-NMR (400 MHz, CDCl₃) δ 7.86 (d,J=1.4 Hz, 1H), 7.61 (d, J=1.4 Hz, 1H), 4.20 (m, 2H), 4.07 (d, J=6.5 Hz,2H), 3.50 (m, 4H), 3.39 (m, 4H), 3.07 (s, 2H), 2.74 (dd, J=12.4, 12.3Hz, 2H), 2.37 (s, 6H), 1.94 (m, 1H), 1.79 (m, 2H), 1.55 (s, 3H), 1.25(m, 2H), 0.93 (m, 2H), 0.86 (m, 4H); ESIMS calcd. for C₂₃H₃₇N₆O₅S [M+H]⁺509.3, found 509.5.

Example M37 1-methylcyclopropyl4-((5-(4-((1-(benzyloxy)cyclopropyl)methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of M33f (147 mg, 0.23 mmol) in benzyl alcohol (1 mL) istreated with sodium hydride (12 mg, 0.5 mmol) and stirred for 24 hours.The reaction is purified directly via a mass-directed HPLC to affordM37; ¹H-NMR (400 MHz, CDCl₃) δ 7.84 (d, J=1.4 Hz, 1H), 7.56 (d, J=1.4Hz, 1H), 7.25 (m, 5H), 4.55 (s, 2H), 4.20 (m, 2H), 4.07 (d, J=6.5 Hz,2H), 3.46 (m, 8H), 3.31 (s, 2H), 2.75 (dd, J=12.3, 12.3 Hz, 2H), 1.94(m, 1H), 1.80 (m, 2H), 1.54 (s, 3H), 1.25 (m, 2H), 1.08 (m, 2H), 0.87(m, 4H), 0.62 (m, 2H); ESIMS calcd. for C₃₀H₄₂N₅O₆S [M+H]⁺ 600.3, found600.5.

Example M38 1-Methylcyclopropyl4-((5-(4-((1-hydroxycyclopropyl)methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of M33f (11.6 mg, 0.018 mmol) in tetrahydrofuran (0.5 mL) istreated with potassium tert-butoxide (2 mg, 0.02 mmol) and stirred for 5minutes. The reaction is then treated with water (50 mL) andtrimethylphosphine (9 μL of a 1 M solution in tetrahydrofuran, 0.009mmol) and stirred at 45° C. overnight. The reaction is diluted withethyl acetate and washed with water. The organics are dried over MgSO₄,filtered evaporated and purified via a mass-directed HPLC to afford M38;¹H-NMR (400 MHz, CDCl₃) δ 7.87 (s, 1H), 7.62 (s, 1H), 4.18 (m, 2H), 4.07(d, J=6.5 Hz, 2H), 3.51 (m, 8H), 3.21 (s, 2H), 2.75 (dd, J=12.4, 12.4Hz, 2H), 2.34 (bs, 1H), 1.94 (m, 1H), 1.79 (m, 2H), 1.54 (s, 3H), 1.28(m, 2H), 1.10 (m, 2H), 0.86 (m, 4H), 0.62 (m, 2H); ESIMS calcd. forC₂₃H₃₆N₅O₆S [M+H]⁺ 510.2, found 510.4.

Example M39 1-Methylcyclopropyl4-((5-(4-(2-hydroxyethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: By following a similar procedure as the one used for preparingM1 from M1c except substituting benzyl 2-(chlorosulfonyl)acetate formethyl 3-(chlorosulfonyl)propanoate, M39a is prepared; ESIMS m/z for(M+H)⁺ C₂₈H₃₈N₅O₇S calcd: 588.3, found: 588.2.

Step B: A solution of M39a (20 mg, 0.034 mmol) in methanol (3 mL) istreated with sodium borohydride (13 mg, 0.34 mmol) and heated at 80° C.for 2 hours. The mixture is cooled, diluted with water and extractedwith ethyl acetate. The organic layer is washed with brine, dried(MgSO₄), filtered, concentrated and purified using mass-triggeredreverse phase HPLC to afford M39; ¹H NMR (400 MHz, CDCl₃) δ 7.89 (d,J=1.6 Hz, 1H), 7.64 (d, J=1.6 Hz, 1H), 4.11 (s, 4H), 3.54 (m, 4H), 3.47(m, 4H), 3.21 (m, 2H), 2.77 (m, 2H), 1.96 (m, 1H), 1.82 (m, 2H), 1.57(s, 3H), 1.28 (m, 2H), 0.89 (m, 2H), 0.65 (m, 2H); ESIMS m/z for (M+H)⁺C₂₁H₃₄N₅O₆S calcd: 484.2, found: 484.2.

Example M40 1-Methylcyclopropyl4-((5-(4-(1-hydroxy-2-methylpropan-2-ylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of M39a (40 mg, 0.068 mmol) in dimethylformamide (2mL) is treated with potassium carbonate (50 mg, 0.36 mmol) and methyliodide (46 mg, 0.32 mmol) and heated to 60° C. for 2 hours. The reactionis then partitioned between ethyl acetate and water. The organics arewashed with water and brine, dried over MgSO₄, filtered evaporated andused crude for the next step; ESIMS m/z for (M+H)⁺ C₃₀H₄₂N₅O₇S calcd:616.3, found: 616.3.

By following a similar procedure as the one used for preparing M39 fromM39a except substituting M40a for M39a, M40 is prepared; ¹H NMR (400MHz, CDCl₃) δ 7.89 (d, J=1.6 Hz, 1H), 7.62 (d, J=1.6 Hz, 1H), 4.10 (d,J=6.4 Hz, 2H), 3.75 (s, 2H), 3.59 (m, 4H), 3.48 (m, 4H), 2.76 (m, 2H),1.97 (m, 1H), 1.81 (m, 2H), 1.57 (s, 3H), 1.40 (m, 6H), 1.27 (m, 2H),0.89 (m, 2H), 0.64 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₃H₃₈N₅O₆S calcd:512.3, found: 512.2.

Example M41 1-Methylcyclopropyl4-((5-(4-((3-methyloxetan-3-yl)methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of M41a (1.01 g, 3.9 mmol) in ethanol (25 mL) istreated with potassium thiocyanate (767 mg, 7.9 mmol) and stirred atreflux overnight. The solvent is then removed to afford M41b which isused crude. ESIMS m/z for (M+H)⁺ C₆H₁₀NOS calcd: 144.1, found: 144.0.

Step B: A suspension of M41b (crude from step A) in water (5 mL) iscooled in an ice/water bath and treated with a slow stream of chlorinegas for 30 minutes. The reaction is then extracted with diethyl etherand the organics are washed with saturated aqueous sodium bisulfatesolution followed by saturated aqueous sodiumhydrogencarbonate solution.The organics are then dried over Na₂SO₄, filtered and evaporated toafford M41b which was used crude in the next reaction; ESIMS m/z for(M+H)⁺ C₅H₁₀ClO₃S calcd: 185.0, found: 185.0.

Step C: By following a similar procedure as the one used for preparingM1 from M1c except substituting M41c for methyl3-(chlorosulfonyl)propanoate, M41 is prepared; ¹H-NMR (400 MHz, CDCl₃) δ7.87 (d, J=1.4 Hz, 1H), 7.62 (d, J=1.5 Hz, 1H), 4.64 (d, J=6.3 Hz, 2H),4.46 (d, J=6.4 Hz, 2H), 4.22 (m, 2H), 4.08 (d, J=6.6 Hz, 2H), 3.53 (m,4H), 3.40 (m, 4H), 3.25 (s, 2H), 2.74 (dd, J=12.4, 12.4 Hz, 2H), 1.94(m, 1H), 1.79 (m, 2H), 1.65 (s, 3H), 1.55 (s, 3H), 1.25 (m, 2H), 0.86(m, 2H), 0.62 (m, 2H); ESIMS calcd. for C₂₄H₃₈N₅O₆S [M+H]⁺ 524.3, found524.2.

Example M42 1-Methylcyclopropyl4-((5-(4-(3-acetoxy-2,2-dimethylpropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of M42a (2 g, 12 mmol) in N,N-dimethylformamide (7.2mL) is treated with potassium thiocyanate (1.75 g, 18 mmol) and stirredat 140° C. for 4 hours. The reaction is cooled to room temperature andpartitioned between diethyl ether and water. The aqueous phase isextracted with diethyl ether once more and discarded. The combinedorganics are dried over MgSO₄, filtered, evaporated and distilled on aKugelrohr apparatus to afford M42b; ESIMS m/z for (M+H)⁺ C₆H₁₂NOS calcd:146.1, found: 146.1.

Step B: A solution of M42b (1.54 g, 10.6 mmol) in pyridine (10 mL) iscooled in an ice/water bath and treated with acetic anhydride (10 mL).The reaction is allowed to stir overnight as the ice bath melts. Thesolvent is removed and the residue is partitioned between ethyl acetateand water. The organics are washed with 1 M HCl twice and then saturatedaqueous sodiumhydrogencarbonate solution. The organics are then driedover MgSO₄, filtered and evaporated to afford M42c which was used crudein the next reaction; ESIMS m/z for (M+H)⁺ C₈H₁₄NO₂S calcd: 188.1,found: 188.1.

Step C: By following a similar procedure as the one used for preparingM41 from M41b except substituting M42c for M41b, M42 is obtained; ¹H NMR(400 MHz, CD₃CN) δ 7.86 (d, J=1.4 Hz, 1H), 7.61 (d, J=1.4 Hz, 1H), 4.19(m, 2H), 4.07 (d, J=6.5 Hz, 2H), 4.00 (s, 2H), 3.50 (m, 5H), 3.37 (m,4H), 2.86 (s, 2H), 2.73 (dd, J=12.4, 12.3 Hz, 2H), 2.08 (s, 3H), 1.94(m, 1H), 1.79 (m, 2H), 1.54 (s, 3H), 1.27 (m, 2H), 1.22 (s, 6H), 0.86(m, 2H), 0.62 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₆H₄₂N₅O₇S calcd: 568.3,found: 568.4.

Example M43 1-Methylcyclopropyl4-((5-(4-(3-hydroxy-2,2-dimethylpropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of M42 (48 mg, 0.085 mmol) in tetrahydrofuran (1.5mL) is treated with lithium hydroxide (7 mg, 0.17 mmol) and stirred for1 day. The solvent is removed and the residue is purified on silica gelusing a linear gradient of 0-100% ethyl acetate in hexane to afford M43;¹H NMR (400 MHz, CD₃CN) δ 7.89 (d, J=1.4 Hz, 1H), 7.67 (s, 1H), 4.36 (s,2H), 4.17 (m, 2H), 4.07 (d, J=6.5 Hz, 2H), 3.51 (m, 4H), 3.37 (m, 4H),2.87 (s, 2H), 2.76 (dd, J=12.2, 11.6 Hz, 2H), 1.94 (m, 2H), 1.80 (m,2H), 1.53 (s, 3H), 1.26 (m, 2H), 1.24 (s, 6H), 1.14 (s, 1H), 0.87 (m,2H), 0.62 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₄H₄₀N₅O₆S calcd: 526.3, found:526.2.

Example M44 1-Methylcyclopropyl4-((5-(4-(3-acetoxy-3-methylbutylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of M44a (1.48 g, 8.9 mmol) in dichloromethane (49 mL)is cooled in an ice/water bath and treated with pyridine (913 mg, 12mmol) and acetyl chloride (868 mg, 11 mmol) and the reaction is allowedto stir overnight as the ice bath melts. The reaction is then quenchedwith water. The organic phase is isolated, dried over MgSO₄, filtered,evaporated and the residue is purified on silica gel using a lineargradient of 0-100% ethyl acetate in hexane to afford M44b; Asatisfactory ESIMS could not be obtained.

Step B: A solution of M44b (750 mg, 3.6 mmol) in N,N-dimethylfromamide(10 mL) is cooled in an ice/water bath and treated with potassiumthioacetate (410 mg, 3.6 mmol). The reaction is stirred overnight andpartitioned between ethyl acetate and water. The organics are extractedwith water once more, dried over MgSO₄, filtered and evaporated toafford M44c which is used in the next step crude; ESIMS m/z for (M+Na)⁺C₉H₁₆NaO₃S calcd: 227.1, found: 227.0.

Step C: By following a similar procedure as the one used for preparingM32 from M32d except substituting M44c for M32d, M44 is prepared; ¹H-NMR(400 MHz, CDCl₃) δ 7.86 (d, J=1.4 Hz, 1H), 7.61 (d, J=1.5 Hz, 1H), 4.20(m, 2H), 4.07 (d, J=6.5 Hz, 2H), 3.50 (m, 4H), 3.44 (m, 4H), 3.02 (m,2H), 2.74 (dd, J=13.2, 12.6 Hz, 2H), 2.22 (m, 2H), 1.98 (s, 3H), 1.96(m, 1H), 1.80 (m, 2H), 1.55 (s, 3H), 1.48 (s, 6H), 1.25 (m, 2H), 0.86(m, 2H), 0.62 (m, 2H); ESIMS calcd. for C₂₄H₃₈N₅O₅S [M-OAc]⁺ 508.3,found 508.4.

Example M45 1-Methylcyclopropyl4-((5-(4-(3-hydroxy-3-methylbutylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of M44 (199 mg, 0.35 mmol) in methanol (3.9 mL) is treatedwith NaOMe (1.1 mL of a 6.4M solution, 7 mmol) and stirred for 2.5hours. The reaction is quenched with saturated aqueous ammonium chlorideand the solvent is removed. The residue is dissolved in dichloromethaneand washed with water, dried over MgSO₄, filtered, evaporated and theresidue is purified on silica gel using a linear gradient of 0-100%ethyl acetate in hexane to afford M45; ¹H-NMR (400 MHz, CDCl₃) δ 7.86(d, J=1.5 Hz, 1H), 7.62 (d, J=1.5 Hz, 1H), 4.20 (m, 2H), 4.07 (d, J=6.5Hz, 2H), 3.50 (m, 4H), 3.44 (m, 4H), 3.09 (m, 2H), 2.74 (dd, J=12.9,12.7 Hz, 2H), 1.92-2.01 (m, 3H), 1.79 (m, 2H), 1.55 (s, 3H), 1.27 (m,8H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS calcd. for C₂₄H₄₀N₅O₆S [M+H]⁺526.3, found 526.2.

Example M46 1-Methylcyclopropyl4-((5-(4-(2-(1-acetoxycyclopropyl)ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of M46a (1.99 g, 12 mmol) in diethyl ether (40 mL) istreated with titanium(IV)isopropoxide (369 mg, 1.2 mmol) followed bydropwise addition of ethylmagnesium bromide (8.8 mL of a 3 M solution indiethyl ether, 26 mmol). The reaction is quenched into ice cold 10%sulfuric acid and the aqueous phase is extracted with ether once more.The combined organics are dried over MgSO₄, filtered, evaporated and theresidue is purified on silica gel using a linear gradient of 0-100%ethyl acetate in hexane to afford M46b; ¹H-NMR (400 MHz, CDCl₃) δ 3.60(dd, J=7.3, 7.3 Hz, 2H), 2.41 (s, 1H), 2.10 (dd, J=7.3, 7.3 Hz, 2H),0.78 (m, 2H), 0.52 (m, 2H); A satisfactory ESIMS spectrum could not beobtained.

Step B: By following a similar procedure as the one used for preparingM33 from M33c except substituting M46b for M33c, M46 is prepared; ¹H-NMR(400 MHz, CDCl₃) δ 7.86 (d, J=1.4 Hz, 1H), 7.61 (d, J=1.4 Hz, 1H), 4.20(m, 2H), 4.07 (d, J=6.5 Hz, 2H), 3.49 (m, 4H), 3.41 (m, 4H), 3.11 (ddd,J=8.2, 5.2, 5.2 Hz, 2H), 2.74 (dd, J=12.2, 12.0 Hz, 2H), 2.25 (ddd,J=8.2, 4.7, 4.7 Hz, 2H), 2.00 (s, 3H), 1.94 (m, 1H), 1.79 (m, 2H), 1.54(s, 3H), 1.25 (m, 2H), 0.93 (m, 2H), 0.86 (m, 2H), 0.76 (m, 2H), 0.62(m, 2H); ESIMS calcd. for C₂₆H₄₀N₅O₇S [M+H]⁺ 566.3, found 566.4.

Example M47 1-Methylcyclopropyl4-((5-(4-(2-(1-hydroxycyclopropyl)ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing M43 fromM42 except substituting M46 for M42, M47 is prepared; ¹H-NMR (400 MHz,CDCl₃) δ 7.87 (d, J=1.5 Hz, 1H), 7.62 (d, J=1.4 Hz, 1H), 4.19 (m, 2H),4.08 (d, J=6.5 Hz, 2H), 3.51 (m, 4H), 3.43 (m, 4H), 3.21 (m, 2H), 2.74(dd, J=12.3, 12.3 Hz, 2H), 2.27 (bs, 1H), 2.08 (m, 2H), 1.94 (m, 1H),1.79 (m, 2H), 1.55 (s, 3H), 1.25 (m, 2H), 0.86 (m, 4H), 0.62 (m, 2H),0.56 (m, 2H); ESIMS calcd. for C₂₄H₃₈N₅O₆S [M+H⁺] 524.3, found 524.5.

Example M48 (R)-1-methylcyclopropyl4-((5-(4-(pyrrolidin-3-ylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of M48a (10 g, 45.2 mmol) in dichloromethane (200 mL)is cooled in an ice/water bath and treated with diisopropylethylamine(9.4 mL, 54.3 mmol) followed by dropwise addition of methanesulfonylchloride (3.8 mL, 50 mmol). The resulting solution is stirred at 0° C.for 1 hour, concentrated and purified on silica gel using a lineargradient of 0-100% ethyl acetate in hexane to afford M48b; ESIMS m/z for(M+H)⁺ C₁₃H₁₈NO₅S calcd: 300.1, found: 300.0.

Step B: A solution of M48b (14.1 g, 45 mmol) and thiolacetic acid (6.4mL, 90 mmol) in dimethylformamide (200 mL) is treated with Cs₂CO₃ (30 g,90 mmol) and heated at 60° C. for 14 hours. The mixture is diluted withwater and extracted with ethyl acetate (3×). The organic layers arecombined, washed with water (2×) and brine, dried over MgSO₄, filtered,concentrated, and purified on silica gel using a linear gradient of0-100% ethyl acetate in hexane to afford M48c; ESIMS m/z for (M+H)⁺C₁₄H₁₈NO₃S calcd: 280.1, found: 280.0.

Step C: A solution of N-chlorosuccinimide (16.7 g, 125 mmol) in 2N HCl(24 mL) and acetonitrile (120 mL) is cooled in an ice/water bath andtreated dropwise with a solution of M48c (9.2 g, 31 mmol) inacetonitrile (20 mL) over 1 hour. The solution is concentrated andpartitioned between ethyl acetate and a saturated aqueoussodiumhydrogencarbonate solution. The organic layer is washed withaqueous sodium thiosulfate and brine, dried (MgSO₄), filtered andconcentrated to provide M48d as a golden oil; ESIMS m/z for (M+H)⁺C₁₂H₁₅ClNO₄S calcd: 304.0, found: 304.0.

Step D: A solution of M1c (74 mg, 0.2 mmol) and M48d (67 mg, 0.22 mmol)in dichloromethane (5 mL) is treated with diisopropylethylamine (69 μL,0.4 mmol) and stirred at room temperature for 3 hours. The mixture isconcentrated and purified on silica gel using 0-100% ethyl acetate inhexane to afford M48e; ESIMS m/z for (M+H)⁺ C₃₁H₄₃N₆O₇S calcd: 643.3,found: 643.2.

Step E: A solution of M48e (104 mg, 0.16 mmol) in methanol (10 mL) istreated with Pd/C (10%, wet) and stirred under 1 atm H₂ for 14 hours.The mixture is filtered through Celite®, concentrated, and purified onsilica gel using 0-10% MeOH in dichloromethane to afford M48: ¹H NMR(400 MHz, CDCl₃) δ 7.79 (d, J=1.2 Hz, 1H), 7.54 (d, J=1.2 Hz, 1H), 4.01(d, J=4.8 Hz, 2H), 3.52 (m, 1H), 3.40 (m, 9H), 3.14 (m, 1H), 3.07 (dd,J=5.2, 8.4 Hz, 1H), 2.80 (m, 1H), 2.67 (m, 2H), 2.08 (m, 2H), 1.98 (s,2H), 1.87 (m, 1H), 1.72 (m, 2H), 1.48 (s, 3H), 1.18 (m, 2H), 0.79 (m,2H), 0.55 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₃H₃₇N₆O₅S calcd: 509.3, found:509.2.

By following the procedure for making M48 from M48a using theappropriate commercially available starting alcohols in place of M48aand in some cases performing reductive methylations, the followingexamples are prepared;

Example Structure Analytical data M49

¹H NMR (400 MHz, CD₃CN) δ 7.82 (d, J = 1.6 Hz, 1H), 7.70 (d, J = 1.6 Hz,1H), 4.06 (d, J = 6.8 Hz, 2H), 4.00 (m, 2H), 3.63 (m ,1H), 3.46 (m, 4H),3.36 (m, 4H), 3.12 (m, 2H), 2.95 (m, 1H), 2.77 (m, 3H), 2.10 (m, 5H),1.76 (m, 2H), 1.73 (s, 3H), 1.18 (m, 2H), 0.79 (m, 2H), 0.59 (m, 2H);ESIMS m/z for (M + H)⁺ C₂₃H₃₇N₆O₅S calcd: 509.3, found: 509.2. M50

¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, J = 0.8 Hz, 1H), 7.54 (d, J = 0.8 Hz,1H), 4.01 (d, J = 4.8 Hz, 2H), 3.53 (m, 1H), 3.40 (m, 9H), 3.14 (m, 1H),3.08 (dd, J = 5.2, 8.4 Hz, 1H), 2.81 (m, 1H), 2.68 (m, 2H), 2.08 (m,2H), 2.00 (s, 2H), 1.87 (m, 1H), 1.72 (m, 2H), 1.48 (s, 3H), 1.18 (m,2H), 0.79 (m, 2H), 0.55 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₃H₃₇N₆O₅Scalcd; 509.3, found: 509.2. M51

¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, J = 1.2 Hz, 1H), 7.54 (d, J = 1.2 Hz,1H), 4.01 (d, J = 4.8 Hz, 2H), 3.64 (m, 1H), 3.40 (m, 8H), 2.87 (m, 1H),2.73 (m, 1H), 2.67 (m, 2H), 2.61 (m, 1H), 2.31 (s, 3H), 2.00 (m, 2H),1.98 (s, 2H), 1.72 (m, 2H), 1.48 (s, 3H), 1.18 (m, 2H), 0.79 (m, 2H),0.55 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₄H₃₉N₆O₅S calc: 523.3, found:523.2. M52

¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, J = 1.2 Hz, 1H), 7.54 (d, J = 1.2 Hz,1H), 4.01 (d, J = 4.8 Hz, 2H), 3.64 (m, 1H), 3.40 (m, 8H), 2.87 (m, 1H),2.73 (m, 1H), 2.67 (m, 2H), 2.61 (m, 1H), 2.31 (s, 3H), 2.00 (m, 2H),1.98 (s, 2H), 1.72 (m, 2H), 1.48 (s, 3H), 1.18 (m, 2H), 0.79 (m, 2H),0.55 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₄H₃₉N₆O₅S calcd: 523.3, found:523.2. M53

¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, J = 1.0 Hz, 1H), 7.53 (d, J = 1.0 Hz,1H), 4.09 (m, 1H), 4.05 (m, 2H), 4.01 (d, J = 4.4 Hz, 2H), 3.40 (m, 4H),3.38 (m, 4H), 2.67 (m, 2H), 1.94 (br s, 1H), 1.87 (m, 1H), 1.71 (m, 2H),1.48 (s, 3H), 1.18 (m, 2H), 0.79 (m, 2H), 0.55 (m, 2H); ESIMS m/z for(M + H)⁺ C₂₂H₃₅N₆O₅S calcd: 495.2, found: 495.2. M54

¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, J = 0.8 Hz, 1H), 7.53 (d, J = 0.8 Hz,1H), 4.00 (d, J = 4.4 Hz, 2H), 3.85 (m, 1H), 3.57 (m, 2H), 3.41 (m, 4H),3.34 (m, 4H), 2.67 (m, 2H), 2.29 (s, 3H), 1.87 (m, 1H), 1.72 (m, 2H),1.48 (s, 3H), 1.18 (m, 2H), 0.79 (m, 2H), 0.55 (m, 2H); ESIMS m/z for(M + H)⁺ C₂₃H₃₇N₆O₅S calcd: 509.3, found: 509.2. M55

¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, J = 1.4 Hz, 1H), 7.53 (d, J = 1.4 Hz,1H), 4.01 (d, J = 6.8 Hz, 2H), 3.75 (m, 2H), 3.43 (m, 6H), 3.33 (m, 4H),3.16 (m, 2H), 2.67 (m, 2H), 1.87 (m, 1H), 1.72 (m, 2H), 1.48 (s, 3H),1.18 (m, 3H), 0.79 (m, 2H), 0.54 (m, 2H); ESIMS m/z for (M + H)⁺C₂₃H₃₇N₆O₅S calcd: 509.3, found: 509.2 M56

¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, J = 1.6 Hz, 1H), 7.53 (d, J = 1.6 Hz,1H), 4.01 (d, J = 6.8 Hz, 2H), 3.42 (m, 6H), 3.33 (m, 4H), 3.14 (d, J =7.2 Hz, 2H), 2.98 (m, 2H), 2.69 (m, 2H), 2.25 (s, 3H), 1.87 (m, 1H),1.72 (m, 2H), 1.48 (s, 3H), 1.18 (m, 3H), 0.80 (m, 2H), 0.54 (m, 2H);ESIMS m/z for (M + H)⁺ C₂₄H₃₉N₆O₅S calcd: 523.3, found: 523.2.

Example M57 1-Methylcyclopropyl4-((5-(4-(2-(pyridin-3-yl)ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A sealed vessel containing M26 (50 mg, 0.11 mmol),3-bromopyridine (10 μL, 0.11 mmol), Pd₂ dba₃ (3.0 mg, 0.0032 mmol),tri-t-butylphosphonium tetrafluoroborate (2.0 mg, 0.0064 mmol),dicyclohexylmethylamine (45 mL, 0.21 mmol), and dioxane (1 mL) is heatedat 120° C. overnight. The reaction is cooled to room temperature and isdiluted with water and extracted with ethyl acetate. The organic phaseis dried over MgSO₄, filtered, evaporated, and purified on silica gelusing a linear gradient of 0 to 100% ethyl acetate in dichloromethane toafford M57a; ESIMS m/z for (M+H)⁺ C₂₆H₃₄N₆O₅S calcd: 543.2, found:543.2.

Step B: A solution of M57a from the previous step in ethanol (1 mL) issparged with H₂ (g) for 30 minutes and then left under an atmosphere ofH₂ (g) overnight. The reaction is filtered over Celite®, concentrated,and purified by mass directed HPLC using a linear gradient of 10 to 90%acetonitrile in water to afford M57; ¹H NMR (CDCl₃, 400 MHz): δ 8.79 (s,1H), 8.65 (m, 1H), 8.09 (m, 1H), 7.86 (d, J=1.4 Hz, 1H), 7.68 (m, 1H),7.61 (d, J=1.4 Hz, 1H), 4.20 (m, 2H), 4.08 (d, J=6.5 Hz, 2H), 3.50 (m,4H), 3.42 (m, 2H), 3.33 (m, 2H), 3.24 (m, 2H), 2.74 (m, 2H), 1.79 (m,2H), 1.55 (s, 3H), 1.25 (m, 3H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS m/zfor (M+H)⁺ C₂₆H₃₇N₆O₅S calcd.: 545.3, found: 545.3.

Example M58 1-Methylcyclopropyl4-((5-(4-(2-(pyridin-4-yl)ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as for the preparation of M57 from M26except substituting 4-bromopyridine for 3-bromopyridine, M58 isprepared; ¹H NMR (CDCl₃, 400 MHz): δ 8.80 (s, 2H), 7.87 (s, 1H), 7.74(s, 2H), 7.63 (s, 1H), 4.20 (m, 2H), 4.07 (d, J=6.5 Hz, 2H), 3.50 (m,4H), 3.43 (m, 4H), 3.40 (m, 2H), 3.26 (m, 2H), 2.74 (m, 2H), 1.94 (m,1H), 1.78 (m, 2H), 1.54 (s, 3H), 1.24 (m, 2H), 0.86 (m, 2H), 0.62 (m,2H); ESIMS m/z for (M+H)⁺ C₂₆H₃₇N₆O₅S calcd.: 545.3, found: 545.4.

Example M59 1-Methylcyclopropyl4-((5-(4-sulfamoylpiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of chlorosulfonyl isocyanate (230 μL, 2.65 mmol) inn-hexanes (2.4 mL) is added dropwise to a solution M1c (1.0 g, 2.7 mmol)in n-hexanes (5 mL) and stirred at room temperature for 45 minutes. Asolution of benzyl alcohol (274A, 2.65 mmol) and triethylamine (554 μL,3.97 mmol) in tetrahydrofuran (10 mL) is then introduced dropwise. After2 hr., the reaction is treated with water and extracted withdichloromethane. The organic phase is dried (MgSO₄), filtered,evaporated and chromatographed on silica gel using a linear gradient of0 to 100% ethyl acetate in dichloromethane to afford M59a. ESIMS m/z for(M+H)⁺ C₂₇H₃₇N₆O₇S calcd.: 589.2, found: 589.3.

Step B: A solution of M59a (300 mg, 0.509 mmol) in ethanol (5 mL) istreated with 5% Pd/C (30 mg) and subjected to a H₂ (g) flush for 30minutes. The reaction is left under an atmosphere of H₂ (g) overnightand is then filtered over Celite® and concentrated to afford M59; ESIMSm/z for (M+H)⁺ C₁₉H₃₁N₆O₅S calcd.: 455.2, found: 455.3.

Example M60 tert-Butyl4-((5-(4-(morpholinosulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A sample of M60a is prepared in an analogous manner to M30. A microwavereaction vial is charged M60a (64 mg, 0.14 mmol), 2-bromoethyl ether (18μL, 0.14 mmol), potassium carbonate (40 mg, 0.28 mmol) andN,N-dimethylformamide (2 mL), sealed and heated to 150° C. for 5 minutesvia microwave. The reaction is cooled to room temperature and pouredover water and extracted with ethyl acetate. The organic phase is dried(MgSO₄), filtered, evaporated, and purified on silica gel using a lineargradient of 0 to 100% ethyl acetate in hexane to afford M60; ¹H NMR(CDCl₃, 400 MHz): δ 7.95 (s, 1H), 7.91 (s, 1H), 4.16 (m, 2H), 4.11 (d,J=6.5 Hz, 2H), 3.74 (m, 4H), 3.53 (m, 6H), 3.44 (m, 1H), 3.27 (m, 5H),2.73 (m, 2H), 1.96 (m, 1H), 1.78 (m, 2H), 1.46 (s, 9H), 1.26 (m, 2H).ESIMS m/z for (M+H—CO₂ ^(t)Bu)⁺ C₁₈H₃₁N₆O₄S calcd.: 427.2, found: 427.2.

Example M61 1-Methylcyclopropyl4-((6-(4-(ethylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

Step A: By following a similar procedure as for the one used for thepreparation of M1c from B12a except substituting B2b for B12a, M61a isprepared; ESIMS m/z for (M+H)⁺ C₂₀H₃₁N₄O₃ calcd.: 375.2, found: 375.2.

Step A: By following a similar procedure as the one used for preparingM1 from M1c except substituting M61a for M1c and ethanesulfonyl chloridefor methyl 3-(chlorosulfonyl)propanoate, M61 is prepared; ¹H NMR (400MHz, CD₃CN) δ 7.80 (m, 1H), 7.26 (m, 1H), 6.65 (m, 1H), 4.05 (m, 2H),3.70 (d, J=6.3 Hz, 2H), 3.52 (m, 3H), 3.37 (m, 4H), 3.21 (m, 1H), 2.92(m, 2H), 2.67 (dd, J=12.4, 12.4 Hz, 2H), 1.86 (m, 1H), 1.72 (m, 2H),1.47 (s, 3H), 1.31 (t, J=7.3 Hz, 3H), 1.17 (m, 2H), 0.79 (m, 2H), 0.55(m, 2H); ESIMS m/z for (M+H)⁺ C₂₂H₃₅N₄O₅S calcd: 467.2, found: 467.2.

By following a similar procedure as for the one used for the preparationof M61 from M61a except substituting commercially available sulfonylchlorides for M61a, the following examples are obtained:

Example Structure Analytical data M62

¹H NMR (400 MHz, CD₃CN) δ 7.88 (m, 1H), 7.24 (m, 1H), 6.71 (m, 1H), 4.13(m, 2H), 3.78 (d, J = 6.3 Hz, 2H), 3.59 (m, 3H), 3.43 (m, 4H), 3.28 (m,1H), 2.91 (m, 2H), 2.74 (dd, J = 12.2, 12.1 Hz, 2H), 1.89 (m, 3H), 1.80(m, 2H), 1.55 (s, 3H), 1.24 (m, 2H), 1.07 (t, J = 7.4 Hz, 3H), 0.86 (m,2H), 0.62 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₃H₃₇N₄O₅S calcd: 481.2,found: 481.2. M63

¹H NMR (400 MHz, CD₃CN) δ 7.89 (d, J = 2.8 Hz, 1H), 7.24 (m, 1H), 6.67(d, J = 8.9 Hz, 1H), 4.12 (m, 2H), 3.77 (d, J = 6.3 Hz, 2H), 3.50 (m,8H), 3.22 (sept., J = 6.8 Hz, 1H), 2.74 (dd, J = 12.4, 12.3 Hz, 2H),1.93 (m, 1H), 1.80 (m, 2H), 1.55 (s, 3H), 1.36 (d, J = 6.9 Hz, 6H), 1.23(m, 2H), 0.86 (m, 2H); 0.62 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₃H₃₇N₄O₅Scalcd; 481.2, found: 481.2. M64

¹H NMR (400 MHz, CD₃CN) δ 7.88 (m, 1H), 7.24 (m, 1H), 6.71 (m, 1H), 4.13(m, 2H), 3.78 (d, J = 6.3 Hz, 2H), 3.59 (m, 3H), 3.40 (m, 4H), 3.29 (m,1H), 2.77 (d, J = 6.6 Hz, 2H), 2.74 (dd, J = 12.6, 12.6 Hz, 2H), 2.31(m, 1H), 1.94 (m, 1H), 1.80 (m, 2H), 1.55 (s, 3H), 1.24 (m, 2H), 1.12(d, J = 6.7 Hz, 6H), 0.86 (m, 2H), 0.62 (m, 1H); ESIMS m/z for (M + H)⁺C₂₄H₃₉N₄O₅S calcd: 495.3, found: 495.3.

Example M65 1-Methylcyclopropyl4-((6-(4-(3-hydroxypropylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1

Step A: By following a similar procedure as for the one used for thepreparation of M6 from M1c except substituting M61a for M1c, M65a isprepared; ESIMS m/z for (M+H)⁺ C₂₃H₃₆ClN₄O₅S calcd.: 515.2, found:515.2.

Step B: By following a similar procedure as the one used for preparingM19 from M5 except substituting M65a for M5, M65b is prepared; ESIMS m/zfor (M+H)⁺ C₂₅H₃₉N₄O₇S calcd: 539.3, found: 539.2.

Step C: By following a similar procedure as the one used for preparingM43 from M42 except substituting M65b for M42, Example 65 is prepared;¹H NMR (400 MHz, CD₃CN) δ 7.88 (d, J=3.0 Hz, 1H), 7.19 (dd, J=9.2, 2.8Hz, 1H), 6.68 (d, J=9.1 Hz, 1H), 4.11 (m, 2H), 3.77 (m, 4H), 3.55 (m,4H), 3.41 (m, 4H), 3.08 (m, 2H), 2.74 (dd, J=12.3, 12.3 Hz, 2H), 2.08(m, 2H), 1.92 (m, 2H), 1.80 (m, 2H), 1.54 (s, 3H), 1.24 (m, 2H), 0.85(m, 2H), 0.62 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₃H₃₇N₄O₆S calcd: 497.2,found: 497.3.

Example M66 1-Methylcyclopropyl4-((6-(4-(3-aminopropylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as for the one used for the preparationof M18 from M16 except substituting M65a for M16, M66 is prepared; ESIMSm/z for (M+H)⁺ C₂₃H₃₈N₅O₅S calcd: 496.3, found: 496.3.

Example M67 1-Methylcyclopropyl4-((6-(4-(3-(azetidin-1-yl)propylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as for the one used for the preparationof M21 from M6 except substituting M65a for M21 and azetidine for2-methylimidazole, M67 is prepared; ¹H NMR (400 MHz, Acetone-d₆) δ 7.91(d, J=3.2 Hz, 1H), 7.27 (dd, J=3.2, 9.2 Hz, 1H), 6.84 (d, J=8.8 Hz, 1H),4.06 (m, 2H), 3.85 (d, J=6.4 Hz, 2H), 3.52 (m, 4H), 3.34 (m, 4H), 3.09(t, J=6.8 Hz, 4H), 3.05 (m, 2H), 2.80 (m, 2H), 2.44 (d, J=6.8 Hz, 2H),1.96 (m, 3H), 1.78 (m, 4H), 1.50 (s, 3H), 1.23 (m, 2H), 0.79 (m, 2H),0.58 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₆H₄₁N₅O₅S calcd: 535.3, found:536.3.

Example M68 1-Methylcyclopropyl4-((6-(4-((1-(azetidin-1-yl)cyclopropyl)methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as for the one used for the preparationof M35 from M1c except substituting M61a for M1c, M68 is prepared;¹H-NMR (400 MHz, CDCl₃) δ 7.92 (d, J=2.9 Hz, 1H), 7.14 (dd, J=9.1, 3.0Hz, 1H), 6.64 (d, J=9.1 Hz, 1H), 4.13 (m, 2H), 3.77 (d, J=6.3 Hz, 2H),3.54 (m, 4H), 3.49 (m, 4H), 3.06 (m, 4H), 3.01 (s, 2H), 2.74 (m, 2H),1.91 (m, 2H), 1.85 (m, 2H), 1.80 (m, 2H), 1.55 (s, 3H), 1.25 (m, 2H),0.86 (m, 4H), 0.70 (m, 2H), 0.62 (m, 2H); ESIMS calcd. for C₂H₄₂N₅O₅S[M+H]⁺ 548.3, found 548.4.

Example M69 1-Methylcyclopropyl4-((6-(4-(2-hydroxy-2-methylpropylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

A solution of E10 (50 mg, 0.11 mmol) in tetrahydrofuran (3 mL) is cooledto −78° C. and treated excess butyllithium in hexane (2M, 250 μL). Afterstirring for 15 minutes, excess dry acetone is added and the reaction isstirred for an additional 30 minutes. The reaction is quenched withsaturated aqueous ammonium chloride solution, warmed to room temperatureand partitioned between ethyl acetate and water. The organics areisolated, dried over MgSO₄, filtered, evaporated and purified on silicagel using a linear gradient of 0-100% ethyl acetate in hexane to affordM69; ¹H NMR (400 MHz, CDCl₃) δ 7.90 (d, J=2.8 Hz, 1H), 7.15 (dd, J=3.0,9.1 Hz, 1H), 6.64 (d, J=9.1 Hz, 1H), 4.13 (m, 2H), 3.77 (d, J=6.3 Hz,2H), 3.52 (m, 5H), 3.36 (m, 4H), 3.04 (s, 2H), 2.73 (m, 2H), 1.93 (m,1H), 1.80 (m, 2H), 1.54 (s, 3H), 1.44 (s, 6H), 1.25 (m, 2H), 0.87 (m,2H), 0.61 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₄H₃₉N₄O₆S calcd: 511.3, found:511.5.

Example N1 1-Methylcyclopropyl4-((5-fluoro-6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of N1a (100 mg, 0.678 mmol) and N1b (219 mg, 0.746mmol) in N-methylpyrrolidinone (2 mL) is treated with Cs₂CO₃ (331 mg,1.01 mmol) and heated to 80° C. for 2 hours. The reaction is cooled toroom temperature, diluted with ethyl acetate and extracted with watertwice. The organics are dried over MgSO₄, filtered, evaporated andpurified on silica using a linear gradient of 0 to 50% ethyl acetate inhexanes to afford N1c. ESIMS m/z for (M+H)⁺ C₁₆H₂₃ClFN₂O₃ calcd: 345.1,found: 289.0 (M-tBu+H⁺).

Step B: By following a similar procedure as the one used for preparingB1 from isopropyl4-((6-chloropyridin-3-yloxy)methyl)piperidine-1-carboxylate exceptsubstituting N1c for isopropyl4-((6-chloropyridin-3-yloxy)methyl)piperidine-1-carboxylate and benzylpiperazine-1-carboxylate for 1-(methylsulfonyl)piperazine, N1d isprepared; ESIMS m/z for (M+H)⁺ C₂₈H₃₈FN₄O₅ calcd: 529.3, found: 529.2.

Step C: A solution of N1d (132 mg, 0.25 mmol) in a mixture of methanoland dioxane (2 mL, 1:1) is treated with 10 mg of 5% Pd/C andhydrogenated overnight at balloon pressure. The atmosphere in thereaction is then exchanged back to N₂ and the reaction is filteredthrough Celite® and the solvent is removed. The resulting oil iscoevaporated with toluene twice, dissolved in dichloromethane (2 mL)containing triethylamine (51 mg, 0.50 mmol) and treated withmethanesulfonyl chloride (43 mg, 0.38 mmol) as a solution indichloromethane (1 mL) and stirred for 1 hour. The solvent is removedand the reaction is treated with neat trifluoroacetic acid (3 mL). After20 minutes of stirring, the solvent is removed and the reaction iscoevaporated with toluene twice and treated with dichlormethane (2 mL),E3b (71 mg, 0.30 mmol) and excess triethylamine. After 2 h of stirring,the reaction is diluted with ethyl acetate, extracted with 1 M NaOHtwice, saturated sodiumhydrogencarbonate once, dried over MgSO₄,filtered, evaporated and purified on silica gel using a linear gradientof 0 to 100% ethyl acetate in hexane; ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d,J=2.5 Hz, 1H), 7.07 (dd, J=2.5, 13.0 Hz, 1H), 4.14 (m, 2H), 3.80 (d,J=6.3 Hz, 2H), 3.53 (m, 4H), 3.40 (m, 4H), 2.82 (s, 3H), 2.74 (m, 2H),1.95 (m, 1H), 1.80 (m, 2H), 1.55 (s, 3H), 1.26 (m, 2H), 0.86 (m, 2H),0.62 (m, 2H); ESIMS m/z for (M+H)⁺ C_(2i)H₃₂EN₄O₅S calcd: 471.2, found:471.2.

Example O1 tert-Butyl4-((5-(4-(methylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A sealable flask is charged with B4b (4.00 g, 11 mmol) andbenzyl 3-oxopiperazine-1-carboxylate (3.02 g, 13 mmol), Pd₂dba₃ (295 mg,0.32 mmol), Xantphos (560 mg, 0.97 mmol) and Cs₂CO₃ (10.5 g, 32 mmol).The flask is evacuated and back filled with nitrogen, sealed, treatedwith dioxane (60 mL) and dipped into a pre-heated 120° C. bathours.After 2 hours, the reaction is cooled to room temperature, diluted withethyl acetate and extracted with water twice. The organics are driedover MgSO₄, filtered, evaporated and purified on silica using a stepgradient of 25, 50 and 75% ethyl acetate in hexanes to afford O1a; ESIMSm/z for (M-Boc+H)⁺ C₂₂H₂₈N₅O₄ calcd: 426.2, found: 426.1.

Step B: A solution of O1a (80 mg, 0.15 mmol) in MeOH (2 mL) is treatedwith 10 mg of 5% Pd/C and hydrogenated at balloon pressure overnight.The catalyst is removed by filtration through Celite® and the solvent isremoved. The residue is coevaporated with toluene twice, dissolved indichloromethane (2 mL) and treated with excess triethylamine followed bymethanesulfonyl chloride (21 mg, 0.18 mmol) dissolved in dichloromethane(1 mL). After 1 hour of stirring, the reaction is diluted with ethylacetate and extracted with water twice. The organics are dried overMgSO₄, filtered, evaporated and purified on silica using a lineargradient of 30 to 100% ethyl acetate in hexanes to afford O1; ¹H NMR(400 MHz, CDCl₃) δ 8.66 (d, J=1.4 Hz, 1H), 8.02 (d, J=1.4 Hz, 1H), 4.19(d, J=6.5 Hz, 2H), 4.15 (m, 2H), 4.13 (s, 2H), 4.08 (m, 2H), 3.68 (m,2H), 2.92 (s, 3H), 2.74 (m, 2H), 1.98 (m, 1H), 1.79 (m, 2H), 1.46 (s,9H), 1.27 (m, 2H); ESIMS m/z for (M+Na)⁺ C₂₀H₃₁N₅NaO₆S calcd: 492.2,found: 492.2.

Example O2 1-Methylcyclopropyl4-((5-(4-(methylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A sample of O1 (50 mg, 0.11 mmol) is treated with trifluoroacetic acid(1 mL) and aged for 20 minutes. The solvent is removed and the residueis treated with dichloromethane (2 mL), excess triethylamine and E3b(30.3 mg, 0.13 mmol). After stirring for 3 hours, the reaction isdiluted with ethyl acetate, extracted with 1 M NaOH twice, saturatedsodiumhydrogencarbonate once, dried over MgSO₄, filtered, evaporated andpurified on silica gel using a linear gradient of 0 to 100% ethylacetate in hexane; ¹H NMR (400 MHz, CDCl₃) δ 8.65 (d, J=1.4 Hz, 1H),8.02 (d, J=1.4 Hz, 1H), 4.18 (d, J=6.5 Hz, 2H), 4.12 (s, 2H), 4.12 (m,2H), 4.07 (m, 2H), 3.67 (m, 2H), 2.93 (s, 3H), 2.72 (m, 2H), 1.98 (m,1H), 1.79 (m, 2H), 1.54 (s, 3H), 1.25 (m, 2H), 0.87 (m, 2H), 0.62 (m,2H); ESIMS m/z for (M+H)⁺ C₂₀H₃₀N₅O₆S calcd: 468.2, found: 468.1.

Example O3 1-Methylcyclopropyl4-((5-(2-oxo-4-(propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: By following a similar procedure as the one used for preparingO1a from B4b except substituting M1a for B4b, O3a is prepared; ESIMS m/zfor (M+H)⁺ C₂₇H₃₄N₅O₆ calcd: 524.2, found: 524.2.

Step B: A solution of O3a (3.01 g, 0.15 mmol) in MeOH (30 mL) is treatedwith 101 mg of 20% Pd(OH)₂/C and hydrogenated at balloon pressure for 5hours. The catalyst is removed by filtration through Celite® and thesolvent is removed to afford O3b; ESIMS m/z for (M+H)⁺ C₁₉H₂₈N₅O₄ calcd:390.2, found: 390.1.

Step C: A solution of O3b (203 mg, 0.52 mmol) in dichloromethane (1.5mL) is treated with triethylamine (55 mg, 0.54 mmol) andn-propanesulfonyl chloride (77 mg, 0.54 mmol) and stirred for 4 hours.Then, another identical portion of triethylamine and n-propylsulfonylchloride is added and the reaction is stirred overnight. The reactionmixture is then loaded directly onto a silica gel column and eluted witha linear gradient of 0 to 100% ethyl acetate in hexane to afford O3; ¹HNMR (400 MHz, CDCl₃) δ 8.65 (d, J=1.4 Hz, 1H), 8.02 (d, J=1.4 Hz, 1H),4.18 (d, J=6.5 Hz, 1H), 4.17 (m, 2H), 4.15 (s, 2H), 4.05 (m, 2H), 3.70(m, 2H), 3.01 (m, 2H), 2.75 (dd, J=12.3, 12.2 Hz, 2H), 1.98 (m, 1H),1.89 (m, 2H), 1.79 (m, 2H), 1.55 (s, 3H), 1.26 (m, 2H), 1.09 (t, J=7.4Hz, 3H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₂H₃₄N₅O₆Scalcd: 496.2, found: 496.2.

Example O4 1-Methylcyclopropyl4-((5-(4-(isopropylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing O3 fromO3b except substituting 3-chloropropanesulfonyl chloride forn-propanesulfonyl chloride, O4 is prepared; ¹H NMR (400 MHz, CDCl₃) δ8.65 (d, J=1.4 Hz, 1H), 8.02 (d, J=1.4 Hz, 1H), 4.21 (s, 2H), 4.19 (m,2H), 4.19 (d, J=6.5 Hz, 2H), 4.04 (m, 2H), 3.75 (m, 2H), 3.28 (sept.,J=6.8 Hz, 1H), 2.75 (dd, J=12.3, 12.3 Hz, 2H), 1.98 (m, 1H), 1.78 (m,2H), 1.55 (s, 3H), 1.40 (d, J=6.8 Hz, 6H), 1.26 (m, 2H), 0.87 (m, 2H),0.62 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₂H₃₄N₅O₆S calcd: 496.2, found:496.2.

Example O5 1-Methylcyclopropyl4-((5-(4-(3-chloropropylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing O3 fromO3b except substituting iso-propylsulfonyl chloride for n-propylsulfonylchloride, O5 is prepared; ¹H-NMR (400 MHz, CDCl₃) δ 8.65 (d, J=1.4 Hz,1H), 8.02 (d, J=1.4 Hz, 1H), 4.21 (m, 2H), 4.18 (d, J=6.6 Hz, 2H), 4.17(s, 2H), 4.07 (m, 2H), 3.71 (m, 4H), 3.21 (m, 2H), 2.75 (dd, J=12.4,12.3 Hz, 2H), 2.33 (m, 2H), 1.97 (m, 1H), 1.79 (m, 2H), 1.55 (s, 3H),1.26 (m, 2H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS calcd. for C₂₂H₃₃ClN₅O₆S[M+H]⁺ 530.2, found 530.3.

Example O6 1-Methylcyclopropyl4-((5-(2-oxo-4-(3-(pyrrolidin-1-yl)propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of O5 (15 mg, 0.03 mmol) in N,N-dimethylformamide (700 μL) istreated with pyrrolidine (23 μL, 0.28 mmol) and subjected to microwaveirradiation (200° C., 5 min) The solution is purified using massdirected reverse phase HPLC to afford O6; ¹H NMR (400 MHz, CDCl₃) δ 8.67(d, J=1.2 Hz, 1H), 8.04 (d, J=1.2 Hz, 1H), 4.20 (d, J=6.8 Hz, 2H), 4.18(s, 2H), 4.07 (m, 2H), 3.72 (m, 2H), 3.18 (m, 2H), 2.77 (m, 2H), 2.66(m, 2H), 2.59 (br s, 3H), 2.07 (m, 3H), 1.83 (m, 5H), 1.57 (s, 3H), 1.28(m, 2H), 0.89 (m, 2H), 0.65 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₆H₄₁N₆O₆Scalcd: 565.3, found: 565.2.

By following a similar procedure as for the one used for the preparationof O6 from O5 except substituting the appropriate amines forpyrrolidine, the following examples are obtained:

O7

¹H NMR (400 MHz, CDCl₃) δ 8.64 d, J = 1.6 Hz, 1H), 8.04 (d, J = 1.6 Hz,1H), 4.20 (d, J = 6.4 Hz, 2H), 4.18 (s, 2H), 4.07 (m, 2H), 3.72 (m, 4H),3.32 (m, 8H), 3.15 (m, 2H), 2.77 (m, 2H), 2.46 (m, 4H), 2.02 (m, 4H),1.80 (m, 2H), 1.56 (s, 3H), 1.29 (m, 2H), 0.87 (m, 2H), 0.64 (m, 2H);ESIMS m/z for (M + H)⁺ C₂₆H₄₁N₆O₇S calcd: 581.3, found: 581.2. O8

¹H NMR (400 MHz, CDCl₃) δ 8.49 d, J = 1.4 Hz, 1H), 7.86 (d, J = 1.4 Hz,1H), 4.03 (d, J = 6.4 Hz, 2H), 4.00 (s, 2H), 3.89 (m, 2H), 3.54 (m, 2H),2.97 (m, 2H), 2.59 (m, 2H), 2.33 (m, 2H), 2.12 (s, 6H), 1.87 (m, 4H),1.64 (m, 2H), 1.39 (s, 3H), 1.10 (m, 2H), 0.71 (m, 2H), 0.46 (m, 2H);ESIMS m/z for (M + H)⁺ C₂₄H₃₉N₆O₆S calcd: 539.3, found: 539.2. O9

¹H NMR (400 MHz, CDCl₃) δ 8.44 (d, J = 1.6 Hz, 1H), 7.81 (d, J = 1.6 Hz,1H), 3.98 (d, J = 6.8 Hz, 2H), 3.94 (s, 2H), 3.84 (m, 2H), 3.48 (m, 2H),2.98 (m, 3H), 2.89 (m, 2H), 2.54 (m, 2H), 2.31 (m, 2H), 1.86 (m, 2H),1.78 (m, 1H), 1.65 (m, 4H), 1.34 (s, 3H), 1.05 (m, 2H), 0.66 (m, 2H),0.41 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₅H₃₉N₆O₆S calcd: 551.3, found:551.3. O10

¹H NMR (400 MHz, CDCl₃) δ 8.51(d, J = 1.2 Hz, 1H), 7.88 (d, J = 1.2 Hz,1H), 4.04 (d, J = 6.4 Hz, 2H), 4.01 (s, 2H), 3.91 (m, 3H), 3.56 (m, 2H),3.43 (t, J = 12.0 Hz, 4H), 2.97 (m, 2H), 2.56 (m, 4H), 1.84 (m, 1H),1.78 (m, 2H), 1.66 (m, 2H), 1.41 (s, 3H), 1.13 (m, 2H), 0.73 (m, 2H),0.48 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₅H₃₇F₂N₆O₆S calcd; 587.3, found:587.2. O11

¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, J = 1.4 Hz, 1H), 7.95 (d, J = 1.4 Hz,1H), 4.12 (d, J = 6.4 Hz, 2H), 4.10 (s, 2H), 4.06 (m, 2H), 3.98 (m, 3H),3.64 (m, 2H), 3.07 (m, 2H), 2.94 (m, 2H), 2.68 (m, 2H), 2.58 (m, 2H),2.43 (dd, J = 3.6, 10.4 Hz, 2H), 1.95 (m, 4H), 1.72 (m, 2H), 1.48 (s,3H), 1.18 (m, 2H), 0.80 (m, 2H), 0.56 (m, 2H); ESIMS m/z for (M + H)⁺C₂₆H₄₁NO₈S calcd: 597.3, found: 597.3. O12

¹H NMR (400 MHz, CDCl₃) δ 8.67 (d, J = 1.2 Hz, 1H), 8.04 (d, J = 1.2 Hz,1H), 7.54 (d, J = 1.6 Hz, 1H), 7.46 (d, J = 1.6 Hz, 1H), 6.29 (m, 1H),4.35 (m, 2H), 4.20 (d, J = 6.4 Hz, 2H), 4.12 (s, 2H), 4.05 (m, 3H), 3.68(m, 2H), 2.99 (m, 2H), 2.77 (m, 2H), 2.45 (m, 2H), 2.00 (m, 1H), 1.82(m, 2H), 1.57 (s, 3H), 1.28 (m, 2H), 0.89 (m, 2H), 0.64 (m, 2H); ESIMSm/z for (M + H)⁺ C₂₅H₃₆N₇O₆S calcd: 562.2, found: 562.3.

Example O13 1-Methylcyclopropyl4-((5-(2-oxo-4-(2-(pyrrolidin-1-yl)ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of O3b (600 mg, 1.51 mmol) in dichloromethane (10 mL)is treated with N,N-diisopropylethylamine (521 μL, 3.02 mmol) and2-chloroethanesulfonyl chloride (173 μL, 1.66 mmol) and stirred for 2hours. The reaction mixture is then loaded directly onto a silica gelcolumn and eluted with a linear gradient of 0 to 100% ethyl acetate inhexane to afford O13a. ESIMS m/z for (M+H)⁺ C₂₁H₃₀N₅O₆S calcd: 480.2,found: 480.2.

Step B: A solution of O13a (15 mg, 0.03 mmol) in N,N-dimethylformamide(1 mL) is treated with pyrrolidine (26 μL, 0.31 mmol) and stirred for 16hours at room temperature. The solution is purified using mass-triggeredreverse phase HPLC to afford O13. ¹H NMR (400 MHz, CDCl₃) δ 8.68 (d,J=1.4 Hz, 1H), 8.04 (d, J=1.4 Hz, 1H), 4.20 (m, 4H), 4.06 (m, 3H), 3.72(m, 2H), 3.34 (m, 2H), 3.04 (m, 2H), 2.75 (m, 6H), 2.00 (m, 1H), 1.83(m, 6H), 1.57 (s, 3H), 1.28 (m, 2H), 0.89 (m, 2H), 0.64 (m, 2H); ESIMSm/z for (M+H)⁺ C₂₅H₃₉N₆O₆S calcd: 551.3, found: 551.2.

By following a similar procedure as for the one used for the preparationof O13 from O13a except substituting the appropriate amines forpyrrolidine, the following examples are obtained:

Ex. Structure Analytical data O14

¹H NMR (400 MHz, CDCl₃) δ 8.67 (d, J = 1.4 Hz, 1H), 8.04 (d, J = 1.4 Hz,1H), 4.20 (m, 4H), 4.06 (m, 3H), 3.73 (m, 2H), 3.26 (m, 2H), 2.84 (m,2H), 2.77 (m, 2H), 2.33 (s, 6H), 2.00 (m, 1H), 1.82 (m, 2H), 1.57 (s,3H), 1.28 (m, 2H), 0.89 (m, 2H), 0.64 (m, 2H); ESIMS m/z for (M + H)⁺C₂₃H₃₇N₆O₆S calcd: 525.3, found: 525.2. O15

¹H NMR (400 MHz, CDCl₃) δ 8.68 (d, J = 1.2 Hz, 1H), 8.04 (d, J = 1.2 Hz,1H), 4.21 (m, 4H), 4.08 (m, 2H), 3.72 (m, 6H), 3.25 (m, 2H), 2.88 (m,2H), 2.77 (m, 2H), 2.53 (m, 4H), 2.00 (m, 1H), 1.81 (m, 2H), 1.57 (s,3H), 1.28 (m, 2H), 0.89 (m, 2H), 0.64 (m, 2H); ESIMS m/z for (M + H)⁺C₂₅H₃₉N₆O₇S calcd: 567.3, found: 567.2. O16

¹ H NMR (400 MHz, CDCl₃) δ 8.60 (d, J = 1.2 Hz, 1H), 7.95 (d, J = 1.2Hz, 1H), 4.15 (s, 2H), 4.12 (d, J = 6.4 Hz, 2H), 3.97 (m, 2H), 3.65 (m,3H), 3.15 (m, 3H), 2.98 (m, 2H), 2.77 (m, 2H), 2.68 (m, 2H), 1.98 (m,2H), 1.94 (m, 1H), .1.73 (m, 2H), 1.48 (s, 3H), 1.19 (m, 2H), 0.80 (m,2H), 0.55 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₄H₃₇N₆O₆S calcd: 537.3,found: 567.3. O17

¹H NMR (400 MHz, CDCl₃) δ 8.68 (d, J = 1.6 Hz, 1H), 8.04 (d, J = 1.6 Hz,1H), 4.20 (m, 5H), 4.07 (m, 3H), 3.74 (m, 2H), 3.66 (t, J = 11.6 Hz,4H), 3.09 (m, 4H), 2.77 (m, 2H), 2.00 (m, 1H), 1.81 (m, 2H), 1.57 (s,3H), 1.29 (m, 2H), 0.89 (m, 2H), 0.64 (m, 2H); ESIMS m/z for (M + H)⁺C₂₄H₃₅F₂N₆O₆S calcd: 573.2, found: 573.2. O18

¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, J = 1.4 Hz, 1H), 7.95 (d, J = 1.4 Hz,1H), 4.15 (s, 2H), 4.12 (d, J = 6.4 Hz, 2H), 4.03 (m, 2H), 3.98 (m, 2H),3.66 (m, 2H), 3.26 (m, 2H), 2.95 (m, 4H), 2.68 (m, 2H), 2.48 (dd, J =3.2, 10 Hz, 2H), 1.91 (m, 1H), 1.72 (m, 2H), 1.48 (s, 3H), 1.20 (m, 2H),0.80 (m, 2H), 0.56 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₅H₃₉N₆O₈S calcd:583.3, found: 583.3. O19

¹H NMR (400 MHz, CDCl₃) δ 8.55 (d, J = 1.2 Hz, 1H), 7.94 (d, J = 1.2 Hz,1H), 7.48 (d, J = 2.0 Hz, 1H), 7.41 (d, J = 2.0 Hz, 1H), 6.19 (m, 1H),4.52 (m, 2H), 4.11 (d, J = 6.4 Hz, 2H), 3.87 (s, 2H), 3.85 (m, 2H), 3.65(m, 2H), 3.40 (m, 2H) 2.68 (m, 2H), 1.91 (m, 1H), 1.72 (m, 2H), 1.48 (s,3H), 1.18 (m, 2H), 0.80 (m, 2H), 0.56 (m, 2H); ESIMS m/z for (M + H)⁺C₂₄H₃₄N₇O₆S calcd: 548.2, found: 548.2.

Example O20 1-methylcyclopropyl4-((5-(4-((1-(dimethylamino)cyclopropyl)methylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of piperazin-2-one (36.5 mg, 3.7 mmol) indichloromethane (10 mL) is treated with triethylamine (74 mg, 0.73 mmol)followed by M33e (108 mg, 3.7 mmol) and stirred overnight. The solventis removed and the residue is dissolved in dimethylformamide, filteredand purified by mass triggered reverse phase HPLC to afford O20a; ESIMSm/z for (M+H)⁺ C₁₄H₁₉N₂O₅S₂ calcd: 359.1, found: 359.0.

Step B: A solution of O20a (71.7 mg, 0.20 mmol) in 2 M dimethylamine intetrahydrofuran solution (6 mL, 12 mmol) is treated with potassiumtert-butoxide (34 mg, 0.30 mmol) and stirred for 1 hour at roomtemperature. The solvent is removed and the residue is dissolved indimethylformamide, filtered and purified by mass triggered reverse phaseHPLC to afford O20a; ESIMS m/z for (M+H)⁺ C₁₀H₂₀N₃O₃S calcd: 262.1,found: 262.1.

Step C: By following a similar procedure as the one used for preparingO3a from M1a except substituting O20b for benzyl3-oxopiperazine-1-carboxylate, O20 is prepared; ¹H-NMR (400 MHz, CDCl₃)δ 8.65 (d, J=1.4 Hz, 1H), 8.02 (d, J=1.4 Hz, 1H), 4.25 (m, 2H), 4.19 (d,J=6.5 Hz, 2H), 4.17 (s, 2H), 4.04 (m, 2H), 3.70 (m, 2H), 3.16 (s, 2H),2.75 (dd, J=15.2, 13.8 Hz, 2H), 2.29 (s, 6H), 1.98 (m, 1H), 1.80 (m,2H), 1.55 (s, 3H), 1.27 (m, 2H), 0.88 (m, 6H), 0.62 (m, 2H); ESIMScalcd. for C₂₅H₃₉N₆O₆S [M+H]⁺ 551.3, found 551.4.

Example O21 1-Methylcyclopropyl4-((5-(4-(3-hydroxypropylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of O5 (2.76 g, 5.2 mmol), NaI (790 mg, 5.3 mmol) andsodium formate (1.06 g, 15.6 mmol) in dimethylformamide (30 mL) isheated at 120° C. for 2 hours. The mixture is diluted with water,extracted with ethyl acetate (2×) and the organics are washed with water& brine, dried (MgSO₄), filtered and concentrated to provide crude O21a,which is used in the next step without further purification; ESIMS m/zfor (M+H)⁺ C₂₃H₃₄N₅O₈S calcd: 540.2, found: 540.2.

Step B: A solution of O21a (crude from the last step) in a 1:1 mixtureof methanol and water (40 mL) is treated with sodiumhydrogencarbonate(2.2 g, 26.0 mmol) and stirred at room temperature for 1 hour. Themixture is extracted with ethyl acetate and the organics are washed withbrine, dried (MgSO₄), filtered and concentrated. The residue is purifiedon silica gel using 0-10% methanol in dichloromethane to afford O21; ¹HNMR (400 MHz, CDCl₃) 8.66 (d, J=1.4 Hz, 1H), 8.04 (d, J=1.4 Hz, 1H),4.20 (m, 4H), 4.08 (m, 2H), 3.82 (m, 2H), 3.74 (m, 2H), 3.22 (m, 2H),2.77 (m, 2H), 2.12 (m, 2H), 2.00 (m, 1H), 1.83 (m, 2H), 1.74 (t, J=4.8Hz, 1H), 1.60 (s, 2H), 1.57 (s, 3H), 1.28 (m, 2H), 0.89 (m, 2H), 0.65(m, 2H); ESIMS m/z for (M+H)⁺ C₂₂H₃₄N₅O₇S calcd: 512.2, found: 512.2.

Example O22 1-Methylcyclopropyl4-((5-(4-(3-acetoxypropylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing M19 fromM5 except substituting O5 for M5, O22 is prepared; ¹H-NMR (400 MHz,CDCl₃) δ 8.65 (d, J=1.4 Hz, 1H), 8.02 (d, J=1.4 Hz, 1H), 4.19 (m, 8H),4.06 (m, 2H), 3.72 (m, 2H), 3.12 (m, 2H), 2.75 (dd, J=12.4, 12.4 Hz,2H), 2.15-2.22 (m, 2H), 2.08 (s, 3H), 1.98 (m, 1H), 1.79 (m, 2H), 1.55(s, 3H), 1.27 (m, 2H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS calcd. forC₂₄H₃₆N₅O₈S [M+H]⁺ 554.2, found 554.2.

Example O23 1-Methylcyclopropyl4-((5-(4-(2-(1-hydroxycyclopropyl)ethylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: By following a similar procedure as the one used for preparingM46 from M46b except substituting piperazin-2-one for M1c and purifyingby HPLC, O23a is prepared; ESIMS calcd. for C₁₁H₁₉N₂O₅S [M+H]⁺ 291.1,found 291.1.

Step B: By following a similar procedure as the one used for preparingO3a from M1a except substituting O23b for benzyl3-oxopiperazine-1-carboxylate, O23b is prepared; ESIMS calcd. forC₂₆H₃₈N₅O₈S [M+H]⁺ 580.2, found 580.3.

Step C: A solution of O23b (37.4 mg, 0.65 mmol) in methanol (1 mL) andwater (0.1 mL) is treated with LiOH (5.7 mg, 0.1 mmol) and stirredovernight. The reaction is then purified directly by mass triggeredreverse phase HPLC to afford O23c. ESIMS calcd. for C₂₄H₃₈N₅O₈S [M+H]⁺556.2, found 556.2.

Step D: A solution of O23c (20 mg, 0.036 mmol) in dichloromethane (1 mL)is treated with HATU (13.7 mg, 0.036 mmol) and N,N-diisopropylethylamine(4.6 mg, 0.036 mmol) and stirred overnight. The solvent is removed andthe residue is dissolved in methanol and purified directly by masstriggered reverse phase HPLC. ¹H-NMR (400 MHz, CDCl₃) δ 8.64 (d, J=1.4Hz, 1H), 8.02 (d, J=1.4 Hz, 1H), 4.25 (m, 2H), 4.20 (s, 2H), 4.18 (s,2H), 4.06 (m, 2H), 3.73 (m, 2H), 3.33 (ddd, J=7.7, 5.3, 5.3 Hz, 2H),2.74 (dd, J=12.3, 12.1 Hz, 2H), 2.27 (s, 1H), 2.07 (ddd, J=7.7, 5.2, 5.2Hz, 2H), 1.98 (m, 1H), 1.80 (m, 2H), 1.55 (s, 3H), 1.26 (m, 2H), 0.86(m, 4H), 0.62 (m, 2H), 0.57 (m, 2H); ESIMS calcd. for C₂₄H₃₆N₅O₇S [M+H]⁺538.2, found 538.8.

Example O24 1-Methylcyclopropyl4-((5-(4-(3-aminopropylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing M18 fromM6 except substituting O5 for M6, O23b is prepared; ¹H NMR (400 MHz,CDCl₃) δ 8.45 (d, J=1.4 Hz, 1H), 7.82 (d, J=1.4 Hz, 1H), 3.99 (d, J=6.8Hz, 2H), 3.97 (s, 2H), 3.86 (m, 2H), 3.51 (m, 2H), 2.96 (m, 2H), 2.68(t, J=6.8 Hz, 2H), 2.55 (m, 2H), 1.78 (m, 3H), 1.60 (m, 2H), 1.35 (s,3H), 1.18 (br s, 2H), 1.06 (m, 2H), 0.67 (m, 2H), 0.42 (m, 2H); ESIMSm/z for (M+H)⁺ C₂₂H₃₅N₆O₆S calcd: 511.2, found: 511.2.

Example O25 1-Methylcyclopropyl4-((5-(4-(2-(1,3-dioxoisoindolin-2-yl)ethylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing O3 fromO3b except substituting 2-(1,3-dioxoisoindolin-2-yl)ethanesulfonylchloride for n-propanesulfonyl chloride, O25 is prepared; ¹H NMR (400MHz, CDCl₃) δ 8.58 (d, J=1.4 Hz, 1H), 7.94 (d, J=1.4 Hz, 1H), 7.80 (m,2H), 7.67 (m, 2H), 4.10 (s, 7H), 3.99 (m, 2H), 3.67 (m, 2H), 3.40 (t,J=6.8 Hz, 2H), 2.68 (m, 2H), 1.94 (m, 1H), 1.73 (m, 2H), 1.50 (s, 3H),1.20 (m, 2H), 0.80 (m, 2H), 0.55 (m, 2H); ESIMS m/z for (M+H)⁺C₂₉H₃₅N₆O₈S calcd: 627.2, found: 627.2.

Example O26 1-Methylcyclopropyl4-((5-(4-(2-aminoethylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of O25 (15 mg, 0.02 mmol) in ethanol (2 mL) is treated withhydrazine (8 μL, 0.24 mmol) and stirred for 1 hour. The solution isconcentrated and purified using mass-triggered reverse phase HPLC toafford O26; ¹H NMR (400 MHz, CDCl₃) δ 8.51 (d, J=1.4 Hz, 1H), 7.88 (d,J=1.4 Hz, 1H), 4.05 (m, 4H), 3.92 (m, 2H), 3.58 (m, 2H), 3.10 (m, 2H),3.03 (m, 2H), 2.61 (m, 2H), 1.85 (m, 1H), 1.66 (m, 2H), 1.41 (s, 3H),1.13 (m, 2H), 0.73 (m, 2H), 0.49 (m, 2H); ESIMS m/z for (M+H)⁺C₂₁H₃₃N₆O₆S calcd: 497.2, found: 497.2.

Example O27 1-Methylcyclopropyl4-((5-(4-(2-amino-2-oxoethylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: By following a similar procedure as the one used for preparingO3 from O3b except substituting benzyl 2-(chlorosulfonyl)acetate forn-propanesulfonyl chloride, O27a is prepared; ESIMS m/z for (M+H)⁺C₂₈H₃₆N₅O₈S calcd: 602.2, found: 602.1.

Step B: By following a similar procedure as the one used for preparingM48 from M48e, O27b is prepared; ¹H NMR (400 MHz, CDCl₃) δ 8.37 (d,J=1.2 Hz, 1H), 7.80 (d, J=1.2 Hz, 1H), 4.11 (s, 2H), 3.96 (m, 3H), 3.84(m, 5H), 3.59 (m, 2H), 2.53 (m, 2H), 1.76 (m, 1H), 1.57 (m, 2H), 1.32(s, 3H), 1.05 (m, 2H), 0.64 (m, 2H), 0.40 (m, 2H); ESIMS m/z for (M+H)⁺C₂₁H₃₀N₅O₈S calcd: 512.2, found: 512.1.

Step C: A solution of O27b (60 mg, 0.12 mmol), HATU (89 mg, 0.23 mmol)and 2,4,6-trimethoxybenzylamine-HCl (33 mg, 0.14 mmol) indichloromethane (10 mL) is treated with diisopropylethylamine (61 μL,0.35 mmol) and the mixture is stirred at room temperature for 14 hours.The mixture is diluted with water and extracted with dichloromethane.The organics are dried, filtered, and concentrated to provide O27c,which was used without further purification. ESIMS m/z for (M+H)⁺C₃₁H₄₃N₆O₁₀S calcd: 691.3, found: 691.2.

Step B: A solution of O27c (0.12 mmol) in dichloromethane (2 mL) istreated with TFA (1 mL) and aged for 1 hour at room temperature. Theresidue is concentrated and purified using mass-triggered reverse phaseHPLC to afford O27; ¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, J=1.6 Hz, 1H),7.95 (d, J=1.6 Hz, 1H), 4.19 (s, 2H), 4.12 (d, J=6.4 Hz, 2H), 3.99 (m,2H), 3.90 (s, 2H), 3.72 (m, 2H), 2.68 (m, 3H), 1.89 (m, 1H), 1.72 (m,2H), 1.48 (s, 3H), 1.13 (m, 2H), 0.80 (m, 2H), 0.55 (m, 2H); ESIMS m/zfor (M+H)⁺ C₂₁H₃₁N₆O₇S calcd: 511.2, found: 511.2.

Example O28 1-Methylcyclopropyl4-((5-(4-(2-(dimethylamino)-2-oxoethylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing O27c fromO27b except substituting dimethylamine-HCl for2,4,6-trimethoxybenzylamine-HCl, O28 is prepared; ¹H NMR (400 MHz,CDCl₃) δ 8.67 (d, J=1.6 Hz, 1H), 8.03 (d, J=1.6 Hz, 1H), 4.28 (s, 2H),4.19 (m, 4H), 4.06 (m, 2H), 3.82 (s, 2H), 3.23 (s, 3H), 3.04 (s, 3H),2.77 (m, 2H), 2.00 (m, 1H), 1.81 (m, 2H), 1.57 (s, 3H), 1.28 (m, 2H),0.88 (m, 2H), 0.64 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₃H₃₅N₆O₇S calcd:539.2, found: 539.2.

Example O29 1-Methylcyclopropyl4-((5-(4-(1-(dimethylamino)-2-methyl-1-oxopropan-2-ylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of O27a (200 mg, 0.33 mmol) in dimethylformamide (5mL) is treated with potassium carbonate (138 mg, 1.0 mmol) andiodomethane (63 μL, 1.0 mmol) and heated at 70° C. for 1 hour. Themixture is diluted with water and extracted with ethyl acetate. Theorganic layer is washed with water and brine, dried (MgSO₄), filteredand concentrated to provide O29a; ESIMS m/z for (M+H)⁺ C₃₀H₄₀N₅O₈Scalcd: 630.3, found: 630.3.

Step B: A solution of O29a (crude from Step A) and ammonium formate (˜1mmol) in methanol (5 mL) is treated with Pd/C (wet, 10%) and heated at80° C. for 1 hour. The mixture is cooled, filtered, and the filtrate iswashed with water and ethyl acetate. The layers are separated and theorganic layer is washed with 1N HCl and brine, then dried over MgSO₄,filtered and concentrated. The residue is purified using mass-triggeredreverse phase HPLC to afford O29b; ¹H NMR (400 MHz, CDCl₃) δ 8.61 (d,J=1.6 Hz, 1H), 8.05 (d, J=1.6 Hz, 1H), 4.43 (s, 2H), 4.21 (d, J=6.4 Hz,2H), 4.05 (m, 2H), 3.87 (br s, 2H), 2.78 (m, 2H), 2.03 (m, 1H), 1.82 (s,6H), 1.57 (s, 3H), 1.28 (m, 2H), 0.89 (m, 2H), 0.65 (m, 2H); ESIMS m/zfor (M+H)⁺ C₂₃H₃₄N₅O₈S calcd: 540.2, found: 540.1.

Step C: By following a similar procedure as the one used for preparingO27c from O27b except substituting dimethylamine-HCl for2,4,6-trimethoxybenzylamine-HCl and O29b for O27c, O29 is prepared; ¹HNMR (400 MHz, CDCl₃) δ 8.51 (d, J=1.4 Hz, 1H), 7.87 (d, J=1.4 Hz, 1H),4.14 (s, 2H), 4.04 (d, J=6.4 Hz, 2H), 3.88 (m, 2H), 3.66 (s, 2H), 2.60(m, 2H), 1.84 (m, 1H), 1.65 (m, 2H), 1.54 (s, 6H), 1.41 (s, 6H), 1.11(m, 2H), 0.73 (m, 2H), 0.48 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₅H₃₉N₆O₇Scalcd: 567.3, found: 567.2.

Example O30 1-Methylcyclopropyl4-((5-(4-(1-amino-2-methyl-1-oxopropan-2-ylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing O27 fromO27b except substituting O29b for O27b, O30 is prepared; ¹H NMR (400MHz, CDCl₃) δ 8.66 (d, J=1.4 Hz, 1H), 8.03 (d, J=1.4 Hz, 1H), 4.23 (s,2H), 4.20 (d, J=6.4 Hz, 2H), 4.02 (m, 2H), 3.78 (s, 2H), 2.77 (m, 2H),2.00 (m, 1H), 1.81 (s, 6H), 1.57 (s, 3H), 1.27 (m, 2H), 0.89 (m, 2H),0.64 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₃H₃₅N₆O₇S calcd: 539.2, found:539.2.

Example O31 1-Methylcyclopropyl4-((5-(4-(2-(2-tert-butoxy-2-oxoethylamino)ethylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of O13a (50 mg, 0.10 mmol), t-butylglycine-HCl (105 mg, 0.62mmol) and diisopropylethylamine (108 μL, 0.62 mmol) in methanol (2 mL)and dimethylformamide (2 mL) and stirred at room temperature for 14hours. The mixture is diluted with water and extracted with ethylacetate. The organics are washed with water then brine, dried overMgSO₄, and filtered. The residue is concentrated and purified usingmass-triggered reverse phase HPLC to afford O31; ¹H NMR (400 MHz, CDCl₃)δ 8.66 (d, J=1.2 Hz, 1H), 8.04 (d, J=1.2 Hz, 1H), 4.20 (s, 4H), 4.07 (m,2H), 3.76 (m, 2H), 3.48 (s, 2H), 3.40 (m, 2H), 3.28 (m, 2H), 2.77 (m,2H), 2.00 (m, 1H), 1.82 (m, 2H), 1.57 (s, 3H), 1.49 (s, 9H), 1.28 (m,2H), 0.89 (m, 2H), 0.64 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₇H₄₃N₆O₈S calcd:611.3, found: 611.2.

Example O322-(2-(4-(5-((1-((1-Methylcyclopropoxy)carbonyl)piperidin-4-yl)methoxy)pyrazin-2-yl)-3-oxopiperazin-1-ylsulfonyl)ethylamino)aceticacid

A solution of O31 (31 mg, 0.05 mmol) in dichloromethane (1 mL) istreated with HCl (1 mL of 4N in dioxane) and aged for 2 hours at roomtemperature. The mixture is concentrated and purified usingmass-triggered reverse phase HPLC to afford the O32; ¹H NMR (400 MHz,CDCl₃) δ 8.51 (d, J=1.4 Hz, 1H), 7.90 (d, J=1.4 Hz, 1H), 4.01 (m, 4H),3.88 (m, 2H), 3.46 (m, 8H), 2.69 (m, 2H), 1.88 (m, 1H), 1.69 (m, 2H),1.47 (s, 3H), 1.18 (m, 2H), 0.80 (m, 2H), 0.55 (m, 2H); ESIMS m/z for(M+H)⁺ C₂₃H₃₅N₆O₈S calcd: 555.2, found: 555.1.

Example O33 1-Methylcyclopropyl4-((5-(4-(2-guanidinoethylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of O26 (22 mg, 0.044 mmol) and3,5-dimethoxypyrazole-1-carboxamidine nitrate (13 mg, 0.066 mmol) indimethylformamide (3 mL) is treated with diisopropylethylamine (23 μL,0.13 mmol) and stirred at room temperature for 14 hours. The mixture isdiluted with aqueous sodiumhydrogencarbonate and extracted with ethylacetate. The organic layer is washed with brine, dried over MgSO₄,filtered, concentrated and purified using mass-triggered reverse phaseHPLC to afford O33; ¹H NMR (400 MHz, CDCl₃) δ 8.48 (d, J=1.4 Hz, 1H),7.93 (d, J=1.4 Hz, 1H), 4.11 (m, 4H), 4.06 (m, 2H), 3.92 (m, 2H), 3.62(m, 3H), 2.68 (m, 2H), 1.80 (m, 1H), 1.72 (m, 2H), 1.18 (m, 3H), 0.80(m, 2H), 0.56 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₂H₃₅N₈O₆S calcd: 539.2,found: 539.2.

Example O34 1-Methylcyclopropyl4-((5-(4-(3-methyl-3-nitrobutylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of O13a (62 mg, 0.13 mmol) and 2-nitropropane (116 μL, 1.29mmol) in methanol (0.5 mL) and tetrahydrofuran (1 mL) is treated with1,8-diazabicyclo[5.4.0]undec-7-ene (154 μL, 1.03 mmol) and stirred atroom temperature for 14 hours. The mixture is diluted with water,extracted with ethyl acetate, and washed with brine. The organic layeris dried (MgSO₄), filtered, concentrated and purified on silica gelusing 0-100% ethyl acetate in dichloromethane to afford O34; ¹H NMR (400MHz, CDCl₃) δ 8.59 (d, J=1.4 Hz, 1H), 7.95 (d, J=1.4 Hz, 1H), 4.11 (m,4H), 4.00 (m, 2H), 3.65 (m, 2H), 2.99 (m, 2H), 2.68 (m, 2H), 2.35 (m,2H), 1.92 (m, 1H), 1.72 (m, 2H), 1.59 (s, 6H), 1.48 (s, 3H), 1.18 (m,2H), 0.80 (m, 2H), 0.56 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₄H₃₇N₆O₈S calcd:569.2, found: 569.2.

Example O35 1-Methylcyclopropyl4-((5-(4-(3-amino-3-methylbutylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of O34 (105 mg, 0.18 mmol) in a mixture of methanol (5 mL)and tetrahydrofuran (4 mL) is treated with NiCl₂ (72 mg, 0.55 mmol)followed by sodium borohydride (21 mg, 0.55 mmol) and the resultingmixture is stirred at room temperature for 3 hours. The mixture isdiluted with ethyl acetate and filtered, then washed with saturatedaqueous sodium hydrogencarbonate and brine. The organic layer is dried(MgSO₄), filtered, concentrated and purified using mass-triggeredreverse phase HPLC to afford O35; ¹H NMR (400 MHz, CDCl₃) δ 8.63 (d,J=1.2 Hz, 1H), 8.04 (d, J=1.2 Hz, 1H), 4.20 (d, J=6.4 Hz, 2H), 4.18 (s,2H), 4.05 (m, 2H), 3.74 (m, 2H), 3.27 (m, 2H), 2.75 (m, 2H), 2.00 (m,3H), 1.80 (m, 2H), 1.56 (s, 3H), 1.35 (m, 2H), 1.29 (s, 6H), 0.88 (m,2H), 0.64 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₄H₃₉N₆O₆S calcd: 539.3, found:539.2.

Example O36 1-Methylcyclopropyl4-((5-(4-(3-(dimethylamino)-3-methylbutylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of O35 (56 mg, 0.10 mmol) in dimethylformamide (2 mL) istreated with K₂CO₃ (43 mg, 0.31 mmol) and iodomethane (13 μL, 0.21 mmol)and stirred at room temperature for 3 hours. The mixture is diluted withwater, extracted with ethyl acetate, and washed with water and brine.The organic extracts are dried (MgSO₄), filtered, concentrated andpurified using mass-triggered reverse phase HPLC to afford O36; ¹H NMR(400 MHz, CDCl₃) δ 8.66 (d, J=1.2 Hz, 1H), 8.04 (d, J=1.2 Hz, 1H), 4.20(d, J=6.4 Hz, 2H), 4.18 (s, 2H), 4.07 (m, 2H), 3.72 (m, 2H), 3.21 (m,2H), 2.77 (m, 2H), 2.35 (br s, 4H), 2.02 (m, 3H), 1.82 (m, 2H), 1.57 (s,3H), 1.29 (m, 2H), 1.15 (br s, 6H), 0.88 (m, 2H), 0.64 (m, 2H); ESIMSm/z for (M+H)⁺ C₂₆H₄₃N₆O₆S calcd: 567.3, found: 567.2.

Example O37 1-Methylcyclopropyl4-((5-(4-(1-benzylpyrrolidin-3-ylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of O13a (96 mg, 0.20 mmol) andN-trimethylsilyl-N-cyanomethylbenzylamine (104 μL, 0.42 mmol) inacetonitrile (5 mL) is treated with AgF (54 mg, 0.42 mmol) and heated at75° C. for 4 hours. The mixture is filtered, washed with ethyl acetate,concentrated and purified on silica gel using 0-100% ethyl acetate inhexane to afford O37; ESIMS m/z for (M+H)⁺ C₃₀H₄₁N₆O₆S calcd: 613.3,found: 613.2.

Example O38 1-Methylcyclopropyl4-((5-(2-oxo-4-(pyrrolidin-3-ylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of O37 (45 mg) in EtOH (5 mL) is hydrogenated in an H-cube®(Pd/C, 50 bar H₂, 70° C., 1 mL/min) device. The residue is concentratedto provide O38 ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, J=1.4 Hz, 1H), 7.95(d, J=1.4 Hz, 1H), 4.11 (m, 4H), 3.98 (m, 2H), 3.68 (m, 2H), 3.50 (m,1H), 3.40 (dd, J=4.0, 13.2 Hz, 1H), 3.13 (m, 2H), 2.83 (m, 1H), 2.68 (m,2H), 2.10 (m, 2H), 1.89 (m, 1H), 1.73 (m, 5H), 1.48 (s, 3H), 1.18 (m,2H), 0.80 (m, 2H), 0.56 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₃H₃₅N₆O₆S calcd:523.2, found: 523.2.

Example O39 1-Methylcyclopropyl4-((5-(4-(1-methylpyrrolidin-3-ylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of O38 (24 mg, 0.05 mmol) and paraformaldehyde (˜0.25 mmol)in 1,2-dichloroethane (5 mL) was treated with acetic acid (50 μL) andheated at 80° C. for 1 hour. NaBH(OAc)₃ (20 mg, 0.09 mmol) is added andthe mixture is stirred at 80° C. for an additional 2 hours. The mixtureis cooled, diluted with saturated aqueous sodiumhydrogencarbonate, andextracted with dichloromethane (2×). The organic layers are dried overMgSO₄, filtered, concentrated, and purified using mass-triggered reversephase HPLC to afford O39; ¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, J=1.4 Hz,1H), 7.95 (d, J=1.4 Hz, 1H), 4.17 (d, J=7.2 Hz, 2H), 4.12 (d, J=6.4 Hz,2H), 3.71 (m, 3H), 2.86 (m, 1H), 2.66 (m, 3H), 2.33 (s, 3H), 2.18 (m,2H), 1.91 (m, 1H), 1.73 (m, 2H), 1.48 (s, 3H), 1.20 (m, 2H), 0.80 (m,2H), 0.55 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₄H₃₇N₆O₆S calcd: 537.3, found:537.2.

Example O40 1-Methylcyclopropyl4-((5-(4-(1-isobutylpyrrolidin-3-ylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing O39 fromO38 except substituting isobutyraldehyde for paraformaldehyde, O40 isprepared; ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, J=1.2 Hz, 1H), 7.94 (d,J=1.2 Hz, 1H), 4.18 (d, J=6.0 Hz, 2H), 4.12 (d, J=4.4 Hz, 2H), 3.96 (m,2H), 3.69 (m, 2H), 2.80 (m, 2H), 2.68 (m, 2H), 2.58 (m, 2H), 2.17 (m,3H), 1.91 (m, 1H), 1.73 (m, 2H), 1.65 (m, 1H), 1.48 (s, 3H), 1.20 (m,2H), 0.84 (m, 6H), 0.79 (m, 2H), 0.55 (m, 2H); ESIMS m/z for (M+H)⁺C₂₇H₄₃N₆O₆S calcd: 579.3, found: 579.2

By following a similar procedure as the one used for preparing M48 fromM48a except substituting the appropriate alcohol for M48a and O3b forM1c, followed in some cases by reductive aminations as in thepreparation of O39 and O40, the following compounds are prepared;

Ex. Structure Analytical data O41

¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, J = 1.4 Hz, 1H), 7.95 (d, J = 1.4 Hz,1H), 4.11 (m, 4H), 3.97 (m, 2H), 3.68 (m, 2H), 3.60 (m, 1H), 3.39 (dd, J= 4.0, 12.8 Hz, 1H), 3.10 (m, 2H), 2.82 (m, 1H), 2.68 (m, 2H), 2.08 (m,2H), 1.91 (s, 1H), 1.72 (m, 2H), 1.48 (s, 3H), 1.20 (m, 2H), 0.80 (m,2H), 0.55 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₃H₃₅N₆O₆S calcd: 523.2found: 523.2. O42

¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, J = 1.4 Hz, 1H), 7.95 (d, J = 1.4 Hz,1H), 4.11 (m, 4H), 3.97 (m, 2H), 3.68 (m, 2H), 3.60 (m, 1H), 3.39 (dd, J= 4.0, 12.8 Hz, 1H), 3.10 (m, 2H), 2.82 (m, 1H), 2.68 (m, 2H), 2.08 (m,2H), 1.91 (s, 1H), 1.72 (m, 2H), 1.48 (s, 3H), 1.20 (m, 2H), 0.80 (m,2H), 0.55 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₃H₃₅N₆O₆S calcd: 523.2,found: 523.2. O43

¹H NMR (400 MHz, CDCl₃) δ 8.45 (d, J = 1.4 Hz, 1H), 7.82 (d, J = 1.4 Hz,1H), 3.98 (d, J = 6.4 Hz, 2H), 3.95 (s, 2H), 3.85 (m, 2H), 3.50 (m, 2H),3.13 (m, 2H), 2.89 (m, 4H), 2.61 (m, 5H), 1.97 (m, 5H), 1.78 (m, 2H),1.59 (m, 2H), 1.44 (m, 2H), 1.35 (s, 3H), 1.05 (m, 2H), 0.67 (m, 2H),0.43 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₄H₃₇N₆O₆S calcd: 537.3, found:537.3. O44

¹H NMR (400 MHz, CDCl₃) δ 8.85 (d, J = 1.2 Hz, 1H), 7.95 (d, J = 1.2 Hz,1H), 4.11 (d, J = 6.4 Hz, 2H), 4.08 (s, 2H), 3.98 (m, 2H), 3.62 (m, 2H),3.04 (m, 2H), 2.68 (m, 6H), 2.50 (m, 2H), 2.33 (s, 3H), 2.17 (m, 1H),1.91 (m, 2H), 1.72 (m,5H), 1.62 (m, 2H), 1.48 (s, 3H), 1.18 (m, 2H),0.79 (m, 2H), 0.55 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₅H₃₉N₆O₆S calcd:551.3, found: 551.2. O45

¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, J = 1.2 Hz, 1H), 7.94 (d, J = 1.2 Hz,1H), 4.15 (m, 5H), 3.99 (m, 2H), 3.65 (m, 3H), 3.24 (m, 1H), 3.12 (dd, J= 4.0, 14.0 Hz, 1H), 2.99 (m, 2H), 2.68 (m, 2H), 2.04 (m, 2H), 1.85 (m,9H), 1.48 (s, 3H), 1.20 (m, 2H), 0.80 (m, 2H), 0.56 (m, 2H); ESIMS m/zfor (M + H)⁺ C₂₄H₃₇N₆O₆S calcd: 537.3, found: 537.3. O46

¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, J = 1.2 Hz, 1H), 7.95 (d, J = 1.2 Hz,1H), 4.11 (d, J = 6.4 Hz, 2H), 4.10 (s, 2H), 3.99 (m, 2H), 3.64 (m, 2H),2.68 (m, 2H), 2.37 (s, 2H), 2.20 (s, 2H), 1.90 (m, 1H), 1.74 (m, 4H),1.48 (s, 3H), 1.20 (m, 2H), 0.79 (m, 2H), 0.55 (m, 2H); ESIMS m/z for(M + H)⁺ C₂₅H₃₉N₆O₆S calcd: 551.3, found: 551.2. O47

¹H NMR (400 MHz, CDCl₃) δ 8.57 (s, 1H), 7.95 (s, 1H), 4.16 (m, 2H), 4.12(m, 4H), 4.02 (m, 2H), 3.97 (m, 2H), 3.82 (m, 2H), 3.66 (m, 3H), 2.68(m, 2H), 2.04 (m, 2H), 1.91 (m, 1H), 1.72 (m, 2H), 1.48 (s, 3H), 1.18(m, 2H), 0.80 (m, 2H), 0.55 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₂H₃₃N₆O₆Scalcd: 509.2, found: 509.2. O48

¹H NMR (400 mHz, CDCl₃) δ 8.57 (d, J = 1.0 Hz, 1H), 7.95 (d, J = 1.0 Hz,1H), 4.14 (s, 2H), 4.12 (d, J = 4.4 Hz, 2H), 3.96 (m, 2H), 3.90 (m, 1H),3.67 (m, 2H), 3.54 (m, 2H), 3.44 (m, 2H), 2.68 (m, 2H), 2.30 (s, 3H),1.91 (m, 1H), 1.72 (m, 2H), 1.48 (s, 3H), 1.18 (m, 2H), 0.80 (m, 2H),0.55 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₃H₃₅N₆O₆S calcd: 523.2, found:523.2. O49

¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, J = 1.2 Hz, 1H), 7.94 (d, J = 1.4 Hz,1H), 4.12 (d, J = 6.8 Hz, 2H), 4.06 (s, 2H), 3.98 (m, 2H), 3.7 7(m, 2H),3.72 (m, 1H), 3.62 (m, 2H), 3.44 (m, 2H), 3.26 (m, 2H), 3.18 (m, 1H),2.68 (m, 2H), 1.90 (m, 1H), 1.73 (m, 2H), 1.48 (s, 3H), 1.20 (m, 3H),0.80 (m, 2H), 0.55 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₃H₃₅N₆O₆S calcd:523.2, found: 523.2. O50

¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, J = 1.6 Hz, 1H), 7.94 (d, J = 1.6 Hz,1H), 4.12 (d, J = 6.8 Hz, 2H), 3.98 (m, 3H), 3.72 (m, 1H), 3.62 (m, 2H),3.43 (m, 2H), 3.23 (d, J = 7.2 Hz, 2H), 2.95 (m, 2H), 2.84 (m, 1H), 2.68(m, 2H), 2.23 (s, 3H), 1.91 (m, 1H), 1.72 (m, 2H), 1.48 (s, 3H), 1.20(m, 3H), 0.80 (m, 2H), 0.55 (m, 2H); ESIMS m/z for (M + H)⁺ C₂₄H₃₇N₆O₆Scalcd: 537.3, found: 537.2. O51

¹H NMR (400 MHz, CDCl₃) δ 8.64 (d, J = 1.4 Hz, 1H), 8.02 (d, J = 1.4 Hz,1H), 4.23 (m, 2H), 4.19 (m, 2H), 4.06-4.06 (m, 5H), 3.84 (m, 2H), 3.76(m, 2H), 2.74 (m, 2H), 2.33 (m, 2H), 1.98 (m, 1H), 1.80 (m, 2H), 1.55(s, 3H), 1.26 (m, 2H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS calcd. forC₂₃H₃₄N₅O₇S [M + H]⁺ 524.2, found 524.3. O52

¹H-NMR( 400 MHz, CDCl₃) δ 8.65 (d, J = 1.4 Hz, 1H), 8.02 (d, J = 1.4 Hz,1H), 4.21 (m ,2H), 4.18 (d, J = 6.5 Hz, 2H), 4.11-4.16 (m, 2H),3.98-4.06 (m, 5H), 3.84 (m, 2H), 3.76 (m, 2H), 2.75 (dd, J = 12.3, 12.3Hz, 2H), 2.33 (m, 2H), 1.97 (m, 1H), 1.79 (m, 2H), 1.55 (s, 3H), 1.26(m, 2H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS calcd. for C₂₃H₃₄N₅O₇S [M +H]⁺ 524.2, found 524.4. O53

¹H-NMR (400 MHz, CDCl₃) δ 8.65 (d, J = 1.4 Hz, 1H), 8.02 (d, J = 1.4 Hz,1H), 4.93 (m, 4H), 4.51 (tt, J = 8.0, 6.4 Hz, 1H), 3.95-4.30 (m, 8H),3.75 (m ,2H), 2.75 (m, 2H), 1.98 (m, 1H), 1.79 (m, 2H), 1.55 (s, 3H),1.26 (m, 2H), 0.87 (m, 2H), 0.63 (m, 2H); ESIMS calcd. for C₂₂H₃₂N₅O₇S[M + H]⁺ 510.2, found 510.2.

Example O54 1-Methylcyclopropyl4-((5-(4-(isopropylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: By following a similar procedure as the one used for preparingO1a from B4b except substituting B2b for B4b, O54a is prepared; ESIMSm/z for (M+H)⁺ C₂₈H₃₇N₄O₆ calcd: 525.3, found: 525.2.

Step B: A sample of O54a (200 mg, 0.38 mmol) is treated withtrifluoroacetic acid (3 mL) and aged for 30 minutes. The solvent isremoved and the reaction is treated with ethyl acetate and extractedwith 1 M HCl three times. The organics are discarded and the aqueouslayer is made basic with solid Na₂CO₃ and extracted with ethyl acetatethree times. The combined organics are dried over MgSO₄, filtered andevaporated to afford O54b; ESIMS m/z for (M+H)⁺ C₂₃H₂₉N₄O₄ calcd: 425.2,found: 425.2.

Step C: By following a similar procedure as the one used for preparingO2 from O1 except substituting O54b for O1, O54c is prepared; ESIMS m/zfor (M+H)⁺ C₂₈H₃₅N₄O₆ calcd: 523.3, found: 523.2.

Step D: By following a similar procedure as the one used for preparingO3b from O3a except substituting O54c for O3a, O54d is prepared; ESIMSm/z for (M+H)⁺ C₂₀H₂₉N₄O₄ calcd: 389.2, found: 389.2.

Step E: By following a similar procedure as the one used for preparingO3 from O3b except substituting O54d for O3b and methanesulfonylchloride for n-propanesulfonyl chloride, O54 is prepared; ¹H NMR (400MHz, CDCl₃) δ 8.00 (d, J=2.9 Hz, 1H), 7.66 (d, J=9.0 Hz, 1H), 7.17 (dd,J=2.9, 9.0, 1H), 4.10 (m, 2H), 4.05 (m, 2H), 4.03 (s, 2H), 3.77 (d,J=6.3 Hz, 2H), 3.58 (m, 2H), 2.48 (s, 3H), 2.69 (m, 2H), 1.90 (m, 1H),1.74 (m, 2H), 1.48 (s, 3H), 1.20 (m, 2H)), 0.79 (m, 2H), 0.57 (m, 2H);ESIMS m/z for (M+H)⁺ C₂₁H₃₁N₄O₆S calcd: 467.2, found: 467.2.

By following a similar procedure as the one used for preparing O54 fromO54d except substituting the appropriate sulfonyl chloride formethanesulfonyl chloride, the following compounds are made;

Ex. Structure Analytical data O55

¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, J = 2.9 Hz, 1H), 7.73 (d, J = 9.0 hz,1H), 7.24 (dd, J = 9.0, 3.0 Hz, 1H), 4.20 (m, 2H), 4.13 (s, 2H), 4.09(m, 2H), 3.84 (d, J = 6.3 Hz, 2H), 3.68 (m, 2H), 3.00 (m, 2H), 2.76 (dd,J = 12.4, 12.4 Hz, 2H), 1.98 (m, 1H), 1.89 (m, 2H), 1.82 (m, 2H), 1.55(s, 3H), 1.27 (m, 2H), 1.08 (t, J = 7.5 Hz, 3H), 0.87 (m, 2H), 0.63 (m,2H); ESIMS m/z for (M + H)⁺ C₂₃H₃₅N₄O₆S calcd.: 495.2, found: 495.6. O56

¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, J = 2.7 Hz, 1H), 7.73 (d, J = 9.0 Hz,1H), 7.24 (dd, J = 9.0, 3.0 Hz, 1H), 4.18 (s, 2H), 4.16 (m, 2H), 4.08(m, 2H), 3.84 (d, J = 6.3 Hz, 2H), 3.73 (m, 2H), 3.27 (sept., J = 6.8Hz, 1H), 2.76 (dd, J = 12.3, 12.3 Hz, 2H), 1.97 (m, 1H), 1.82 (m, 2H),1.55 (s, 3H), 1.40 (d, J = 6.8 Hz, 6H), 1.27 (m, 2H), 0.87 (m, 2H), 0.63(m, 2H); ESIMS m/z for (M + H)⁺ C₂₃H₃₅N₄O₆S calcd.: 495.2, found: 495.6.O57

¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, J = 2.8 Hz, 1H), 7.67 (d, J = 9.2 Hz,1H), 7.17 (dd, J = 9.2, 3.2 Hz, 1H), 4.15 (m, 2H), 4.08 (m, 2H), 4.04(m, 2H), 3.78 (d, J = 6.4 Hz, 2H), 3.63 (m, 2H), 3.15 (m, 2H), 2.69 (t,J = 12.4 Hz, 2H), 2.26 (m, 2H), 1.91 (m, 1H), 1.75 (d, J = 12.4 Hz, 2H),1.49 (s, 3H), 1.20 (m, 2H), 0.80 (m, 2H), 0.56 (m, 2H); ESIMS m/z for(M + H)⁺ C₂₃H₃₄ClN₄O₆S calcd.: 529.2, found: 529.1.

Example O58 1-Methylcyclopropyl4-((6-(4-(3-hydroxypropylsulfonyl)-2-oxopiperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing O21 fromO5 except substituting O57 for O5, O58 is prepared; ¹H NMR (400 MHz,CD₃CN) δ 8.09 (d, J=2.1 Hz, 1H), 7.65 (d, J=6.9 Hz, 1H), 7.34 (dd,J=3.0, 6.6 Hz, 1H), 4.02 (s, 2H), 4.01 (m, 2H), 3.96 (m, 2H), 3.90 (d,J=4.8 Hz, 2H), 3.63 (m, 2H), 3.59 (dd, J=4.5, 9.0 Hz, 2H), 3.16 (m, 2H),2.79 (m, 3H), 1.92 (m, 1H), 1.77 (m, 2H), 1.49 (s, 3H), 1.19 (m, 2H),0.80 (m, 2H), 0.59 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₃H₅₄N₄O₇S calcd.:511.2, found: 511.1.

Example O59 1-Methylcyclopropyl4-((6-(4-(3-(azetidin-1-yl)propylsulfonyl)-2-oxopiperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as the one used for preparing O16 fromO5 except substituting O57 for O5, O59 is prepared; ¹H NMR (400 MHz,CD₃CN) δ 8.09 (d, J=3.2 Hz, 1H), 7.66 (d, J=9.2 Hz, 1H), 7.33 (dd,J=9.2, 3.2 Hz, 1H), 4.02 (m, 2H), 4.01 (m, 2H), 3.97 (m, 2H), 3.90 (d,J=6.4 Hz, 2H), 3.63 (m, 2H), 3.41 (m, 2H), 3.19 (m, 2H), 2.70 (m, 4H),2.10 (m, 4H), 1.80 (m, 4H), 1.49 (s, 3H), 1.20 (m, 2H), 0.80 (m, 2H),0.59 (m, 2H); ESIMS m/z for (M+H)⁺ C₂₆H₄₀N₅O₆S calcd.: 550.3, found:550.1.

Example O601-(5-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)pyrazin-2-yl)-4-(methylsulfonyl)piperazin-2-one

Step A: By following a procedure similar to the one used for preparingE1 from E1a, except substituting B4b for E1a, O60a is prepared; ESIMSm/z for (M+H)⁺ C₁₆H₂₁BrN₅O calcd: 378.1, found: 378.1.

Step B: By following a procedure similar to the one used for preparingO1a from B4b, except substituting O60a for B4b, O60b is prepared; ESIMSm/z for (M+H)⁺ C₂₈H₃₄N₇O₄ calcd: 532.3, found: 532.2.

Step C: By following a procedure similar to the one used for preparingO3 from O3b, except substituting O60b for O3b, and methanesulfonylchloride for n-propanesulfonyl chloride, O60 is prepared; ¹H NMR (400MHz, CDCl₃) δ 8.65 (d, J=1.4 Hz, 1H), 8.41 (s, 2H), 8.04 (d, J=1.4 Hz,1H), 4.72 (m, 2H), 4.25 (d, J=6.4, 2H), 4.14 (s, 2H), 4.09 (m, 2H), 3.68(m, 2H), 3.21 (m, 2H), 2.94 (s, 3H), 2.60 (dd, J=15.2, 7.6, 2H), 2.22(m, 1H), 2.05 (m, 2H), 1.48 (m, 2H), 1.26 (dd, J=7.6, 7.6, 3H); ESIMSm/z for (M+H)⁺ C₂₁H₂₉N₇O₄S calcd: 476.2, found: 476.3.

Example O611-(5-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)pyridin-2-yl)-4-(methylsulfonyl)piperazin-2-one

By following a procedure similar to the one used for preparing O60 fromB4b, except substituting B2b for B4b, O61b is prepared; ¹H NMR (400 MHz,CDCl₃) δ 8.18 (s, 2H), 8.09 (d, J=2.9 Hz, 1H), 7.73 (d, J=9.0 Hz, 1H),7.25 (dd, J=9.0, 2.9), 4.79 (m, 2H), 4.12 (m, 2H), 4.10 (s, 2H), 3.87(d, J=6.4, 2H), 3.64 (m, 2H), 2.92 (s, 3H), 2.91 (m, 2H), 2.46 (dd,J=15.2, 7.6, 2H), 2.11 (m, 1H), 1.93 (m, 2H), 1.37 (m, 2H), 1.19 (dd,J=7.6, 7.6, 3H); ESIMS m/z for (M+H)⁺ C₂₂H₃₁N₆O₄S calcd: 475.2, found:475.2.

Example O62 1-Methylcyclopropyl4-((5-(4-(methylsulfonyl)-2-thioxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of O2 (121 mg, 0.26 mmol) in tetrahydrofuran (3 mL) istreated with Lawesson's reagent (115 mg, 0.29 mmol), sealed in areaction vessel and stirred at 90° C. overnight. The reaction is cooledto room temperature, evaporated to dryness and purified on silica gelusing a linear gradient of 0-100% ethyl acetate in hexane to afford O62;¹H NMR (400 MHz, CDCl₃) δ 8.39 (d, J=1.3 Hz, 1H), 8.12 (d, J=1.4 Hz,1H), 4.58 (s, 2H), 4.21 (m, 2H), 4.21 (d, J=6.5 Hz, 2H), 4.03 (m, 2H),3.78 (m, 2H), 2.98 (s, 3H), 2.77 (m, 2H), 1.99 (m, 1H), 1.81 (m, 2H),1.55 (s, 3H), 1.29 (m, 2H), 0.87 (m, 2H), 0.62 (m, 2H); ESIMS m/z for(M+Na)⁺ C₂₀H₂₉N₅O₅S₂Na calcd: 506.2, found: 506.1 (M+Na⁺).

Example O63 1-Methylcyclopropyl4-((5-(2-(hydroxyimino)-4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

A solution of O62 (30 mg, 0.062 mmol) in ethanol (1 mL) is treated withhydroxylamine (7 μL of a 50% solution, 0.12 mmol) sealed in a reactionvessel and stirred at 80° C. overnight. The reaction is cooled to roomtemperature and evaporated to dryness to afford 63; ¹H-NMR (400 MHz,CDCl₃) δ 8.46 (d, J=1.4 Hz, 1H), 7.96 (d, J=1.4 Hz, 1H), 4.47 (s, 2H),4.21 (m, 2H), 4.14 (d, J=6.5 Hz, 2H), 3.87 (m, 2H), 3.62 (m, 2H), 3.52(m, 1H), 2.92 (s, 3H), 2.74 (m, 2H), 1.95 (m, 1H), 1.79 (m, 2H), 1.55(s, 3H), 1.26 (m, 2H), 0.86 (m, 2H), 0.62 (m, 2H); ESIMS calcd. forC₂₀H₃₁N₆O₆S [M+H]⁺ 483.2, found 483.4.

Example P1 tert-Butyl4-((2,6-difluoro-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate

Step A: A mixture of P1a (1.67 g, 8 mmol), tert-butyl4-((methylsulfonyloxy)methyl)piperidine-1-carboxylate (2.35 g, 8 mmol),and Cs₂CO₃ (3.91 g, 12 mmol) in N,N-dimethylformamide (30 mL) is heatedat 90° C. overnight. The reaction mixture is poured into water (200 mL),extracted with ethyl acetate (3×50 mL), washed with water (2×30 mL),dried (Na₂SO₄) and concentrated to give P1b; ESIMS calcd. forC₁₇H₂₂BrF₂NNaO₃ (M+Na)⁺ 428.1, found 428.2. The product is used withoutpurification.

Step B: A mixture P1b (2.03 g, 5 mmol), pyridin-4-ylboronic acid (0.80g, 6.5 mmol), Na₂CO₃ (2.65, 25 mmol), and Pd(PPh₃)₄ (289 mg, 0.25 mmol)in water (13 mL) and DME (52 mL)) is heated at 80° C. overnight under anitrogen atmosphere. The reaction mixture is concentrated, water (200mL) added, extracted with ethyl acetate (3×100 mL), washed with water(2×30 mL), dried (Na₂SO₄) and concentrated. Silica gel chromatography(0% to 5% gradient of MeOH in dichloromethane) gave P1c; ESIMS calcd.for C₂₂H₂₇E₂N₂O₃ (M+H)⁺ 405.2, found 405.2.

Step C: A solution P1c (654 mg, 1.59 mmol) and TFA (118 μL, 1.59 mmol)in EtOH (100 ml) is hydrogenated using a 10% Pd/C cartridge on H-Cube(flow 1 mL/min) at 70 atm and 90° C. To the resulting solution is addeda saturated solution of sodiumhydrogencarbonate (1 mL) and the EtOH isevaporated. To the residue is added water (50 mL) and dichloromethane(30 mL). The aqueous phase is further extracted with dichloromethane(2×30 mL) and discarded. The combined organics are dried over Na₂SO₄ andconcentrated to yield P1d; ESIMS calcd. for C₂₂H₃₃F₂N₂O₃ (M+H)⁺ 411.2,found 411.2.

Step D: Methanesulfonyl chloride (117 μL, 1.5 mmol) is added dropwise toa cold (ice/water bath) solution P1d (411 mg, 1 mmol) and Et₃N (418 μL,3 mmol) in dry dichloromethane (6 mL). The resulting solution is stirredat room temperature for 2 hours. The reaction mixture is added to water(40 mL) and extracted with dichloromethane (3×40 mL). The combinedorganic layers are dried (Na₂SO₄) and concentrated to yield P1; ¹H-NMR(600 MHz, CDCl₃) δ6.74 (m, 2H), 4.14 (m, 2H), 3.94 (m, 4H), 2.82 (s,3H), 2.75 (td, J=12.1, 2.5 Hz, 4H), 2.53 (tt, J=12.1, 3.6 Hz, 1H), 1.93(m, 3H), 1.84 (m, 2H), 1.74 (m, 2H), 1.46 (s, 9H), 1.25 (qd, J=12.4, 4.2Hz, 2H). ESIMS calcd. for C₁₈H₂₇F₂N₂O₃S (M-Boc+H)⁺ 389.2, found 389.2.

By following a procedure similar to the one used for preparing P1 fromP1a, except substituting the appropriate commercially availablehalophenol for P1a, the following examples are prepared;

P2

¹H-NMR (600 MHz, CDCl₃) δ 6.97 (m, 2H), 6.73 (d, J = 8.2 Hz, 1H), 4.15(m, 2H), 3.92 (dt, J = 11.7, 2.1 Hz, 2H), 3.79 (d, J = 6.2 Hz, 2H), 2.81(s, 3H), 2.75 (m, 4H), 2.52 (tt, J = 12.1, 3.6 Hz, 1H), 2.21 (s, 3H),1.98 (m, 1H), 1.92 (m, 2H), 1.80 (m, 4H), 1.47 (s, 9H), 1.30 (qd, J =12.4, 4.2 Hz, 2H). ESIMS calcd. for C₁₉H₃₁N₂O₃S (M − Boc + H)⁺ 367.2,found 367.2. P3

¹H-NMR (600 MHz, CDCl₃) δ 7.02 (d, J = 8.1 Hz, 1H), 6.43 (m, 2H), 4.15(m, 2H), 3.91 (m, 2H), 3.79 (m, 5H), 2.94 (tt, J = 12.2, 3.4 Hz, 1H),2.91 (s, 3H), 2.77 (m, 4H), 1.95 (m, 1H), 1.89 (m, 2H), 1.83 (m, 2H),1.77 (m, 2H), 1.47 (s, 9H), 1.28 (qd, J = 12.4, 4.2 Hz, 2H), ESIMScalcd. for C₁₉H₃₁N₂O₄S (M − Boc + H)⁺ 383.2, found 383.2. P4

¹H-NMR (600 MHz, CDCl₃) δ 7.26 (s, 2H), 4.17 (m, 2H), 3.92 (m, 2H), 3.58(d, J = 6.3 Hz, 2H), 2.81 (s, 3H), 2.75 (m, 4H), 2.48 (tt, J = 12.2, 3.6Hz, 1H), 2.24 (s, 6H), 1.98 (m, 1H), 1.90 (m, 4H), 1.79 (m, 2H), 1.47(s, 9H), 1.33 (qd, J = 12.4, 4.1 Hz, 2H). ESIMS calcd. for C₂₀H₃₃N₂O₃S(M − Boc + H)⁺ 381.2, found 381.2. P5

¹H-NMR (600 MHz, CDCl₃) δ 6.94 (s, 1H), 6.58 (s, 1H), 4.15 (m, 2H), 3.94(m, 2H), 3.77 (d, J = 6.2 Hz, 2H), 2.82 (s, 3H), 2.75 (m, 5H), 2.29 (s,3H), 2.17 (s, 3H), 1.97 (m, 1H), 1.81 (m, 6H), 1.47 (s, 9H), 1.29 (m,2H). ESIMS calcd. for C₂₀H₃₃N₂O₃S (M − Boc + H)⁺ 381.2, found 381.2. P6

¹H-NMR (400 MHz, CDCl₃) δ 7.63 (d, J = 2.4 Hz, 1H), 7.28 (dd, J = 8.7,2.5 Hz, 1H), 6.89 (d, J = 8.6 Hz, 1H), 4.16 (m, 2H), 3.93 (m, 2H), 3.88(s, 3H), 3.85 (d, J = 6.2 Hz, 2H), 2.82 (s, 3H), 2.75 (m, 4H), 2.58 (tt,J = 12.1, 3.6 Hz, 1H), 1.74-2.07 (m, 7H), 1.46 (s, 9H), 1.29 (m, 2H).ESIMS calcd. for C₂₀H₃₁N₂O₅S (M − Boc + H)⁺ 411.2, found 410.8. P7

¹H-NMR (400 MHz, CDCl₃) δ 7.20 (d, J = 2.2 Hz, 1H), 7.03 (dd, J = 8.4,2.2 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 4.16 (m, 2H), 3.93 (m, 2H), 3.84(d, J = 6.4 Hz, 2H), 2.82 (s, 3H), 2.75 (m, 4H), 2.53 (tt, J = 12.1, 3.6Hz, 1H), 2.02 (m ,1H), 1.92 (m, 2H), 1.71 (m, 4H), 1.46 (s, 9H), 1.29(m, 2H). ESIMS calcd. for C₁₈H₂₈ClN₂O₃S (M − Boc + H)⁺ 387.2, found386.8. P8

¹H-NMR (400 MHz, CDCl₃) δ 7.08 (d, J = 8.2 Hz, 1H), 6.71 (m, 2H), 4.14(m, 2H), 3.94 (m, 2H), 3.77 (d, J = 6.4 Hz, 2H), 2.82 (s, 3H), 2.76 (m,5H), 2.31 (s, 3H), 1.93 (m, 1H), 1.81 (m, 6H), 1.46 (s, 9H), 1.25 (m,2H). ESIMS calcd. for C₁₉H₃₁N₂O₃S (M − Boc + H)⁺ 367.2, found 367.2. P9

¹H-NMR (400 MHz, CDCl₃) δ 6.99 (d, J = 8.8 Hz, 1H), 6.69 (d, J = 8.7 Hz,1H), 4.16 (m, 2H), 3.95 (m, 2H), 3.78 (d, J = 6.2 Hz, 2H), 2.72-2.84 (m,8H), 2.24 (s, 3H), 2.18 (s, 3H), 1.83 (m, 7H), 1.47 (s, 9H), 1.30 (m,2H). ESIMS calcd. for C₂₀H₃₃N₂O₃S (M − Boc + H)⁺ 381.2, found 381.2. P10

¹H-NMR (400 MHz, CDCl₃) δ 6.90 (m, 3H), 4.15 (m, 2H), 3.93 (m, 2H), 3.84(d, J = 6.5 Hz, 2H), 2.82 (s, 3H), 2.75 (m, 4H), 2.54 (tt, J = 12.1, 3.6Hz, 1H), 1.99 (m, 1H), 1.93 (m, 1H), 1.84 (m, 2H), 1.77 (m, 2H), 1.46(s, 9H), 1.26 (m, 2H). ESIMS calcd. for C₁₈H₂₈FN₂O₃S (M − Boc + H)⁺371.2, found 371.2. P11

¹H-NMR (400 MHz, CDCl₃) δ 7.39 (d, J = 2.1 Hz, 1H), 7.30 (dd, J = 8.6,2.1 Hz, 1H), 6.92 (d, J = 8.6 Hz, 1H), 4.16 (m, 2H), 3.94 (m, 2H), 3.85(d, J = 6.1 Hz, 2H), 2.82 (s, 3H), 2.76 (m, 4H), 2.60 (tt, J = 12.1, 3.6Hz, 1H), 2.00 (m, 1H), 1.94 (m, 2H), 1.82 (m, 4H), 1.46 (s, 9H), 1.27(m, 2H). ESIMS calcd. for C₁₉H₂₈F₃N₂O₃S (M − Boc + H)⁺ 421.2, found421.1.

Example P122-(4-((2,6-Difluoro-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)-5-ethylpyrimidine

By following a procedure similar to the one used for preparing E1 fromB2, except substituting P1 for B2, P12 is prepared; ¹H-NMR (400 MHz,CDCl₃) δ 8.18 (s, 2H), 6.67 (d, J=9.2 Hz, 2H), 4.70 (m, 2H), 2.91 (dt,J=2.0, 12.4 Hz, 2H), 2.75 (s, 3H), 2.68 (dt, J=2.4, 12.4 Hz, 2H), 2.43(m, 3H), 2.01 (m, 3H), 1.70 (m, 2H), 1.31 (m, 2H), 1.13 (t, J=7.6 Hz,3H); ESIMS calcd. for C₂₄H₃₃F₂N₄O₃S [M+H]⁺ 495.2, found 495.2.

Example P13 1-Methylcyclopropyl4-((2,6-difluoro-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate

By following a procedure similar to the one used for preparing E3 fromB4, except substituting P1 for B4, P12 is prepared; ¹H-NMR (400 MHz,CDCl₃) δ 6.74 (d, J=8.8 Hz, 2H), 4.22 (m, 2H), 3.95 (m, 4H), 2.83 (s,3H), 2.76 (dt, J=2.4, 12.0 Hz, 4H), 2.55 (tt, J=3.6, 12.4 Hz, 1H), 1.94(m, 3H), 1.85 (m, 2H), 1.78 (m, 2H), 1.56 (s, 3H), 1.26 (m, 2H), 0.87(m, 2H), 0.63 (m, 2H); ESIMS calcd. for C₂₃H₃₃F₂N₂O₅S [M+H]⁺ 487.2,found 487.2.

Example P143-(4-(4-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)-3,5-difluorophenyl)piperidin-1-ylsulfonyl)propylacetate

Step A: A solution of P1d (200 mg, 0.49 mmol) and3-chloropropanesulfonyl chloride (65 μL, 0.54 mmol) in dichloromethane(10 mL) is treated with triethylamine (75 μL, 0.54 mmol) and the mixtureis stirred at room temperature for 1 hour. The mixture is diluted withwater (10 mL), extracted with dichloromethane, dried over MgSO₄,filtered and concentrated. The residue is purified on silica gel using alinear gradient of 0 to 100% ethyl acetate in hexane to afford P14a:¹H-NMR (400 MHz, CDCl₃) δ 6.74 (d, J=9.2 Hz, 2H), 4.06 (m, 2H), 3.87 (m,4H), 3.64 (t, J=6.0 Hz, 2H), 3.04 (t, J=6.0 Hz, 2H), 2.80 (dt, J=2.4,12.4 Hz, 2H), 2.65 (m, 2H), 2.49 (tt, J=3.6, 12.4 Hz, 1H), 2.25 (m, 2H),1.85 (m, 2H), 1.77 (m, 2H), 1.65, m, 2H), 1.39 (s, 9H), 1.18 (m, 2H);ESIMS calcd. for C₂₁H₃₀ClF₂N₂O₅S [M+H—C₄H₈]⁺ 495.2, found 495.2.

Step B: A solution of P14a (138 mg, 0.25 mmol), NaOAc (62 mg, 0.75 mmol)and NaI (38 mg, 0.25 mmol) in N,N-dimethylformamide (1 mL) is heated at120° C. for 2 hours. The mixture is cooled, diluted with water (10 mL)and extracted with ethyl acetate (10 mL). The organic layer is washedwith water (10 mL) and brine (10 mL), dried (MgSO₄), filtered andconcentrated to provide P14b which is used without further purification;ESIMS calcd. for C₂₃H₃₃F₂N₂O₇S [M+H—C₄H₈]⁺ 519.2, found 519.2.

Step C: By following a procedure similar to the one used for preparingE1 from B2, except substituting P14b for B2, P14 is prepared; ¹H-NMR(400 MHz, CDCl₃) δ 8.36 (s, 2H), 6.76 (m, 2H), 4.76 (m, 2H), 4.22 (t,J=6.4 Hz, 2H), 3.96 (m, 4H), 3.06 (m, 4H), 2.88 (dt, J=2.4, 12.0 Hz,2H), 2.56 (m, 3H), 2.17 (m, 3H), 2.11 (s, 3H), 2.04 (m, 2H), 1.97 (m,2H), 1.71 (m, 2H), 1.42 (m, 2H), 1.24 (t, J=7.6 Hz, 3H); ESIMS calcd.for C₂₈H₃₉F₂N₄O₅S [M+H]⁺ 581.3, found 581.2.

Example P15 1-Methylcyclopropyl4-((4-(1-(3-acetoxypropylsulfonyl)piperidin-4-yl)-2,6-difluorophenoxy)methyl)piperidine-1-carboxylate

By following a procedure similar to the one used for preparing P14 fromP1d, except substituting the procedure for preparing P13 from P1 forstep C, P15 is prepared; ¹H-NMR (400 MHz, CDCl₃) δ 6.75 (m, 2H), 4.22(t, J=6.0 Hz, 2H), 3.95 (m, 4H), 3.03 (m, 2H), 2.88 (dt, J=2.4, 12.4 Hz,2H), 2.76 (m, 2H), 2.57 (m, 1H), 2.17 (m, 2H), 2.09 (s, 3H), 1.92 (m,2H), 1.88 (m, 2H), 1.72 (m, 2H), 1.56 (s, 3H), 1.25 (m, 2H), 0.87 (m,2H), 0.63 (m, 2H); ESIMS calcd. for C₂₇H₃₉F₂N₂O₇S [M+H]⁺ 573.2, found573.2.

Example P163-(4-(4-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)-3,5-difluorophenyl)piperidin-1-ylsulfonyl)propan-1-ol

A solution of P14 (30 mg, 0.05 mmol) in tetrahydrofuran (3 mL) istreated with LiOH hydrate (50 mg, 1.2 mmol) and the mixture is heated at90° C. for 12 hours. The mixture is filtered, concentrated and purifiedby mass triggered reverse phase HPLC to afford P16; ¹H-NMR (400 MHz,CDCl₃) δ 8.36 (s, 2H), 6.67 (m, 2H), 4.68 (m, 2H), 3.88 (m, 5H), 3.74(t, J=5.6 Hz, 2H), 3.00 (m, 4H), 2.78 (dt, J=2.4, 12.0 Hz, 2H), 2.45 (m,3H), 2.17 (m, 3H), 2.11 (s, 3H), 2.04 (m, 4H), 1.97 (m, 2H), 1.84 (m,2H), 1.65 (m, 2H), 1.31 (m, 2H), 1.47 (t, J=7.6 Hz, 3H); ESIMS calcd.for C₂₆H₃₇F₂N₄O₄S [M+H]⁺539.3, found 539.2.

Example P17 1-Methylcyclopropyl4-((2,6-difluoro-4-(1-(3-hydroxypropylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate

By following a procedure similar to the one used for preparing P16 fromP14, except substituting P15 for P14, P17 is prepared; ¹H-NMR (400 MHz,CDCl₃) δ 6.66 (m, 2H), 3.85 (m, 4H), 3.74 (t, J=6.0 Hz, 2H), 3.02 (m,2H), 2.79 (dt, J=2.4, 12.0 Hz, 2H), 2.71 (m, 2H), 2.48 (m, 2H), 2.03 (m,2H), 1.80 (m, 5H), 1.69 (m, 2H), 1.48 (s, 3H), 1.19 (m, 2H), 0.87 (m,2H), 0.63 (m, 2H); ESIMS calcd. for C₂₅H₃₇F₂N₂O₆S [M+H]⁺ 531.2, found531.2.

Example Q1 Isopropyl4-((5-(1,2,3,6-tetrahydro-1-methanesulfonylpyridin-4-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of A1c (0.86 g, 3.1 mmol) and2-bromo-5-hydroxypyrazine (0.52 g, 3.0 mmol) in dry acetonitrile (7 mL)is treated with powdered cesium carbonate (1.62 g, 5 mmol) and themixture is stirred at 60° C. for 24 hours. Filtration, concentration,and purification on silica gel using a linear gradient of 0 to 100%ethyl acetate in hexane affords Q1a; ESIMS calcd. for C₁₄H₂₁BrN₃O₃(M+H⁺) 358.1, found 358.0.

Step B: To a solution of Q1a (83.5 mg, 0.2 mmol) in 1,2-dimethoxyethane(1.5 mL) are added tert-butyl5,6-dihydro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-1(2H)-carboxylate(66.7 mg, 0.2 mmol), powdered potassium carbonate (0.10 g, 0.7 mmol),and water (0.5 g). The mixture is degassed using argon, thentetrakis-(triphenylphosphino)palladium(0) (0.08 g, 0.07 mmol) is addedand the mixture is heated to 180° C. for 5 min in a microwave reactor.Cooling, extraction with ethyl acetate, washing with water and brine,drying over Na₂SO₄ and concentration, followed by purification on silicagel using a linear gradient of 5 to 70% ethyl acetate in hexane affordsQ1b; ESIMS calcd. for C₂₄H₃₇N₄O₅ (M+H⁺) 461.3, found 461.1.

Step C: To a solution of Q1b (0.2 mmol) in dioxane (2 mL) is addedhydrogen chloride in dioxane (4N, 1 mL), slowly, with stiffing. Theresulting solution is stirred at room temperature for 4 hours. Afterremoving the solvent, the residue is dissolved in dichloromethane (3 mL)and treated with triethylamine (0.2 mL, 1.4 mmol). Then methanesulfonylchloride (0.04 mL, 0.5 mmol) is added dropwise, with stirring, over 5minutes. The resulting solution is stirred at room temperature for 2hours. The solvent is removed and the residue is purified usingmass-triggered reverse phase HPLC to yield Q1; ESIMS calcd. forC₂₀H₃₁N₄O₅S (M+H⁺) 439.2, found 439.1.

Example Q2 1-Methylcyclopropyl4-((6-(1,2,3,6-tetrahydro-1-methanesulfonylpyridin-4-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate

Step A: A solution of A1a (0.51 g, 4.4 mmol) in dichloromethane (7 mL)is treated with triethylamine (0.9 mL, 6.4 mmol) in one portion,followed by E3b (0.96 g, 4 mmol). The suspension is stirred at roomtemperature for 24 hours, diluted with more dichloromethane (25 mL),washed with water, saturated aqueous sodiumhydrogencarbonate (3×25 mL),and saturated aqueous ammonium chloride, dried over MgSO₄ andconcentrated to yield Q2a; ¹H NMR (CDCl₃, 400.13 MHz): δ 4.13 (br. s,1H), 4.03 (br. s, 1H), 3.50 (m, 2H), 2.71 (t, J=12 Hz, 2H), 1.67 (m,3H), 1.38 (br. s, 1H), 1.54 (s, 3H), 1.14 (br. s, 2H), 0.86 (m, 2H),0.62 (m, 2H); ESIMS calcd. for C₁₁H₂₀NO₃ (M+H⁺) 214.1, found 214.1.

Step B: To a solution of Q2a (0.71 g, 3.4 mmol) in dichloromethane (20mL) is added triethylamine (0.9 mL, 6.4 mmol) in one portion. Theresulting mixture is cooled in an ice/water bath and methanesulfonylchloride (0.35 mL, 4.5 mmol) is added slowly, with stirring. The bath isremoved and the resulting solution is stirred at room temperature for 2hours. The reaction mixture is diluted with more dichloromethane (20mL), washed with water and saturated aqueous ammonium chloride, driedover MgSO₄ and concentrated to yield Q2b; ¹H NMR (CDCl₃, 400.13 MHz): δ4.22 (br. s, 2H), 4.07 (s, 2H), 3.23 (m, 1H), 3.17 (s, 3H), 2.72 (m,2H), 1.92 (m, 1H), 1.74 (m, 2H), 1.54 (s, 3H), 1.22 (br. s, 2H), 0.86(m, 2H), 0.63 (m, 2H); ESIMS calcd. for C₁₂H₂₂NO₅S (M+H⁺) 292.1, found292.0.

Step C: To a solution of B2a (0.1 g, 0.6 mmol) in 1,2-dimethoxyethane(1.5 mL) is added tert-butyl5,6-dihydro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-1(2H)-carboxylate(0.13 g, 0.4 mmol), powdered potassium carbonate (0.15 g, 1.1 mmol), andwater (0.5 g). The mixture is degassed using argon, thentetrakis-(triphenylphosphino)palladium(0) (0.08 g, 0.07 mmol) is addedand the mixture is heated to 180° C. for 5 min in a microwave reactor.Cooling, extraction with ethyl acetate, washing with water and brine,drying over Na₂SO₄ and concentration, followed by purification on silicagel using a linear gradient of 5 to 100% ethyl acetate in hexane affordsQ2c. ESIMS calcd. for C₁₅H₂₁N₂O₃ (M+H⁺) 277.2, found 277.0.

Step D: A solution of Q2b (0.05 g, 0.17 mmol) and Q2c (0.04 g, 0.15mmol) in dry acetonitrile (2 mL) is treated with powdered cesiumcarbonate (0.1 g, 0.3 mmol) and the mixture is stirred at 60° C. for 24hours. Filtration, concentration, and purification on silica gel using alinear gradient of 0 to 100% ethyl acetate in hexane affords Q2d; ESIMScalcd. for C₂₆H₃₈N₃O₅ (M+H⁺) 472.3, found 472.0.

Step E: To a solution of Q2d (0.15 mmol) in dioxane (2 mL) is addedhydrogen chloride in dioxane (4N, 0.5 mL), slowly, with stiffing. Theresulting solution is stirred at room temperature for 4 hours. Thesolvent is removed and the residue is dissolved in dichloromethane (3mL) and treated with triethylamine (0.1 mL, 0.7 mmol) followed bymethanesulfonyl chloride (0.025 mL, 0.3 mmol) dropwise, with stirring,over 5 minutes. The resulting solution is stirred at room temperaturefor 2 hours. The solvent is removed and the resulting residue ispurified by mass triggered HPLC to afford Q2; ESIMS calcd. forC₂₂H₃₂N₃O₅S (M+H⁺) 450.2, found 450.1.

Example Q3 Isopropyl4-(2-(6-(1,2,3,6-tetrahydro-1-methanesulfonylpyridin-4-yl)pyridin-3-yloxy)ethyl)piperidine-1-carboxylate

By following a procedure similar to the one used for preparing Q1 fromA1c, except substituting isopropyl4-(2-(methylsulfonyloxy)ethyl)piperidine-1-carboxylate for A1c, Q3 isprepared; ESIMS calcd. for C₂₂H₃₄N₃O₅S (M+H⁺) 452.2, found 452.1.

Example Q42-(4-((5-(1,2,3,6-Tetrahydro-1-methanesulfonylpyridin-4-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-5-ethylpyrimidine

By following a procedure similar to the one used for preparing Q2 fromA1a, except substituting B4a for B2a in Step A and Q4b (see schemebelow) for Q2b in Step D, Q4 is prepared; ESIMS calcd. for C₂₂H₃₁N₆O₃S(M+H⁺) 459.2, found 459.1.

Step A: A solution of A1a (1.03 g, 9 mmol) and2-chloro-5-ethylpyrimidine (1.1 mL, 9 mmol) in dimethylacetamide (7 mL)is treated with powdered cesium carbonate (4 g, 12.3 mmol) and thesuspension is stirred at 75° C. for 48 hours. The reaction is thendiluted with water (150 mL) and extracted with ethyl acetate/diethylether (1:1) (2×100 mL). The combined extracts are washed with water,saturated aqueous ammonium chloride, and brine, dried over Na₂SO₄ andconcentrated to yield Q4a; ¹H NMR (CDCl₃, 400.13 MHz): δ 8.16 (s, 2H),4.74 (m, 2H), 3.53 (t, J=5.9 Hz, 2H), 2.87 (td, J=13.2, 2.4 Hz, 2H),2.45 (q, J=7.6 Hz, 2H), 1.85 (m, 2H), 1.77 (m, 1H), 1.44 (t, J=5.5 Hz,1H), 1.23 (m, 2H), 1.18 (t, J=7.6 Hz, 3H); ESIMS calcd. for C₁₂H₂₀N₃O(M+H⁺) 222.2, found 222.1.

Step B: To a solution of Q4a (0.92 g, 4.2 mmol) in dichloromethane (20mL) is added triethylamine (1.0 mL, 7.1 mmol) in one portion. Theresulting mixture is cooled in an ice/water bath and methanesulfonylchloride (0.45 mL, 5.8 mmol) is added slowly, with stirring. The bath isremoved and the resulting solution is stirred at room temperature for 2hours. The reaction mixture is diluted with more dichloromethane (20mL), washed with water and saturated aqueous ammonium chloride, driedover MgSO₄ and concentrated to yield Q4b; ¹H NMR (CDCl₃, 400.13 MHz): ¹HNMR (CDCl₃, 400.13 MHz): δ 8.17 (s, 2H), 4.78 (m, 2H), 4.09 (d, J=6.6Hz, 2H), 3.02 (s, 3H), 2.88 (td, J=13.2, 2.6 Hz, 2H), 2.46 (q, J=7.6 Hz,2H), 2.05 (m, 2H), 1.84 (m, 1H), 1.29 (ddd, J=4.4, 12.4, 12.7 Hz, 2H),1.19 (t, J=7.6 Hz, 3H); ESIMS calcd. for C₁₃H₂₂N₃O₃S (M+H⁺) 300.1, found300.0.

Example Q52-(4-((6-(1,2,3,6-Tetrahydro-1-methanesulfonylpyridin-4-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)-5-ethylpyrimidine

By following a procedure similar to the one used for preparing Q2 fromQ2b, except substituting Q4b for Q2b, Q5 is prepared; ESIMS calcd. forC₂₃H₃₂N₅O₃S (M+H⁺) 458.2, found 458.1.

Example Q62-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)-5-(1-methanesulfonylpiperidin-4-yl)pyrazine

Example Q6 may be made from Q5 above, by hydrogenation with palladium oncarbon. However, an alternate synthesis is as follows:

Step A: A solution of diisopropylamine (2 mL, 14.2 mmol) in drytetrahydrofuran (10 mL) at −78° C. under nitrogen is treated withn-Butyllithium (2.46 M solution in hexanes; 5 mL, 12.25 mmol) and themixture is stirred for 15 min at −78° C. A solution of Q6a (2.55 g, 10.9mmol) in dry tetrahydrofuran (25 mL) is slowly added and stiffing iscontinued at −78° C. for 2 hours. N-Phenyltriflimide (4.42 g, 12.4 mmol)in dry tetrahydrofuran (25 mL) is added dropwise at −78° C. The mixtureis stirred at −78° C. for 2.5 hours and at room temperature for 30minutes. Dilution with ethyl acetate (200 mL) and saturated aqueousammonium chloride (50 mL), washing with water and brine, drying overNa₂SO₄ and concentration followed by purification on silica gel using alinear gradient of 0 to 40% ethyl acetate in hexane affords Q6b; ¹H NMR(CDCl₃, 400.13 MHz): δ 7.3-7.4 (m, 5H), 5.78 (m, 1H), 5.16 (s, 2H), 4.13(br. s, 2H), 3.72 (br. s, 2H), 2.47 (br. s, 2H); ¹⁹F NMR (CDCl₃, 376MHz): δ −75.32; ESIMS calcd. for C₁₄H₁₅F₃NO₅S (M+H⁺) 366.1, found 366.1.

Step B: To a solution of Q6a (1.22 g, 3.3 mmol) in 1,4-dioxane (25 mL)is added4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane(1.02 g, 4 mmol), 1,1′-bis(diphenylphosphino)ferrocene (0.08 g, 0.14mmol), [1′,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane complex (0.11 g, 0.13 mmol) and potassium acetate powder(1.26 g, 12.8 mmol). The mixture is degassed using argon and stirred at80° C. for 18 hours. Cooling, diluting with water (50 mL), extractionwith ethyl acetate, washing with water and brine, drying over Na₂SO₄ andconcentration, followed by by purification on silica gel using a lineargradient of 0 to 50% ethyl acetate in hexane affords Q6b; ¹H NMR (CDCl₃,400.13 MHz): δ 7.3-7.4 (m, 5H), 6.5 (m, 1H), 5.16 (s, 2H), 4.05 (m, 2H),3.54 (m, 2H), 2.27 (br. s, 2H), 1.28 (s, 12H); ESIMS calcd. forC₁₉H₂₇BNO₄ (M+H⁺) 344.2, found 344.1.

Step C: A solution of B4a (0.84 g, 4.8 mmol) and intermediate Q4b (1.28g, 4.3 mmol) in dry dimethylacetamide (25 mL) is treated with powderedcesium carbonate (2.31 g, 7.1 mmol) and the mixture is stirred at 65° C.for 24 hours. Filtration, concentration, and by purification on silicagel using a linear gradient of 10 to 50% ethyl acetate in hexane affordsQ4d; ¹H NMR (CDCl₃, 400.13 MHz): δ 8.17 (s, 2H), 8.16 (d, J=1.4 Hz, 1H),8.02 (d, J=1.4 Hz, 1H), 4.77 (m, 2H), 4.17 (d, J=6.6 Hz, 2H), 2.88 (td,J=13.1, 2.6 Hz, 2H), 2.46 (q, J=7.6 Hz, 2H), 2.10 (m, 2H), 1.89 (m, 1H),1.34 (ddd, J=4.3, 12.4, 12.6 Hz, 2H), 1.19 (t, J=7.6 Hz, 3H); ESIMScalcd. for C₁₆H₂₁BrN₅O (M+H⁺) 378.1, found 378.1.

Step D: To a solution of Q6d (0.8 g, 2.1 mmol) in 1,2-dimethoxyethane (5mL) is added intermediate Q6c (0.91 g, 2.7 mmol), powdered potassiumcarbonate (0.72 g, 5.2 mmol), and water (0.5 g). The mixture is degassedusing argon, then tetrakis-(triphenylphosphino)palladium(0) (0.23 g, 0.2mmol) is added and the mixture is heated to 180° C. for 20 min in amicrowave reactor. Cooling, dilution with ethyl acetate, drying overNa₂SO₄ and concentration, followed by purification on silica gel using alinear gradient of 10 to 50% ethyl acetate in hexane affords Q6e; ESIMScalcd. for C₂₉H₃₅N₆O₃ (M+H⁺) 515.3, found 515.1.

Step E: A solution of Q6e (0.6 g, 1.2 mmol) in ethyl acetate (100 mL)and ethanol (40 mL) is treated with palladium on carbon (5%; 0.85 g, 0.4mmol) and the mixture is saturated with hydrogen gas and is then stirredat room temperature under 1 atmosphere of hydrogen for 3 hours. Afterfiltration of the reaction through a pad of Celite® and concentrationthe residue is dissolved in dichloromethane (10 mL) and triethylamine(0.6 mL, 4.3 mmol). Methanesulfonyl chloride (0.15 mL, 1.9 mmol) is thenslowly added, with stirring. After 2 hours, the mixture is concentratedand purified on silica gel using a linear gradient of 10 to 65% ethylacetate in hexane to afford Q6. ESIMS calcd. for C₂₂H₃₃N₆O₃S (M+H⁺)461.2, found 461.1.

Example Q72-(4-((6-(1-Methanesulfonylpiperidin-4-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)-5-ethylpyrimidine

By following a procedure similar to the one used for preparing Q6 fromB4a, except substituting B2a for B4a in Step C, Q7 is prepared; ESIMScalcd. for C₂₃H₃₄N₅O₃S (M+H⁺) 460.2, found 460.1.

Example Q83-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)-6-(1-methanesulfonylpiperidin-4-yl)pyridazine

Step A: A solution of Q8a (0.64 g, 2.9 mmol) and Q4a (0.49 g, 3.3 mmol)in dry dimethylacetamide (6 mL) is treated with powdered potassiumcarbonate (0.7 g, 5.0 mmol) and the mixture is stirred at 150° C. for 2days. Cooling, dilution with water (100 mL), extraction with ethylacetate (2×100 mL), drying over Na₂SO₄, filtration, concentration, andpurification on silica gel using a linear gradient of 10 to 100% ethylacetate in hexane affords Q8b; ¹H NMR (CDCl₃, 400.13 MHz): δ 8.17 (s,2H), 7.67 (d, J=9.2 Hz, 1H), 6.96 (d, J=9.2 Hz, 1H), 4.77 (m, 2H), 4.37(d, J=6.6 Hz, 2H), 2.90 (td, J=13.1, 2.6 Hz, 2H), 2.46 (q, J=7.6 Hz,2H), 2.15 (m, 2H), 1.89 (m, 1H), 1.36 (ddd, J=4.3, 12.4, 12.6 Hz, 2H),1.19 (t, J=7.6 Hz, 3H); ESIMS calcd. for C₁₆H₂₁ClN₅O (M+H⁺) 334.1, found334.1.

Step B: To a solution of Q8b (0.11 g, 0.3 mmol) in 1,2-dimethoxyethane(2 mL) is added intermediate Q6b (0.15 g, 0.4 mmol), powdered potassiumcarbonate (0.18 g, 1.3 mmol), and water (0.5 g). The mixture is degassedusing argon, then tetrakis-(triphenylphosphino)palladium(0) (0.05 g,0.04 mmol) is added and the mixture is heated to 180° C. for 20 min in amicrowave reactor. Cooling, dilution with ethyl acetate, drying overNa₂SO₄ and concentration, followed by purification on silica gel using alinear gradient of 10 to 75% ethyl acetate in hexane affords Q8c; ESIMScalcd. for C₂₉H₃₅N₆O₃ (M+H⁺) 515.3, found 515.1.

Step C: A solution of Q8c (0.15 g, 0.3 mmol) in ethyl acetate (20 mL)and ethanol (20 mL) is treated with palladium black on carbon (5%; 0.4g, 0.2 mmol), saturated with hydrogen and then stirred at roomtemperature under 1 atmosphere of hydrogen for 6 hours. After exchangingthe atmosphere for N₂, the reaction is filtered through a pad of Celite®and concentrated. The resulting oil is dissolved in dichloromethane (10mL) and triethylamine (0.3 mL, 2.1 mmol). Methanesulfonyl chloride (0.05mL, 0.6 mmol) is then slowly added, with stirring. After 2 hours, themixture is concentrated and purified using mass-triggered reverse phaseHPLC to afford Q8; ESIMS calcd. for C₂₂H₃₃N₆O₃S (M+H⁺) 461.2, found461.1.

Example Q92-(4-((5-(1-Methanesulfonylpiperidin-4-yl)pyridin-2-yloxy)methyl)piperidin-1-yl)-5-ethylpyrimidine

By following a procedure similar to the one used for preparing Q8 fromQ8a, except substituting C1a for 8a, Q9 is prepared; ESIMS calcd. forC₂₃H₃₄N₅O₃S (M+H⁺) 460.2, found 460.2.

Example R1 1-tert-Butyl4-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)piperazine-1,4-dicarboxylate

Step A: A solution of R1a (2.2 g, 8.2 mmol) in dichloromethane (10 mL)is cooled in an ice/water bath and treated with neat BBr₃ (9.21 g, 37mmol). The reaction is stirred at ice bath temperature for 10 minutesand at room temperature for 1 hour. The reaction is then poured on tocrushed ice and allowed to quenchours. The resulting solid is collectedand dried to afford R1b; ESIMS calcd. for C₁₂H₁₇NO₃S (M+H⁺) 256.1, found256.1.

Step B: A solution of R1b (100 mg, 0.39 mmol) and nitrophenylchloroformate (87 mg, 0.43 mmol) in acetonitrile (5 mL) is treated withK₂CO₃ (108 mg, 0.78 mmol) and the mixture is stirred at room temperaturefor 2 hours, then is filtered, concentrated, and purified on silica gelusing a linear gradient of 0 to 100% ethyl acetate in hexane to affordR1c; ESIMS calcd. for C₁₉H₂₁N₂O₇S [M+H]⁺ 421.1, found 421.1.

Step C: A solution of R1c (41 mg, 0.10 mmol), 1-Boc-piperazine (20 mg,0.11 mmol) and triethylamine (68 μL, 0.50 mmol) in 1,2-dichloroethane (5mL) is heated at 50° C. for 12 hours. The mixture is concentrated invacuo and purified using mass-triggered reverse phase HPLC to afford R1;¹H-NMR (400 MHz, CDCl₃) δ 7.12 (d, J=8.4 Hz, 2H), 6.98 (d, J=8.8 Hz,2H), 3.87 (m, 3H), 3.56 (m, 2H), 3.45 (m, 6H), 2.75 (s, 3H), 2.70 (m,3H), 2.55 (m, 2H), 1.90 (m, 3H), 1.77 (m, 3H), 1.42 (s, 9H); ESIMScalcd. for C₂₂H₃₃N₃NaO₆S [M+Na]⁺ 490.2, found 490.1.

Example S1N-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methyl)-4-(1-(methylsulfonyl)piperidin-4-yl)aniline

Step A: A solution of Q4a (444 mg, 2 mmol) in anhydrous dichloromethane(5 mL) is added to a solution of Dess-Martin periodinane (1.018 g, 2.4mmol) in anhydrous dichloromethane (10 mL) and stirred overnight at roomtemperature. Additional dichloromethane (30 mL) is added and thereaction is filtered through Celite® and concentrated. Purification onsilica gel using a linear gradient of 0 to 50% ethyl acetate in hexaneto affords S1a; ESIMS calcd. for C₁₂H₁₈N₃O (M+H⁺) 220.1, found 220.1.

Step B: A mixture of S1a (318 mg, 1.5 mmol), tert-butyl4-(4-aminophenyl)piperidine-1-carboxylate (482 mg, 1.74 mmol), andNaBH(OAc)₃ (636 mg, 3 mmol) in dichloromethane (7 mL) is stirred at roomtemperature for 5 hours. The reaction is quenched with water (20 mL) andextracted with dichloromethane (3×20 mL), washed with water (20 mL),dried (Na₂SO₄), and concentrated. Purification on silica gel using alinear gradient of 0 to 50% ethyl acetate in hexane to affords S1b;ESIMS calcd. for C₂₈H₄₂N₅O₂ (M+H⁺) 480.3, found 480.4.

Step C: A solution of S1b (600 mg, 1.25 mmol) in MeOH (10 mL) is treatedwith a 4 M solution of HCl in dioxane (25 mL, 100 mmol) and stirred atroom temperature overnight. The reaction mixture is concentrated,dioxane (20 mL) added and concentrated again to form the hydrochloridesalt of S1c; ESIMS calcd. for C₂₃H₃₄N₅ (M+H⁺) 380.3, found 380.3.

Step D: A cold (0° C.) mixture of S1c (810 mg, 1.25 mmol) andtriethylamine (0.892 mL, 6.4 mmol) in dichloromethane (30 mL) is treatedwith methanesulfonyl chloride (0.152 mL, 1.96 mmol) dropwise and stirredat room temperature for 3 hours. Additional triethylamine (0.5 mL, 3.6mmol) and methanesulfonyl chloride (0.076 mL, 0.98 mmol) are added andthe reaction is stirred at room temperature for another 30 minutes. Thereaction is quenched with water (20 mL), extracted with dichloromethane(3×20 mL), washed with water (20 mL), dried over Na₂SO₄, andconcentrated. Purification using mass-triggered reverse phase HPLCaffords S1; ¹H NMR (CDCl₃, 400 MHz): δ 8.24 (s, 2H), 7.05 (m, 2H), 6.70(m, 2H), 4.61 (m, 2H), 3.64 (m, 2H), 2.96 (m, 2H), 2.88 (s, 3H), 2.80(m, 4H), 2.42 (q, J=7.6 Hz, 2H), 1.84 (m, 5H), 1.60 (m, 2H), 1.12 (m,5H); ESIMS calcd. for C₂₄H₃₆N₅O₂S (M+H⁺) 458.3, found 458.3.

Example S2N-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methyl)-N-methyl-4-(1-(methylsulfonyl)piperidin-4-yl)aniline

A solution of S1 (46 mg, 0.1 mmol) in tetrahydrofuran (1 mL) is addeddropwise to an ice-cold solution of 10% aqueous H₂SO₄ (0.2 mL) and 37%aqueous formaldehyde (0.1 mL, 1.2 mmol) in tetrahydrofuran (0.5 mL).NaBH₄ (30 mg, 0.79 mmol) is added and the reaction mixture is warmed toroom temperature. After stirring for 30 minutes the reaction is quenchedwith 0.2 M NaOH (10 mL) and extracted with ethyl acetate (3×15 mL),washed with brine (10 mL), dried over Na₂SO₄ and concentrated. Thecompound is purified using mass-triggered reverse phase HPLC to affordS2; ¹H NMR (CDCl₃, 400 MHz): δ 8.23 (s, 2H), 7.08 (m, 2H), 6.68 (m, 2H),4.60 (m, 2H), 3.64 (m, 2H), 3.19 (m, 2H), 2.92 (bs, 3H), 2.88 (s, 3H),2.78 (m, 4H), 2.42 (q, J=7.6 Hz, 2H), 1.93 (m, 1H), 1.81 (m, 2H), 1.62(m, 4H), 1.12 (m, 5H); ESIMS calcd. for C₂₅H₃₈N₅O₂S (M+H⁺) 472.3, found472.3.

Examples T1f and T14-(4-((1-(5-fluoropyrimidin-2-yl)piperidin-4-yl)methoxy)phenyl)-1-(methylsulfonyl)piperidine-4-carbonitrileand4-(4-((1-(5-fluoropyrimidin-2-yl)piperidin-4-yl)methoxy)phenyl)-1-(methylsulfonyl)piperidine-4-carboxylicacid

Step A: To an ice-cold suspension of NaH (60% in oil, 120 mg, 3 mmol) inanhydrous N,N-dimethylformamide (2 mL) is added T1a (142 μL, 1.05 mmol)and stirred for 30 minutes under a nitrogen atmosphere. To the resultingbrown solution is added tert-butyl bis(2-chloroethyl)carbamate (242 mg,1 mmol) in N,N-dimethylformamide (0.2 mL) and the cooling bath isremoved after 15 min. The reaction mixture is heated overnight at 75°C., cooled to room temperature and quenched with water (1 mL). Morewater is added (50 mL) and the reaction is extracted with dichlormethane(3×30 mL), dried over Na₂SO₄ and concentrated. Purification on silicagel using a linear gradient of 0 to 50% ethyl acetate in hexane toaffords T1b; ¹H-NMR (400 MHz, CDCl₃) δ 7.38 (m, 2H), 6.93 (m, 2H), 4.26(m, 2H), 3.82 (s, 3H), 3.19 (m, 2H), 2.08 (d, J=12.9 Hz, 2H), 1.90 (td,J=13.0, 4.0 Hz, 2H), 1.48 (s, 9H); ESIMS calcd. for C₁₈H₂₄N₂NaO₃ (M+Na⁺)339.2, found 388.8.

Step B: To a solution of T1b (218 mg, 0.69 mmol) in dioxane (1 mL) isadded 4 M solution of HCl in dioxane (2 mL, 8 mmol) and the reaction isstirred for 2 hours at room temperature. The solvent is removed and theresidue is coevaporated with dioxane (10 mL) to afford T1c; ESIMS calcd.for C₁₃H₁₇N₂O (M+H⁺) 217.1, found 216.9.

Step C: A cold (ice/water bath) solution of T1c (0.69 mmol) andtriethylamine (385 μL, 2.76 mmol) in dry dichloromethane (10 mL) istreated with methanesulfonyl chloride (64 μL, 0.83 mmol) dropwise. Theresulting solution is stirred at room temperature overnight. Thereaction mixture is added to water (40 mL) and extracted withdichloromethane (3×40 mL). The combined organic layers are dried overNa₂SO₄ and concentrated to yield T1d; ESIMS calcd. for C₁₄H₁₉N₂O₃S(M+H⁺) 295.1, found 295.0.

Step D: A solution of T1d (208 mg, 0.7 mmol) in anhydrousdichloromethane (3.5 mL) is cooled to −78° C. under nitrogen atmosphereand a 1M solution of BBr₃ (3.5 mL, 3.5 mmol) in dichloromethane is addeddropwise. The reaction is stirred at room temperature overnight, thencooled to 0° C. and quenched with MeOH (2 mL). The reaction mixture isrepeatedly concentrated with MeOH (3×20 mL) to afford T1e; ESIMS calcd.for C₁₃H₁₇N₂O₃S (M+H⁺) 281.1, found 281.0.

Step E: A mixture of T1e (196 mg, 0.7 mmol),(1-(5-fluoropyrimidin-2-yl)piperidin-4-yl)methyl methanesulfonate (202mg, 0.7 mmol; prepared by following the procedure for Q4a except using2-chloro-5-fluoropyrimidine as the electrophile), and Cs₂CO₃ (456 mg,1.4 mmol) in acetonitrile (10 mL) is heated to 70° C. for 48 hours. Thereaction mixture is concentrated and partitioned between water (20 mL)and ethyl acetate, the aqueous phase is extracted with ethyl acetate(2×20 mL). The combined organics are washed with water (2×10), driedover Na₂SO₄ and concentrated. Purification on silica gel using a lineargradient of 0 to 60% ethyl acetate in hexane to affords T1f; ¹H-NMR (400MHz, DMSO) δ 8.43 (d, J=0.8 Hz, 2H), 7.46 (m, 2H), 7.00 (m, 2H), 4.61(m, 2H), 3.87 (d, J=6.4 Hz, 2H), 3.74 (m, 2H), 3.00 (m, 5H), 2.92 (m,2H), 2.24 (m, 2H), 2.05 (m, 3H), 1.83 (m, 2H), 1.23 (m, 2H); ESIMScalcd. for C₂₃H₂₉FN₅O₃S (M+H⁺) 474.2, found 474.2.

Step F: A solution of T1f (30 mg, 0.063 mmol) and KOH (105 mg, 2.6 mmol)in 2-methoxyethanol (1 mL) and water (0.5 mL) is heated to 110° C. for72 hours. The reaction mixture is acidified with 1N HCl to pH 2-3 andextracted with ethyl acetate (3×20 mL). The combined organics are driedover Na₂SO₄, and concentrated. The residue is purified usingmass-triggered reverse phase HPLC to afford T1; ¹H-NMR (400 MHz,DMSO-d6) δ 8.42 (d, J=0.8 Hz, 2H), 7.30 (m, 2H), 6.92 (m, 2H), 4.60 (m,2H), 3.83 (d, J=6.4 Hz, 2H), 2.88 (m, 7H), 2.48 (m, 2H), 2.04 (m, 1H),1.83 (m, 4H), 1.22 (m, 2H). ESIMS calcd. for C₂₃H₃₀FN₄O₅S (M+H⁺) 493.2,found 493.1

Example U1 1-methylcyclopropyl4-((2,6-difluoro-4-(3-(methylsulfonamido)azetidin-1-yl)phenoxy)methyl)piperidine-1-carboxylate

Step A: By following a similar procedure as that used to prepare E3 fromE3a, except substituting P1b for E3a, U1a is prepared; ESIMS calcd. forC₁₇H₂₁BrF₂NO₃ [M+H]⁺: 404.1, found: 404.0.

Step B: By following a similar procedure as that used to prepare B2 fromB2b, except substituting benzyl azetidin-3-ylcarbamate for benzylpiperazine-1-carboxylate, U1b is prepared; It is observed that the Cbzgroup is removed under reaction conditions; ESIMS calcd. forC₂₀H₂₈F₂N₃O₃ [M+H⁺] 396.2, found 369.3.

Step C: By following a similar procedure as that used to prepare G1 fromG1a, except substituting U1b for G1a, U1 is prepared; ¹H-NMR (400 MHz,CDCl₃) δ 5.95 (d, J=9.7 Hz, 2H), 4.85 (d, J=9.4 Hz, 1H), 4.40 (m, 1H),4.20 (t, J=7.5 Hz, 2H), 4.29-3.94 (m, 2H), 3.80 (d, J=6.0 Hz, 2H), 3.65(dd, J=5.3, 8.0 Hz, 2H), 3.00 (s, 3H), 2.74 (t, J=12.4 Hz, 2H), 1.9 (m,1H), 1.82 (d, J=13.1 Hz, 2H), 1.54 (s, 3H), 1.22 (m, 2H), 0.86 (t, J=6.4Hz, 2H), 0.62 (t, J=6.4 Hz, 2H). ESIMS calcd. for C₂₁H₃₀F₂N₃O₅S [M+H⁺]474.2, found 474.1.

Example U2 1-methylcyclopropyl4-((2,6-difluoro-4-(3-(2-methylpropylsulfonamido)azetidin-1-yl)phenoxy)methyl)piperidine-1-carboxylate

By following a similar procedure as that used to prepare U1 from U1c,except substituting isobutanesulfonyl chloride for methanesulfonylchloride, U2 is prepared; ¹H-NMR (400 MHz, CDCl₃) δ 5.96 (d, J=9.6 Hz,2H), 4.87 (d, J=9.5 Hz, 1H), 4.40 (m, 1H), 4.20 (t, J=7.5 Hz, 2H),4.29-3.94 (m, 2H), 3.82 (d, J=4.8 Hz, 2H), 3.65 (dd, J=7.9, 5.4 Hz, 2H),2.93 (d, J=6.4 Hz, 2H), 2.75 (m, 2H), 2.28 (septet, J=6.7 Hz, 1H), 1.92(m, 1H), 1.83 (d, J=12.6 Hz, 2H), 1.56 (s, 3H), 1.24 (m, 2H), 1.13 (d,J=6.7 Hz, 6H), 0.87 (t, J=6.3 Hz, 2H), 0.63 (t, J=6.3 Hz, 2H). ESIMScalcd. for C₂₄H₃₆F₂N₃O₅S [M+H⁺] 516.2, found 516.2.

Example U3 1-methylcyclopropyl4-((2,6-difluoro-4-(3-(N-methylmethylsulfonamido)azetidin-1-yl)phenoxy)methyl)piperidine-1-carboxylate

To a solution of U1 (25 mg, 0.05 mmol) and iodomethane (4 uL, 0.06 mmol)in dry N,N-dimethylformamide (1 mL) at 0° C. is added sodium hydride (5mg, 0.2 mmol) in one portion. The mixture is allowed to warm slowly toroom temperature and stirred an additional 1 hour. The mixture ispartitioned between water and dichloromethane, and the organics washedwith brine, dried over MgSO₄, filtered, evaporated and purified onsilica gel using 0-50% ethyl acetate in dichloromethane to afford U3;¹H-NMR (400 MHz, CDCl₃) δ 5.97 (d, J=9.6 Hz, 2H), 4.71 (m, 1H), 4.06 (t,J=7.8 Hz, 2H), 4.29-3.95 (m, 2H), 3.88 (dd, J=8.0, 5.6 Hz, 2H), 3.81 (d,J=5.8 Hz, 2H), 2.97 (s, 3H), 2.83 (s, 3H), 2.74 (m, 2H), 1.91 (m, 1H),1.83 (d, J=13.4 Hz, 2H), 1.54 (s, 3H), 1.24 (m, 2H), 0.86 (t, J=6.3 Hz,2H), 0.62 (t, J=6.3 Hz, 2H). ESIMS calcd. for C₂₂H₃₂F₂N₃O₅S [M+H⁺]488.2, found 488.2.

Example U4 1-methylcyclopropyl4-((4-(3-(N,2-dimethylpropylsulfonamido)azetidin-1-yl)-2,6-difluorophenoxy)methyl)piperidine-1-carboxylate

By following a similar procedure as that used to prepare U3 from U1,except substituting U2 for U1, U2 is prepared; ¹H-NMR (400 MHz, CDCl₃) δ5.96 (d, J=9.7 Hz, 2H), 4.77 (m, 1H), 4.04 (t, J=7.9 Hz, 2H), 4.25-3.96(m, 2H), 3.87 (dd, J=5.6, 7.8 Hz, 2H), 3.81 (d, J=6.3 Hz, 2H), 2.97 (s,3H), 2.77 (d, J=6.7 Hz, 2H), 2.74 (m, 2H), 2.24 (septet, J=6.6 Hz, 1H),1.91 (m, 1H), 1.83 (d, J=13.3 Hz, 2H), 1.54 (s, 3H), 1.24 (m, 2H), 1.11(d, J=6.5 Hz, 6H), 0.86 (t, J=6.3 Hz, 2H), 0.61 (t, J=6.3 Hz, 2H). ESIMScalcd. for C₂₅H₃₈F₂N₃O₅S [M+H⁺] 530.3, found 530.2.

Example U5 1-Methylcyclopropyl4-((5-(3-(methylsulfonamido)azetidin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate

By following a similar procedure as that used to prepare M1 from M1a,except substituting benzyl azetidin-3-ylcarbamate for benzylpiperazine-1-carboxylate in step A and methanesulfonyl chloride formethyl 3-(chlorosulfonyl)propanoate in step d, U5 is prepared; ¹H NMR(400 MHz, CDCl₃) δ 7.72 (d, J=1.4 Hz, 1H), 7.24 (d, J=1.4 Hz, 1H), 4.73(d, J=9.2 Hz, 1H), 4.37 (m, 1H), 4.28 (m, 2H), 3.97 (d, J=6.4 Hz, 2H),3.75 (m, 2H), 3.27 (s, 3H), 2.65 (m, 2H), 1.85 (m, 1H), 1.70 (m, 2H),1.46 (s, 3H), 1.17 (m, 3H), 0.77 (m, 2H), 0.53 (m, 2H); ESIMS m/z for(M+H)⁺ C₁₉H₃₀N₅O₅S calcd: 440.2, found: 440.2.

Example U6 1-Methylcyclopropyl4-((2,6-difluoro-4-(4-(methylsulfonyl)-2-oxopiperazin-1-yl)phenoxy)methyl)piperidine-1-carboxylate

By following a similar procedure as that used to prepare O2 from B4b,except substituting P1b for B4b, U6 is prepared; ¹H-NMR (400 MHz,DMSO-d6) δ 7.28 (m, 2H), 3.94 (m, 6H), 3.77 (m, 2H), 3.53 (m, 2H), 3.05(s, 3H), 2.75 (m, 2H), 1.88 (m, 2H), 1.74 (m, 2H), 1.46 (s, 3H), 1.14(m, 2H), 0.76 (m, 2H), 0.59 (m, 2H); ESIMS calcd. for C₂₂H₃₀F₂N₃O₆S[M+H]⁺ 502.2, found 502.2.

Example V18-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)-2-(methylsulfonyl)-1,2,3,4-tetrahydropyrazino[1,2-a]indole

Step A: A suspension of V1a (2.26 g, 11.8 mmol) in methanol (20 mL) istreated with thionyl chloride (1.0 mL, 13.8 mmol) dropwise, withstirring. The resulting mixture is stirred at room temperature for 18 h,and then concentrated to dryness. The resulting solid is triturated with1:1 water/aqueous saturated sodiumhydrogencarbonate, filtered, washedwith water and dried to afford V1b; ¹H NMR (DMSO-d₆, 400.13 MHz): δ11.80 (s, 1H), 7.37 (d, J=8.9 Hz, 1H), 7.11 (d, J=2.2 Hz, 1H), 7.06 (d,J=2.2 Hz, 1H), 6.92 (dd, J=2.4, 8.9 Hz, 1H), 3.86 (s, 3H), 3.76 (s, 3H);ESIMS calcd. for C₁₁H₁₂NO₃ (M+H⁺) 206.1, found 206.1.

Step B: A solution of V1b (1.86 g, 9.1 mmol) is in N,N-dimethylacetamide(25 mL) is treated with powdered cesium carbonate (5.31 g, 16.3 mmol)and chloroacetonitrile (0.90 mL, 14.3 mmol) and the mixture is stirredat 65° C. for 18 hours. Cooling to room temperature, dilution with ethylacetate, washing with water (2×), saturated aqueous ammonium chlorideand brine, drying over Na₂SO₄, filtration and concentration yields asolid. The residue is purified on silica gel using 5-30% ethyl acetatein hexanes to afford V1c; ¹H NMR (CDCl₃, 400.13 MHz): δ 7.33 (d, J=8.9Hz, 1H), 7.30 (d, J=1.0 Hz, 1H), 7.12 (m, 2H), 5.59 (s, 2H), 3.95 (s,3H), 3.87 (s, 3H); ESIMS calcd. for C₁₃H₁₃N₂O₃ (M+H⁺) 245.1, found245.0.

Step C: V1d is prepared from V1c according to the literature proceduredescribed in Bioorg. Med. Chem. Lett. 2002, 12, 155-158; ESIMS calcd.for C₁₂H₁₅N₂O (M+H⁺) 203.1, found 203.1.

Step D: To a solution of V1d (0.58 g, 2.5 mmol) in dichloromethane (15mL) is added triethylamine (0.7 mL, 5 mmol) in one portion. Theresulting mixture is cooled in an ice/water bath and methanesulfonylchloride (0.25 mL, 3.2 mmol) is added dropwise, with stirring, over 5minutes. The bath is removed and the resulting solution is stirred atroom temperature for 30 minutes. The reaction mixture is added to water(40 mL) and extracted with dichloromethane (2×40 mL). The combinedorganic extracts are washed with saturated aqueous ammonium chloridesolution, dried over MgSO₄, and concentrated to yield V1e; ESIMS calcd.for C₁₃H₁₇N₂O₃S (M+H⁺) 281.1, found 281.2.

Step E: A solution of V1e (0.60 g, 2.1 mmol) in dichloromethane (15 mL)is treated with neat boron tribromide (0.8 mL, 8.3 mmol) at roomtemperature. The resulting solution is stirred at room temperature for30 minutes. The reaction mixture is carefully added to methanol (50 mL),treated with solid Na₂CO₃ (0.4 g), filtered and concentrated to dryness.The crude V1f is used as such in the next step; ESIMS calcd. forC₁₂H₁₅N₂O₃S (M+H⁺) 267.1, found 267.1.

Step F: A solution of V1f and Q4b (0.03 g, 0.1 mmol) in dry acetonitrile(2 mL) is treated with powdered cesium carbonate (0.1 g, 0.3 mmol) andthe mixture is stirred at 75° C. for 24 hours. Filtration and massdirected reverse phase HPLC purification yields V1; ESIMS calcd. forC₂₄H₃₂N₅O₃S (M+H⁺) 470.2, found 470.1.

By following a similar procedure as the one used for preparing V1 fromV1f except substituting the appropriate mesylate for Q4b the followingcompounds are prepared;

Example Structure Analytical data V2

¹H NMR (CDCl₃, 400.13 MHz): δ 7.17 (d, J = 8.8 Hz, 1H), 7.03 (d, J = 2.3Hz, 1H), 6.85 (dd, J = 2.3, 8.8 Hz, 1H), 6.24 (d, J = 0.7 Hz, 1H), 4.67(s, 2H), 4.16 (br. 2H), 4.15 (t, J = 5.4 Hz, 2H), 3.84 (m, 4H), 2.87 (s,3H), 2.76 (t, J = 12.2 Hz, 2H), 1.98 (m, 1H), 1.85 (t, J = 12.6 Hz, 2H),1.47 (s, 9H), 1.28 (ddd, J = 4.7, 12.4, 12.4 Hz, 2H); ESIMS calcd. forC₂₃H₃₄N₃O₅S (M + H)⁺ 464.2, found 464.1. V3

ESIMS calcd. for C₂₃H₃₂N₃O₅S (M + H⁺) 462.2, found 462.2.

Example V47-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)-2-(methylsulfonyl)-1,2,3,4-tetrahydrobenzofuro[2,3-c]pyridine

Step A: A suspension of V4a (3.99 g, 19.4 mmol) is in dichloromethane(50 mL) is treated with oxalyl chloride (1.8 mL, 21.3 mmol) slowly, withstiffing, followed by dimethylformamide (0.01 mL). The resulting mixtureis stirred at room temperature for 1 hour, and then concentrated todryness to yield V4b; ¹H NMR (CDCl₃, 400.13 MHz): δ 7.58 (t, J=1.0 Hz,1H), 7.37 (d, J=8.6 Hz, 1H), 7.03 (d, J=2.2 Hz, 1H), 6.92 (dd, J=2.2,8.6 Hz, 1H), 4.21 (d, J=1.0 Hz, 2H), 3.84 (s, 3H).

Step B: A solution of V4b (19.4 mmol) in dichloromethane (100 mL) istreated with ammonia gas by slow bubbling through the stiffing solutionfor 5 minutes. The resulting suspension is stirred in a closed flask for2 hours. The resulting suspension is filtered, the collected solids arewashed with more dichloromethane and air dried to yield V4c; ¹H NMR(CDCl₃, 400.13 MHz): δ 7.52 (t, J=0.7 Hz, 1H), 7.43 (d, J=8.6 Hz, 1H),7.03 (d, J=2.2 Hz, 1H), 6.92 (dd, J=2.2, 8.6 Hz, 1H), 5.61 (s, 1H), 5.45(s, 1H), 3.86 (s, 3H), 3.63 (d, J=0.7 Hz, 2H); ESIMS calcd. forC₁₁H₁₂NO₃ (M+H⁺) 206.1, found 206.1.

Step C: A solution of V4c (2.79 g, 13.6 mmol) in dry tetrahydrofuran(100 mL) is treated with borane solution in tetrahydrofuran (1.0 N; 50mL, 50 mmol) and the resulting solution is stirred in a closed flaskovernight. The reaction mixture is carefully treated with methanol (50mL) and concentrated to dryness. The residue is purified by silica gelchromatography using a linear gradient of 20 to 100% ethyl acetate inhexanes to afford V4d; ¹H NMR (CDCl₃, 400.13 MHz): δ 7.46 (s, 1H), 7.38(d, J=8.6 Hz, 1H), 7.02 (d, J=2.2 Hz, 1H), 6.90 (dd, J=2.2, 8.6 Hz, 1H),3.85 (s, 3H), 3.63 (br. s, 2H), 3.14 (tt, J=6.4, 6.8 Hz, 2H), 3.02 (t,J=6.4 Hz, 2H); ESIMS calcd. for C₁₁H₁₄NO₂ (M+H⁺) 192.1, found 192.1.

Step D: V4e acetic acid salt is prepared from V4d according to theprocedure described in WO2000/020421, p. 15; ¹H NMR (CDCl₃, 400.13 MHz):δ 7.30 (d, J=8.5 Hz, 1H), 6.99 (d, J=2.2 Hz, 1H), 6.86 (dd, J=2.2, 8.5Hz, 1H), 3.88 (br. s, 2H), 3.85 (s, 3H), 3.06 (t, J=5.8 Hz, 2H), 2.85(m, 2H), 2.72 (m, 1H); ESIMS calcd. for C₁₂H₁₄NO₂ (M+H⁺) 204.1, found204.1.

Step E: A solution of V4e acetic acid salt (0.18 g, 0.7 mmol) indichloromethane (5 mL) is treated with triethylamine (0.2 mL, 1.4 mmol)and methanesulfonic anhydride (0.15 g, 0.86 mmol) and the mixture isstirred at room temperature for 1 hour. Washing with water, drying overMgSO₄ and concentration yields V4f; ¹H NMR (CDCl₃, 400.13 MHz): δ 7.29(d, J=8.5 Hz, 1H), 6.98 (d, J=2.2 Hz, 1H), 6.84 (dd, J=2.2, 8.5 Hz, 1H),3.84 (s, 3H), 2.77 (m, 2H), 2.73 (m, 2H), 2.54 (s, 3H); ESIMS calcd. forC₁₃H₁₆NO₄S (M+H⁺) 282.1, found 282.0.

Step F: A solution of V4f (0.15 g, 0.5 mmol) in dichloromethane (5 mL)is treated with neat boron tribromide (0.2 mL, 2.1 mmol) at roomtemperature. The resulting solution is stirred at room temperature for30 minutes. The reaction mixture is carefully added to methanol (50 mL),treated with solid Na₂CO₃ (0.4 g), filtered and concentrated to drynessto afford V4g; ESIMS calcd. for C₁₂H₁₄NO₄S (M+H⁺) 268.1, found 268.1.

Step G: A solution of V4g and Q4b (0.03 g, 0.1 mmol) in dry acetonitrile(2 mL) is treated with powdered cesium carbonate (0.08 g, 0.2 mmol) andthe mixture is stirred at 75° C. for 24 hours. Filtration and massdirected HPLC purification yields V4; ESIMS calcd. for C₂₄H₃₁N₄O₄S(M+H⁺) 471.2, found 471.2.

Example V57-(1-(5-Ethylpyrimidin-2-yl)piperidin-4-yloxy)-2-(methylsulfonyl)-1,2,3,4-tetrahydrobenzofuro[2,3-c]pyridine

By following a similar procedure as the one used for preparing V4 fromV4g except substituting 1-(5-ethylpyrimidin-2-yl)piperidin-4-ylmethanesulfonate for Q4b the V5 is prepared; ESIMS calcd. forC₂₃H₂₉N₄O₄S (M+H⁺) 457.2, found 457.1.

Biological Assays Generation of Stable Cell Line

Flp-In-CHO cells (Invitrogen, Cat. #R758-07) are maintained in Ham's F12medium supplemented with 10% fetal bovine serum, 1% antibiotic mixtureand 2 mM L-glutamine. The cells are transfected with a DNA mixturecontaining human GPR119 (hGPR119) or mouse GPR119 (mGPR119) in thepcDNA5/FRT vector (Invitrogen) and the pOG44 vector (Invitrogen) in a1:9 ratio using Fugene6 (Roche), according to the manufacturer'sinstructions. After 48 hours, the medium is changed to mediumsupplemented with 400 μg/mL hygromycin B to initiate the selection ofstably transfected cells. The resultant cell lines are designatedCHO-hGPR119 and CHO-mGPR119 respectively.

Cyclic AMP Assays

To test the activity of compounds of the invention on human GPR119,CHO-hGPR119 cells are harvested and resuspended at 300,000 cells/mL inassay media (Ham's F12 medium plus 3% lipid-depleted fetal bovine serum,1 mM 3-isobutyl-1-methyl-xanthine (IBMX)). Cells (5 μl) are placed ineach well of a white 1536-well plate. A compound of the invention (50nL) diluted in 100% dimethyl sulfoxide (DMSO) is added to each well andthe plates are incubated at 37° C. for 30 minutes. cAMP concentrationsare then measured using the cAMP dynamic 2 kit (Cisbio Bioassays)according to the manufacturer's instructions. 2.5 μL of dilutedcAMP-XL665 is added to each well, followed by 2.5 μL dilutedanti-cAMP-Cryptate. The plate is covered and incubated for one hour atroom temperature, then read on an Envision plate reader (Perkin Elmer)using the HTRF method with excitation at 337 nm, and emissions measuredat 620 nm and 655 nm

Activity of compounds of the invention on mouse GPR119 is measured by asimilar method in 384-well plates. CHO-mGPR119 cells are harvested andresuspended in assay media at 500,000 cells/mL. 50 μl cells are placedin each well of a white 384-well plate. A compound of the invention (500mL) diluted in 100% DMSO is added to each well and the plates areincubated at 37° C. for 30 minutes. cAMP concentrations are measured asabove except that 20 μL of diluted cAMP-XL665 followed by 20 μL dilutedanti-cAMP-Cryptate is added to each well.

Compounds of the invention, in free form or in pharmaceuticallyacceptable salt form, produced a concentration-dependent increase inintracellular cAMP level. Compounds of the invention show an EC₅₀ ofbetween 1×10⁻⁵ and 1×10⁻¹⁰M, preferably less than 500 nM, morepreferably less than 100 nM. The following table shows a non-limitingsample of EC₅₀ measurements for compounds of the invention whereby +, ++and +++ represent EC₅₀ ranges of >800 nM, 200-800 nM and <200 nM,respectively:

Compound Structure EC₅₀ Activity A3

+ C2

+ D2

++ E3

+++ E9

++ G1

+ G4

+++ H3

+++ I1

+++ J7

+++ J22

+++ K3

+++ O9

+++ O41

+++ P13

+++ T1

++ U5

+++ V5

+++

GLUTag GLP-1 Assay

The effect of compounds of the invention on GLP-1 secretion can bestudied in GLUTag cells (a mouse entereoendocrine cell line thatsecretes GLP-1). GLUTag cells are plated in poly-D-lysine-coated 96-wellplates on day one in complete medium (DMEM/10% FBS). On day two, theculture medium is replaced with a low glucose medium (DMEM/5.5 mMglucose/10% FBS). One day three, cells are washed twice andpre-incubated in glucose free EBSS buffer (100 mM NaCl, 5 mM KCl, 0.8 mMMgSO₄.7H₂O, 1.65 mM NaH₂PO₄.2H₂O, 26 mM NaHCO₃, 1.6 mM CaCl₂, 0.1% fattyacid-free bovine serum albumin, pH 7.35) for two hours at 37° C. with 5%CO₂. After this pre-incubation period, the cells are washed again withglucose free EBSS buffer, and then stimulated with a compound of theinvention at various concentrations in EBSS buffer plus 10 mM glucoseand a DPP-4 inhibitor at 37° C. in the presence of 5% CO₂. At the end ofthe incubation, the supernatants are then collected and transferred to aHEK293 cell line that over expresses human GLP-1 receptor and aCRE-luciferase reporter construct. The CRE-luciferase constructexpresses luciferase gene under the control of a cAMP response element(CRE). GLP-1-stimulated GLP-1 receptor leads to cAMP production, whichin turn, up regulates luciferase expression. The HEK293-GLP-1R reportercells are plated the night before in white 384-well plates. Afterincubation with the supernatants from GLUTag cells treated with acompound of the invention, the HEK293-GLP-1R reporter cells areincubated at 37° C. in the presence of 5% CO₂ for 18 hours. Luciferaseproduced from the treatment is measured by the addition of Steady-Gloreagent (Promega, Cat. # E2550). The EC₅₀ values are calculated withnonlinear regression using Graphpad Prism.

HIT-T15 Insulin Assay

The effect of GPR119 agonist on insulin secretion is studied in HIT-T15cells (a hamster beta cell line that secrets insulin). HIT-T15 cells areobtained from ATCC and are cultured in Ham's F12 Kaighn's medium plus10% horse serum and 2.5% fetal bovine serum. On day one, HIT-T15 cellsare plated in 96-well plates and cultured for 24 hours and then themedium is replaced with a low-glucose medium (RPMI 1640 mediumsupplemented with 10% horse serum, 2.5% fetal bovine serum and 3.0 mMD-(+)-glucose). On day three, the cells are washed twice and thenpre-incubated with glucose-free Krebs-Ringer bicarbonate buffer (KRBB)that contains 119 mM NaCl, 4.74 mM KCl, 2.54 mM CaCl₂, 1.19 mM KH₂PO₄,1.19 mM MgCl₂, 25 mM NaHCO₃, 10 mM HEPES and 0.1% fatty-acid-free bovineserum albumin at pH 7.4. One hour later, the cells are washed again forthree times and incubated with a compound of the invention in KRBB plus16.5 mM glucose for 3 hours at 37° C. After a 5 minute centrifugation at1,000 rpm, supernatant is removed from each well and transferred into aseparate plate for insulin measurement following the instructions forCisbio insulin HTRF assay kit (Cisbio, Cat. #621NSPEC). The EC₅₀ valuesare calculated with nonlinear regression using Graphpad Prism.

GLP-1 Assay

Adult male wild-type C57BL/6J mice (age 9 weeks, JAX) are used as theexperimental animals. In all experiments, mice are housed in a 12 hourlight/dark cycle facility (light on from 5:00 a.m. to 5:00 p.m) and haveaccess to food (Purina 5001) and water ad libitum. Mice (8 per group)are randomized into treatment groups based on their initial body weight.They are orally dosed with vehicle, DPP4 inhibitor alone, or DPP4inhibitor and a compound of the invention, in a single dose. A glucosebolus (2 g/kg) is delivered sixty minutes post dosing. A sample iscollected 2 minutes post glucose bolus.

Plasma active GLP-1 is measured in C57BL/6 mice following a single oraladministration of increasing doses of a compound of the invention (3, 10and 30 mg/kg). Animals are fasted for 16 hours prior to compoundadministration. Oral doses are administered at approximately 10:00 am ina 75% PEG300:25% D5W suspension. Blood is obtained (via retro-orbitalbleeding) to measure plasma levels of active GLP-1. Approximately 200 μLsamples of blood are removed for analysis at 62 minutes post dosing (2minutes post glucose bolus). All data are expressed as the mean±SEM foreach experimental group of mice. Statistical analysis of data isperformed using a one-way ANOVA with a Bonferroni's Multiple ComparisonPost Test (GraphPad Prism 4.02).

Treatment of mice with increasing doses of a compound of the invention(in combination with a DPP4 inhibitor) results in increasing levels ofplasma active GLP-1. The magnitude of GLP-1 increase observed in the 10mg/kg group demonstrate that some compounds of the invention canincrease circulating levels of active GLP-1 by about 2.2× fold relativeto the effect with a DPP4 inhibitor alone.

OGTT Assay

Adult male Zucker fa/fa rats (age 11 weeks, Charles River Labs) are usedas the experimental animals. In all experiments, rats are housed in a 12hour light/dark cycle facility (light on from 5:00 a.m. to 5:00 p.m) andhave access to food (Purina 5001) and water ad libitum. Rats (6 pergroup) are randomized into treatment groups based on their initial bodyweight and are dosed (orally) with vehicle orally, a DPP4 inhibitor, ora compound of the invention. Sixty minutes after dosing, a 3 g/kgglucose bolus is administered.

A compound of the invention is dissolved in vehicle for dosing (orallyusing a gavage needle) at a final concentration of 0.2, 2 or 6 mg/mL.Oral doses are administered at approximately 7:30 am in a 75% PEG300:25%D5W.

OGTT evaluations are performed in conscious rats that are 11 weeks ofage. The rats are fasted by removing food at 6 pm the day before. Abaseline blood sample is taken at t=minus 60 minutes and the rats arethen dosed orally with the a compound of the invention. A baseline bloodsample is taken at t=zero minutes and the animals are then administeredan oral glucose bolus (3 g/kg) immediately. Blood is obtained (via tailbleeding) to measure blood glucose (using a glucometer). A single dropof blood from the tail is measured for glucose using a glucometer att=−60, 0, 10, 30, 60, 90, 120 and 180 minutes.

The area under the curve (AUC) is calculated using the trapezoidal rule.All data are expressed as the mean±sem for each experimental group ofrats. Statistical analysis of data is performed using a one-way ANOVAwith a Bonferroni's Multiple Comparison Post Test (GraphPad Prism 4.02).

Some compounds of the invention exhibit a clear dose-dependent effect onimproved glucose clearance at 3, 10, and 30 mg/kg (about 31%, about 48%,and about 56% reduction in glucose AUC, respectively) when dosed in a75% PEG300/25% D5W formulation. The results demonstrate that somecompounds of the invention can lower blood glucose in response toglucose challenge.

It is understood that the examples and embodiments described herein arefor illustrative purposes only and that various modifications or changesin light thereof will be suggested to persons skilled in the art and areto be included within the spirit and purview of this application andscope of the appended claims. All publications, patents, and patentapplications cited herein are hereby incorporated by reference for allpurposes.

1. A compound of Formula I:

in which: Q is a divalent or trivalent radical selected from C₆₋₁₀aryl, C₁₋₁₀heteroaryl, C₃₋₈cycloalkyl and C₃₋₈heterocycloalkyl; wherein said aryl, heteroaryl, cycloalkyl or heterocycloalkyl of Q is optionally substituted with up to 3 radicals independently selected from halo, C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆alkoxy, —C(O)R₂₀ and —C(O)OR₂₀; wherein R₂₀ is selected from hydrogen and C₁₋₆alkyl; and optionally connecting a carbon adjacent to W₂ through a CR₃₁, O, S or NR₃₁ with a carbon of Q to form a 5-membered ring fused to rings A and Q; wherein R₃₁ is selected from hydrogen and C₁₋₆alkyl; W₁ and W₂ are independently selected from CR₂₁ and N; wherein R₂₁ is selected from hydrogen, cyano, C₁₋₆alkyl and —C(O)OR₂₅; wherein R₂₅ is selected from hydrogen and C₁₋₆alkyl; ring A can have up to 2 ring carbons substituted with a group selected from —C(O)—, —C(S)— and —C(═NOR₃₀)— and can be partially unsaturated with up to 2 double bonds; wherein R₃₀ is selected from hydrogen and C₁₋₆alkyl; L is selected from C₁₋₆alkylene, C₂₋₆alkenylene, —(CH₂)_(n)O—, —OC(O)(CH₂)_(n)—, —C(O)O(CH₂)_(n)—, —NR₂₆(CH₂)_(n)— and —0(CH₂)_(n)—; wherein R₂₆ is selected from hydrogen and C₁₋₆alkyl; and n is selected from 0, 1, 2, 3, 4 and 5; wherein any alkyl of L can be optionally substituted with 1 to 3 radicals independently selected from halo, C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆alkoxy, —C(O)R₂₂ and —C(O)OR₂₂; wherein R₂₂ is selected from hydrogen and C₁₋₆alkyl; m is selected from 0, 1, 2, 3 and 4; q is selected from 0, 1, 2, 3 and 4; t₁ t₂, t₃ and t₄ are each independently selected from 0, 1 and 2; R₁ is selected from —X₁S(O)₀₋₂X₂R_(6a), —X₁S(O)₀₋₂X₂OR_(6a), —X₁S(O)₀₋₂X₂C(O)R_(6a), —X₁S(O)₀₋₂X₂C(O)OR_(6a), —X₁S(O)₀₋₂X₂OC(O)R_(6a) and —X₁S(O)₀₋₂NR_(6a)R_(6b); wherein X₁ is selected from a bond, O, NR_(7a)R_(7b) and C₁₋₄alkylene; X₂ is selected from a bond and C₁₋₄alkylene; R_(6a) is selected from hydrogen, halo, C₁₋₆alkyl, C₂₋₆alkenyl, C₆₋₁₀aryl, C₁₋₁₀heteroaryl, C₃₋₈heterocycloalkyl and C₃₋₈cycloalkyl; wherein said aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R_(6a) is optionally substituted with 1 to 3 radicals independently selected from hydroxy, halo, C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl, hydroxy-substituted-C₁₋₆alkyl, cyano-substituted-C₁₋₆alkyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆ alkoxy and C₆₋₁₀aryl-C₁₋₄alkoxy; R_(6b) is selected from hydrogen and C₁₋₆alkyl; and R_(7a) and R_(7b) are independently selected from hydrogen and C₁₋₆alkyl; R₂ and R₃ are independently selected from hydrogen, halo, hydroxy, C₁₋₆alkyl, halo-substituted-C₁₋₆ alkyl, hydroxy-substituted-C₁₋₆ alkyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆alkoxy, —C(O)R₂₃, and —C(O)OR₂₃; wherein R₂₃ is selected from hydrogen and C₁₋₆alkyl; R₄ is selected from R₈ and —C(O)OR₈; wherein R₈ is selected from C₁₋₆alkyl, C₆₋₁₀aryl, C₁₋₁₀heteroaryl, C₃₋₈cycloalkyl and C₃₋₈heterocycloalkyl; wherein said aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R₈ is optionally substituted with 1 to 3 radicals independently selected from halo, C₁₋₆alkyl, C₃₋₈cycloalkyl, C₃₋₈heterocycloalkyl, halo-substituted-C₁₋₆alkyl, hydroxy-substituted-C₁₋₆alkyl, C₁₋₆alkoxy and halo-substituted-C₁₋₆alkoxy; R₅ is selected from hydrogen, C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl, hydroxy-substituted-C₁₋₆alkyl, C₁₋₆alkoxy and halo-substituted-C₁₋₆alkoxy; or the pharmaceutically acceptable salts thereof.
 2. The compound of claim 1 of Formula Ia:

in which: Q is a divalent or trivalent radical selected from C₆₋₁₀aryl, C₁₋₁₀heteroaryl, C₃₋₈cycloalkyl and C₃₋₈heterocycloalkyl; wherein said aryl, heteroaryl, cycloalkyl or heterocycloalkyl of Q is optionally substituted with up to 3 radicals independently selected from halo, C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆alkoxy, —C(O)R₂₀ and —C(O)OR₂₀; wherein R₂₀ is selected from hydrogen and C₁₋₆alkyl; and optionally connecting a carbon adjacent to W₂ through a CR₃₁ or O with a carbon of Q to form a 5-membered ring fused to rings A and Q; wherein R₃₁ is selected from hydrogen and C₁₋₆alkyl; W₁ and W₂ are independently selected from CR₂₁ and N; wherein R₂₁ is selected from hydrogen, cyano, C₁₋₆alkyl and —C(O)OR₂₅; wherein R₂₅ is selected from hydrogen and C₁₋₆alkyl; ring A can have up to 2 ring carbons substituted with a group selected from —C(O)—, —C(S)— and —C(═NOR₃₀)— and can be partially unsaturated with up to 2 double bonds; wherein R₃₀ is selected from hydrogen and C₁₋₆alkyl; L is selected from C₁₋₆alkylene, C₂₋₆alkenylene, —(CH₂)_(n)O—, —NR₂₆(CH₂)_(n)—, —OC(O)(CH₂)_(n)—, —C(O)O(CH₂)_(n)— and —O(CH₂)_(n)—; wherein R₂₆ is selected from hydrogen and C₁₋₆alkyl; wherein n is selected from 0, 1, 2, 3, 4 and 5; wherein any alkyl of L can be optionally substituted with 1 to 3 radicals independently selected from halo, C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆alkoxy, —C(O)R₂₂ and —C(O)OR₂₂; wherein R₂₂ is selected from hydrogen and C₁₋₆alkyl; t₁ and t₂ are each independently selected from 0, 1 and 2; q is selected from 0, 1, 2, 3 and 4; R₁ is selected from —X₁S(O)₀₋₂X₂R_(6a), —X₁S(O)₀₋₂X₂OR_(6a), —X₁S(O)₀₋₂X₂C(O)OR_(6a), —X₁S(O)₀₋₂X₂OC(O)R_(6a) and —X₁S(O)₀₋₂NR_(6a)R_(6b); wherein X₁ is selected from a bond, O, NR_(7a)R_(7b) and C₁₋₄alkylene; X₂ is selected from a bond and C₁₋₄alkylene; R_(6a) is selected from hydrogen, halo, C₁₋₆alkyl, C₂₋₆alkenyl, C₆₋₁₀aryl, C₁₋₁₀heteroaryl, C₃₋₈heterocycloalkyl and C₃₋₈cycloalkyl; wherein said aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R_(6a) is optionally substituted with 1 to 3 radicals independently selected from hydroxy, halo, C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl, hydroxy-substituted-C₁₋₆alkyl, cyano-substituted-C₁₋₆alkyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆alkoxy and C₆₋₁₀aryl-C₁₋₄alkoxy; R_(6b) is selected from hydrogen and C₁₋₆alkyl; and R_(7a) and R_(7b) are independently selected from hydrogen and C₁₋₆alkyl; R₃ is selected from hydrogen, halo, hydroxy, C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl, hydroxy-substituted-C₁₋₆alkyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆alkoxy, —C(O)R₂₃, and —C(O)OR₂₃; wherein R₂₃ is selected from hydrogen and C₁₋₆alkyl; R₄ is selected from R₈ and —C(O)OR₈; wherein R₈ is selected from C₁₋₆alkyl, C₆₋₁₀aryl, C₁₋₁₀heteroaryl, C₃₋₈cycloalkyl and C₃₋₈heterocycloalkyl; wherein said aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R₈ is optionally substituted with 1 to 3 radicals independently selected from halo, C₁₋₆alkyl, C₃₋₈cycloalkyl, C₃₋₈heterocycloalkyl, halo-substituted-C₁₋₆alkyl, hydroxy-substituted-C₁₋₆alkyl, C₁₋₆alkoxy and halo-substituted-C₁₋₆alkoxy; R₅ is selected from hydrogen, C₁₋₆alkyl, halo-substituted-C₁₋₆alkyl, hydroxy-substituted-C₁₋₆alkyl, C₁₋₆alkoxy and halo-substituted-C₁₋₆alkoxy.
 3. The compound of claim 2 in which Q is a divalent or trivalent radical selected from phenyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, 1,2,4-oxadiazolyl, and thiazolyl; wherein said phenyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl and thiazolyl of Q is optionally substituted with up to 3 radicals independently selected from halo, C₁₋₆alkyl, C₁₋₆alkoxy, halo-substituted-C₁₋₆alkyl, —C(O)OR₂₀ and —C(O)R₂₀; wherein R₂₀ is selected from hydrogen and C₁₋₆alkyl; and optionally connecting a carbon adjacent to W₂ through a CR₃₁ or O with a carbon of Q to form a 5-membered ring fused to rings A and Q; wherein R₃₁ is selected from hydrogen and C₁₋₆alkyl.
 4. The compound of claim 3 in which: W₁ and W₂ are independently selected from CR₂₁ and N; wherein R₂₁ is selected from hydrogen, cyano, C₁₋₆alkyl and —C(O)OR₂₅; wherein R₂₅ is selected from hydrogen and C₁₋₆alkyl; with a group selected from —C(O)—, —C(S)— and —C(═NOR₃₀)— and can be partially unsaturated with a double bond; wherein R₃₀ is selected from hydrogen and C₁₋₆alkyl; and L is selected from —O(CH₂)₀₋₄—, —(CH═CH)—, —OC(O)—, —NH(CH₂)₀₋₄—, —NCH₃(CH₂)₀₋₄— and —(CH₂)₁₋₄—.
 5. The compound of claim 4 in which: R₁ is selected from —X₁S(O)₀₋₂X₂R_(6a), —X₁S(O)₀₋₂X₂OR_(6a), —X₁S(O)₀₋₂X₂C(O)OR_(6a), —X₁S(O)₀₋₂X₂OC(O)R_(6a) and —X₁S(O)₀₋₂NR_(6a)R_(6b); wherein X₁ is selected from a bond and O; X₂ is selected from a bond and C₁₋₄alkylene; R_(6a) is selected from hydrogen, halo, cyano, methyl, ethyl, propyl, isopropyl, ethenyl, pyridinyl, pyrrolidinyl, piperidinyl, morpholino, isoxazolyl, tetrazolyl, phenyl and imidazolyl; wherein said piperidinyl, pyridinyl, pyrrolidinyl, morpholino, isoxazolyl, tetrazolyl, phenyl or imidazolyl of R_(6a) is optionally substituted with 1 to 3 radicals independently selected from hydroxy, halo, C₁₋₆alkyl and benzoxy; and R_(6b) is selected from hydrogen, methyl and ethyl.
 6. The compound of claim 5 in which: R₄ is selected from R₈ and —C(O)OR₈; wherein R₈ is selected from isopropyl, cyclopropyl, t-butyl, 1,2,4-oxadiazolyl, pyrimidinyl, pyridinyl, pyridazinyl, tetrahydro-2H-pyranyl, tetrahydrofuranyl, oxetanyl, 2H-tetrazolyl and thiazolyl; wherein said cyclopropyl, 1,2,4-oxadiazolyl, pyrimidinyl, pyridinyl, pyridazinyl, tetrahydro-2H-pyranyl, tetrahydrofuranyl, oxetanyl, 2H-tetrazolyl or thiazolyl of R₈ is optionally substituted with 1 to 3 radicals independently selected from halo, trifluoromethyl, isopropyl, t-butyl, methyl, ethyl and cyclopropyl optionally substituted with methyl; and R₅ is selected from hydrogen and methoxy.
 7. The compound of claim 1 selected from: 1-Methylcyclopropyl 4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, isopropyl 4-((4-((4-methanesulfonylpiperazin)-1-yl)phenoxy)methyl)piperidine-1-carboxylate, isopropyl 4-(2-(4-(4-(methylsulfonyl)piperazin-1-yl)phenoxy)ethyl)piperidine-1-carboxylate, isopropyl 4-(3-(4-(4-(methylsulfonyl)piperazin-1-yl)phenoxy)propyl)piperidine-1-carboxylate, isopropyl 4-(4-(4-(4-(methylsulfonyl)piperazin-1-yl)phenoxy)butyl)piperidine-1-carboxylate, Isopropyl 4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate, tert-Butyl 4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate, Isopropyl 4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, tert-Butyl 4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, 3-Cyclopropyl-5-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole, 5-Cyclopropyl-3-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole, 2-(4-(Methylsulfonyl)piperazin-1-yl)-5-((1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)methoxy)pyrazine, 5-Isopropyl-3-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole, Tetrahydro-2H-pyran-4-yl 4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, (S)-Tetrahydrofuran-3-yl 4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, (R)-Tetrahydrofuran-3-yl 4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, 2-Isopropyl-5-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)thiazole, 2-((1-(2-methyl-2H-tetrazol-5-yl)piperidin-4-yl)methoxy)-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazine, Oxetan-3-yl 4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, Isopropyl 4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidine-1-carboxylate, Isopropyl 4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridazin-3-yloxy)methyl)piperidine-1-carboxylate, Isopropyl 4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrimidin-2-yloxy)methyl)piperidine-1-carboxylate, (E)-isopropyl 4-(2-(6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)vinyl)piperidine-1-carboxylate, Isopropyl 4-(2-(6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yl)ethyl)piperidine-1-carboxylate, (E)-Isopropyl 4-(2-(2-(4-(methylsulfonyl)piperazin-1-yl)pyrimidin-5-yl)vinyl)piperidine-1-carboxylate, 5-Ethyl-2-(4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)pyrimidine, 1-(Methylsulfonyl)-4-(5-((1-(5-(trifluoromethyl)pyridin-2-yl)piperidin-4-yl)methoxy)pyridin-2-yl)piperazine, 5-Ethyl-2-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)pyrimidine, 2-((1-(5-Methylpyridin-2-yl)piperidin-4-yl)methoxy)-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazine, 1-Methylcyclopropyl 4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidine-1-carboxylate, 5-Ethyl-2-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidin-1-yl)pyrimidine, 3-Isopropyl-5-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole, 3-Isopropyl-5-(4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole, 1-Methylcyclopropyl 4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate, 5-Isopropyl-3-(4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole, 2-((1-(5-Fluoropyridin-2-yl)piperidin-4-yl)methoxy)-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazine, 3-Isopropyl-5-(4-((6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole, tert-Butyl 4-((5-(4-(methylsulfonyl)-1,4-diazepan-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, tert-Butyl 4-((5-(4-(methylsulfonyl)-1,4-diazepan-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, tert-butyl 4-((5-(4-(methylsulfonyl)piperidin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, 1-Methylcyclopropyl 4-((5-(4-(methylsulfonyl)piperidin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, tert-Butyl 4-(2-(3-(4-(methylsulfonyl)piperazin-1-yl)-1,2,4-oxadiazol-5-yl)ethyl)piperidine-1-carboxylate, tert-Butyl 4-(3-(3-(4-(methylsulfonyl)piperazin-1-yl)-1,2,4-oxadiazol-5-yl)propyl)piperidine-1-carboxylate, 5-(3-(1-(5-ethylpyrimidin-2-yl)piperidin-4-yl)propyl)-3-(4-(methylsulfonyl)piperazin-1-yl)-1,2,4-oxadiazole, Isopropyl 4-(3-(3-(4-(methylsulfonyl)piperazin-1-yl)-1,2,4-oxadiazol-5-yl)propyl)piperidine-1-carboxylate, 3-Isopropyl-5-(4-(2-(5-(4-(methylsulfonyl)piperazin-1-yl)thiazol-2-yl)ethyl)piperidin-1-yl)-1,2,4-oxadiazole, Isopropyl 4-((4-(1-methanesulfonyl-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)methyl)piperidine-1-carboxylate, isopropyl 4-(4-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)piperidine-1-carboxylate, isopropyl 4-(2-(4-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)ethyl)piperidine-1-carboxylate, isopropyl 4-(3-(4-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)propyl)piperidine-1-carboxylate, isopropyl 4-(4-(4-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)butyl)piperidine-1-carboxylate, 1-methylcyclopropyl 4-((4-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)methyl)piperidine-1-carboxylate, 5-isopropyl-3-(4-((4-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole, Isopropyl 4-((4-(1-methanesulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate, isopropyl 4-(4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)piperidine-1-carboxylate, isopropyl 4-(2-(4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)ethyl)piperidine-1-carboxylate, isopropyl 4-(3-(4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)propyl)piperidine-1-carboxylate, isopropyl 4-(4-(4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)butyl)piperidine-1-carboxylate, 1-Methylcyclopropyl 4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate, 2-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)-5-(trifluoromethyl)pyridine, 5-isopropyl-3-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole, 3-chloro-2-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)-5-(trifluoromethyl)pyridine, 5-chloro-2-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)pyridine, 3-chloro-6-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)pyridazine, 5-bromo-2-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)pyrimidine, 5-ethyl-2-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)pyrimidine, 5-fluoro-2-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)pyridine, 3-isopropyl-5-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole, 3-tert-butyl-6-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)pyridazine, 5-fluoro-2-(4-((4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)pyrimidine, Isopropyl 4-(2-(3-(1-methanesulfonyl-1,2,3,6-tetrahydropyridin-4-yl)phenoxy)ethyl)piperidine-1-carboxylate, 1-Methylcyclopropyl 4-methoxy-4-((5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, 1-methylcyclopropyl 4-((6-formyl-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, 1-Methylcyclopropyl 4-((6-chloro-5-(4-(methylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, 1-Methylcyclopropyl 4-((5-(4-(3-methoxy-3-oxopropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate, 3-(4-(5-((1-((1-methylcyclopropoxy)carbonyl)-piperidin-4-yl)methoxy)pyrazin-2-yl)piperazin-1-ylsulfonyl)propanoic acid, 3-(4-(5-((1-((1-methylcyclopropoxy)carbonyl)piperidin-4-yl)methoxy)pyrazin-2-yl)piperazin-1-ylsulfonyl)propanoic acid, 3-(4-(5-((1-((1-methylcyclopropoxy)carbonyl)piperidin-4-yl)methoxy)pyrazin-2-yl)piperazin-1-ylsulfonyl)propanoic acid, 3-(4-(5-((1-((1-methylcyclopropoxy)carbonyl)piperidin-4-yl)methoxy)pyrazin-2-yl)piperazin-1-ylsulfonyl)propanoic acid, 3-(4-(5-((1-((1-methylcyclopropoxy)carbonyl)piperidin-4-yl)methoxy)pyrazin-2-yl)piperazin-1-ylsulfonyl)propanoic acid, 3-(4-(5-((1-((1-methylcyclopropoxy)carbonyl)piperidin-4-yl)methoxy)pyrazin-2-yl)piperazin-1-ylsulfonyl)propanoic acid; 1-methylcyclopropyl 4-((5-(4-(3-cyanopropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(3-(1H-tetrazol-5-yl)propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(vinylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(2-(piperidin-1-yl)ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(2-morpholinoethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(2-(dimethylamino)ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; tert-butyl 4-((5-(4-(3-chloropropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; tert-butyl 4-((5-(4-(3-acetoxypropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(3-aminopropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(2-ethoxyethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(3-(pyrrolidin-1-yl)propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(3-(2-methyl-1H-imidazol-1-yl)propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(3-(dimethylamino)propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(isopropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(isobutylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(sec-butylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(3-acetoxy-2,2-dimethylpropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((5-(4-(3-hydroxy-2,2-dimethylpropylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-Methylcyclopropyl 4-((5-(4-(2-(pyridin-3-yl)ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-Methylcyclopropyl 4-((5-(4-(2-(pyridin-4-yl)ethylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-Methylcyclopropyl 4-((5-(4-sulfamoylpiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; tert-Butyl 4-((5-(4-(morpholinosulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((6-(4-(ethylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((6-(4-(ethylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((6-(4-(ethylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((6-(4-(ethylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((6-(4-(ethylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((6-(4-(ethylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate; 1-Methylcyclopropyl 4-((5-fluoro-6-(4-(methylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate; tert-Butyl 4-((5-(4-(methylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-Methylcyclopropyl 4-((5-(4-(methylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-Methylcyclopropyl 4-((5-(2-oxo-4-(propylsulfonyl)piperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-Methylcyclopropyl 4-((5-(4-(isopropylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-Methylcyclopropyl 4-((5-(4-(isopropylsulfonyl)-2-oxopiperazin-1-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((6-(2-oxo-4-(propylsulfonyl)piperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-((6-(4-(isopropylsulfonyl)-2-oxopiperazin-1-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate; 1-(5-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)pyrazin-2-yl)-4-(methylsulfonyl)piperazin-2-one; 1-(5-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)pyridin-2-yl)-4-(methylsulfonyl)piperazin-2-one; tert-Butyl 4-((2,6-difluoro-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate; tert-butyl 4-((2-methyl-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate; tert-butyl 4-((3-methoxy-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate; tert-butyl 4-((2,6-dimethyl-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate; tert-butyl 4-((2,5-dimethyl-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate; tert-butyl 4-((2-(methoxycarbonyl)-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate; tert-butyl 4-((2-chloro-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate; tert-butyl 4-((3-methyl-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate; tert-butyl 4-((2,3-dimethyl-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate; tert-butyl 4-((2-fluoro-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate; tert-butyl 4-((4-(1-(methylsulfonyl)piperidin-4-yl)-2-(trifluoromethyl)phenoxy)methyl)piperidine-1-carboxylate; 2-(4-((2,6-Difluoro-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidin-1-yl)-5-ethylpyrimidine; 1-Methylcyclopropyl 4-((2,6-difluoro-4-(1-(methylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate; 3-(4-(4-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)-3,5-difluorophenyl)piperidin-1-ylsulfonyl)propyl acetate; 1-Methylcyclopropyl 4-((4-(1-(3-acetoxypropylsulfonyl)piperidin-4-yl)-2,6-difluorophenoxy)methyl)piperidine-1-carboxylate; 3-(4-(4-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)-3,5-difluorophenyl)piperidin-1-ylsulfonyl)propan-1-ol; 1-Methylcyclopropyl 4-((2,6-difluoro-4-(1-(3-hydroxypropylsulfonyl)piperidin-4-yl)phenoxy)methyl)piperidine-1-carboxylate; Isopropyl 4-((5-(1,2,3,6-tetrahydro-1-methanesulfonylpyridin-4-yl)pyrazin-2-yloxy)methyl)piperidine-1-carboxylate; 1-Methylcyclopropyl 4-((6-(1,2,3,6-tetrahydro-1-methanesulfonylpyridin-4-yl)pyridin-3-yloxy)methyl)piperidine-1-carboxylate; Isopropyl 4-(2-(6-(1,2,3,6-tetrahydro-1-methanesulfonylpyridin-4-yl)pyridin-3-yloxy)ethyl)piperidine-1-carboxylate; 2-(4-((5-(1,2,3,6-Tetrahydro-1-methanesulfonylpyridin-4-yl)pyrazin-2-yloxy)methyl)piperidin-1-yl)-5-ethylpyrimidine; 2-(4-((6-(1,2,3,6-Tetrahydro-1-methanesulfonylpyridin-4-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)-5-ethylpyrimidine; 2-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)-5-(1-methanesulfonylpiperidin-4-yl)pyrazine; 2-(4-((6-(1-Methanesulfonylpiperidin-4-yl)pyridin-3-yloxy)methyl)piperidin-1-yl)-5-ethylpyrimidine; 3-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methoxy)-6-(1-methanesulfonylpiperidin-4-yl)pyridazine; 2-(4-((5-(1-Methanesulfonylpiperidin-4-yl)pyridin-2-yloxy)methyl)piperidin-1-yl)-5-ethylpyrimidine; 1-tert-Butyl 4-(4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)piperazine-1,4-dicarboxylate; N-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methyl)-4-(1-(methylsulfonyl)piperidin-4-yl)aniline; N-((1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)methyl)-N-methyl-4-(1-(methylsulfonyl)piperidin-4-yl)aniline; 4-(4-((1-(5-fluoropyrimidin-2-yl)piperidin-4-yl)methoxy)phenyl)-1-(methyl sulfonyl)piperidine-4-carboxylic acid; 2-[(2-{4-[5-({1-[(1-methylcyclopropoxy)carbonyl]piperidin-4-yl}methoxy)pyrazin-2-yl]-3-oxopiperazine-1-sulfonyl}ethyl)amino]acetic acid; 1-methylcyclopropyl 4-{[(5-{4-[(2-carbamimidamidoethane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(3-methyl-3-nitrobutane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-(1-benzylpyrrolidine-3-sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[5-{4-[(carbamoylmethane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(1-carbamoyl-1-methylethane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(2-oxo-4-{[2-(pyrrolidin-1-yl)ethane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[2-(morpholin-4-yl)ethane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[3-(dimethylamino)propane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)ethane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[(dimethylcarbamoyl)methane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[1-(2-methylpropyl)pyrrolidine-3-sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(2-oxo-4-{[3-(1H-pyrazol-1-yl)propane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[2-oxo-4-(pyrrolidine-3-sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(2-amino-2-methylpropane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[(1-methylpyrrolidin-3-yl)methane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[2-(azetidin-1-yl)ethane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(2-oxo-4-{[2-(1H-pyrazol-1-yl)ethane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-(1-methylpyrrolidine-3-sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[1-(dimethylcarbamoyl)-1-methylethane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[2-(3,3-difluoroazetidin-1-yl)ethane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[3-(dimethylamino)-3-methylbutane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(2-{[2-(tert-butoxy)-2-oxoethyl]amino}ethane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-(azetidine-3-sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[3-(3,3-difluoroazetidin-1-yl)propane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[3-(azetidin-1-yl)propane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{2-oxo-4-[(3S)-pyrrolidine-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(3S)-1-methylpyrrolidine-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(3R)-1-methylpyrrolidine-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(3S)-pyrrolidine-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(3R)-pyrrolidine-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-(azetidine-3-sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{2-oxo-4-[(pyrrolidin-3-ylmethane)sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-(1-hydroxy-2-methylpropane-2-sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(2-hydroxyethane)sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(azetidin-3-ylmethane)sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[(1-methylpyrrolidin-2-yl)methane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{2-oxo-4-[(3R)-pyrrolidine-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-(1-methylazetidine-3-sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-(1-methylazetidine-3-sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[(1-methylazetidin-3-yl)methane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[(1-methylazetidin-3-yl)methane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-({3-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]propane}sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-({2-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]ethane}sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(azetidin-3-ylmethane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{2-oxo-4-[(pyrrolidin-2-ylmethane)sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(3-aminopropane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(2-aminoethane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(3-methanesulfonamidoazetidin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[2-(dimethylamino)ethane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(2-oxo-4-{[3-(pyrrolidin-1-yl)propane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[3-(morpholin-4-yl)propane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[(3-methyloxetan-3-yl)methane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[3-(acetyloxy)propane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[3,3,3-trifluoropropane)sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[(2E)-2-(hydroxyimino)-4-methanesulfonylpiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(3-chloropropane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(3-hydroxypropane)sulfonyl]-2-oxopiperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-({[1-(dimethylamino)cyclopropyl]methane}sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-({[1-(dimethylamino)cyclopropyl]methane}sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[(3-hydroxy-3-methylbutane)sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{2-oxo-4-[(3R)-oxolane-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{2-oxo-4-[(3S)-oxolane-3-sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[3-(acetyloxy)-3-methylbutane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({6-[4-({[1-(azetidin-1-yl)cyclopropyl]methane}sulfonyl)piperazin-1-yl]pyridin-3-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-({[1-(benzylamino)cyclopropyl]methane}sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-({[1-(azetidin-1-yl)cyclopropyl]methane}sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[(1-hydroxycyclopropyl)methane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[2-(1-hydroxycyclopropyl)ethane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-({2-[1-(acetyloxy)cyclopropyl]ethane}sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-({[1-(benzyloxy)cyclopropyl]methane}sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[(1-aminocyclopropyl)methane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[2-(1-hydroxycyclopropyl)ethane]sulfonyl}-2-oxopiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-{2,6-difluoro-4-[3-(N-methylmethanesulfonamido)azetidin-1-yl]phenoxymethyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-[2,6-difluoro-4-(3-methanesulfonamidoazetidin-1-yl)phenoxymethyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-{2,6-difluoro-4-[3-(2-methylpropane-1-sulfonamido)azetidin-1-yl]phenoxymethyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{4-[3-(N,2-dimethylpropane-1-sulfonamido)azetidin-1-yl]-2,6-difluorophenoxymethyl}piperidine-1-carboxylate; 5-ethyl-2-{4-[({2-methanesulfonyl-1H,2H,3H,4H-pyrazino[1,2-a]indol-8-yl}oxy)methyl]piperidin-1-yl}pyrimidine; 11-{[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]oxy}-5-methanesulfonyl-8-oxa-5-azatricyclo[7.4.0.0{2,7}]-trideca-1(13),2(7),9,11-tetraene; 11-{[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]methoxy}-5-methanesulfonyl-8-oxa-5-azatricyclo[7.4.0.0{2,7}]-trideca-1(13),2(7),9,11-tetraene; tert-butyl 4-[({2-methanesulfonyl-1H,2H,3H,4H-pyrazino[1,2-a]indol-8-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({2-methanesulfonyl-1H,2H,3H,4H-pyrazino[1,2-a]indol-8-yl}oxy)methyl]piperidine-1-carboxylate; propan-2-yl 4-{3-[3-(1-methanesulfonylpiperidin-4-yl)phenoxy]propyl}piperidine-1-carboxylate; propan-2-yl 4-{2-[3-(1-methanesulfonylpiperidin-4-yl)phenoxy]ethyl}piperidine-1-carboxylate; propan-2-yl 4-[3-(1-methanesulfonylpiperidin-4-yl)phenoxymethyl]piperidine-1-carboxylate; propan-2-yl 4-{3-[3-(1-methanesulfonyl-1,2,3,6-tetrahydropyridin-4-yl)phenoxy]propyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-methanesulfonyl-2-sulfanylidenepiperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl (3S,4S)-3-hydroxy-4-{[(6-{4-[(2-methylpropane)sulfonyl]piperazin-1-yl}pyridin-3-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl (3R,4S)-3-hydroxy-4-{[(6-{4-[(2-methylpropane)sulfonyl]piperazin-1-yl}pyridin-3-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-hydroxy-4-{[(6-{4-[(2-methylpropane)sulfonyl]piperazin-1-yl}pyridin-3-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(6-{4-[(2-hydroxy-2-methylpropane)sulfonyl]piperazin-1-yl}pyridin-3-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl (3S,4R)-3-methoxy-4-{[(6-{4-[(2-methylpropane)sulfonyl]piperazin-1-yl}pyridin-3-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[3-(3,3-difluoroazetidin-1-yl)propane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[3-(azetidin-1-yl)propane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(5-{4-[3-methoxypropane)sulfonyl]piperazin-1-yl}pyrazin-2-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(6-{4-[(3-chloropropane)sulfonyl]-2-oxopiperazin-1-yl}pyridin-3-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[2-(azetidin-1-yl)ethane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[6-(4-{[3-(azetidin-1-yl)propane]sulfonyl}piperazin-1-yl)pyridin-3-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-[({5-[4-(pyrrolidine-3-sulfonyl)piperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[5-(4-{[2(3,3-difluoroazetidin-1-yl)ethane]sulfonyl}piperazin-1-yl)pyrazin-2-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-{[(6-{4-[(3-hydroxypropane)sulfonyl]-2-oxopiperazin-1-yl}pyridin-3-yl)oxy]methyl}piperidine-1-carboxylate; 1-methylcyclopropyl 4-({[6-(4-{[3-(azetidin-1-yl)propane]sulfonyl}-2-oxopiperazin-1-yl)pyridin-3-yl]oxy}methyl)piperidine-1-carboxylate; 1-methylcyclopropyl 4-[2,6-difluoro-4-(4-methanesulfonyl-2-oxopiperazin-1-yl)phenoxymethyl]piperidine-1-carboxylate; and 1-methylcyclopropyl 4-[({5-[4-(oxetane-3-sulfonyl)-2-oxopiperazin-1-yl]pyrazin-2-yl}oxy)methyl]piperidine-1-carboxylate.
 8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable excipient.
 9. A method for modulating GPR119 activity, comprising administering to a system or a subject in need thereof, a therapeutically effective amount of the compound of claim 1 or pharmaceutically acceptable salts or pharmaceutical compositions thereof, thereby modulating said GPR119 activity.
 10. The method of claim 9, wherein the compound of claim 1 directly contacts GPR119.
 11. The method of claim 10, wherein the contacting occurs in vitro or in vivo.
 12. A method for treating a disease or condition wherein modulation of GPR119 activity can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease or condition, comprising administering to a subject a therapeutically effective amount of the compound of claim 1 or pharmaceutically acceptable salts or pharmaceutical compositions thereof.
 13. The method of claim 12, wherein said disease or condition is selected from obesity, type 1 diabetes, type 2 diabetes mellitus, hyperlipidemia, idiopathic type 1 diabetes, latent autoimmune diabetes in adults, early-onset type 2 diabetes, youth-onset atypical diabetes, maturity onset diabetes of the young, malnutrition-related diabetes and gestational diabetes.
 14. The method of claim 12, wherein said disease or condition is selected from coronary heart disease, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction, dyslipidemia, post-prandial lipemia, conditions of impaired glucose tolerance, conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, osteoporosis, hypertension, congestive heart failure, left ventricular hypertrophy, peripheral arterial disease, diabetic retinopathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, metabolic syndrome, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, thrombosis, atherosclerosis, myocardial infarction, transient ischemic attacks, stroke, vascular restenosis, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertrygliceridemia, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance, conditions of impaired fasting plasma glucose, obesity, erectile dysfunction, skin and connective tissue disorders, foot ulcerations and ulcerative colitis, endothelial dysfunction and impaired vascular compliance. 